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DYNAMIC	 ﾠSURFACTANT	 ﾠMETABOLISM	 ﾠIN	 ﾠPRETERM	 ﾠ
INFANTS	 ﾠ
	 ﾠ
by	 ﾠKevin	 ﾠColin	 ﾠWilliam	 ﾠGoss	 ﾠ
	 ﾠ
Exogenous	 ﾠ surfactant	 ﾠ therapy	 ﾠ has	 ﾠ dramatically	 ﾠ improved	 ﾠ survival	 ﾠ in	 ﾠ extremely	 ﾠ
preterm	 ﾠinfants,	 ﾠhowever	 ﾠthe	 ﾠturnover	 ﾠof	 ﾠexogenous	 ﾠand	 ﾠsynthesis	 ﾠof	 ﾠendogenous	 ﾠ
surfactant	 ﾠcomponents	 ﾠare	 ﾠstill	 ﾠpoorly	 ﾠunderstood	 ﾠin	 ﾠthis	 ﾠgroup.	 ﾠAdditionally	 ﾠthere	 ﾠ
is	 ﾠevidence	 ﾠfor	 ﾠthis	 ﾠpatient	 ﾠgroup	 ﾠthat	 ﾠimproving	 ﾠnutrition	 ﾠimproves	 ﾠlong-ﾭ‐term	 ﾠ
outcomes	 ﾠin	 ﾠrespiratory	 ﾠfunction,	 ﾠgrowth	 ﾠand	 ﾠneurodevelopment.	 ﾠ
	 ﾠ	 ﾠPhosphatidylcholine	 ﾠ(PC)	 ﾠis	 ﾠthe	 ﾠdominant	 ﾠphospholipid	 ﾠin	 ﾠboth	 ﾠsurfactant	 ﾠand	 ﾠin	 ﾠ
plasma	 ﾠand	 ﾠcan	 ﾠbe	 ﾠsynthesised	 ﾠfrom	 ﾠcholine	 ﾠby	 ﾠone	 ﾠof	 ﾠtwo	 ﾠpathways:	 ﾠthe	 ﾠCDP-ﾭ‐
choline	 ﾠpathway,	 ﾠwhich	 ﾠis	 ﾠpresent	 ﾠin	 ﾠall	 ﾠnucleated	 ﾠcells,	 ﾠor	 ﾠby	 ﾠthree	 ﾠsequential	 ﾠ
methylations	 ﾠ of	 ﾠ phosphatidylethanolamine	 ﾠ in	 ﾠ the	 ﾠ PEMT	 ﾠ pathway,	 ﾠ which	 ﾠ is	 ﾠ
localised	 ﾠto	 ﾠhepatocytes	 ﾠand	 ﾠis	 ﾠthe	 ﾠprimary	 ﾠsource	 ﾠof	 ﾠpolyunsaturated	 ﾠPC	 ﾠspecies	 ﾠ
and	 ﾠ de	 ﾠ novo	 ﾠ synthesis	 ﾠ of	 ﾠ choline.	 ﾠ This	 ﾠ study	 ﾠ quantified	 ﾠ choline	 ﾠ phospholipid	 ﾠ
metabolism	 ﾠand	 ﾠpulmonary	 ﾠsurfactant	 ﾠkinetics	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠin	 ﾠvivo.	 ﾠChildren	 ﾠ
aged	 ﾠbetween	 ﾠ23	 ﾠand	 ﾠ28	 ﾠweeks	 ﾠgestation	 ﾠand	 ﾠin	 ﾠreceipt	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠ
were	 ﾠintravenously	 ﾠinfused	 ﾠwith	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠwithin	 ﾠ48	 ﾠhours	 ﾠof	 ﾠ
birth.	 ﾠLipid	 ﾠextracts	 ﾠfrom	 ﾠsequential	 ﾠplasma	 ﾠand	 ﾠendotracheal	 ﾠaspirate	 ﾠsamples	 ﾠ
were	 ﾠthen	 ﾠanalysed	 ﾠby	 ﾠelectrospray	 ﾠionisation	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ(ESI-ﾭ‐
MS/MS).	 ﾠ Fractional	 ﾠ incorporation	 ﾠ into	 ﾠ newly	 ﾠ synthesised	 ﾠ PC	 ﾠ species	 ﾠ is	 ﾠ
demonstrated	 ﾠrapidly	 ﾠin	 ﾠplasma	 ﾠsamples	 ﾠat	 ﾠa	 ﾠhigher	 ﾠrate	 ﾠthan	 ﾠpreviously	 ﾠreported	 ﾠ
in	 ﾠadults,	 ﾠindicating	 ﾠa	 ﾠhigh	 ﾠlevel	 ﾠof	 ﾠhepatic	 ﾠactivity	 ﾠfor	 ﾠCDP-ﾭ‐choline.	 ﾠAnalysis	 ﾠof	 ﾠthe	 ﾠ
PC	 ﾠspecies	 ﾠderived	 ﾠfrom	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠshows	 ﾠsignificantly	 ﾠlower	 ﾠflux	 ﾠin	 ﾠthis	 ﾠ
pathway	 ﾠthan	 ﾠreported	 ﾠin	 ﾠadults.	 ﾠFinally	 ﾠincorporation	 ﾠinto	 ﾠsurfactant	 ﾠPC	 ﾠspecies	 ﾠis	 ﾠ
very	 ﾠlow	 ﾠinitially	 ﾠbefore	 ﾠrising	 ﾠslowly	 ﾠover	 ﾠseveral	 ﾠdays	 ﾠand	 ﾠwith	 ﾠthe	 ﾠrapid	 ﾠchanges	 ﾠ
in	 ﾠ other	 ﾠ acidic	 ﾠ phospholipids	 ﾠ suggests	 ﾠ a	 ﾠ rapid	 ﾠ recycling	 ﾠ of	 ﾠ components	 ﾠ of	 ﾠ the	 ﾠ
exogenous	 ﾠ surfactant	 ﾠ not	 ﾠ equilibrating	 ﾠ with	 ﾠ the	 ﾠ CDP-ﾭ‐choline	 ﾠ pathway	 ﾠ thereby	 ﾠ
providing	 ﾠ evidence	 ﾠ for	 ﾠ the	 ﾠ first	 ﾠ time	 ﾠ of	 ﾠ differing	 ﾠ rates	 ﾠ of	 ﾠ exogenous	 ﾠ surfactant	 ﾠ
recycling	 ﾠversus	 ﾠde	 ﾠnovo	 ﾠsynthesis	 ﾠin	 ﾠthe	 ﾠhuman	 ﾠpreterm	 ﾠinfant.	 ﾠ
	 ﾠ	 ﾠThis	 ﾠ study	 ﾠ proves	 ﾠ that	 ﾠ the	 ﾠ technique	 ﾠ works	 ﾠ in	 ﾠ the	 ﾠ clinical	 ﾠ environment,	 ﾠ is	 ﾠ
sensitive	 ﾠ and	 ﾠ rapid	 ﾠ enough	 ﾠ to	 ﾠ provide	 ﾠ data	 ﾠ in	 ﾠ a	 ﾠ clinically	 ﾠ relevant	 ﾠ timeframe,	 ﾠ
opening	 ﾠ the	 ﾠ possibility	 ﾠ for	 ﾠ translational	 ﾠ use	 ﾠ to	 ﾠ identify	 ﾠ biomarkers	 ﾠ for	 ﾠ disease	 ﾠ
progression.	 ﾠ
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 ﾠof	 ﾠD9-ﾭ‐containing	 ﾠPC	 ﾠphospholipids	 ﾠin	 ﾠ
plasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠD9	 ﾠenrichment	 ﾠhas	 ﾠbeen	 ﾠ
expressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠmeasured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠ
point.	 ﾠThe	 ﾠerror	 ﾠbars	 ﾠrepresent	 ﾠa	 ﾠsingle	 ﾠstandard	 ﾠdeviation	 ﾠfrom	 ﾠthe	 ﾠmean.	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Figure	 ﾠ21.	 ﾠThe	 ﾠmean	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐containing	 ﾠPC	 ﾠphospholipids	 ﾠin	 ﾠ
plasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠD9	 ﾠenrichment	 ﾠhas	 ﾠbeen	 ﾠ
expressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠmeasured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠ
point.	 ﾠThe	 ﾠerror	 ﾠbars	 ﾠrepresent	 ﾠa	 ﾠsingle	 ﾠstandard	 ﾠdeviation	 ﾠfrom	 ﾠthe	 ﾠmean.	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Figure	 ﾠ22.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ6	 ﾠhours	 ﾠafter	 ﾠ
recruitment.	 ﾠ For	 ﾠ each	 ﾠ pair	 ﾠ of	 ﾠ columns	 ﾠ the	 ﾠ endogenous	 ﾠ PC	 ﾠ proportions	 ﾠ are	 ﾠ
shown	 ﾠas	 ﾠthe	 ﾠleft-ﾭ‐hand	 ﾠcolumn,	 ﾠwhile	 ﾠthe	 ﾠright-ﾭ‐hand	 ﾠcolumn	 ﾠis	 ﾠthe	 ﾠD9-ﾭ‐labelled	 ﾠ
species.	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Figure	 ﾠ23.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ48	 ﾠhours	 ﾠafter	 ﾠ
recruitment.	 ﾠThe	 ﾠcolumns	 ﾠare	 ﾠnow	 ﾠmore	 ﾠsimilar	 ﾠthan	 ﾠat	 ﾠ6	 ﾠhours.	 ﾠFor	 ﾠeach	 ﾠpair	 ﾠ
of	 ﾠcolumns	 ﾠthe	 ﾠendogenous	 ﾠPC	 ﾠproportions	 ﾠare	 ﾠshown	 ﾠas	 ﾠthe	 ﾠleft-ﾭ‐hand	 ﾠcolumn,	 ﾠ
while	 ﾠthe	 ﾠright-ﾭ‐hand	 ﾠcolumn	 ﾠis	 ﾠthe	 ﾠD9-ﾭ‐labelled	 ﾠspecies.	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Figure	 ﾠ24.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠPC	 ﾠspecies	 ﾠup	 ﾠto	 ﾠ120	 ﾠ
hours	 ﾠafter	 ﾠrecruitment.	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Figure	 ﾠ25.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠdiunsaturated	 ﾠand	 ﾠ
arachidonoyl-ﾭ‐containing	 ﾠPC	 ﾠspecies	 ﾠup	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	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Figure	 ﾠ26.	 ﾠTurnover	 ﾠof	 ﾠselected	 ﾠenriched	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma.	 ﾠHigher	 ﾠturnover,	 ﾠor	 ﾠ
relative	 ﾠloss,	 ﾠof	 ﾠa	 ﾠspecies	 ﾠis	 ﾠreflected	 ﾠin	 ﾠa	 ﾠsteeper	 ﾠslope	 ﾠafter	 ﾠthe	 ﾠpeak	 ﾠat	 ﾠ12	 ﾠ
hours.	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Figure	 ﾠ27.	 ﾠTurnover	 ﾠof	 ﾠenriched	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠwith	 ﾠa	 ﾠ16:0	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐1	 ﾠ
position.	 ﾠHigher	 ﾠturnover,	 ﾠor	 ﾠrelative	 ﾠloss,	 ﾠof	 ﾠa	 ﾠspecies	 ﾠis	 ﾠreflected	 ﾠin	 ﾠa	 ﾠsteeper	 ﾠ
slope	 ﾠafter	 ﾠthe	 ﾠpeak	 ﾠat	 ﾠ12	 ﾠhours.	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Figure	 ﾠ28.	 ﾠTurnover	 ﾠof	 ﾠenriched	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠwith	 ﾠa	 ﾠ18:0	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐1	 ﾠ
position.	 ﾠHigher	 ﾠturnover,	 ﾠor	 ﾠrelative	 ﾠloss,	 ﾠof	 ﾠa	 ﾠspecies	 ﾠis	 ﾠreflected	 ﾠin	 ﾠa	 ﾠsteeper	 ﾠ
slope	 ﾠafter	 ﾠthe	 ﾠpeak	 ﾠat	 ﾠ12	 ﾠhours.	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Figure	 ﾠ29.	 ﾠTurnover	 ﾠof	 ﾠenriched	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠwith	 ﾠa	 ﾠpolyunsaturated	 ﾠfatty	 ﾠ
acid	 ﾠ on	 ﾠ the	 ﾠ sn-ﾭ‐2	 ﾠ position.	 ﾠ Higher	 ﾠ turnover,	 ﾠ or	 ﾠ relative	 ﾠ loss,	 ﾠ of	 ﾠ a	 ﾠ species	 ﾠ is	 ﾠ
reflected	 ﾠin	 ﾠa	 ﾠsteeper	 ﾠslope	 ﾠafter	 ﾠthe	 ﾠpeak	 ﾠat	 ﾠ12	 ﾠhours.	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Figure	 ﾠ30.	 ﾠBottom	 ﾠ-ﾭ‐	 ﾠAn	 ﾠexample	 ﾠof	 ﾠa	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠ(P184)	 ﾠscan	 ﾠ
spectrum.	 ﾠIt	 ﾠillustrates	 ﾠa	 ﾠtypical	 ﾠplasma	 ﾠlipid	 ﾠextract	 ﾠscan	 ﾠafter	 ﾠ72	 ﾠhours.	 ﾠTop	 ﾠ-ﾭ‐	 ﾠ
The	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+187	 ﾠ(P187)	 ﾠscan	 ﾠof	 ﾠthe	 ﾠsame	 ﾠlipid	 ﾠextract.	 ﾠ
There	 ﾠis	 ﾠa	 ﾠsimilar	 ﾠpattern	 ﾠof	 ﾠpeaks	 ﾠbut	 ﾠoffset	 ﾠby	 ﾠa	 ﾠmass/charge	 ﾠof	 ﾠthree	 ﾠhigher.
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Figure	 ﾠ31.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ12	 ﾠhours	 ﾠafter	 ﾠ
recruitment.	 ﾠ For	 ﾠ each	 ﾠ pair	 ﾠ of	 ﾠ columns	 ﾠ the	 ﾠ endogenous	 ﾠ PC	 ﾠ proportions	 ﾠ are	 ﾠ
shown	 ﾠ as	 ﾠ the	 ﾠ left-ﾭ‐hand	 ﾠ column,	 ﾠ while	 ﾠ the	 ﾠ right-ﾭ‐hand	 ﾠ column	 ﾠ is	 ﾠ the	 ﾠ PEMT	 ﾠ
derived	 ﾠD3-ﾭ‐labelled	 ﾠspecies.	 ﾠError	 ﾠbars	 ﾠrepresent	 ﾠone	 ﾠstandard	 ﾠdeviation.	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Figure	 ﾠ32.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠD3-ﾭ‐PC	 ﾠspecies,	 ﾠfrom	 ﾠ
the	 ﾠPEMT	 ﾠpathway,	 ﾠup	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	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Figure	 ﾠ33.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ72	 ﾠhours	 ﾠafter	 ﾠ
recruitment.	 ﾠ For	 ﾠ each	 ﾠ pair	 ﾠ of	 ﾠ columns	 ﾠ the	 ﾠ endogenous	 ﾠ PC	 ﾠ proportions	 ﾠ are	 ﾠ
shown	 ﾠ as	 ﾠ the	 ﾠ left-ﾭ‐hand	 ﾠ column,	 ﾠ while	 ﾠ the	 ﾠ right-ﾭ‐hand	 ﾠ column	 ﾠ is	 ﾠ the	 ﾠ PEMT	 ﾠ
derived	 ﾠD3-ﾭ‐labelled	 ﾠspecies.	 ﾠError	 ﾠbars	 ﾠrepresent	 ﾠone	 ﾠstandard	 ﾠdeviation.	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Figure	 ﾠ 34.	 ﾠ Concentrations	 ﾠ of	 ﾠ D3-ﾭ‐phosphatidylcholine	 ﾠ phospholipids	 ﾠ in	 ﾠ preterm	 ﾠ
plasma	 ﾠincrease	 ﾠwith	 ﾠtime	 ﾠfrom	 ﾠrecruitment	 ﾠto	 ﾠ72	 ﾠhours.	 ﾠThe	 ﾠerror	 ﾠbars	 ﾠshow	 ﾠ
the	 ﾠmedian	 ﾠvalues	 ﾠand	 ﾠinterquartile	 ﾠranges.	 ﾠComparison	 ﾠof	 ﾠdata	 ﾠusing	 ﾠMann-ﾭ‐
Whitney	 ﾠ non-ﾭ‐parametric	 ﾠ significance	 ﾠ testing	 ﾠ shows	 ﾠ significant	 ﾠ increase	 ﾠ
between	 ﾠtimes	 ﾠ12	 ﾠand	 ﾠ72	 ﾠhours	 ﾠ(****	 ﾠp<0.0001)	 ﾠand	 ﾠbetween	 ﾠ12	 ﾠand	 ﾠ120	 ﾠ
hours	 ﾠ(**	 ﾠp=0.0064)	 ﾠ..................................................................................................................	 ﾠ88	 ﾠ
Figure	 ﾠ35.	 ﾠAverage	 ﾠconcentrations	 ﾠof	 ﾠselected	 ﾠD3-ﾭ‐phosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠ
preterm	 ﾠplasma.	 ﾠThe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠassociated	 ﾠwith	 ﾠPUFA	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠ
adults	 ﾠ but	 ﾠ PC16:0/18:1	 ﾠ is	 ﾠ the	 ﾠ most	 ﾠ abundant	 ﾠ species	 ﾠ produced	 ﾠ by	 ﾠ this	 ﾠ
pathway	 ﾠfrom	 ﾠ48	 ﾠhours	 ﾠin	 ﾠthis	 ﾠpopulation.	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Figure	 ﾠ36.	 ﾠAverage	 ﾠconcentrations	 ﾠof	 ﾠselected	 ﾠD3-ﾭ‐phosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠ
preterm	 ﾠplasma.	 ﾠThe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠassociated	 ﾠwith	 ﾠPUFA	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠ
adults	 ﾠ but	 ﾠ PC16:0/18:1	 ﾠ is	 ﾠ the	 ﾠ most	 ﾠ abundant	 ﾠ species	 ﾠ produced	 ﾠ by	 ﾠ this	 ﾠ
pathway	 ﾠfrom	 ﾠ48	 ﾠhours	 ﾠin	 ﾠthis	 ﾠpopulation	 ﾠand	 ﾠcontinues	 ﾠto	 ﾠbe	 ﾠmost	 ﾠabundant	 ﾠ
until	 ﾠthe	 ﾠend	 ﾠof	 ﾠthe	 ﾠstudy	 ﾠat	 ﾠ240	 ﾠhours.	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Figure	 ﾠ 37.	 ﾠ Fractional	 ﾠ incorporation	 ﾠ of	 ﾠ D3-ﾭ‐phosphatidylcholine	 ﾠ phospholipids	 ﾠ in	 ﾠ
preterm	 ﾠ plasma.	 ﾠ The	 ﾠ box	 ﾠ and	 ﾠ whisker	 ﾠ plots	 ﾠ show	 ﾠ the	 ﾠ median	 ﾠ values,	 ﾠ
interquartile	 ﾠranges	 ﾠand	 ﾠoutliers.	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Figure	 ﾠ38.	 ﾠThe	 ﾠmean	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD3-ﾭ‐containing	 ﾠPC	 ﾠphospholipids	 ﾠin	 ﾠ
plasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠD3	 ﾠenrichment	 ﾠhas	 ﾠbeen	 ﾠ
expressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠmeasured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠ
point.	 ﾠThe	 ﾠerror	 ﾠbars	 ﾠrepresent	 ﾠa	 ﾠsingle	 ﾠstandard	 ﾠdeviation	 ﾠfrom	 ﾠthe	 ﾠmean.	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Figure	 ﾠ 39.	 ﾠ The	 ﾠ mean	 ﾠ fractional	 ﾠ incorporation	 ﾠ of	 ﾠ selected	 ﾠ D3-ﾭ‐containing	 ﾠ PC	 ﾠ
phospholipids	 ﾠ in	 ﾠ plasma	 ﾠ over	 ﾠ the	 ﾠ first	 ﾠ 120	 ﾠ hours	 ﾠ after	 ﾠ recruitment.	 ﾠ
Proportionally	 ﾠmore	 ﾠPUFA	 ﾠspecies	 ﾠare	 ﾠsynthesised	 ﾠby	 ﾠthe	 ﾠPEMT	 ﾠpathway.	 ﾠD3	 ﾠ
enrichment	 ﾠhas	 ﾠbeen	 ﾠexpressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠ
measured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint.	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Figure	 ﾠ 40.	 ﾠ The	 ﾠ mean	 ﾠ fractional	 ﾠ incorporation	 ﾠ of	 ﾠ selected	 ﾠ D3-ﾭ‐containing	 ﾠ PC	 ﾠ
phospholipids	 ﾠ in	 ﾠ plasma	 ﾠ over	 ﾠ the	 ﾠ first	 ﾠ 240	 ﾠ hours	 ﾠ after	 ﾠ recruitment.	 ﾠ
Proportionally	 ﾠmore	 ﾠPUFA	 ﾠspecies	 ﾠare	 ﾠsynthesised	 ﾠby	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠand	 ﾠ
this	 ﾠ is	 ﾠ maintained	 ﾠ throughout	 ﾠ the	 ﾠ study	 ﾠ period.	 ﾠ D3	 ﾠ enrichment	 ﾠ has	 ﾠ been	 ﾠ
expressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠmeasured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠ
point.	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Figure	 ﾠ41.	 ﾠEnrichment	 ﾠby	 ﾠS-ﾭ‐Adenosyl	 ﾠ[methyl-ﾭ‐D3]methionine	 ﾠin	 ﾠpreterm	 ﾠplasma	 ﾠ
showing	 ﾠmedian	 ﾠvalues	 ﾠand	 ﾠinterquartile	 ﾠrange	 ﾠplus	 ﾠoutliers	 ﾠ...............................	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Figure	 ﾠ42.	 ﾠFractional	 ﾠsynthesis	 ﾠby	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠto	 ﾠ240	 ﾠ
hours	 ﾠafter	 ﾠrecruitment	 ﾠshowing	 ﾠmedian	 ﾠvalues	 ﾠwith	 ﾠinterquartile	 ﾠrange	 ﾠand	 ﾠ
outliers.	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Figure	 ﾠ43.	 ﾠSynthetic	 ﾠrate	 ﾠof	 ﾠflux	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠto	 ﾠ
peak	 ﾠat	 ﾠ72	 ﾠhours	 ﾠafter	 ﾠinfusion	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline.	 ﾠOverall	 ﾠrate	 ﾠof	 ﾠsynthetic	 ﾠ
flux	 ﾠis	 ﾠ0.06%,	 ﾠsignificantly	 ﾠlower	 ﾠthan	 ﾠadult	 ﾠvolunteer	 ﾠvalues	 ﾠof	 ﾠ0.53%	 ﾠ(Pynn	 ﾠ
et	 ﾠal.,	 ﾠ2011)	 ﾠ....................................................................................................................................	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Figure	 ﾠ 44.	 ﾠ Synthetic	 ﾠ rate	 ﾠ of	 ﾠ flux	 ﾠ for	 ﾠ individual	 ﾠ PC	 ﾠ species	 ﾠ through	 ﾠ the	 ﾠ PEMT	 ﾠ
pathway	 ﾠ in	 ﾠ preterm	 ﾠ infants	 ﾠ up	 ﾠ to	 ﾠ 24	 ﾠ hours	 ﾠ after	 ﾠ infusion	 ﾠ of	 ﾠ [methyl-ﾭ‐
D9]choline.	 ﾠSynthetic	 ﾠflux	 ﾠvaries	 ﾠfrom	 ﾠ0.325%	 ﾠfor	 ﾠPC18:0/22:6	 ﾠto	 ﾠ0.027%	 ﾠfor	 ﾠ
the	 ﾠsurface-ﾭ‐active	 ﾠPC16:0/16:0	 ﾠ............................................................................................	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Figure	 ﾠ 45.	 ﾠ Concentration	 ﾠ of	 ﾠ choline	 ﾠ in	 ﾠ plasma	 ﾠ of	 ﾠ preterm	 ﾠ infants	 ﾠ over	 ﾠ first	 ﾠ 24	 ﾠ
hours	 ﾠ of	 ﾠ study.	 ﾠ Administration	 ﾠ of	 ﾠ [methyl-ﾭ‐D9]choline	 ﾠ chloride	 ﾠ at	 ﾠ t=0	 ﾠ  xiv	 ﾠ
produced	 ﾠa	 ﾠsmall,	 ﾠbut	 ﾠstatistically	 ﾠnot	 ﾠsignificant,	 ﾠrise	 ﾠin	 ﾠplasma	 ﾠcholine	 ﾠat	 ﾠ6	 ﾠ
hours.	 ﾠ............................................................................................................................................	 ﾠ102	 ﾠ
Figure	 ﾠ46.	 ﾠConcentration	 ﾠof	 ﾠcholine	 ﾠin	 ﾠplasma	 ﾠof	 ﾠindividual	 ﾠpreterm	 ﾠinfants	 ﾠover	 ﾠ
first	 ﾠ 24	 ﾠ hours	 ﾠ of	 ﾠ study.	 ﾠ Individual	 ﾠ babies	 ﾠ are	 ﾠ arranged	 ﾠ in	 ﾠ the	 ﾠ legend	 ﾠ by	 ﾠ
gestation	 ﾠfrom	 ﾠ23	 ﾠweeks	 ﾠ(blue)	 ﾠto	 ﾠ28	 ﾠweeks	 ﾠ(grey).	 ﾠThere	 ﾠis	 ﾠno	 ﾠmeasured	 ﾠ
correlation	 ﾠbetween	 ﾠcholine	 ﾠlevel	 ﾠand	 ﾠgestational	 ﾠage.	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Figure	 ﾠ 47.	 ﾠ Enrichment	 ﾠ of	 ﾠ D9-ﾭ‐choline	 ﾠ in	 ﾠ plasma.	 ﾠ The	 ﾠ proportion	 ﾠ of	 ﾠ choline	 ﾠ
measured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠenriched	 ﾠwith	 ﾠnine	 ﾠdeuterium	 ﾠatoms.	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Figure	 ﾠ48.	 ﾠEnrichment	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠin	 ﾠplasma	 ﾠplotted	 ﾠfor	 ﾠeach	 ﾠpatient.	 ﾠIndividual	 ﾠ
babies	 ﾠare	 ﾠarranged	 ﾠin	 ﾠthe	 ﾠlegend	 ﾠby	 ﾠgestation	 ﾠfrom	 ﾠ23	 ﾠweeks	 ﾠ(blue)	 ﾠto	 ﾠ28	 ﾠ
weeks	 ﾠ (grey).	 ﾠ There	 ﾠ is	 ﾠ no	 ﾠ measured	 ﾠ correlation	 ﾠ between	 ﾠ D9-ﾭ‐choline	 ﾠ
enrichment	 ﾠand	 ﾠgestational	 ﾠage.	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Figure	 ﾠ 49.	 ﾠ Concentration	 ﾠ of	 ﾠ betaine	 ﾠ in	 ﾠ plasma	 ﾠ of	 ﾠ preterm	 ﾠ infants	 ﾠ over	 ﾠ first	 ﾠ 24	 ﾠ
hours	 ﾠ of	 ﾠ study.	 ﾠ Administration	 ﾠ of	 ﾠ [methyl-ﾭ‐D9]choline	 ﾠ chloride	 ﾠ at	 ﾠ t=0	 ﾠ
produced	 ﾠno	 ﾠstatistically	 ﾠsignificant	 ﾠrise	 ﾠin	 ﾠplasma	 ﾠbetaine	 ﾠover	 ﾠ24	 ﾠhours.	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Figure	 ﾠ50.	 ﾠEnrichment	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠand	 ﾠD9-ﾭ‐betaine	 ﾠin	 ﾠplasma.	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Figure	 ﾠ51.	 ﾠPeak	 ﾠenrichment	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠand	 ﾠD9-ﾭ‐betaine	 ﾠat	 ﾠ6	 ﾠhours	 ﾠin	 ﾠplasma	 ﾠ
plotted	 ﾠ against	 ﾠ corresponding	 ﾠ peak	 ﾠ enrichment	 ﾠ value	 ﾠ of	 ﾠ D9-ﾭ‐
phosphatidylcholine	 ﾠat	 ﾠ12	 ﾠhours.	 ﾠThe	 ﾠtrendlines	 ﾠshow	 ﾠthat	 ﾠthere	 ﾠis	 ﾠa	 ﾠweak	 ﾠ
correlation	 ﾠbetween	 ﾠa	 ﾠlower	 ﾠpeak	 ﾠD9-ﾭ‐choline	 ﾠor	 ﾠD9-ﾭ‐betaine	 ﾠenrichment	 ﾠand	 ﾠa	 ﾠ
higher	 ﾠpeak	 ﾠD9-ﾭ‐PC	 ﾠenrichment.	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Figure	 ﾠ52.	 ﾠAn	 ﾠexample	 ﾠof	 ﾠa	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠ(P184)	 ﾠscan	 ﾠspectrum.	 ﾠ
It	 ﾠ illustrates	 ﾠ a	 ﾠ typical	 ﾠ endotracheal	 ﾠ aspirate	 ﾠ (ETA)	 ﾠ lipid	 ﾠ extract	 ﾠ scan	 ﾠ at	 ﾠ
recruitment	 ﾠ(time	 ﾠpoint	 ﾠ=	 ﾠ0)	 ﾠless	 ﾠthan	 ﾠ48	 ﾠhours	 ﾠafter	 ﾠpreterm	 ﾠbirth.	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Figure	 ﾠ 53.	 ﾠ Relative	 ﾠ proportions	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ species	 ﾠ measured	 ﾠ in	 ﾠ
baseline	 ﾠ (t=0)	 ﾠ endotracheal	 ﾠ aspirate	 ﾠ samples.	 ﾠ PC16:0/16:0	 ﾠ constitutes	 ﾠ the	 ﾠ
largest	 ﾠ percentage	 ﾠ of	 ﾠ PC	 ﾠ species	 ﾠ measured.	 ﾠ Error	 ﾠ bar	 ﾠ demonstrates	 ﾠ one	 ﾠ
standard	 ﾠdeviation.	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Figure	 ﾠ54.	 ﾠComparison	 ﾠof	 ﾠP+184	 ﾠscans	 ﾠfrom	 ﾠETA	 ﾠand	 ﾠCurosurf®	 ﾠshowing	 ﾠsimilar	 ﾠ
species	 ﾠand	 ﾠproportions	 ﾠof	 ﾠpeaks.	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Figure	 ﾠ 55.	 ﾠ Relative	 ﾠ proportions	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ species	 ﾠ measured	 ﾠ in	 ﾠ
baseline	 ﾠ(t=0)	 ﾠendotracheal	 ﾠaspirate	 ﾠsamples	 ﾠ(left)	 ﾠcompared	 ﾠwith	 ﾠmeasured	 ﾠ
proportions	 ﾠ of	 ﾠ PC	 ﾠ species	 ﾠ in	 ﾠ Curosurf®	 ﾠ (right).	 ﾠ The	 ﾠ proportions	 ﾠ are	 ﾠ very	 ﾠ
similar	 ﾠwith	 ﾠPC16:0/16:0	 ﾠconstituting	 ﾠthe	 ﾠlargest	 ﾠpercentage	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠ  xv	 ﾠ
measured	 ﾠ in	 ﾠ both	 ﾠ sample	 ﾠ types.	 ﾠ Error	 ﾠ bars	 ﾠ demonstrate	 ﾠ one	 ﾠ standard	 ﾠ
deviation	 ﾠfor	 ﾠthe	 ﾠETA	 ﾠsamples.	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Figure	 ﾠ56.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠETA	 ﾠmeasured	 ﾠat	 ﾠ
each	 ﾠtime	 ﾠpoint	 ﾠto	 ﾠ240	 ﾠhours.	 ﾠThe	 ﾠproportions	 ﾠof	 ﾠmajor	 ﾠPC	 ﾠspecies	 ﾠremain	 ﾠ
steady	 ﾠ throughout	 ﾠ the	 ﾠ study	 ﾠ period.	 ﾠ Error	 ﾠ bars	 ﾠ demonstrate	 ﾠ one	 ﾠ standard	 ﾠ
deviation	 ﾠfor	 ﾠthe	 ﾠtwo	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠshown.	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Figure	 ﾠ 57.	 ﾠ Log	 ﾠ transformation	 ﾠ graph	 ﾠ showing	 ﾠ relative	 ﾠ proportions	 ﾠ of	 ﾠ
phosphatidylcholine	 ﾠspecies	 ﾠmeasured	 ﾠin	 ﾠETA	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠto	 ﾠ240	 ﾠhours.	 ﾠ
The	 ﾠ proportions	 ﾠ of	 ﾠ major	 ﾠ PC	 ﾠ species	 ﾠ remain	 ﾠ steady	 ﾠ throughout	 ﾠ the	 ﾠ study	 ﾠ
period	 ﾠ but	 ﾠ PC18:1/18:2	 ﾠ rises	 ﾠ proportionally	 ﾠ from	 ﾠ 120	 ﾠ hours	 ﾠ while	 ﾠ
PC16:0/14:0	 ﾠfalls	 ﾠin	 ﾠthe	 ﾠsame	 ﾠperiod.	 ﾠError	 ﾠbars	 ﾠdemonstrate	 ﾠone	 ﾠstandard	 ﾠ
deviation	 ﾠfor	 ﾠthe	 ﾠtwo	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠshown.	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Figure	 ﾠ 58.	 ﾠ Concentration	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ measured	 ﾠ in	 ﾠ endotracheal	 ﾠ
aspirates	 ﾠ over	 ﾠ the	 ﾠ 120	 ﾠ hours	 ﾠ of	 ﾠ study.	 ﾠ There	 ﾠ is	 ﾠ no	 ﾠ significant	 ﾠ difference	 ﾠ
between	 ﾠmeasurements.	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Figure	 ﾠ 59.	 ﾠ Concentration	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ measured	 ﾠ in	 ﾠ endotracheal	 ﾠ
aspirates	 ﾠ over	 ﾠ the	 ﾠ 240	 ﾠ hours	 ﾠ of	 ﾠ study.	 ﾠ There	 ﾠ is	 ﾠ no	 ﾠ significant	 ﾠ difference	 ﾠ
between	 ﾠmeasurements.	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Figure	 ﾠ 60.	 ﾠ Concentration	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ measured	 ﾠ in	 ﾠ endotracheal	 ﾠ
aspirates	 ﾠ over	 ﾠ the	 ﾠ 240	 ﾠ hours	 ﾠ of	 ﾠ study	 ﾠ for	 ﾠ the	 ﾠ 10	 ﾠ children	 ﾠ who	 ﾠ remained	 ﾠ
intubated	 ﾠand	 ﾠventilated	 ﾠat	 ﾠ120	 ﾠhours	 ﾠand	 ﾠreceived	 ﾠa	 ﾠsecond	 ﾠdose	 ﾠof	 ﾠ[methyl-ﾭ‐
D9]choline.	 ﾠThere	 ﾠis	 ﾠno	 ﾠsignificant	 ﾠdifference	 ﾠbetween	 ﾠmeasurements	 ﾠin	 ﾠthis	 ﾠ
subgroup.	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Figure	 ﾠ 61.	 ﾠ Average	 ﾠ concentration	 ﾠ of	 ﾠ individual	 ﾠ PC	 ﾠ species	 ﾠ from	 ﾠ preterm	 ﾠ
endotracheal	 ﾠaspirates	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	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Figure	 ﾠ62.	 ﾠAverage	 ﾠconcentration	 ﾠof	 ﾠPC	 ﾠfrom	 ﾠpreterm	 ﾠendotracheal	 ﾠaspirates	 ﾠup	 ﾠto	 ﾠ
24	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠand	 ﾠcorrected	 ﾠfor	 ﾠtime	 ﾠfrom	 ﾠbirth.	 ﾠNeither	 ﾠthe	 ﾠtime	 ﾠ
from	 ﾠ birth	 ﾠ of	 ﾠ sample	 ﾠ collection	 ﾠ nor	 ﾠ gestation	 ﾠ affect	 ﾠ concentration	 ﾠ of	 ﾠ PC	 ﾠ
collected	 ﾠfrom	 ﾠETA.	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Figure	 ﾠ63.	 ﾠComparison	 ﾠof	 ﾠP+184	 ﾠand	 ﾠP+193	 ﾠscans	 ﾠfrom	 ﾠan	 ﾠETA	 ﾠsample	 ﾠ(at	 ﾠtime	 ﾠ72	 ﾠ
hours)	 ﾠshowing	 ﾠincorporation	 ﾠof	 ﾠdeuterated	 ﾠcholine	 ﾠas	 ﾠthe	 ﾠdisplacement	 ﾠof	 ﾠ
nine	 ﾠmass	 ﾠunits	 ﾠon	 ﾠthe	 ﾠP+193	 ﾠscan.	 ﾠ.................................................................................	 ﾠ128	 ﾠ  xvi	 ﾠ
Figure	 ﾠ 64.	 ﾠ Concentration	 ﾠ of	 ﾠ D9-ﾭ‐PC	 ﾠ phospholipids	 ﾠ from	 ﾠ preterm	 ﾠ endotracheal	 ﾠ
aspirates	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠThe	 ﾠrise	 ﾠin	 ﾠconcentration	 ﾠbecomes	 ﾠ
statistically	 ﾠsignificant	 ﾠabove	 ﾠbackground	 ﾠlevels	 ﾠat	 ﾠ48	 ﾠhours.	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Figure	 ﾠ 65.	 ﾠ Concentration	 ﾠ of	 ﾠ D9-ﾭ‐PC	 ﾠ phospholipids	 ﾠ from	 ﾠ preterm	 ﾠ endotracheal	 ﾠ
aspirates	 ﾠto	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠA	 ﾠstatistically	 ﾠsignificant	 ﾠrise	 ﾠfrom	 ﾠ
baseline	 ﾠoccurs	 ﾠto	 ﾠ120	 ﾠhours	 ﾠbut	 ﾠvariation	 ﾠin	 ﾠconcentration	 ﾠafter	 ﾠ120	 ﾠhours	 ﾠis	 ﾠ
not	 ﾠstatistically	 ﾠsignificant.	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Figure	 ﾠ 66.	 ﾠ Concentration	 ﾠ of	 ﾠ D9-ﾭ‐PC	 ﾠ phospholipids	 ﾠ from	 ﾠ preterm	 ﾠ endotracheal	 ﾠ
aspirates	 ﾠto	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠin	 ﾠthe	 ﾠ10	 ﾠchildren	 ﾠwho	 ﾠreceived	 ﾠa	 ﾠ
second	 ﾠ dose	 ﾠ of	 ﾠ choline	 ﾠ at	 ﾠ 120	 ﾠ hours.	 ﾠ A	 ﾠ statistically	 ﾠ significant	 ﾠ rise	 ﾠ from	 ﾠ
baseline	 ﾠoccurs	 ﾠto	 ﾠ120	 ﾠhours	 ﾠbut	 ﾠvariation	 ﾠin	 ﾠconcentration	 ﾠafter	 ﾠ120	 ﾠhours	 ﾠis	 ﾠ
not	 ﾠstatistically	 ﾠsignificant.	 ﾠ..................................................................................................	 ﾠ131	 ﾠ
Figure	 ﾠ67.	 ﾠAverage	 ﾠconcentration	 ﾠof	 ﾠindividual	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠpreterm	 ﾠ
endotracheal	 ﾠaspirates	 ﾠto	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠSignificant	 ﾠdifferences	 ﾠ
between	 ﾠnewly	 ﾠsynthesised	 ﾠspecies	 ﾠdemonstrated	 ﾠfrom	 ﾠ24	 ﾠto	 ﾠ48	 ﾠhours	 ﾠwith	 ﾠ
concentration	 ﾠof	 ﾠD9PC16:0/16:0	 ﾠrising	 ﾠmost	 ﾠrapidly.	 ﾠThe	 ﾠfall	 ﾠin	 ﾠconcentration	 ﾠ
after	 ﾠ 120	 ﾠ hours	 ﾠ is	 ﾠ not	 ﾠ statistically	 ﾠ significant	 ﾠ and	 ﾠ reflects	 ﾠ smaller	 ﾠ patient	 ﾠ
numbers.	 ﾠImportantly	 ﾠthe	 ﾠrelative	 ﾠabundance	 ﾠof	 ﾠspecies	 ﾠdoes	 ﾠnot	 ﾠchange	 ﾠafter	 ﾠ
120	 ﾠhours.	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Figure	 ﾠ68.	 ﾠAverage	 ﾠconcentration	 ﾠof	 ﾠindividual	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠpreterm	 ﾠ
endotracheal	 ﾠaspirates	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠLog	 ﾠtransformation	 ﾠof	 ﾠ
y-ﾭ‐axis	 ﾠto	 ﾠallow	 ﾠcomparison	 ﾠof	 ﾠspecies	 ﾠback	 ﾠto	 ﾠ6	 ﾠhours.	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Figure	 ﾠ69.	 ﾠAverage	 ﾠenrichment	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠpreterm	 ﾠendotracheal	 ﾠ
aspirates	 ﾠto	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	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Figure	 ﾠ 70.	 ﾠ Relative	 ﾠ proportions	 ﾠ of	 ﾠ selected	 ﾠ PC	 ﾠ species	 ﾠ at	 ﾠ 12	 ﾠ hours	 ﾠ after	 ﾠ
recruitment.	 ﾠColumns	 ﾠon	 ﾠthe	 ﾠleft	 ﾠare	 ﾠendogenous	 ﾠ(non-ﾭ‐labelled)	 ﾠand	 ﾠcolumns	 ﾠ
on	 ﾠthe	 ﾠright	 ﾠare	 ﾠthe	 ﾠnewly-ﾭ‐synthesised	 ﾠ(D9-ﾭ‐labelled)	 ﾠPC	 ﾠspecies.	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Figure	 ﾠ 71.	 ﾠ Relative	 ﾠ proportions	 ﾠ of	 ﾠ selected	 ﾠ PC	 ﾠ species	 ﾠ at	 ﾠ 48	 ﾠ hours	 ﾠ after	 ﾠ
recruitment.	 ﾠColumns	 ﾠon	 ﾠthe	 ﾠleft	 ﾠare	 ﾠendogenous	 ﾠ(non-ﾭ‐labelled)	 ﾠand	 ﾠcolumns	 ﾠ
on	 ﾠthe	 ﾠright	 ﾠare	 ﾠthe	 ﾠnewly-ﾭ‐synthesised	 ﾠ(D9-ﾭ‐labelled)	 ﾠPC	 ﾠspecies.	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Figure	 ﾠ 72.	 ﾠ Relative	 ﾠ proportions	 ﾠ of	 ﾠ selected	 ﾠ PC	 ﾠ species	 ﾠ at	 ﾠ 120	 ﾠ hours	 ﾠ after	 ﾠ
recruitment.	 ﾠColumns	 ﾠon	 ﾠthe	 ﾠleft	 ﾠare	 ﾠendogenous	 ﾠ(non-ﾭ‐labelled)	 ﾠand	 ﾠcolumns	 ﾠ
on	 ﾠthe	 ﾠright	 ﾠare	 ﾠthe	 ﾠnewly-ﾭ‐synthesised	 ﾠ(D9-ﾭ‐labelled)	 ﾠPC	 ﾠspecies.	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Figure	 ﾠ73.	 ﾠFractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐label	 ﾠinto	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠover	 ﾠ240	 ﾠ
hours	 ﾠafter	 ﾠrecruitment	 ﾠto	 ﾠstudy.	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Figure	 ﾠ74.	 ﾠFractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐label	 ﾠinto	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠover	 ﾠthe	 ﾠ
first	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠto	 ﾠstudy.	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Figure	 ﾠ75.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠnewly	 ﾠsynthesised	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠendotracheal	 ﾠ
aspirates	 ﾠfrom	 ﾠpreterm	 ﾠinfants	 ﾠover	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠto	 ﾠthe	 ﾠstudy.
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Figure	 ﾠ 76.	 ﾠ A	 ﾠ mass	 ﾠ spectrum	 ﾠ negative	 ﾠ ionisation	 ﾠ scan	 ﾠ (MS-ﾭ‐)	 ﾠ of	 ﾠ Curosurf®	 ﾠ
illustrating	 ﾠ the	 ﾠ major	 ﾠ acidic	 ﾠ phospholipid	 ﾠ species.	 ﾠ 	 ﾠ Three	 ﾠ major	 ﾠ
phosphatidylglycerol	 ﾠ(PG)	 ﾠspecies	 ﾠand	 ﾠthree	 ﾠmajor	 ﾠphosphatidylinositol	 ﾠ(PI)	 ﾠ
species	 ﾠare	 ﾠlabelled.	 ﾠ	 ﾠOf	 ﾠthe	 ﾠacidic	 ﾠphospholipids,	 ﾠPG	 ﾠspecies	 ﾠare	 ﾠpredominant	 ﾠ
in	 ﾠCurosurf®	 ﾠpreparations.	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Figure	 ﾠ 77.	 ﾠ Relative	 ﾠ proportions	 ﾠ of	 ﾠ phosphatidylglycerol	 ﾠ species	 ﾠ and	 ﾠ
phosphatidylinositol	 ﾠspecies	 ﾠchange	 ﾠfrom	 ﾠa	 ﾠmature	 ﾠto	 ﾠan	 ﾠimmature	 ﾠratio	 ﾠwith	 ﾠ
time	 ﾠfrom	 ﾠadministration	 ﾠof	 ﾠCurosurf®.	 ﾠThis	 ﾠprovides	 ﾠvery	 ﾠearly	 ﾠevidence	 ﾠof	 ﾠ
active	 ﾠ metabolism	 ﾠ of	 ﾠ Curosurf®	 ﾠ from	 ﾠ the	 ﾠ ET	 ﾠ aspirates	 ﾠ of	 ﾠ preterm	 ﾠ infants	 ﾠ
despite	 ﾠrelatively	 ﾠslow	 ﾠphosphatidylcholine	 ﾠmetabolism.	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Chapter	 ﾠ1.	 ﾠIntroduction	 ﾠ
1.1	 ﾠOverview	 ﾠ
There	 ﾠ are	 ﾠ many	 ﾠ reasons	 ﾠ why	 ﾠ a	 ﾠ newborn	 ﾠ infant	 ﾠ may	 ﾠ need	 ﾠ to	 ﾠ be	 ﾠ treated	 ﾠ in	 ﾠ a	 ﾠ
neonatal	 ﾠintensive	 ﾠcare	 ﾠunit	 ﾠ(NICU)	 ﾠbut	 ﾠone	 ﾠof	 ﾠthe	 ﾠmore	 ﾠfrequently	 ﾠencountered	 ﾠ
and	 ﾠcomplex	 ﾠis	 ﾠprematurity.	 ﾠThe	 ﾠlast	 ﾠ20	 ﾠyears	 ﾠhave	 ﾠseen	 ﾠsignificant	 ﾠimprovements	 ﾠ
in	 ﾠthe	 ﾠcare	 ﾠof	 ﾠthe	 ﾠpremature	 ﾠinfant,	 ﾠwith	 ﾠsurvival	 ﾠat	 ﾠ28	 ﾠweeks	 ﾠgestation	 ﾠnow	 ﾠseen	 ﾠ
as	 ﾠ almost	 ﾠ routine.	 ﾠ However,	 ﾠ while	 ﾠ children	 ﾠ born	 ﾠ at	 ﾠ the	 ﾠ limits	 ﾠ of	 ﾠ viability	 ﾠ have	 ﾠ
improved	 ﾠsurvival	 ﾠchances	 ﾠthey	 ﾠare	 ﾠstill	 ﾠat	 ﾠsignificant	 ﾠrisk	 ﾠof	 ﾠdeveloping	 ﾠlong-ﾭ‐term	 ﾠ
problems	 ﾠdirectly	 ﾠas	 ﾠa	 ﾠresult	 ﾠof	 ﾠbeing	 ﾠborn	 ﾠprematurely	 ﾠ(Costeloe	 ﾠet	 ﾠal.,	 ﾠ2012).	 ﾠ
Survival	 ﾠof	 ﾠbabies	 ﾠborn	 ﾠat	 ﾠless	 ﾠthan	 ﾠ23	 ﾠweeks	 ﾠgestation	 ﾠis	 ﾠvery	 ﾠrarely	 ﾠseen	 ﾠand	 ﾠthen	 ﾠ
long	 ﾠterm	 ﾠsevere	 ﾠneurodevelopmental	 ﾠdisability	 ﾠis	 ﾠnear	 ﾠuniversal.	 ﾠBabies	 ﾠdelivered	 ﾠ
at	 ﾠ23	 ﾠweeks	 ﾠstill	 ﾠhave	 ﾠseverely	 ﾠlimited	 ﾠchances	 ﾠof	 ﾠsurvival	 ﾠand	 ﾠmost	 ﾠhave	 ﾠsevere	 ﾠ
respiratory	 ﾠand	 ﾠneurodevelopmental	 ﾠproblems	 ﾠat	 ﾠdischarge	 ﾠhome	 ﾠ(Costeloe	 ﾠet	 ﾠal.,	 ﾠ
2012).	 ﾠThe	 ﾠchances	 ﾠof	 ﾠsurvival	 ﾠincrease	 ﾠfrom	 ﾠ24	 ﾠweeks	 ﾠuntil	 ﾠabout	 ﾠ30-ﾭ‐32	 ﾠweeks	 ﾠ
gestation	 ﾠwhen	 ﾠmost	 ﾠbabies	 ﾠare	 ﾠexpected	 ﾠto	 ﾠsurvive	 ﾠwith	 ﾠfew	 ﾠlong-ﾭ‐term	 ﾠproblems.	 ﾠ
A	 ﾠdeterminant	 ﾠfor	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠlong-ﾭ‐term	 ﾠproblems	 ﾠin	 ﾠpreterm	 ﾠsurvivors	 ﾠis	 ﾠ
their	 ﾠ clinical	 ﾠ course	 ﾠ in	 ﾠ the	 ﾠ first	 ﾠ hours	 ﾠ and	 ﾠ days	 ﾠ of	 ﾠ life.	 ﾠ The	 ﾠ introduction	 ﾠ of	 ﾠ
exogenous	 ﾠ surfactant	 ﾠ has	 ﾠ dramatically	 ﾠ reduced	 ﾠ the	 ﾠ severity	 ﾠ of	 ﾠ the	 ﾠ initial	 ﾠ
respiratory	 ﾠ distress	 ﾠ symptoms	 ﾠ experienced	 ﾠ by	 ﾠ preterm	 ﾠ newborn	 ﾠ children	 ﾠ
(Schwartz	 ﾠet	 ﾠal.,	 ﾠ1994)	 ﾠand	 ﾠnow	 ﾠit	 ﾠis	 ﾠroutinely	 ﾠused	 ﾠas	 ﾠprophylaxis	 ﾠin	 ﾠany	 ﾠbaby	 ﾠ
born	 ﾠin	 ﾠthe	 ﾠUK	 ﾠat	 ﾠless	 ﾠthan	 ﾠ29	 ﾠweeks	 ﾠgestation.	 ﾠHowever,	 ﾠlittle	 ﾠis	 ﾠknown	 ﾠabout	 ﾠhow	 ﾠ
this	 ﾠ exogenous	 ﾠ surfactant	 ﾠ affects	 ﾠ the	 ﾠ infants	 ﾠ own	 ﾠ surfactant	 ﾠ production	 ﾠ and	 ﾠ
metabolism	 ﾠin	 ﾠthe	 ﾠclinical	 ﾠsetting.	 ﾠ  2	 ﾠ
Another	 ﾠpotential	 ﾠarea	 ﾠfor	 ﾠintervention	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠdays	 ﾠof	 ﾠpreterm	 ﾠlife	 ﾠhas	 ﾠsought	 ﾠ
an	 ﾠimprovement	 ﾠin	 ﾠthe	 ﾠnutrition	 ﾠfor	 ﾠpreterm	 ﾠinfants.	 ﾠRecent	 ﾠstudies	 ﾠin	 ﾠthe	 ﾠUK	 ﾠand	 ﾠ
abroad	 ﾠ have	 ﾠ shown	 ﾠ that,	 ﾠ even	 ﾠ with	 ﾠ well-ﾭ‐recognised	 ﾠ recommendations	 ﾠ for	 ﾠ
nutritional	 ﾠ intake,	 ﾠ many	 ﾠ preterm	 ﾠ infants	 ﾠ show	 ﾠ severe	 ﾠ growth	 ﾠ restriction	 ﾠ and	 ﾠ
stunting	 ﾠby	 ﾠthe	 ﾠtime	 ﾠof	 ﾠdischarge	 ﾠfrom	 ﾠthe	 ﾠNICU	 ﾠ(Wood	 ﾠet	 ﾠal.,	 ﾠ2003,	 ﾠCosteloe	 ﾠet	 ﾠal.,	 ﾠ
2000).	 ﾠAs	 ﾠthese	 ﾠchildren	 ﾠfail	 ﾠto	 ﾠmeet	 ﾠtheir	 ﾠmacronutrient	 ﾠtargets	 ﾠit	 ﾠis	 ﾠlikely	 ﾠthat	 ﾠ
they	 ﾠalso	 ﾠfail	 ﾠto	 ﾠmeet	 ﾠminimum	 ﾠmicronutrient	 ﾠrecommendations.	 ﾠ
Of	 ﾠparticular	 ﾠinterest	 ﾠin	 ﾠSouthampton	 ﾠis	 ﾠthe	 ﾠrole	 ﾠof	 ﾠphospholipid	 ﾠmetabolism	 ﾠin	 ﾠ
health	 ﾠand	 ﾠdisease	 ﾠ(Todd	 ﾠet	 ﾠal.,	 ﾠ2009,	 ﾠBurdge	 ﾠet	 ﾠal.,	 ﾠ1994,	 ﾠAshton	 ﾠet	 ﾠal.,	 ﾠ1992).	 ﾠ
Much	 ﾠ work	 ﾠ has	 ﾠ looked	 ﾠ at	 ﾠ the	 ﾠ metabolism	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ (PC)	 ﾠ
phospholipids	 ﾠin	 ﾠboth	 ﾠhuman	 ﾠand	 ﾠanimal	 ﾠstudies.	 ﾠPC	 ﾠis	 ﾠa	 ﾠfundamentally	 ﾠimportant	 ﾠ
phospholipid	 ﾠ building	 ﾠ block	 ﾠ for	 ﾠ lipid	 ﾠ membranes,	 ﾠ both	 ﾠ in	 ﾠ cell	 ﾠ membranes	 ﾠ and	 ﾠ
monolayers.	 ﾠ The	 ﾠ disaturated	 ﾠ dipalmitoylphosphatidylcholine	 ﾠ (DPPC)	 ﾠ is	 ﾠ the	 ﾠ
predominant	 ﾠsurface-ﾭ‐active	 ﾠphospholipid	 ﾠin	 ﾠlung	 ﾠsurfactant	 ﾠ–	 ﾠthe	 ﾠcomplex	 ﾠsurface	 ﾠ
tension	 ﾠlowering	 ﾠsubstance	 ﾠthat	 ﾠis	 ﾠknown	 ﾠto	 ﾠbe	 ﾠdeficient	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠlung	 ﾠ
(Clements,	 ﾠ1997).	 ﾠThe	 ﾠbuilding	 ﾠblocks	 ﾠfor	 ﾠPC	 ﾠare	 ﾠderived	 ﾠfrom	 ﾠnutritional	 ﾠsources,	 ﾠ
namely	 ﾠcholine	 ﾠand	 ﾠfatty	 ﾠacid	 ﾠintake.	 ﾠCholine	 ﾠis	 ﾠan	 ﾠessential	 ﾠnutrient	 ﾠ(Zeisel	 ﾠand	 ﾠda	 ﾠ
Costa,	 ﾠ2009)	 ﾠand	 ﾠwhile	 ﾠpreterm	 ﾠinfants	 ﾠwill	 ﾠreceive	 ﾠsome	 ﾠduring	 ﾠtheir	 ﾠstay	 ﾠin	 ﾠNICU	 ﾠ
their	 ﾠ nutritional	 ﾠ requirement	 ﾠ has	 ﾠ not	 ﾠ been	 ﾠ firmly	 ﾠ established.	 ﾠ Choline	 ﾠ is	 ﾠ
metabolised	 ﾠby	 ﾠtwo	 ﾠdistinct	 ﾠpathways	 ﾠto	 ﾠproduce	 ﾠPC.	 ﾠThe	 ﾠfirst	 ﾠpathway,	 ﾠknown	 ﾠas	 ﾠ
the	 ﾠCDP-ﾭ‐choline	 ﾠpathway,	 ﾠis	 ﾠin	 ﾠmost	 ﾠcells	 ﾠin	 ﾠthe	 ﾠbody,	 ﾠincluding	 ﾠthe	 ﾠlungs	 ﾠ(Vance	 ﾠ
and	 ﾠVance,	 ﾠ1985),	 ﾠso	 ﾠif	 ﾠit	 ﾠwere	 ﾠpossible	 ﾠto	 ﾠmeasure	 ﾠPC	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠlung	 ﾠit	 ﾠ
would	 ﾠbe	 ﾠpossible	 ﾠto	 ﾠdescribe	 ﾠits	 ﾠmetabolism,	 ﾠnot	 ﾠonly	 ﾠin	 ﾠterms	 ﾠof	 ﾠthe	 ﾠexogenous	 ﾠ
surfactant	 ﾠthat	 ﾠall	 ﾠof	 ﾠthese	 ﾠbabies	 ﾠreceive,	 ﾠbut	 ﾠalso	 ﾠin	 ﾠterms	 ﾠof	 ﾠa	 ﾠbaby’s	 ﾠability	 ﾠto	 ﾠ
synthesise	 ﾠnew	 ﾠPC	 ﾠmolecules	 ﾠthereby	 ﾠacting	 ﾠa	 ﾠmarker	 ﾠfor	 ﾠlung	 ﾠmaturity.	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The	 ﾠsecond	 ﾠpathway,	 ﾠknown	 ﾠas	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠspecific	 ﾠto	 ﾠhepatocytes	 ﾠand	 ﾠ
acts	 ﾠ through	 ﾠ methyl	 ﾠ transfer	 ﾠ to	 ﾠ produce	 ﾠ PC	 ﾠ from	 ﾠ another	 ﾠ phospholipid,	 ﾠ
phosphatidylethanolamine	 ﾠ(PE)	 ﾠ(Vance	 ﾠet	 ﾠal.,	 ﾠ1997).	 ﾠInvestigation	 ﾠand	 ﾠmonitoring	 ﾠ
of	 ﾠ this	 ﾠ system	 ﾠ would	 ﾠ provide	 ﾠ further	 ﾠ information	 ﾠ on	 ﾠ how	 ﾠ these	 ﾠ babies	 ﾠ handle	 ﾠ
choline	 ﾠfrom	 ﾠnutritional	 ﾠsources	 ﾠand	 ﾠmay	 ﾠprovide	 ﾠinformation	 ﾠon	 ﾠhow	 ﾠthe	 ﾠmethyl	 ﾠ
transfer	 ﾠsystem	 ﾠin	 ﾠgeneral	 ﾠis	 ﾠworking.	 ﾠMethylation	 ﾠis	 ﾠan	 ﾠessential	 ﾠcomponent	 ﾠof	 ﾠ
epigenetic	 ﾠ gene	 ﾠ expression	 ﾠ and	 ﾠ it’s	 ﾠ function	 ﾠ in	 ﾠ early	 ﾠ life	 ﾠ and	 ﾠ development	 ﾠ is	 ﾠ
theorised	 ﾠ to	 ﾠ impact	 ﾠ directly	 ﾠ on	 ﾠ future	 ﾠ health	 ﾠ (Menon	 ﾠ et	 ﾠ al.,	 ﾠ 2012,	 ﾠ Barnes	 ﾠ and	 ﾠ
Ozanne,	 ﾠ2011,	 ﾠThornburg	 ﾠet	 ﾠal.,	 ﾠ2010,	 ﾠBurdge	 ﾠand	 ﾠLillycrop,	 ﾠ2010,	 ﾠMathers	 ﾠand	 ﾠ
McKay,	 ﾠ2009).	 ﾠ
In	 ﾠsummary,	 ﾠa	 ﾠbetter	 ﾠunderstanding	 ﾠof	 ﾠcholine	 ﾠmetabolism	 ﾠin	 ﾠthese	 ﾠvulnerable	 ﾠand	 ﾠ
under	 ﾠresearched	 ﾠinfants	 ﾠwill	 ﾠprovide	 ﾠimportant	 ﾠinsights	 ﾠto	 ﾠboth	 ﾠnutritional	 ﾠand	 ﾠ
respiratory	 ﾠmetabolic	 ﾠfunction	 ﾠand	 ﾠmay	 ﾠoffer	 ﾠbiomarkers	 ﾠfor	 ﾠfuture	 ﾠdisease	 ﾠand	 ﾠ
inform	 ﾠ future	 ﾠ monitoring	 ﾠ of	 ﾠ disease	 ﾠ progression	 ﾠ in	 ﾠ a	 ﾠ clinical	 ﾠ setting.	 ﾠ A	 ﾠ better	 ﾠ
understanding	 ﾠ of	 ﾠ surfactant	 ﾠ turnover	 ﾠ and	 ﾠ of	 ﾠ nutritional	 ﾠ metabolism	 ﾠ can	 ﾠ be	 ﾠ
obtained	 ﾠthrough	 ﾠthe	 ﾠinvestigation	 ﾠof	 ﾠcholine	 ﾠmetabolism,	 ﾠwhich	 ﾠin	 ﾠturn	 ﾠcan	 ﾠlead	 ﾠ
to	 ﾠimproved	 ﾠtreatment	 ﾠfor	 ﾠindividual	 ﾠinfants	 ﾠon	 ﾠthe	 ﾠNICU	 ﾠand	 ﾠultimately	 ﾠbetter	 ﾠ
outcomes	 ﾠin	 ﾠthe	 ﾠshort	 ﾠand	 ﾠlong	 ﾠterm.	 ﾠ
To	 ﾠclarify	 ﾠthe	 ﾠsubsequent	 ﾠsteps	 ﾠtaken	 ﾠin	 ﾠthis	 ﾠresearch	 ﾠproject	 ﾠit	 ﾠis	 ﾠnecessary	 ﾠto	 ﾠ
review	 ﾠthe	 ﾠbackground	 ﾠto	 ﾠthe	 ﾠinvestigation	 ﾠof	 ﾠsurfactant	 ﾠin	 ﾠthis	 ﾠage	 ﾠgroup	 ﾠand	 ﾠto	 ﾠ
establish	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠnormal	 ﾠin	 ﾠutero	 ﾠnutrition.	 ﾠ
1.2	 ﾠHistory	 ﾠof	 ﾠpulmonary	 ﾠsurfactant	 ﾠresearch	 ﾠ
	 ﾠ“Surfactant”	 ﾠis	 ﾠa	 ﾠcontraction	 ﾠof	 ﾠsurface-ﾭ‐active	 ﾠagent	 ﾠand,	 ﾠgenerically,	 ﾠsurfactants	 ﾠ
are	 ﾠdefined	 ﾠas	 ﾠsubstances	 ﾠthat	 ﾠspread	 ﾠover	 ﾠthe	 ﾠsurface	 ﾠof	 ﾠa	 ﾠliquid	 ﾠand,	 ﾠby	 ﾠadsorbing	 ﾠ
at	 ﾠthe	 ﾠliquid-ﾭ‐gas	 ﾠinterface,	 ﾠlower	 ﾠthe	 ﾠsurface	 ﾠtension.	 ﾠ  4	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The	 ﾠalveolar-ﾭ‐capillary	 ﾠunit	 ﾠis	 ﾠthe	 ﾠsite	 ﾠof	 ﾠgas	 ﾠexchange	 ﾠin	 ﾠthe	 ﾠlung	 ﾠand	 ﾠto	 ﾠreduce	 ﾠ
surface	 ﾠ tension	 ﾠ in	 ﾠ the	 ﾠ alveolus	 ﾠ and	 ﾠ small	 ﾠ airways	 ﾠ the	 ﾠ mature	 ﾠ mammalian	 ﾠ lung	 ﾠ
produces	 ﾠpulmonary	 ﾠsurfactant,	 ﾠa	 ﾠlipoprotein	 ﾠcomplex	 ﾠformed	 ﾠby	 ﾠthe	 ﾠpulmonary	 ﾠ
alveolar	 ﾠ type	 ﾠ II	 ﾠ (AT-ﾭ‐II)	 ﾠ cells.	 ﾠ In	 ﾠ human	 ﾠ embryological	 ﾠ development,	 ﾠ full	 ﾠ term	 ﾠ
gestation	 ﾠis	 ﾠ40	 ﾠweeks	 ﾠwith	 ﾠinitial	 ﾠproduction	 ﾠof	 ﾠpulmonary	 ﾠsurfactant	 ﾠoccurring	 ﾠ
between	 ﾠ 24	 ﾠ and	 ﾠ 34	 ﾠ weeks	 ﾠ gestation.	 ﾠ When	 ﾠ combined	 ﾠ with	 ﾠ immature	 ﾠ lung	 ﾠ
microanatomy,	 ﾠ absence	 ﾠ of	 ﾠ this	 ﾠ complex	 ﾠ surface-ﾭ‐active	 ﾠ compound	 ﾠ means	 ﾠ that	 ﾠ
babies	 ﾠ born	 ﾠ before	 ﾠ 24	 ﾠ weeks	 ﾠ rarely	 ﾠ survive	 ﾠ (Costeloe	 ﾠ et	 ﾠ al.,	 ﾠ 2012,	 ﾠ Allen	 ﾠ et	 ﾠ al.,	 ﾠ
1993).	 ﾠ In	 ﾠ the	 ﾠ last	 ﾠ two	 ﾠ decades	 ﾠ major	 ﾠ advances	 ﾠ in	 ﾠ the	 ﾠ provision	 ﾠ of	 ﾠ improved	 ﾠ
neonatal	 ﾠintensive	 ﾠcare,	 ﾠincluding	 ﾠthe	 ﾠreplacement	 ﾠof	 ﾠpulmonary	 ﾠsurfactant	 ﾠwith	 ﾠ
exogenous	 ﾠ material	 ﾠ (Merenstein	 ﾠ et	 ﾠ al.,	 ﾠ 1991),	 ﾠ have	 ﾠ resulted	 ﾠ in	 ﾠ a	 ﾠ marked	 ﾠ
improvement	 ﾠin	 ﾠthe	 ﾠoutcome	 ﾠand	 ﾠsurvival	 ﾠof	 ﾠthe	 ﾠextreme	 ﾠpreterm	 ﾠinfants	 ﾠborn	 ﾠ
between	 ﾠ24	 ﾠand	 ﾠ28	 ﾠweeks	 ﾠgestation	 ﾠ(Goldenberg	 ﾠet	 ﾠal.,	 ﾠ2006).	 ﾠ
	 ﾠ
The	 ﾠtheory	 ﾠof	 ﾠsurface	 ﾠforces	 ﾠhad	 ﾠbeen	 ﾠelaborated	 ﾠat	 ﾠthe	 ﾠend	 ﾠof	 ﾠthe	 ﾠ19th	 ﾠcentury	 ﾠby	 ﾠ
Lord	 ﾠRayleigh,	 ﾠwho	 ﾠdetermined	 ﾠmolecular	 ﾠsize	 ﾠby	 ﾠpreparing	 ﾠmonomolecular	 ﾠfilms	 ﾠ
(Rayleigh,	 ﾠ1890)	 ﾠand	 ﾠthen	 ﾠobtained	 ﾠthe	 ﾠNobel	 ﾠprize	 ﾠin	 ﾠ1904	 ﾠfor	 ﾠthis	 ﾠwork.	 ﾠIn	 ﾠtheir	 ﾠ
comprehensive	 ﾠ reviews	 ﾠ of	 ﾠ the	 ﾠ early	 ﾠ years	 ﾠ of	 ﾠ surfactant	 ﾠ research	 ﾠ both	 ﾠ Halliday	 ﾠ
(Halliday,	 ﾠ2008)	 ﾠand	 ﾠWrobel	 ﾠ(Wrobel	 ﾠand	 ﾠClements,	 ﾠ2004)	 ﾠcite	 ﾠthe	 ﾠwork	 ﾠof	 ﾠVon	 ﾠ
Neergaard	 ﾠ(Von	 ﾠNeergaard,	 ﾠ1929)	 ﾠin	 ﾠthe	 ﾠ1920’s	 ﾠas	 ﾠthe	 ﾠstarting	 ﾠpoint	 ﾠin	 ﾠthe	 ﾠstory	 ﾠof	 ﾠ
the	 ﾠdevelopment	 ﾠof	 ﾠsurfactant	 ﾠas	 ﾠa	 ﾠtreatment	 ﾠfor	 ﾠrespiratory	 ﾠdistress	 ﾠsyndrome	 ﾠ
(RDS).	 ﾠOnly	 ﾠin	 ﾠthe	 ﾠ1950’s	 ﾠwas	 ﾠthis	 ﾠpioneering	 ﾠwork	 ﾠrevisited	 ﾠwhen	 ﾠClements,	 ﾠusing	 ﾠ
a	 ﾠ homemade	 ﾠ dynamic	 ﾠ tensiometer	 ﾠ measured	 ﾠ the	 ﾠ surface	 ﾠ tension	 ﾠ of	 ﾠ films	 ﾠ from	 ﾠ
mammalian	 ﾠlung	 ﾠpreparations	 ﾠ(Clements,	 ﾠ1957).	 ﾠIn	 ﾠhis	 ﾠfamous	 ﾠpaper,	 ﾠoriginally	 ﾠ
published	 ﾠin	 ﾠ1957,	 ﾠClements	 ﾠconfirmed	 ﾠthat	 ﾠsurface	 ﾠtension	 ﾠis	 ﾠlow	 ﾠin	 ﾠthe	 ﾠtissue	 ﾠ
extracts	 ﾠcontaining	 ﾠthe	 ﾠlining	 ﾠof	 ﾠthe	 ﾠlung.	 ﾠBuilding	 ﾠon	 ﾠthis	 ﾠwork,	 ﾠhe	 ﾠdiscovered	 ﾠthat	 ﾠ  5	 ﾠ
the	 ﾠsurface	 ﾠtension	 ﾠrose	 ﾠwhen	 ﾠthe	 ﾠsurface	 ﾠlayer	 ﾠof	 ﾠthe	 ﾠlung	 ﾠextracts	 ﾠwere	 ﾠexpanded.	 ﾠ
In	 ﾠa	 ﾠworking	 ﾠlung,	 ﾠthe	 ﾠhigher	 ﾠsurface	 ﾠtension	 ﾠwould	 ﾠtherefore	 ﾠprevent	 ﾠthe	 ﾠlung	 ﾠ
from	 ﾠover-ﾭ‐expanding	 ﾠand	 ﾠhelp	 ﾠit	 ﾠreturn	 ﾠto	 ﾠits	 ﾠnormal	 ﾠsize.	 ﾠ	 ﾠAlso	 ﾠwhen	 ﾠthe	 ﾠsurface	 ﾠ
layer	 ﾠwas	 ﾠcompressed	 ﾠthe	 ﾠsurface	 ﾠtension	 ﾠfell	 ﾠ(Wrobel	 ﾠand	 ﾠClements,	 ﾠ2004).	 ﾠAgain,	 ﾠ
in	 ﾠa	 ﾠworking	 ﾠlung,	 ﾠthis	 ﾠlower	 ﾠsurface	 ﾠtension	 ﾠwould	 ﾠallow	 ﾠthe	 ﾠalveoli	 ﾠto	 ﾠstay	 ﾠopen	 ﾠ
at	 ﾠ normal	 ﾠ pressure	 ﾠ –	 ﾠ instead	 ﾠ of	 ﾠ failing	 ﾠ to	 ﾠ expand.	 ﾠ In	 ﾠ summary,	 ﾠ Clements	 ﾠ had	 ﾠ
revealed	 ﾠ that	 ﾠ pulmonary	 ﾠ surfactant	 ﾠ behaved	 ﾠ dynamically	 ﾠ throughout	 ﾠ the	 ﾠ
respiratory	 ﾠcycle.	 ﾠ
Later	 ﾠin	 ﾠthe	 ﾠsame	 ﾠdecade,	 ﾠand	 ﾠfollowing	 ﾠon	 ﾠfrom	 ﾠClements’	 ﾠinvestigations,	 ﾠAvery	 ﾠ
and	 ﾠMead	 ﾠ(Avery	 ﾠand	 ﾠMead,	 ﾠ1959)	 ﾠpublished	 ﾠa	 ﾠpaper	 ﾠdemonstrating	 ﾠthat	 ﾠa	 ﾠlack	 ﾠof	 ﾠ
pulmonary	 ﾠsurfactant	 ﾠplayed	 ﾠa	 ﾠrole	 ﾠin	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠRDS	 ﾠin	 ﾠinfants.	 ﾠ
A	 ﾠ number	 ﾠ of	 ﾠ surfactant	 ﾠ replacement	 ﾠ trials	 ﾠ followed,	 ﾠ using	 ﾠ naturally	 ﾠ derived	 ﾠ
products,	 ﾠand	 ﾠlater,	 ﾠsynthetic	 ﾠcompounds	 ﾠ(Adams	 ﾠet	 ﾠal.,	 ﾠ1978,	 ﾠEnhorning	 ﾠet	 ﾠal.,	 ﾠ
1973,	 ﾠFujiwara	 ﾠet	 ﾠal.,	 ﾠ1980,	 ﾠEnhorning	 ﾠet	 ﾠal.,	 ﾠ1985,	 ﾠNoack	 ﾠet	 ﾠal.,	 ﾠ1987,	 ﾠHallman	 ﾠet	 ﾠal.,	 ﾠ
1985).	 ﾠ
Fujiwara’s	 ﾠ paper	 ﾠ (Fujiwara	 ﾠ et	 ﾠ al.,	 ﾠ 1980),	 ﾠ published	 ﾠ in	 ﾠ the	 ﾠ Lancet	 ﾠ in	 ﾠ 1980,	 ﾠ
demonstrated	 ﾠthe	 ﾠefficacy	 ﾠof	 ﾠmodified	 ﾠbovine	 ﾠsurfactant	 ﾠin	 ﾠhuman	 ﾠpreterm	 ﾠinfants.	 ﾠ
Using	 ﾠ a	 ﾠ surfactant	 ﾠ isolated	 ﾠ by	 ﾠ saline	 ﾠ extraction	 ﾠ from	 ﾠ minced	 ﾠ bovine	 ﾠ lung	 ﾠ and	 ﾠ
enriched	 ﾠwith	 ﾠsynthetic	 ﾠlipids,	 ﾠthe	 ﾠstudy	 ﾠrevealed	 ﾠan	 ﾠincrease	 ﾠin	 ﾠarterial	 ﾠoxygen	 ﾠ
tension	 ﾠand	 ﾠa	 ﾠdecrease	 ﾠin	 ﾠventilator	 ﾠpressure	 ﾠrequirements	 ﾠin	 ﾠall	 ﾠten	 ﾠof	 ﾠthe	 ﾠrecruits	 ﾠ
within	 ﾠthree	 ﾠhours	 ﾠof	 ﾠexogenous	 ﾠadministration	 ﾠvia	 ﾠendotracheal	 ﾠtube.	 ﾠ
In	 ﾠ 1968,	 ﾠ the	 ﾠ Auckland-ﾭ‐based	 ﾠ obstetrician	 ﾠ Graham	 ﾠ Liggins	 ﾠ noted	 ﾠ that	 ﾠ following	 ﾠ
infusion	 ﾠof	 ﾠadrenocorticotropic	 ﾠhormone,	 ﾠcortisol	 ﾠor	 ﾠdexamethasone	 ﾠto	 ﾠthe	 ﾠmother,	 ﾠ
premature	 ﾠlambs	 ﾠhad	 ﾠunexpectedly	 ﾠmature	 ﾠlungs	 ﾠdue	 ﾠto	 ﾠenzyme	 ﾠinduction	 ﾠ(Liggins,	 ﾠ
1969).	 ﾠHis	 ﾠconclusion	 ﾠthat	 ﾠthis	 ﾠmay	 ﾠbe	 ﾠused	 ﾠto	 ﾠreduce	 ﾠmorbidity	 ﾠand	 ﾠmortality	 ﾠ  6	 ﾠ
from	 ﾠ RDS	 ﾠ led,	 ﾠ in	 ﾠ collaboration	 ﾠ with	 ﾠ Dr	 ﾠ Ross	 ﾠ Howie,	 ﾠ to	 ﾠ the	 ﾠ controlled	 ﾠ trial	 ﾠ of	 ﾠ
betamethasone	 ﾠthat	 ﾠproved	 ﾠhis	 ﾠhypothesis	 ﾠ(Liggins	 ﾠand	 ﾠHowie,	 ﾠ1972).	 ﾠ
Surfactant	 ﾠsubstitution	 ﾠhas	 ﾠbecome	 ﾠthe	 ﾠmainstay	 ﾠof	 ﾠtreatment	 ﾠfor	 ﾠRDS	 ﾠand	 ﾠthe	 ﾠ
evidence	 ﾠ has	 ﾠ been	 ﾠ reinforced	 ﾠ by	 ﾠ a	 ﾠ number	 ﾠ of	 ﾠ carefully	 ﾠ controlled	 ﾠ multicentre	 ﾠ
clinical	 ﾠtrials	 ﾠglobally	 ﾠ(Hallman	 ﾠet	 ﾠal.,	 ﾠ1986,	 ﾠKwong	 ﾠet	 ﾠal.,	 ﾠ1985,	 ﾠEnhorning	 ﾠet	 ﾠal.,	 ﾠ
1985).	 ﾠ
To	 ﾠreview	 ﾠthe	 ﾠhistory	 ﾠof	 ﾠpulmonary	 ﾠsurfactant	 ﾠresearch	 ﾠsince	 ﾠthe	 ﾠ1950’s	 ﾠis	 ﾠto	 ﾠbegin	 ﾠ
to	 ﾠappreciate	 ﾠa	 ﾠcase	 ﾠstudy	 ﾠin	 ﾠthe	 ﾠimprovements	 ﾠin	 ﾠtreatment	 ﾠoptions	 ﾠthat	 ﾠbecome	 ﾠ
available	 ﾠwith	 ﾠan	 ﾠenhanced	 ﾠunderstanding	 ﾠof	 ﾠbiological	 ﾠand	 ﾠmetabolic	 ﾠprocesses	 ﾠof	 ﾠ
a	 ﾠsingle	 ﾠdisease.	 ﾠWhile	 ﾠthe	 ﾠrelative	 ﾠabsence	 ﾠof	 ﾠsurfactant,	 ﾠin	 ﾠthe	 ﾠhuman	 ﾠpreterm	 ﾠ
infant,	 ﾠis	 ﾠwell	 ﾠdocumented,	 ﾠthe	 ﾠmetabolism	 ﾠof	 ﾠpulmonary	 ﾠsurfactant	 ﾠis	 ﾠdependent	 ﾠ
on	 ﾠan	 ﾠindividual	 ﾠchild’s	 ﾠstage	 ﾠof	 ﾠdevelopment	 ﾠas	 ﾠwell	 ﾠas	 ﾠpathological	 ﾠalterations	 ﾠto	 ﾠ
the	 ﾠsurfactant	 ﾠsystem	 ﾠassociated	 ﾠwith	 ﾠpreterm	 ﾠbirth.	 ﾠ	 ﾠ
Many	 ﾠattempts	 ﾠto	 ﾠdefine	 ﾠmetabolism	 ﾠof	 ﾠpulmonary	 ﾠsurfactant	 ﾠhave	 ﾠbeen	 ﾠpublished,	 ﾠ
in	 ﾠaddition	 ﾠto	 ﾠin	 ﾠvivo	 ﾠhuman	 ﾠresearch,	 ﾠmodel	 ﾠsystems	 ﾠand	 ﾠanimal	 ﾠstudies	 ﾠhave	 ﾠbeen	 ﾠ
used	 ﾠ(Carnielli	 ﾠet	 ﾠal.,	 ﾠ2009,	 ﾠZimmermann	 ﾠet	 ﾠal.,	 ﾠ2005,	 ﾠCogo	 ﾠet	 ﾠal.,	 ﾠ2003,	 ﾠPost	 ﾠet	 ﾠal.,	 ﾠ
1983).	 ﾠ
	 ﾠ
1.3	 ﾠ Neonatal	 ﾠ Respiratory	 ﾠ Distress	 ﾠ Syndrome	 ﾠ (RDS)	 ﾠ and	 ﾠ
Pulmonary	 ﾠSurfactant	 ﾠ
Deficiency	 ﾠ of	 ﾠ pulmonary	 ﾠ surfactant	 ﾠ is	 ﾠ the	 ﾠ main	 ﾠ cause	 ﾠ of	 ﾠ RDS	 ﾠ with	 ﾠ premature	 ﾠ
infants	 ﾠat	 ﾠparticularly	 ﾠhigh	 ﾠrisk	 ﾠ(Rubaltelli	 ﾠet	 ﾠal.,	 ﾠ1998).	 ﾠ	 ﾠ	 ﾠ
The	 ﾠ classical	 ﾠ clinical	 ﾠ description	 ﾠ includes	 ﾠ apnoea,	 ﾠ grunting,	 ﾠ nasal	 ﾠ flaring,	 ﾠ
intercostal	 ﾠretractions,	 ﾠtachypnoea	 ﾠassociated	 ﾠwith	 ﾠcyanosis,	 ﾠchest	 ﾠx-ﾭ‐ray	 ﾠchanges	 ﾠ
consistent	 ﾠwith	 ﾠdiffuse	 ﾠatelectasis	 ﾠand	 ﾠarterial	 ﾠblood	 ﾠgases	 ﾠthat	 ﾠshow	 ﾠhypoxia	 ﾠand	 ﾠ  7	 ﾠ
hypercarbia.	 ﾠSymptoms	 ﾠappear	 ﾠat	 ﾠor	 ﾠsoon	 ﾠafter	 ﾠbirth	 ﾠwith	 ﾠpersistence	 ﾠfor	 ﾠat	 ﾠleast	 ﾠ
48	 ﾠhours.	 ﾠIn	 ﾠthe	 ﾠextremely	 ﾠpremature	 ﾠinfant,	 ﾠthe	 ﾠclassical	 ﾠclinical	 ﾠsymptomatology	 ﾠ
is	 ﾠoften	 ﾠmasked	 ﾠby	 ﾠearly	 ﾠventilator	 ﾠsupport.	 ﾠ	 ﾠ
The	 ﾠ mainstay	 ﾠ of	 ﾠ treatment	 ﾠ in	 ﾠ RDS	 ﾠ is	 ﾠ the	 ﾠ early	 ﾠ use	 ﾠ of	 ﾠ end-ﾭ‐expiratory	 ﾠ positive	 ﾠ
pressure	 ﾠventilation,	 ﾠeither	 ﾠintubated	 ﾠor	 ﾠvia	 ﾠcontinuous	 ﾠpositive	 ﾠairways	 ﾠpressure	 ﾠ
(CPAP)	 ﾠ (Morley	 ﾠ and	 ﾠ Davis,	 ﾠ 2008),	 ﾠ and	 ﾠ surfactant	 ﾠ replacement.	 ﾠ 	 ﾠ Exogenous	 ﾠ
treatment	 ﾠwith	 ﾠsurfactant	 ﾠis	 ﾠan	 ﾠeffective	 ﾠtreatment	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠpopulation.	 ﾠIt	 ﾠis	 ﾠ
a	 ﾠ treatment	 ﾠ modality	 ﾠ that	 ﾠ is	 ﾠ well	 ﾠ tolerated	 ﾠ and,	 ﾠ since	 ﾠ its	 ﾠ introduction	 ﾠ to	 ﾠ the	 ﾠ
neonatal	 ﾠ intensive	 ﾠ care	 ﾠ environment,	 ﾠ has	 ﾠ markedly	 ﾠ improved	 ﾠ the	 ﾠ survival	 ﾠ of	 ﾠ
infants	 ﾠbetween	 ﾠ24	 ﾠand	 ﾠ29	 ﾠweeks	 ﾠgestation	 ﾠ(Ferrara	 ﾠet	 ﾠal.,	 ﾠ1994).	 ﾠDetailed	 ﾠreviews	 ﾠ
of	 ﾠthe	 ﾠavailable	 ﾠtrials	 ﾠinto	 ﾠthe	 ﾠuse	 ﾠof	 ﾠsurfactant	 ﾠtherapy	 ﾠfor	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠwith	 ﾠ
RDS	 ﾠ have	 ﾠ shown	 ﾠ improvement	 ﾠ in	 ﾠ survival,	 ﾠ improvement	 ﾠ in	 ﾠ neurological	 ﾠ
development,	 ﾠreduction	 ﾠin	 ﾠoxygen	 ﾠrequirement	 ﾠand	 ﾠimprovement	 ﾠin	 ﾠoxygenation	 ﾠ
(Morley,	 ﾠ 1991,	 ﾠ Ainsworth	 ﾠ and	 ﾠ Milligan,	 ﾠ 2002).	 ﾠ Of	 ﾠ note,	 ﾠ the	 ﾠ animal	 ﾠ derived	 ﾠ
surfactants	 ﾠperformed	 ﾠbetter	 ﾠthan	 ﾠsynthetic	 ﾠsurfactants	 ﾠ(Enhorning	 ﾠet	 ﾠal.,	 ﾠ1985,	 ﾠ
Halliday	 ﾠ et	 ﾠ al.,	 ﾠ 1984,	 ﾠ Ikegami,	 ﾠ 1981,	 ﾠ Kavvadia	 ﾠ et	 ﾠ al.,	 ﾠ 1998,	 ﾠ Morley	 ﾠ et	 ﾠ al.,	 ﾠ 1988,	 ﾠ
Tarnow-ﾭ‐Mordi	 ﾠ and	 ﾠ Soll,	 ﾠ 1994),	 ﾠ reflecting	 ﾠ the	 ﾠ difficulty	 ﾠ and	 ﾠ complexity	 ﾠ of	 ﾠ
reproducing	 ﾠbiologically	 ﾠactive	 ﾠagents	 ﾠartificially.	 ﾠ
In	 ﾠthe	 ﾠextremely	 ﾠpremature	 ﾠinfant,	 ﾠRDS	 ﾠoften	 ﾠleads	 ﾠto	 ﾠthe	 ﾠchronic	 ﾠdevelopment	 ﾠof	 ﾠ
lung	 ﾠ problems,	 ﾠ and	 ﾠ as	 ﾠ the	 ﾠ numbers	 ﾠ of	 ﾠ preterm	 ﾠ survivors	 ﾠ increases	 ﾠ there	 ﾠ is	 ﾠ an	 ﾠ
associated	 ﾠ increase	 ﾠ in	 ﾠ the	 ﾠ numbers	 ﾠ of	 ﾠ children	 ﾠ surviving	 ﾠ with	 ﾠ chronic	 ﾠ lung	 ﾠ
problems	 ﾠand	 ﾠtheir	 ﾠattendant	 ﾠmorbidities.	 ﾠBronchopulmonary	 ﾠdysplasia	 ﾠ(BPD)	 ﾠis	 ﾠa	 ﾠ
subtype	 ﾠof	 ﾠneonatal	 ﾠchronic	 ﾠlung	 ﾠdisease	 ﾠ(nCLD)	 ﾠaffecting	 ﾠup	 ﾠto	 ﾠ40%	 ﾠof	 ﾠextreme	 ﾠ
preterm	 ﾠsurvivors	 ﾠand	 ﾠis	 ﾠa	 ﾠwell-ﾭ‐recognised	 ﾠsequel	 ﾠto	 ﾠRDS	 ﾠ(Manktelow	 ﾠet	 ﾠal.,	 ﾠ2001).	 ﾠ	 ﾠ
The	 ﾠ development	 ﾠ of	 ﾠ nCLD	 ﾠ from	 ﾠ RDS	 ﾠ is	 ﾠ a	 ﾠ process	 ﾠ involving	 ﾠ multiple	 ﾠ and	 ﾠ often	 ﾠ
coexisting	 ﾠ factors	 ﾠ (Bancalari,	 ﾠ 2001).	 ﾠ While	 ﾠ surfactant	 ﾠ deficiency	 ﾠ based	 ﾠ on	 ﾠ lung	 ﾠ  8	 ﾠ
immaturity	 ﾠ is	 ﾠ often	 ﾠ true,	 ﾠ immature	 ﾠ pulmonary	 ﾠ microanatomy,	 ﾠ right-ﾭ‐to-ﾭ‐left	 ﾠ and	 ﾠ
left-ﾭ‐to-ﾭ‐right	 ﾠ shunting	 ﾠ of	 ﾠ blood	 ﾠ through	 ﾠ a	 ﾠ patent	 ﾠ ductus	 ﾠ arteriosis	 ﾠ (PDA),	 ﾠ
hypotension	 ﾠand	 ﾠsurfactant	 ﾠinactivation	 ﾠcan	 ﾠeach	 ﾠcontribute	 ﾠto	 ﾠa	 ﾠpicture	 ﾠof	 ﾠrelative	 ﾠ
surfactant	 ﾠinsufficiency	 ﾠ(Bancalari,	 ﾠ2001).	 ﾠAny	 ﾠof	 ﾠthese	 ﾠfactors	 ﾠcan	 ﾠlead	 ﾠto	 ﾠan	 ﾠinsult	 ﾠ
to	 ﾠthe	 ﾠsurfactant	 ﾠbiology	 ﾠin	 ﾠthe	 ﾠlung	 ﾠand,	 ﾠin	 ﾠtheory,	 ﾠinjury	 ﾠto	 ﾠthe	 ﾠsurfactant	 ﾠsystem	 ﾠ
itself.	 ﾠ
1.4	 ﾠNeonatal	 ﾠchronic	 ﾠlung	 ﾠdisease	 ﾠ
Any	 ﾠ child	 ﾠ born	 ﾠ before	 ﾠ 32	 ﾠ weeks	 ﾠ gestation,	 ﾠ with	 ﾠ classic	 ﾠ bilateral	 ﾠ chest	 ﾠ x-ﾭ‐ray	 ﾠ
changes	 ﾠand	 ﾠwho	 ﾠstill	 ﾠrequires	 ﾠsupplemental	 ﾠoxygen	 ﾠtherapy	 ﾠat	 ﾠ28	 ﾠdays	 ﾠof	 ﾠlife	 ﾠ
qualifies	 ﾠ for	 ﾠ a	 ﾠ diagnosis	 ﾠ of	 ﾠ nCLD.	 ﾠ The	 ﾠ severity	 ﾠ of	 ﾠ the	 ﾠ disease	 ﾠ is	 ﾠ then	 ﾠ clinically	 ﾠ
graded	 ﾠat	 ﾠa	 ﾠsecond	 ﾠtime	 ﾠpoint	 ﾠwhen	 ﾠthe	 ﾠchild	 ﾠhas	 ﾠreached	 ﾠ36	 ﾠweeks	 ﾠcorrected	 ﾠ
gestation.	 ﾠThey	 ﾠare	 ﾠassigned	 ﾠas	 ﾠ“severe	 ﾠnCLD”	 ﾠif	 ﾠthey	 ﾠstill	 ﾠrequire	 ﾠa	 ﾠsupplement	 ﾠof	 ﾠ
≥30%	 ﾠO2,	 ﾠ“moderate	 ﾠnCLD”	 ﾠif	 ﾠ≥21%	 ﾠand	 ﾠ<30%	 ﾠO2,	 ﾠand	 ﾠ“mild	 ﾠnCLD”	 ﾠif	 ﾠthey	 ﾠno	 ﾠ
longer	 ﾠhave	 ﾠan	 ﾠoxygen	 ﾠrequirement	 ﾠ(Ehrenkranz	 ﾠet	 ﾠal.,	 ﾠ2005).	 ﾠThe	 ﾠgrading	 ﾠreflects	 ﾠ
the	 ﾠ spectrum	 ﾠ of	 ﾠ disease	 ﾠ while	 ﾠ acknowledging	 ﾠ that	 ﾠ there	 ﾠ is	 ﾠ a	 ﾠ likelihood	 ﾠ of	 ﾠ
underlying	 ﾠlung	 ﾠdisease	 ﾠpresent	 ﾠeven	 ﾠif	 ﾠthe	 ﾠchild	 ﾠno	 ﾠlonger	 ﾠrequires	 ﾠextra	 ﾠoxygen.	 ﾠ
1.4.1	 ﾠTransition	 ﾠfrom	 ﾠRDS	 ﾠto	 ﾠnCLD	 ﾠ
The	 ﾠtransition	 ﾠfrom	 ﾠRDS	 ﾠto	 ﾠnCLD	 ﾠin	 ﾠsome	 ﾠpremature	 ﾠinfants	 ﾠis	 ﾠwell	 ﾠrecognised	 ﾠ
though	 ﾠnot	 ﾠfully	 ﾠunderstood	 ﾠand,	 ﾠwhile	 ﾠmultifactorial,	 ﾠmay	 ﾠbe	 ﾠsecondary	 ﾠto	 ﾠlung	 ﾠ
injury	 ﾠsustained	 ﾠin	 ﾠthe	 ﾠperinatal	 ﾠperiod.	 ﾠ
Mechanisms	 ﾠ for	 ﾠ potential	 ﾠ lung	 ﾠ injury	 ﾠ in	 ﾠ the	 ﾠ premature	 ﾠ infant	 ﾠ could	 ﾠ include:	 ﾠ
perinatal	 ﾠ asphyxia	 ﾠ delaying	 ﾠ absorption	 ﾠ of	 ﾠ fetal	 ﾠ alveolar	 ﾠ fluid	 ﾠ after	 ﾠ birth	 ﾠ and	 ﾠ
consequently	 ﾠincreased	 ﾠplasma	 ﾠleakage	 ﾠinto	 ﾠalveolar	 ﾠspaces.	 ﾠThe	 ﾠpremature	 ﾠbaby	 ﾠ
requires	 ﾠintubation	 ﾠand	 ﾠventilation	 ﾠwith	 ﾠresultant	 ﾠbarotraumas	 ﾠand	 ﾠdamage	 ﾠto	 ﾠthe	 ﾠ  9	 ﾠ
alveolar-ﾭ‐capillary	 ﾠbed.	 ﾠA	 ﾠcommon	 ﾠcomplication	 ﾠof	 ﾠprematurity,	 ﾠPDA	 ﾠwith	 ﾠleft-ﾭ‐to-ﾭ‐
right	 ﾠshunting,	 ﾠadds	 ﾠto	 ﾠthe	 ﾠleakage	 ﾠof	 ﾠplasma	 ﾠinto	 ﾠthe	 ﾠalveoli	 ﾠand	 ﾠfurther	 ﾠdelays	 ﾠ
fluid	 ﾠabsorption	 ﾠ(Bancalari,	 ﾠ2001).	 ﾠHence,	 ﾠprogressive	 ﾠlung	 ﾠinjury	 ﾠensues	 ﾠin	 ﾠthe	 ﾠ
presence	 ﾠ of	 ﾠ relative	 ﾠ surfactant	 ﾠ deficiency	 ﾠ and	 ﾠ an	 ﾠ immature	 ﾠ lung	 ﾠ microanatomy	 ﾠ
leading	 ﾠto	 ﾠworsening	 ﾠsurfactant	 ﾠinactivation.	 ﾠ
In	 ﾠ addition,	 ﾠ preterm	 ﾠ infants	 ﾠ do	 ﾠ not	 ﾠ benefit	 ﾠ from	 ﾠ the	 ﾠ acquisition	 ﾠ of	 ﾠ passive	 ﾠ
immunisation	 ﾠfrom	 ﾠthe	 ﾠmother	 ﾠin	 ﾠthe	 ﾠthird	 ﾠtrimester,	 ﾠmaking	 ﾠthem	 ﾠmore	 ﾠprone	 ﾠto	 ﾠ
infection	 ﾠ and	 ﾠ inflammation	 ﾠ and	 ﾠ inefficient	 ﾠ at	 ﾠ clearing	 ﾠ dead	 ﾠ and	 ﾠ dying	 ﾠ cells.	 ﾠ
Consequently,	 ﾠapoptosis	 ﾠoccurring	 ﾠafter	 ﾠearly	 ﾠlung	 ﾠinjury	 ﾠleads	 ﾠonly	 ﾠto	 ﾠdefective	 ﾠ
remodelling	 ﾠwith	 ﾠfibrosis	 ﾠand	 ﾠchanges	 ﾠconsistent	 ﾠwith	 ﾠemphysema.	 ﾠ
The	 ﾠaddition	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠto	 ﾠthe	 ﾠarmoury	 ﾠavailable	 ﾠto	 ﾠthe	 ﾠneonatologist	 ﾠ
in	 ﾠ combating	 ﾠ RDS	 ﾠ has	 ﾠ markedly	 ﾠ improved	 ﾠ survival	 ﾠ of	 ﾠ the	 ﾠ smallest	 ﾠ and	 ﾠ sickest	 ﾠ
preterm	 ﾠinfants	 ﾠ(Doyle	 ﾠet	 ﾠal.,	 ﾠ2011,	 ﾠSchwartz	 ﾠet	 ﾠal.,	 ﾠ1994,	 ﾠHallman	 ﾠet	 ﾠal.,	 ﾠ1987).	 ﾠ
Before	 ﾠ it	 ﾠ was	 ﾠ introduced	 ﾠ most	 ﾠ infants	 ﾠ born	 ﾠ before	 ﾠ 28	 ﾠ weeks	 ﾠ gestation	 ﾠ died	 ﾠ of	 ﾠ
progressive	 ﾠ respiratory	 ﾠ compromise.	 ﾠ When	 ﾠ given	 ﾠ early	 ﾠ and	 ﾠ combined	 ﾠ with	 ﾠ
strategies	 ﾠ to	 ﾠ reduce	 ﾠ lung	 ﾠ injury;	 ﾠ namely	 ﾠ permissive	 ﾠ hypercapnia,	 ﾠ avoidance	 ﾠ of	 ﾠ
aggressive	 ﾠventilation,	 ﾠearly	 ﾠeffective	 ﾠnutrition,	 ﾠtreatment	 ﾠof	 ﾠPDA	 ﾠand	 ﾠthe	 ﾠuse	 ﾠof	 ﾠ
prophylactic	 ﾠantibiotics,	 ﾠmore	 ﾠchildren	 ﾠare	 ﾠsurviving	 ﾠto	 ﾠdischarge.	 ﾠHowever,	 ﾠas	 ﾠthe	 ﾠ
number	 ﾠof	 ﾠextremely	 ﾠpremature	 ﾠchildren	 ﾠsurviving	 ﾠincreases	 ﾠthen	 ﾠso	 ﾠtoo	 ﾠdoes	 ﾠthe	 ﾠ
total	 ﾠnumber	 ﾠof	 ﾠchildren	 ﾠdeveloping	 ﾠlonger-ﾭ‐term	 ﾠproblems	 ﾠwith	 ﾠnCLD	 ﾠ(Fawke	 ﾠet	 ﾠal.,	 ﾠ
2010,	 ﾠManktelow	 ﾠet	 ﾠal.,	 ﾠ2001).	 ﾠ
1.4.2	 ﾠCosts	 ﾠof	 ﾠnCLD	 ﾠ
There	 ﾠare	 ﾠsignificant	 ﾠcosts	 ﾠassociated	 ﾠwith	 ﾠsurvival	 ﾠwith	 ﾠnCLD,	 ﾠfor	 ﾠnot	 ﾠonly	 ﾠthe	 ﾠ
child	 ﾠand	 ﾠtheir	 ﾠfamilies	 ﾠbut	 ﾠalso	 ﾠthe	 ﾠhealthcare	 ﾠsystem	 ﾠand	 ﾠwider	 ﾠsociety.	 ﾠ	 ﾠ  10	 ﾠ
Children	 ﾠwith	 ﾠnCLD	 ﾠhave	 ﾠa	 ﾠmedian	 ﾠof	 ﾠtwo	 ﾠhospital	 ﾠadmissions	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠ2	 ﾠyears	 ﾠ
after	 ﾠ discharge	 ﾠ (Greenough	 ﾠ et	 ﾠ al.,	 ﾠ 2001).	 ﾠ They	 ﾠ are	 ﾠ up	 ﾠ to	 ﾠ twice	 ﾠ as	 ﾠ likely	 ﾠ to	 ﾠ be	 ﾠ
admitted	 ﾠto	 ﾠhospital	 ﾠthan	 ﾠan	 ﾠequivalent	 ﾠpreterm	 ﾠinfant	 ﾠwho	 ﾠdid	 ﾠnot	 ﾠdevelop	 ﾠnCLD	 ﾠ
(Gross	 ﾠet	 ﾠal.,	 ﾠ1998).	 ﾠThey	 ﾠare	 ﾠgrowth	 ﾠrestricted	 ﾠwith	 ﾠgrowth	 ﾠfailure	 ﾠsecondary	 ﾠto	 ﾠ
their	 ﾠincreased	 ﾠmetabolic	 ﾠdemands	 ﾠ(Kurzner	 ﾠet	 ﾠal.,	 ﾠ1988).	 ﾠThey	 ﾠare	 ﾠmore	 ﾠlikely	 ﾠto	 ﾠ
wheeze	 ﾠand	 ﾠhave	 ﾠa	 ﾠmeasurably	 ﾠreduced	 ﾠexercise	 ﾠtolerance	 ﾠup	 ﾠto	 ﾠeight	 ﾠyears	 ﾠafter	 ﾠ
discharge	 ﾠ(Smyth	 ﾠet	 ﾠal.,	 ﾠ1981).	 ﾠ
In	 ﾠ 2005	 ﾠ it	 ﾠ cost	 ﾠ the	 ﾠ NHS	 ﾠ around	 ﾠ £1000	 ﾠ per	 ﾠ day	 ﾠ per	 ﾠ Level	 ﾠ 3	 ﾠ NICU	 ﾠ cot	 ﾠ space	 ﾠ
(Winterton,	 ﾠ2005).	 ﾠCurrent	 ﾠcosts	 ﾠin	 ﾠthe	 ﾠUK	 ﾠare	 ﾠover	 ﾠ£1500	 ﾠper	 ﾠday	 ﾠ(from	 ﾠpersonal	 ﾠ
communication).	 ﾠ There	 ﾠ is	 ﾠ a	 ﾠ huge	 ﾠ incentive	 ﾠ to	 ﾠ optimise	 ﾠ the	 ﾠ care	 ﾠ these	 ﾠ children	 ﾠ
receive	 ﾠand	 ﾠto	 ﾠminimise	 ﾠthe	 ﾠcomplications	 ﾠof	 ﾠtheir	 ﾠpremature	 ﾠdelivery.	 ﾠ
1.4.3	 ﾠFuture	 ﾠtreatment	 ﾠstrategies	 ﾠfor	 ﾠnCLD	 ﾠ
Two	 ﾠoptions	 ﾠto	 ﾠimprove	 ﾠthe	 ﾠtreatment	 ﾠavailable	 ﾠto	 ﾠthese	 ﾠchildren	 ﾠwould	 ﾠinclude,	 ﾠ
but	 ﾠwould	 ﾠnot	 ﾠbe	 ﾠlimited	 ﾠto,	 ﾠ	 ﾠ
a)	 ﾠ The	 ﾠ tailoring	 ﾠ of	 ﾠ surfactant	 ﾠ treatment	 ﾠ to	 ﾠ individual	 ﾠ patients	 ﾠ through	 ﾠ better	 ﾠ
understanding	 ﾠand	 ﾠactive	 ﾠmonitoring	 ﾠof	 ﾠtheir	 ﾠsurfactant	 ﾠstatus	 ﾠand	 ﾠ	 ﾠ
b)	 ﾠThe	 ﾠenhancement	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠtreatment	 ﾠwith	 ﾠthe	 ﾠrestoration	 ﾠof	 ﾠthe	 ﾠ
hydrophilic	 ﾠand	 ﾠanti-ﾭ‐inflammatory	 ﾠsurfactant-ﾭ‐associated	 ﾠproteins,	 ﾠSP-ﾭ‐A	 ﾠand	 ﾠSP-ﾭ‐D,	 ﾠ
which	 ﾠare	 ﾠcurrently	 ﾠpurified	 ﾠout	 ﾠin	 ﾠthe	 ﾠpreparation	 ﾠprocess	 ﾠof	 ﾠthe	 ﾠmost	 ﾠeffective	 ﾠ
clinically	 ﾠavailable	 ﾠsurfactants	 ﾠ(Clark,	 ﾠ2010).	 ﾠ
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1.5	 ﾠ Acute	 ﾠ respiratory	 ﾠ distress	 ﾠ syndrome	 ﾠ (ARDS)	 ﾠ and	 ﾠ surfactant	 ﾠ
inactivation	 ﾠ	 ﾠ
The	 ﾠpathological	 ﾠprocess	 ﾠof	 ﾠneonatal	 ﾠRDS	 ﾠas	 ﾠdescribed	 ﾠabove	 ﾠis	 ﾠa	 ﾠmanifestation	 ﾠof	 ﾠ
surfactant	 ﾠ insufficiency.	 ﾠ Acute	 ﾠ respiratory	 ﾠ distress	 ﾠ syndrome	 ﾠ (ARDS),	 ﾠ affecting	 ﾠ
older	 ﾠ children	 ﾠ and	 ﾠ adults,	 ﾠ is	 ﾠ an	 ﾠ illustration	 ﾠ of	 ﾠ surfactant	 ﾠ inactivation	 ﾠ on	 ﾠ a	 ﾠ
background	 ﾠof	 ﾠpreviously	 ﾠnormal	 ﾠsurfactant	 ﾠmetabolism	 ﾠ(Erickson	 ﾠet	 ﾠal.,	 ﾠ2007).	 ﾠ
Albumin	 ﾠleaking	 ﾠfrom	 ﾠthe	 ﾠplasma	 ﾠcan	 ﾠcoat	 ﾠsurfactant	 ﾠvesicles	 ﾠthereby	 ﾠpreventing	 ﾠ
delivery	 ﾠof	 ﾠsurfactant	 ﾠmolecules	 ﾠat	 ﾠthe	 ﾠair-ﾭ‐liquid	 ﾠinterface	 ﾠ(Bummer	 ﾠet	 ﾠal.,	 ﾠ1994).	 ﾠ
Specific	 ﾠmolecular	 ﾠinteractions	 ﾠcan	 ﾠalter	 ﾠconformations	 ﾠof	 ﾠlipids	 ﾠand	 ﾠproteins,	 ﾠfor	 ﾠ
example,	 ﾠ lectin	 ﾠ binding	 ﾠ to	 ﾠ sugars	 ﾠ on	 ﾠ surfactant	 ﾠ proteins	 ﾠ or	 ﾠ anti-ﾭ‐surfactant	 ﾠ
antibodies.	 ﾠSurfactant	 ﾠlipids	 ﾠcan	 ﾠbe	 ﾠbroken	 ﾠdown	 ﾠby	 ﾠphospholipases	 ﾠ(Offenstadt	 ﾠet	 ﾠ
al.,	 ﾠ1981)	 ﾠwith	 ﾠthe	 ﾠsubsequent	 ﾠformation	 ﾠof	 ﾠlysophosphatidylcholine	 ﾠ(lysoPC)	 ﾠor	 ﾠ
lysophoshatidylglycerol	 ﾠ (lysoPG).	 ﾠ Additionally,	 ﾠ inactivation	 ﾠ of	 ﾠ antiproteases	 ﾠ by	 ﾠ
neutrophil	 ﾠ elastase	 ﾠ increases	 ﾠ endothelial	 ﾠ cell	 ﾠ permeability	 ﾠ (Esper	 ﾠ and	 ﾠ Martin,	 ﾠ
2005).	 ﾠ
A	 ﾠpathogenesis	 ﾠexists,	 ﾠwhich	 ﾠis	 ﾠcommon	 ﾠto	 ﾠboth	 ﾠARDS	 ﾠand	 ﾠnCLD,	 ﾠincluding	 ﾠoxygen	 ﾠ
toxicity,	 ﾠbarotraumas,	 ﾠsepsis,	 ﾠinactivation	 ﾠof	 ﾠsurfactant	 ﾠand	 ﾠalveolitis	 ﾠsecondary	 ﾠto	 ﾠ
pulmonary	 ﾠ toxins.	 ﾠ All	 ﾠ or	 ﾠ any	 ﾠ of	 ﾠ these	 ﾠ factors	 ﾠ may	 ﾠ affect	 ﾠ the	 ﾠ activity	 ﾠ and	 ﾠ
effectiveness	 ﾠof	 ﾠpulmonary	 ﾠsurfactant.	 ﾠIt	 ﾠis	 ﾠlikely	 ﾠthat	 ﾠa	 ﾠcombination	 ﾠof	 ﾠsurfactant	 ﾠ
insufficiency	 ﾠand	 ﾠsurfactant	 ﾠinactivation	 ﾠoccurs	 ﾠin	 ﾠthe	 ﾠsick	 ﾠpremature	 ﾠinfant.	 ﾠ
	 ﾠ
1.6	 ﾠNeonatal	 ﾠchronic	 ﾠlung	 ﾠdisease	 ﾠand	 ﾠbiomarkers	 ﾠ
Given	 ﾠ the	 ﾠ multifactorial	 ﾠ pathogenesis	 ﾠ of	 ﾠ neonatal	 ﾠ RDS	 ﾠ and	 ﾠ the	 ﾠ difficulty	 ﾠ in	 ﾠ
ascribing	 ﾠ those	 ﾠ differences	 ﾠ to	 ﾠ clinical	 ﾠ progression	 ﾠ towards	 ﾠ nCLD	 ﾠ and	 ﾠ eventual	 ﾠ
outcome,	 ﾠ work	 ﾠ has	 ﾠ begun	 ﾠ to	 ﾠ describe,	 ﾠ at	 ﾠ a	 ﾠ biochemical	 ﾠ or	 ﾠ molecular	 ﾠ level,	 ﾠ the	 ﾠ  12	 ﾠ
changes	 ﾠ in	 ﾠ surfactant	 ﾠ metabolism	 ﾠ which	 ﾠ occur	 ﾠ around	 ﾠ preterm	 ﾠ birth	 ﾠ and	 ﾠ
subsequent	 ﾠclinical	 ﾠcourse	 ﾠ(Cogo	 ﾠet	 ﾠal.,	 ﾠ2004,	 ﾠCogo	 ﾠet	 ﾠal.,	 ﾠ2002,	 ﾠCogo	 ﾠet	 ﾠal.,	 ﾠ1999,	 ﾠ
Torresin	 ﾠet	 ﾠal.,	 ﾠ2000).	 ﾠThe	 ﾠpublished	 ﾠliterature	 ﾠcontaining	 ﾠanalytical	 ﾠdata	 ﾠon	 ﾠthe	 ﾠ
metabolism	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠgiven	 ﾠto	 ﾠpremature	 ﾠbabies	 ﾠwith	 ﾠRDS	 ﾠhowever	 ﾠ
is	 ﾠ complex	 ﾠ and	 ﾠ has	 ﾠ several	 ﾠ limitations	 ﾠ to	 ﾠ application	 ﾠ in	 ﾠ generating	 ﾠ useful	 ﾠ
biomarkers	 ﾠin	 ﾠa	 ﾠclinical	 ﾠenvironment.	 ﾠ
	 ﾠ
1.7	 ﾠPulmonary	 ﾠSurfactant	 ﾠ
1.7.1	 ﾠComposition	 ﾠof	 ﾠsurfactant	 ﾠ
Human	 ﾠpulmonary	 ﾠsurfactant	 ﾠis	 ﾠcomposed	 ﾠof	 ﾠphospholipids	 ﾠ(~80%),	 ﾠsurfactant-ﾭ‐
associated	 ﾠproteins	 ﾠ(~7%)	 ﾠand	 ﾠplasma-ﾭ‐derived	 ﾠproteins	 ﾠand	 ﾠneutral	 ﾠlipids	 ﾠsuch	 ﾠas	 ﾠ
cholesterol(Halliday,	 ﾠ2008).	 ﾠ
	 ﾠ
1.7.2	 ﾠPhosphatidylcholine-ﾭ‐containing	 ﾠphospholipids	 ﾠin	 ﾠpulmonary	 ﾠsurfactant	 ﾠ	 ﾠ
Phosphatidylcholine	 ﾠ (PC)	 ﾠ species	 ﾠ make	 ﾠ up	 ﾠ around	 ﾠ 80%	 ﾠ of	 ﾠ all	 ﾠ surfactant	 ﾠ
phospholipids	 ﾠ with	 ﾠ dipalmitoylphosphatidylcholine	 ﾠ (DPPC	 ﾠ or	 ﾠ PC16:0/16:0)	 ﾠ
accounting	 ﾠ for	 ﾠ almost	 ﾠ half	 ﾠ of	 ﾠ the	 ﾠ total	 ﾠ amount	 ﾠ (Bernhard	 ﾠ et	 ﾠ al.,	 ﾠ 2004).	 ﾠ A	 ﾠ
phospholipid	 ﾠwith	 ﾠtwo	 ﾠ16-ﾭ‐carbon	 ﾠsaturated	 ﾠchains	 ﾠand	 ﾠa	 ﾠphosphate	 ﾠgroup	 ﾠwith	 ﾠ
quaternary	 ﾠamine	 ﾠattached,	 ﾠDPPC	 ﾠhas	 ﾠa	 ﾠhigh	 ﾠcapacity	 ﾠfor	 ﾠcompaction	 ﾠdue	 ﾠto	 ﾠthe	 ﾠ
relative	 ﾠstraightness	 ﾠof	 ﾠits	 ﾠfully	 ﾠsaturated	 ﾠapolar	 ﾠtail.	 ﾠ 13	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i)	 ﾠPhospholipid	 ﾠnomenclature	 ﾠ
PC	 ﾠ16:0/16:0	 ﾠrefers	 ﾠto	 ﾠthe	 ﾠstructure	 ﾠof	 ﾠthe	 ﾠphospholipid	 ﾠmolecule	 ﾠcontaining	 ﾠPC	 ﾠ
and	 ﾠtwo	 ﾠfully	 ﾠsaturated	 ﾠfatty	 ﾠacid	 ﾠchains	 ﾠof	 ﾠsixteen	 ﾠcarbons	 ﾠin	 ﾠlength	 ﾠattached	 ﾠto	 ﾠ
the	 ﾠfirst	 ﾠ(sn-ﾭ‐1)	 ﾠand	 ﾠsecond	 ﾠ(sn-ﾭ‐2)	 ﾠcarbons.	 ﾠAll	 ﾠphospholipids	 ﾠcan	 ﾠbe	 ﾠdescribed	 ﾠthus:	 ﾠ
𝑷?? ﾠ𝑨:??/𝑪:??	 ﾠ
Where	 ﾠPx	 ﾠis	 ﾠthe	 ﾠphosphate	 ﾠcontaining	 ﾠhead	 ﾠgroup;	 ﾠA	 ﾠ&	 ﾠC	 ﾠare	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠcarbon	 ﾠ
atoms	 ﾠin	 ﾠthe	 ﾠtwo	 ﾠfatty	 ﾠacid	 ﾠchains,	 ﾠsn-ﾭ‐1	 ﾠand	 ﾠsn-ﾭ‐2,	 ﾠwhile	 ﾠb	 ﾠ&	 ﾠd	 ﾠare	 ﾠthe	 ﾠnumber	 ﾠof	 ﾠ
double	 ﾠbonds	 ﾠbetween	 ﾠcarbon	 ﾠatoms	 ﾠin	 ﾠthose	 ﾠfatty	 ﾠacids.	 ﾠ
1.7.3	 ﾠAcidic	 ﾠphospholipids	 ﾠin	 ﾠpulmonary	 ﾠsurfactant	 ﾠ
The	 ﾠ other	 ﾠ main	 ﾠ surfactant	 ﾠ phospholipids	 ﾠ are	 ﾠ the	 ﾠ acidic	 ﾠ species	 ﾠ
phosphatidylglycerol	 ﾠ (PG),	 ﾠ comprising	 ﾠ 10%	 ﾠ of	 ﾠ phospholipids	 ﾠ and	 ﾠ
phosphatidylinositol	 ﾠ (PI)	 ﾠ making	 ﾠ around	 ﾠ 3%	 ﾠ in	 ﾠ mature	 ﾠ lungs	 ﾠ (King,	 ﾠ 1982).	 ﾠ
However,	 ﾠin	 ﾠimmature	 ﾠand	 ﾠpreterm	 ﾠlungs	 ﾠthe	 ﾠratios	 ﾠare	 ﾠreversed	 ﾠtowards	 ﾠPI.	 ﾠPG	 ﾠ
starts	 ﾠto	 ﾠappear	 ﾠin	 ﾠthe	 ﾠsurfactant	 ﾠcompartments	 ﾠof	 ﾠfetal	 ﾠlungs	 ﾠlate	 ﾠin	 ﾠgestation	 ﾠand	 ﾠ
increases	 ﾠin	 ﾠthe	 ﾠneonatal	 ﾠperiod	 ﾠwith	 ﾠa	 ﾠconcomitant	 ﾠproportional	 ﾠdecrease	 ﾠin	 ﾠPI	 ﾠ
(Hallman	 ﾠet	 ﾠal.,	 ﾠ1976).	 ﾠ
This	 ﾠcompositional	 ﾠinterchange	 ﾠbetween	 ﾠthe	 ﾠacidic	 ﾠphospholipids	 ﾠalso	 ﾠoccurs	 ﾠin	 ﾠ
diseased	 ﾠstates	 ﾠsuch	 ﾠas	 ﾠadult	 ﾠrespiratory	 ﾠfailure	 ﾠ(Hallman	 ﾠet	 ﾠal.,	 ﾠ1982),	 ﾠwhere	 ﾠPG	 ﾠ
decreases	 ﾠ and	 ﾠ PI	 ﾠ increases	 ﾠ proportionally.	 ﾠ Therefore,	 ﾠ the	 ﾠ ratio	 ﾠ of	 ﾠ PG	 ﾠ to	 ﾠ PI	 ﾠ is	 ﾠ
markedly	 ﾠchanged	 ﾠin	 ﾠperinatal	 ﾠand	 ﾠpathological	 ﾠlungs.	 ﾠ
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1.7.4	 ﾠProteins	 ﾠin	 ﾠpulmonary	 ﾠsurfactant	 ﾠ
The	 ﾠfour	 ﾠsurfactant-ﾭ‐associated	 ﾠapoproteins	 ﾠA,	 ﾠB,	 ﾠC	 ﾠand	 ﾠD	 ﾠ(SP-ﾭ‐A,	 ﾠSP-ﾭ‐B,	 ﾠSP-ﾭ‐C	 ﾠand	 ﾠSP-ﾭ‐
D)	 ﾠare	 ﾠproduced	 ﾠby	 ﾠthe	 ﾠsecretory	 ﾠpathway	 ﾠof	 ﾠAT-ﾭ‐II	 ﾠcells	 ﾠ(Glasser	 ﾠand	 ﾠMallampalli,	 ﾠ
2012).	 ﾠ
Once	 ﾠ formed,	 ﾠ these	 ﾠ apoproteins	 ﾠ undergo	 ﾠ post-ﾭ‐translational	 ﾠ modification	 ﾠ before	 ﾠ
ending	 ﾠ up	 ﾠ in	 ﾠ the	 ﾠ lamellar	 ﾠ bodies	 ﾠ (LB),	 ﾠ which	 ﾠ are	 ﾠ concentric	 ﾠ rings	 ﾠ of	 ﾠ lipid	 ﾠ and	 ﾠ
protein	 ﾠ~1µm	 ﾠin	 ﾠdiameter,	 ﾠseen	 ﾠin	 ﾠthe	 ﾠcytoplasm	 ﾠof	 ﾠthe	 ﾠAT-ﾭ‐II	 ﾠcells	 ﾠbefore	 ﾠsecretion	 ﾠ
onto	 ﾠthe	 ﾠalveolar	 ﾠsurface.	 ﾠ
SP-ﾭ‐B	 ﾠ(0.7%)	 ﾠ&	 ﾠSP-ﾭ‐C	 ﾠ(0.4%)	 ﾠare	 ﾠhydrophobic	 ﾠand	 ﾠlipophilic	 ﾠmembrane	 ﾠproteins.	 ﾠ
They	 ﾠincrease	 ﾠthe	 ﾠrate	 ﾠat	 ﾠwhich	 ﾠsurfactant	 ﾠspreads	 ﾠover	 ﾠthe	 ﾠlung	 ﾠsurface	 ﾠand	 ﾠare	 ﾠ
required	 ﾠfor	 ﾠnormal	 ﾠbiophysical	 ﾠfunction.	 ﾠ
SP-ﾭ‐A	 ﾠ(5.3%)	 ﾠ&	 ﾠSP-ﾭ‐D	 ﾠ(0.6%)	 ﾠare	 ﾠlarger,	 ﾠhydrophilic	 ﾠand	 ﾠconfer	 ﾠinnate	 ﾠimmunity.	 ﾠ
Belonging	 ﾠto	 ﾠthe	 ﾠgroup	 ﾠof	 ﾠproteins	 ﾠknown	 ﾠas	 ﾠcollectins,	 ﾠthey	 ﾠhave	 ﾠcarbohydrate	 ﾠ
recognition	 ﾠ domains	 ﾠ (CRDs)	 ﾠ that	 ﾠ allow	 ﾠ them	 ﾠ to	 ﾠ coat	 ﾠ bacteria	 ﾠ and	 ﾠ viruses	 ﾠ
promoting	 ﾠ phagocytosis	 ﾠ by	 ﾠ macrophages.	 ﾠ SP-ﾭ‐A	 ﾠ is	 ﾠ thought	 ﾠ to	 ﾠ be	 ﾠ involved	 ﾠ in	 ﾠ a	 ﾠ
negative	 ﾠfeedback	 ﾠmechanism	 ﾠto	 ﾠcontrol	 ﾠsurfactant	 ﾠproduction.	 ﾠDue	 ﾠto	 ﾠtheir	 ﾠstrong	 ﾠ
affinity	 ﾠ for	 ﾠ water,	 ﾠ both	 ﾠ SP-ﾭ‐A	 ﾠ and	 ﾠ SP-ﾭ‐D	 ﾠ are	 ﾠ removed	 ﾠ during	 ﾠ the	 ﾠ processing	 ﾠ of	 ﾠ
animal-ﾭ‐derived	 ﾠmedicinal	 ﾠexogenous	 ﾠsurfactant.	 ﾠThe	 ﾠaddition	 ﾠof	 ﾠthese	 ﾠsurfactant	 ﾠ
proteins,	 ﾠ as	 ﾠ whole	 ﾠ molecules	 ﾠ or	 ﾠ active	 ﾠ subunit	 ﾠ components	 ﾠ to	 ﾠ manufactured	 ﾠ
exogenous	 ﾠsurfactant	 ﾠmay	 ﾠenhance	 ﾠthe	 ﾠability	 ﾠof	 ﾠa	 ﾠpreterm	 ﾠinfant	 ﾠto	 ﾠfight	 ﾠinfection	 ﾠ
or	 ﾠinflammatory	 ﾠlung	 ﾠdiseases,	 ﾠincluding	 ﾠthose	 ﾠmechanisms	 ﾠthat	 ﾠcan	 ﾠlead	 ﾠRDS	 ﾠto	 ﾠ
progress	 ﾠto	 ﾠnCLD	 ﾠ(Clark	 ﾠand	 ﾠReid,	 ﾠ2003,	 ﾠClark,	 ﾠ2010).	 ﾠ
In	 ﾠ1994,	 ﾠNogee	 ﾠreported	 ﾠa	 ﾠfamilial	 ﾠand	 ﾠlethal	 ﾠform	 ﾠof	 ﾠRDS	 ﾠin	 ﾠwhich	 ﾠa	 ﾠmutation	 ﾠin	 ﾠ
the	 ﾠSP-ﾭ‐B	 ﾠgene	 ﾠwas	 ﾠidentified	 ﾠ(Nogee	 ﾠet	 ﾠal.,	 ﾠ1994).	 ﾠSimilar	 ﾠobservations	 ﾠhave	 ﾠbeen	 ﾠ
made	 ﾠin	 ﾠmice	 ﾠ(Yan	 ﾠand	 ﾠDu,	 ﾠ2004)	 ﾠand	 ﾠKala	 ﾠidentified	 ﾠSP-ﾭ‐A	 ﾠand	 ﾠSP-ﾭ‐B	 ﾠcandidate	 ﾠ
genes	 ﾠmarkers	 ﾠin	 ﾠthe	 ﾠpathogenesis	 ﾠof	 ﾠRDS	 ﾠ(Kala	 ﾠet	 ﾠal.,	 ﾠ1998).	 ﾠ	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Early	 ﾠanalyses	 ﾠof	 ﾠSP-ﾭ‐C	 ﾠindicated	 ﾠthat	 ﾠwhile	 ﾠit	 ﾠmay	 ﾠnot	 ﾠbe	 ﾠcritical	 ﾠfor	 ﾠrespiratory	 ﾠ
adaptation	 ﾠat	 ﾠbirth,	 ﾠit	 ﾠwas	 ﾠimportant	 ﾠin	 ﾠpostnatal	 ﾠlung	 ﾠfunction	 ﾠand	 ﾠmutations	 ﾠmay	 ﾠ
be	 ﾠassociated	 ﾠwith	 ﾠfamilial	 ﾠcases	 ﾠof	 ﾠinterstitial	 ﾠlung	 ﾠdiseases	 ﾠ(Nogee	 ﾠet	 ﾠal.,	 ﾠ2001).	 ﾠ	 ﾠ
More	 ﾠ recently,	 ﾠ however,	 ﾠ Poterjoy	 ﾠ reported	 ﾠ a	 ﾠ novel	 ﾠ mutation	 ﾠ affecting	 ﾠ the	 ﾠ SP-ﾭ‐C	 ﾠ
gene	 ﾠwhich	 ﾠwas	 ﾠresponsible	 ﾠfor	 ﾠa	 ﾠcase	 ﾠof	 ﾠneonatal	 ﾠrespiratory	 ﾠfailure	 ﾠrequiring	 ﾠa	 ﾠ
prolonged	 ﾠperiod	 ﾠof	 ﾠextra-ﾭ‐corporeal	 ﾠmembranous	 ﾠoxygenation	 ﾠ(ECMO)	 ﾠand	 ﾠlung	 ﾠ
transplantation	 ﾠ(Poterjoy	 ﾠet	 ﾠal.,	 ﾠ2010).	 ﾠ
1.8	 ﾠPulmonary	 ﾠsurfactant	 ﾠphospholipid	 ﾠmetabolism	 ﾠ
Pulmonary	 ﾠsurfactant	 ﾠis	 ﾠsynthesised,	 ﾠassembled,	 ﾠtransported	 ﾠand	 ﾠsecreted	 ﾠinto	 ﾠthe	 ﾠ
alveolus	 ﾠwhere	 ﾠit	 ﾠis	 ﾠdegraded.	 ﾠIt	 ﾠis	 ﾠthen	 ﾠrecycled	 ﾠin	 ﾠa	 ﾠcomplex	 ﾠand	 ﾠhighly	 ﾠregulated	 ﾠ
mechanism	 ﾠ(Figure	 ﾠ1).	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ1.	 ﾠPulmonary	 ﾠsurfactant	 ﾠmetabolism	 ﾠdemonstrating	 ﾠsynthesis	 ﾠand	 ﾠ
assembly	 ﾠin	 ﾠthe	 ﾠalveolar	 ﾠtype	 ﾠ2	 ﾠcell	 ﾠ(AT-ﾭ‐II),	 ﾠtransport	 ﾠto	 ﾠthe	 ﾠcell	 ﾠsurface,	 ﾠ
secretion	 ﾠof	 ﾠlamellar	 ﾠbodies	 ﾠand	 ﾠformation	 ﾠof	 ﾠtubular	 ﾠmyelin,	 ﾠadsorption	 ﾠat	 ﾠ
air-ﾭ‐liquid	 ﾠinterface	 ﾠbefore	 ﾠdegradation	 ﾠand	 ﾠrecycling.	 ﾠ[Diagram	 ﾠfrom	 ﾠ
Trapnell	 ﾠand	 ﾠWhitsett	 ﾠ2002]	 ﾠ  16	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In	 ﾠ humans,	 ﾠ surfactant	 ﾠ production	 ﾠ begins	 ﾠ in	 ﾠ AT-ﾭ‐II	 ﾠ cells	 ﾠ during	 ﾠ the	 ﾠ terminal	 ﾠ sac	 ﾠ
phase	 ﾠof	 ﾠlung	 ﾠdevelopment.	 ﾠLamellar	 ﾠbodies	 ﾠappear	 ﾠin	 ﾠthe	 ﾠcytoplasm	 ﾠat	 ﾠabout	 ﾠ20	 ﾠ
weeks	 ﾠgestation.	 ﾠThe	 ﾠpoint	 ﾠat	 ﾠwhich	 ﾠthe	 ﾠhuman	 ﾠfetus	 ﾠis	 ﾠcapable	 ﾠof	 ﾠsurvival	 ﾠoutside	 ﾠ
the	 ﾠuterus	 ﾠis	 ﾠmarked	 ﾠby	 ﾠsufficiency	 ﾠof	 ﾠlung	 ﾠdevelopment,	 ﾠwith	 ﾠdifferentiation	 ﾠof	 ﾠthe	 ﾠ
AT-ﾭ‐II	 ﾠ pneumocytes	 ﾠ into	 ﾠ the	 ﾠ alveolar	 ﾠ type	 ﾠ I	 ﾠ (AT-ﾭ‐I)	 ﾠ pneumocytes	 ﾠ capable	 ﾠ of	 ﾠ gas	 ﾠ
exchange.	 ﾠ This	 ﾠ development,	 ﾠ alongside	 ﾠ proliferation	 ﾠ of	 ﾠ capillaries	 ﾠ into	 ﾠ the	 ﾠ
mesenchyme,	 ﾠ at	 ﾠ the	 ﾠ end	 ﾠ of	 ﾠ the	 ﾠ canalicular	 ﾠ phase,	 ﾠ occurs	 ﾠ around	 ﾠ 24	 ﾠ weeks	 ﾠ
gestation	 ﾠ(Figure	 ﾠ2).	 ﾠ
	 ﾠ
Figure	 ﾠ2.	 ﾠThe	 ﾠembryological	 ﾠdevelopment	 ﾠof	 ﾠalveoli	 ﾠshowing	 ﾠabsence	 ﾠof	 ﾠboth	 ﾠ
surfactant	 ﾠsynthesis	 ﾠand	 ﾠalveolar	 ﾠducts	 ﾠcapable	 ﾠof	 ﾠgas	 ﾠexchange	 ﾠprior	 ﾠto	 ﾠ23	 ﾠ
weeks	 ﾠgestation.	 ﾠ[Diagram	 ﾠfrom	 ﾠwww.embryology.ch]	 ﾠ
The	 ﾠamount	 ﾠof	 ﾠsurfactant	 ﾠnaturally	 ﾠproduced	 ﾠby	 ﾠthe	 ﾠpremature	 ﾠinfants	 ﾠlungs	 ﾠat	 ﾠ24	 ﾠ
weeks	 ﾠ gestation	 ﾠ remains	 ﾠ insufficient	 ﾠ to	 ﾠ prevent	 ﾠ alveolar	 ﾠ collapse	 ﾠ or	 ﾠ support	 ﾠ 17	 ﾠ
oxygen	 ﾠ exchange.	 ﾠ For	 ﾠ survival	 ﾠ at	 ﾠ this	 ﾠ gestation,	 ﾠ treatment	 ﾠ with	 ﾠ exogenous	 ﾠ
surfactant	 ﾠis	 ﾠnecessary	 ﾠuntil	 ﾠendogenous	 ﾠsurfactant	 ﾠproduction	 ﾠhas	 ﾠimproved.	 ﾠ
1.8.1	 ﾠIn	 ﾠvivo	 ﾠinvestigation	 ﾠof	 ﾠsurfactant	 ﾠphospholipid	 ﾠmetabolism	 ﾠ
Since	 ﾠthe	 ﾠ1970’s	 ﾠinvestigators	 ﾠof	 ﾠsurfactant	 ﾠsynthetic	 ﾠrates	 ﾠand	 ﾠturnover	 ﾠin	 ﾠvivo	 ﾠ
have	 ﾠfocused	 ﾠon	 ﾠstable	 ﾠand	 ﾠradioactive	 ﾠisotopic	 ﾠtechniques.	 ﾠ
1.8.2	 ﾠInvestigation	 ﾠusing	 ﾠisotopic	 ﾠtechniques	 ﾠ
Stable	 ﾠisotopes	 ﾠof	 ﾠwater	 ﾠ(deuterated	 ﾠwater	 ﾠor	 ﾠD2O)	 ﾠor	 ﾠsubstrates	 ﾠsuch	 ﾠas	 ﾠglucose,	 ﾠ
acetate	 ﾠ and	 ﾠ palmitic	 ﾠ acid	 ﾠ (using	 ﾠ 13C)	 ﾠ have	 ﾠ been	 ﾠ used	 ﾠ in	 ﾠ the	 ﾠ preterm	 ﾠ clinical	 ﾠ
environment.	 ﾠ One	 ﾠ study,	 ﾠ using	 ﾠ uniformly	 ﾠ labelled	 ﾠ Carbon-ﾭ‐13	 ﾠ glucose	 ﾠ ([U-ﾭ‐
13C]glucose)	 ﾠ as	 ﾠ a	 ﾠ precursor	 ﾠ for	 ﾠ palmitic	 ﾠ acid,	 ﾠ and	 ﾠ measuring	 ﾠ 13C-ﾭ‐enrichment	 ﾠ of	 ﾠ
palmitic	 ﾠ acid	 ﾠ in	 ﾠ surfactant	 ﾠ PC	 ﾠ by	 ﾠ gas	 ﾠ chromatography-ﾭ‐combustion	 ﾠ interface-ﾭ‐
isotope	 ﾠ ratio	 ﾠ mass	 ﾠ spectrometry	 ﾠ (GC-ﾭ‐C-ﾭ‐IRMS),	 ﾠ reported	 ﾠ an	 ﾠ absolute	 ﾠ production	 ﾠ
rate	 ﾠfor	 ﾠPC	 ﾠof	 ﾠ4.2mg/kg/day	 ﾠ(Bunt	 ﾠet	 ﾠal.,	 ﾠ1998).	 ﾠIn	 ﾠaddition,	 ﾠthe	 ﾠfractional	 ﾠsynthetic	 ﾠ
rate	 ﾠof	 ﾠsurfactant	 ﾠPC	 ﾠfrom	 ﾠplasma	 ﾠpalmitate	 ﾠwas	 ﾠreported	 ﾠto	 ﾠbe	 ﾠsignificantly	 ﾠhigher	 ﾠ
than	 ﾠthat	 ﾠfrom	 ﾠpalmitate	 ﾠsynthesised	 ﾠde	 ﾠnovo	 ﾠfrom	 ﾠacetate	 ﾠor	 ﾠglucose,	 ﾠbut	 ﾠonly	 ﾠ
accounted	 ﾠfor	 ﾠhalf	 ﾠof	 ﾠthe	 ﾠtotal	 ﾠsurfactant	 ﾠproduction	 ﾠin	 ﾠpreterm	 ﾠbabies	 ﾠ(Bohlin	 ﾠet	 ﾠ
al.,	 ﾠ2005).	 ﾠ	 ﾠUsing	 ﾠporcine-ﾭ‐derived	 ﾠsurfactant	 ﾠwith	 ﾠ13C-ﾭ‐labelled	 ﾠDPPC	 ﾠadministered	 ﾠ
to	 ﾠeight	 ﾠinfants,	 ﾠborn	 ﾠbetween	 ﾠ28	 ﾠand	 ﾠ32	 ﾠweeks	 ﾠgestation	 ﾠand	 ﾠventilated	 ﾠfor	 ﾠRDS,	 ﾠ
Torresin	 ﾠ et	 ﾠ al.	 ﾠ measured	 ﾠ the	 ﾠ enrichment	 ﾠ of	 ﾠ surfactant	 ﾠ disaturated	 ﾠ
phosphatidylcholine	 ﾠ(DSPC)	 ﾠin	 ﾠserial	 ﾠtracheal	 ﾠaspirates	 ﾠby	 ﾠgas	 ﾠchromatography-ﾭ‐
mass	 ﾠspectrometry	 ﾠ(Torresin	 ﾠet	 ﾠal.,	 ﾠ2000).	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1.8.3	 ﾠLimitations	 ﾠof	 ﾠprevious	 ﾠisotopic	 ﾠtechniques	 ﾠ
These	 ﾠ techniques	 ﾠ show	 ﾠ significant	 ﾠ limitations	 ﾠ for	 ﾠ implementation	 ﾠ into	 ﾠ clinical	 ﾠ
practice	 ﾠand	 ﾠresearch.	 ﾠ	 ﾠ
The	 ﾠ substrates	 ﾠ take	 ﾠ a	 ﾠ very	 ﾠ long	 ﾠ time	 ﾠ to	 ﾠ administer,	 ﾠ with	 ﾠ over	 ﾠ 24	 ﾠ hours	 ﾠ of	 ﾠ
continuous	 ﾠinfusion	 ﾠand	 ﾠthe	 ﾠneed	 ﾠto	 ﾠreach	 ﾠa	 ﾠsteady	 ﾠstate.	 ﾠThey	 ﾠrequire	 ﾠseveral	 ﾠ
steps	 ﾠ in	 ﾠ sample	 ﾠ processing	 ﾠ with	 ﾠ analytical	 ﾠ methods	 ﾠ and	 ﾠ techniques	 ﾠ that	 ﾠ are	 ﾠ
complicated,	 ﾠmultistep	 ﾠand	 ﾠhighly	 ﾠspecialised.	 ﾠFurther	 ﾠcomplication	 ﾠarises	 ﾠfrom	 ﾠ
the	 ﾠ incorporation	 ﾠ of	 ﾠ labelled	 ﾠ substrate	 ﾠ into	 ﾠ different	 ﾠ phospholipid	 ﾠ pools,	 ﾠ the	 ﾠ
correspondingly	 ﾠcomplex	 ﾠmathematical	 ﾠmodelling	 ﾠrequired	 ﾠand	 ﾠnecessary	 ﾠuse	 ﾠof	 ﾠ
correction	 ﾠfactors	 ﾠto	 ﾠanalyse	 ﾠthe	 ﾠfindings.	 ﾠThe	 ﾠtests	 ﾠare	 ﾠlimited	 ﾠin	 ﾠapplication,	 ﾠare	 ﾠ
unable	 ﾠ to	 ﾠ distinguish	 ﾠ between	 ﾠ different	 ﾠ PC	 ﾠ species	 ﾠ and	 ﾠ often	 ﾠ refer	 ﾠ only	 ﾠ to	 ﾠ
pulmonary	 ﾠdisaturated	 ﾠPC	 ﾠ(DSPC).	 ﾠThe	 ﾠoverall	 ﾠconsequence	 ﾠis	 ﾠa	 ﾠprolonged	 ﾠtime	 ﾠto	 ﾠ
availability	 ﾠof	 ﾠresults	 ﾠsuch	 ﾠthat	 ﾠit	 ﾠis	 ﾠoutwith	 ﾠa	 ﾠclinically	 ﾠrelevant	 ﾠtimeframe.	 ﾠ
Any	 ﾠ one	 ﾠ of	 ﾠ the	 ﾠ factors	 ﾠ listed	 ﾠ would	 ﾠ make	 ﾠ the	 ﾠ techniques	 ﾠ unhelpful	 ﾠ in	 ﾠ the	 ﾠ
translational	 ﾠ research	 ﾠ environment.	 ﾠ To	 ﾠ produce	 ﾠ meaningful	 ﾠ results	 ﾠ that	 ﾠ can	 ﾠ
impact	 ﾠ clinical	 ﾠ decision-ﾭ‐making	 ﾠ in	 ﾠ a	 ﾠ respiratory	 ﾠ intensive	 ﾠ care	 ﾠ setting,	 ﾠ an	 ﾠ
investigation	 ﾠmust	 ﾠbe	 ﾠacceptable	 ﾠto	 ﾠboth	 ﾠpatient	 ﾠand	 ﾠstaff,	 ﾠbe	 ﾠsimple	 ﾠenough	 ﾠto	 ﾠ
perform	 ﾠ easily,	 ﾠ should	 ﾠ use	 ﾠ analytical	 ﾠ techniques	 ﾠ that	 ﾠ are	 ﾠ readily	 ﾠ available	 ﾠ and	 ﾠ
inexpensive	 ﾠand	 ﾠshould	 ﾠbe	 ﾠable	 ﾠto	 ﾠproduce	 ﾠan	 ﾠinterpretable	 ﾠoutput	 ﾠwithin	 ﾠ24	 ﾠto	 ﾠ48	 ﾠ
hours.	 ﾠ
Animal	 ﾠstudies	 ﾠand	 ﾠlung	 ﾠmodel	 ﾠsystems	 ﾠusing	 ﾠradioactive	 ﾠtritium	 ﾠ[3H]	 ﾠlabelling	 ﾠof	 ﾠ
surfactant	 ﾠmolecules,	 ﾠincluding	 ﾠpalmitic	 ﾠacid	 ﾠand	 ﾠcholine,	 ﾠhad	 ﾠdemonstrated	 ﾠthe	 ﾠ
potential	 ﾠ for	 ﾠ the	 ﾠ isotopic	 ﾠ approach	 ﾠ but	 ﾠ given	 ﾠ the	 ﾠ radioactivity	 ﾠ produced	 ﾠ could	 ﾠ
never	 ﾠbe	 ﾠtranslated	 ﾠinto	 ﾠclinical	 ﾠstudies	 ﾠ(Jobe	 ﾠand	 ﾠGluck,	 ﾠ1979,	 ﾠJacobs	 ﾠet	 ﾠal.,	 ﾠ1982).	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1.9	 ﾠ Mass	 ﾠ spectrometry	 ﾠ and	 ﾠ choline	 ﾠ in	 ﾠ the	 ﾠ investigation	 ﾠ of	 ﾠ
phospholipid	 ﾠmetabolism	 ﾠ
A	 ﾠ major	 ﾠ breakthrough	 ﾠ arrived	 ﾠ by	 ﾠ combination	 ﾠ of	 ﾠ advanced	 ﾠ mass	 ﾠ spectrometry	 ﾠ
techniques	 ﾠand	 ﾠstable	 ﾠisotopes	 ﾠof	 ﾠcholine,	 ﾠa	 ﾠwater-ﾭ‐soluble	 ﾠessential	 ﾠnutrient,	 ﾠwhich	 ﾠ
is	 ﾠ grouped	 ﾠ with	 ﾠ the	 ﾠ B-ﾭ‐complex	 ﾠ vitamins.	 ﾠ Choline	 ﾠ is	 ﾠ a	 ﾠ natural	 ﾠ component	 ﾠ of	 ﾠ a	 ﾠ
healthy	 ﾠdiet	 ﾠand	 ﾠis	 ﾠused	 ﾠas	 ﾠa	 ﾠsubstrate	 ﾠfor	 ﾠthe	 ﾠproduction	 ﾠof	 ﾠsurfactant	 ﾠPC.	 ﾠCholine	 ﾠ
appears	 ﾠin	 ﾠthe	 ﾠhead	 ﾠgroups	 ﾠof	 ﾠboth	 ﾠPC	 ﾠand	 ﾠsphingomyelin.	 ﾠThe	 ﾠcholine	 ﾠmolecule	 ﾠ
contains	 ﾠ three	 ﾠ methyl	 ﾠ (CH3)	 ﾠ groups	 ﾠ and	 ﾠ has	 ﾠ the	 ﾠ chemical	 ﾠ formula	 ﾠ
(CH3)3N+CH2CH2OHX-ﾭ‐,	 ﾠwhere	 ﾠX-ﾭ‐	 ﾠis	 ﾠa	 ﾠcounterion,	 ﾠsuch	 ﾠas	 ﾠchloride	 ﾠ(Figure	 ﾠ3).	 ﾠ
	 ﾠ
Figure	 ﾠ3.	 ﾠStructure	 ﾠof	 ﾠcholine	 ﾠ
It	 ﾠ was	 ﾠ advances	 ﾠ in	 ﾠ laboratory	 ﾠ techniques,	 ﾠ specifically	 ﾠ electrospray	 ﾠ ionisation	 ﾠ
tandem	 ﾠmass	 ﾠspectrometry	 ﾠ(ESI	 ﾠMS/MS),	 ﾠwhich	 ﾠallowed	 ﾠthe	 ﾠnext	 ﾠadvance	 ﾠto	 ﾠmore	 ﾠ
detailed	 ﾠanalysis	 ﾠof	 ﾠintact	 ﾠmolecules	 ﾠ(Fenn,	 ﾠ2002).	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1.9.1	 ﾠElectrospray	 ﾠionisation	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ(ESI	 ﾠMS/MS)	 ﾠ
The	 ﾠuse	 ﾠof	 ﾠmass	 ﾠspectrometry	 ﾠ(MS)	 ﾠto	 ﾠmeasure	 ﾠmass	 ﾠto	 ﾠcharge	 ﾠratios	 ﾠof	 ﾠcharged	 ﾠ
particles	 ﾠ is	 ﾠ in	 ﾠ common	 ﾠ use	 ﾠ in	 ﾠ analytical	 ﾠ laboratories.	 ﾠ The	 ﾠ basic	 ﾠ MS	 ﾠ instrument	 ﾠ
consists	 ﾠof	 ﾠthree	 ﾠsections,	 ﾠnamely,	 ﾠ
i)  A	 ﾠsource	 ﾠwhich	 ﾠcan	 ﾠgenerate	 ﾠgas	 ﾠphase	 ﾠions,	 ﾠ	 ﾠ
ii)  A	 ﾠ mass	 ﾠ analyser	 ﾠ which	 ﾠ sorts	 ﾠ the	 ﾠ ions	 ﾠ according	 ﾠ to	 ﾠ their	 ﾠ masses	 ﾠ by	 ﾠ
application	 ﾠof	 ﾠelectromagnetic	 ﾠfields,	 ﾠand	 ﾠ	 ﾠ
iii)  A	 ﾠdetector	 ﾠto	 ﾠprovide	 ﾠdata	 ﾠfor	 ﾠcalculating	 ﾠthe	 ﾠabundance	 ﾠof	 ﾠeach	 ﾠion	 ﾠ
present.	 ﾠ
In	 ﾠESI	 ﾠMS/MS	 ﾠthe	 ﾠelectrospray	 ﾠion	 ﾠsource	 ﾠmoves	 ﾠions	 ﾠthat	 ﾠexist	 ﾠin	 ﾠsolution	 ﾠinto	 ﾠthe	 ﾠ
gas	 ﾠphase,	 ﾠprior	 ﾠto	 ﾠinjection	 ﾠinto	 ﾠthe	 ﾠfirst	 ﾠquadrupole	 ﾠmass	 ﾠanalyser.	 ﾠA	 ﾠquadrupole	 ﾠ
consists	 ﾠof	 ﾠfour	 ﾠparallel	 ﾠmetal	 ﾠrods	 ﾠwith	 ﾠeach	 ﾠopposing	 ﾠpair	 ﾠrod	 ﾠpair	 ﾠconnected	 ﾠ
electrically	 ﾠand	 ﾠapplication,	 ﾠbetween	 ﾠone	 ﾠpair	 ﾠof	 ﾠrods	 ﾠand	 ﾠthe	 ﾠother,	 ﾠof	 ﾠa	 ﾠradio	 ﾠ
frequency	 ﾠ voltage.	 ﾠ A	 ﾠ DC	 ﾠ voltage	 ﾠ is	 ﾠ then	 ﾠ superimposed	 ﾠ on	 ﾠ the	 ﾠ radio	 ﾠ frequency	 ﾠ
voltage.	 ﾠ Charged	 ﾠ molecules,	 ﾠ travelling	 ﾠ from	 ﾠ the	 ﾠ electrospray	 ﾠ ionisation	 ﾠ source,	 ﾠ
travel	 ﾠdown	 ﾠthe	 ﾠquadrupole	 ﾠbetween	 ﾠthe	 ﾠrods	 ﾠand	 ﾠby	 ﾠvarying	 ﾠthe	 ﾠratio	 ﾠof	 ﾠvoltages	 ﾠ
applied	 ﾠto	 ﾠthe	 ﾠrods	 ﾠmolecules	 ﾠor	 ﾠions	 ﾠof	 ﾠdifferent	 ﾠmass-ﾭ‐to-ﾭ‐charge	 ﾠratio	 ﾠ(m/z)	 ﾠwill	 ﾠ
travel	 ﾠthrough	 ﾠthe	 ﾠquadrupole	 ﾠand	 ﾠout	 ﾠthe	 ﾠother	 ﾠside.	 ﾠFor	 ﾠany	 ﾠgiven	 ﾠvoltage	 ﾠratio	 ﾠ
the	 ﾠmajority	 ﾠof	 ﾠother	 ﾠions	 ﾠwill	 ﾠhave	 ﾠan	 ﾠunstable	 ﾠtrajectory	 ﾠand	 ﾠcollide	 ﾠwith	 ﾠthe	 ﾠrods	 ﾠ
(Fenn	 ﾠet	 ﾠal.,	 ﾠ1989).	 ﾠ
In	 ﾠtandem	 ﾠMS	 ﾠthe	 ﾠtwo	 ﾠquadrupoles	 ﾠare	 ﾠarranged	 ﾠin	 ﾠseries	 ﾠwith	 ﾠa	 ﾠcollision	 ﾠchamber	 ﾠ
containing	 ﾠan	 ﾠinert	 ﾠgas	 ﾠbetween	 ﾠthem	 ﾠand	 ﾠa	 ﾠdetector	 ﾠplaced	 ﾠafter	 ﾠthe	 ﾠsecond.	 ﾠ
1.9.2	 ﾠPrecursor	 ﾠscanning	 ﾠusing	 ﾠESI	 ﾠMS/MS	 ﾠ
With	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠit	 ﾠis	 ﾠpossible	 ﾠto	 ﾠselect	 ﾠa	 ﾠproduct	 ﾠion	 ﾠof	 ﾠinterest	 ﾠ
emerging	 ﾠfrom	 ﾠthe	 ﾠcollision	 ﾠchamber,	 ﾠusing	 ﾠthe	 ﾠsecond	 ﾠquadrupole	 ﾠand	 ﾠthen	 ﾠscan	 ﾠa	 ﾠ 21	 ﾠ
spectrum	 ﾠof	 ﾠa	 ﾠpredefined	 ﾠm/z	 ﾠrange	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠquadrupole	 ﾠto	 ﾠdetermine	 ﾠwhich	 ﾠ
precursor	 ﾠions	 ﾠhave	 ﾠproduced	 ﾠthe	 ﾠproduct	 ﾠion	 ﾠ(Figure	 ﾠ4).	 ﾠ
	 ﾠ
Figure	 ﾠ4.	 ﾠA	 ﾠsimplified	 ﾠschematic	 ﾠof	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ
Ionised	 ﾠmolecules	 ﾠtravelling	 ﾠat	 ﾠspeed	 ﾠand	 ﾠin	 ﾠcollision	 ﾠwith	 ﾠan	 ﾠinert	 ﾠgas	 ﾠmolecule	 ﾠ
will	 ﾠfragment	 ﾠby	 ﾠcollision-ﾭ‐induced	 ﾠdissociation	 ﾠinto	 ﾠproduct	 ﾠions	 ﾠin	 ﾠa	 ﾠconsistent,	 ﾠ
reproducible	 ﾠ manner.	 ﾠ Hence,	 ﾠ for	 ﾠ example,	 ﾠ it	 ﾠ is	 ﾠ possible	 ﾠ to	 ﾠ determine	 ﾠ that	 ﾠ a	 ﾠ
precursor	 ﾠmolecule	 ﾠwith	 ﾠm/z	 ﾠof	 ﾠ734,	 ﾠextracted	 ﾠfrom	 ﾠa	 ﾠsample	 ﾠrich	 ﾠin	 ﾠphospholipid,	 ﾠ
consistently	 ﾠand	 ﾠpredominantly	 ﾠfragments	 ﾠto	 ﾠa	 ﾠproduct	 ﾠionised	 ﾠmolecule	 ﾠwith	 ﾠm/z	 ﾠ
184.	 ﾠIn	 ﾠMS	 ﾠnomenclature,	 ﾠthis	 ﾠwould	 ﾠbe	 ﾠcalled	 ﾠa	 ﾠprecursor	 ﾠof	 ﾠ184	 ﾠ(P184)	 ﾠscan.	 ﾠ	 ﾠ
1.10	 ﾠStable	 ﾠisotope	 ﾠanalysis	 ﾠof	 ﾠcholine	 ﾠmetabolism	 ﾠ
In	 ﾠthe	 ﾠcholine	 ﾠmolecule,	 ﾠeach	 ﾠof	 ﾠthe	 ﾠnine	 ﾠhydrogen	 ﾠatoms,	 ﾠcontained	 ﾠin	 ﾠthe	 ﾠthree	 ﾠ
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isotope	 ﾠatom	 ﾠof	 ﾠhydrogen	 ﾠthat	 ﾠcontains	 ﾠan	 ﾠextra	 ﾠneutron	 ﾠand	 ﾠas	 ﾠa	 ﾠconsequence	 ﾠis	 ﾠ
one	 ﾠmass	 ﾠunit	 ﾠheavier.	 ﾠThis	 ﾠdeuterated	 ﾠcholine	 ﾠis	 ﾠtherefore	 ﾠnine	 ﾠmass	 ﾠunits	 ﾠheavier	 ﾠ
than	 ﾠthe	 ﾠoriginal	 ﾠmolecule	 ﾠand	 ﾠcan	 ﾠbe	 ﾠused	 ﾠto	 ﾠtrace	 ﾠthe	 ﾠcholine	 ﾠmolecule	 ﾠthrough	 ﾠ
its	 ﾠmetabolism	 ﾠand	 ﾠincorporation	 ﾠinto	 ﾠPC	 ﾠas	 ﾠmeasured	 ﾠby	 ﾠESI	 ﾠMS/MS.	 ﾠ	 ﾠ
1.10.1	 ﾠCholine	 ﾠmetabolism	 ﾠby	 ﾠthe	 ﾠcytidine	 ﾠdiphosphate	 ﾠcholine	 ﾠpathway	 ﾠ
Different	 ﾠ phosphatidylcholine	 ﾠ metabolic	 ﾠ pathways	 ﾠ preserve	 ﾠ the	 ﾠ original	 ﾠ methyl	 ﾠ
groups	 ﾠ in	 ﾠ different	 ﾠ proportions.	 ﾠ For	 ﾠ example	 ﾠ the	 ﾠ cytidine	 ﾠ diphosphate	 ﾠ choline	 ﾠ
(CDP-ﾭ‐choline)	 ﾠpathway	 ﾠ(Figure	 ﾠ5),	 ﾠfound	 ﾠthroughout	 ﾠthe	 ﾠbody	 ﾠincluding	 ﾠthe	 ﾠAT-ﾭ‐II	 ﾠ
cells	 ﾠ(Kennedy,	 ﾠ1961),	 ﾠpreserves	 ﾠall	 ﾠthree	 ﾠmethyl	 ﾠgroups	 ﾠfrom	 ﾠthe	 ﾠoriginal	 ﾠcholine	 ﾠ
molecule.	 ﾠ
	 ﾠ
Figure	 ﾠ5.	 ﾠIllustration	 ﾠof	 ﾠCDP-ﾭ‐choline	 ﾠpathway	 ﾠwith	 ﾠpreservation	 ﾠof	 ﾠall	 ﾠthree	 ﾠ
methyl	 ﾠgroups	 ﾠfrom	 ﾠcholine	 ﾠthrough	 ﾠto	 ﾠphosphatidylcholine.	 ﾠDeuterium	 ﾠ
atoms	 ﾠhave	 ﾠreplaced	 ﾠhydrogen	 ﾠatoms	 ﾠin	 ﾠthe	 ﾠmethyl	 ﾠgroups.	 ﾠ
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1.10.2	 ﾠ Choline	 ﾠ metabolism	 ﾠ by	 ﾠ the	 ﾠ phosphatidylethanolamine-ﾭ‐N-ﾭ‐
methyltransferase	 ﾠpathway	 ﾠ
The	 ﾠ phosphatidylethanolamine-ﾭ‐N-ﾭ‐methyltransferase	 ﾠ (PEMT)	 ﾠ pathway	 ﾠ found	 ﾠ in	 ﾠ
hepatocytes	 ﾠ(Vance	 ﾠet	 ﾠal.,	 ﾠ1997)	 ﾠpreserves	 ﾠonly	 ﾠone	 ﾠmethyl	 ﾠgroup	 ﾠfrom	 ﾠcholine	 ﾠon	 ﾠ
each	 ﾠof	 ﾠthree	 ﾠmethylation	 ﾠsteps	 ﾠand	 ﾠhence	 ﾠthe	 ﾠdeuterated	 ﾠPC	 ﾠmolecules	 ﾠproduced	 ﾠ
by	 ﾠ the	 ﾠ different	 ﾠ pathways	 ﾠ will	 ﾠ have	 ﾠ different	 ﾠ masses	 ﾠ measurable	 ﾠ by	 ﾠ mass	 ﾠ
spectrometry	 ﾠ(Figure	 ﾠ6).	 ﾠ
	 ﾠ
Figure	 ﾠ6.	 ﾠThe	 ﾠsynthesis	 ﾠof	 ﾠPC	 ﾠvia	 ﾠthe	 ﾠPEMT	 ﾠpathway.	 ﾠOnly	 ﾠa	 ﾠsingle	 ﾠmethyl	 ﾠ
group	 ﾠis	 ﾠpreserved	 ﾠfrom	 ﾠcholine	 ﾠin	 ﾠthe	 ﾠfinal	 ﾠPC	 ﾠmolecule.	 ﾠIn	 ﾠthis	 ﾠdiagram	 ﾠ
deuterium	 ﾠatoms	 ﾠ(D)	 ﾠhave	 ﾠreplaced	 ﾠhydrogen	 ﾠatoms	 ﾠ(H)	 ﾠin	 ﾠthe	 ﾠcholine's	 ﾠ
methyl	 ﾠgroups.	 ﾠ
1.10.3	 ﾠCombination	 ﾠof	 ﾠESI	 ﾠMS/MS	 ﾠand	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠtechniques	 ﾠ
In	 ﾠ2004,	 ﾠPostle	 ﾠet	 ﾠal.	 ﾠdemonstrated,	 ﾠby	 ﾠanalysis	 ﾠof	 ﾠhuman	 ﾠvolunteer	 ﾠwhite	 ﾠblood	 ﾠ
cells,	 ﾠ that	 ﾠ the	 ﾠ novel	 ﾠ combination	 ﾠ of	 ﾠ tandem	 ﾠ electrospray	 ﾠ ionisation	 ﾠ mass	 ﾠ  24	 ﾠ
spectrometry	 ﾠ (ESI	 ﾠ MS/MS)	 ﾠ analysis	 ﾠ and	 ﾠ an	 ﾠ intravenous	 ﾠ infusion	 ﾠ of	 ﾠ [methyl-ﾭ‐
D9]choline	 ﾠ could	 ﾠ produce	 ﾠ significant	 ﾠ improvements	 ﾠ in	 ﾠ sensitivity,	 ﾠ permitting	 ﾠ
detection	 ﾠof	 ﾠD9	 ﾠenrichment	 ﾠ<0.01%	 ﾠ(Postle	 ﾠet	 ﾠal.,	 ﾠ2004).	 ﾠ
Bernhard	 ﾠet	 ﾠal.	 ﾠfurther	 ﾠdeveloped	 ﾠthis	 ﾠwork	 ﾠwhen	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠwas	 ﾠ
given	 ﾠto	 ﾠadult	 ﾠvolunteers	 ﾠand	 ﾠtheir	 ﾠinduced	 ﾠsputa	 ﾠanalysed.	 ﾠLinear	 ﾠincorporation	 ﾠ
was	 ﾠseen	 ﾠto	 ﾠ30	 ﾠhours	 ﾠwith	 ﾠa	 ﾠfractional	 ﾠincorporation	 ﾠplateau	 ﾠof	 ﾠ0.4%	 ﾠin	 ﾠplasma	 ﾠand	 ﾠ
0.6%	 ﾠin	 ﾠsputum.	 ﾠThe	 ﾠfractional	 ﾠincorporation	 ﾠthen	 ﾠfell	 ﾠto	 ﾠ0.3%	 ﾠby	 ﾠ3	 ﾠdays	 ﾠ(Bernhard	 ﾠ
et	 ﾠal.,	 ﾠ2004).	 ﾠ	 ﾠ
Both	 ﾠstudies	 ﾠconfirmed	 ﾠthat	 ﾠintravenous	 ﾠinfusion	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠ
when	 ﾠcombined	 ﾠwith	 ﾠESI	 ﾠMS/MS	 ﾠis	 ﾠuseful	 ﾠto	 ﾠinvestigate	 ﾠsurfactant	 ﾠmetabolism	 ﾠin	 ﾠ
humans	 ﾠin	 ﾠvivo.	 ﾠ
1.11	 ﾠThe	 ﾠadult	 ﾠliver,	 ﾠphosphatidylcholine	 ﾠand	 ﾠlipid	 ﾠmetabolism	 ﾠ
In	 ﾠthe	 ﾠhuman	 ﾠadult	 ﾠthe	 ﾠliver	 ﾠplays	 ﾠa	 ﾠfundamental	 ﾠrole	 ﾠin	 ﾠthe	 ﾠintegration	 ﾠof	 ﾠlipid	 ﾠ
metabolism.	 ﾠ The	 ﾠ diverse	 ﾠ chylomicrons	 ﾠ and	 ﾠ non-ﾭ‐esterified	 ﾠ fatty	 ﾠ acids	 ﾠ obtained	 ﾠ
from	 ﾠ varied	 ﾠ food	 ﾠ sources	 ﾠ are	 ﾠ converted	 ﾠ into	 ﾠ lipoprotein	 ﾠ lipids	 ﾠ for	 ﾠ export	 ﾠ to	 ﾠ
extrahepatic	 ﾠtissues.	 ﾠ	 ﾠ
Phosphatidylcholine	 ﾠsynthesis	 ﾠis	 ﾠessential	 ﾠfor	 ﾠvery-ﾭ‐low-ﾭ‐density	 ﾠlipoprotein	 ﾠ(VLDL)	 ﾠ
secretion	 ﾠfrom	 ﾠthe	 ﾠliver	 ﾠ(Yao	 ﾠand	 ﾠVance,	 ﾠ1988)	 ﾠand	 ﾠthe	 ﾠmodulation	 ﾠof	 ﾠPC	 ﾠsynthesis	 ﾠ
and	 ﾠmetabolism	 ﾠis	 ﾠdirectly	 ﾠlinked	 ﾠto	 ﾠa	 ﾠnumber	 ﾠof	 ﾠliver	 ﾠdiseases	 ﾠ(Lieber,	 ﾠ2004,	 ﾠSong	 ﾠ
et	 ﾠal.,	 ﾠ2005,	 ﾠVan	 ﾠBiervliet	 ﾠet	 ﾠal.,	 ﾠ2007,	 ﾠZeisel,	 ﾠ1992).	 ﾠ	 ﾠ
While	 ﾠPC	 ﾠlipoprotein	 ﾠis	 ﾠthe	 ﾠmajor	 ﾠvehicle	 ﾠfor	 ﾠexportation	 ﾠof	 ﾠpolyunsaturated	 ﾠfatty	 ﾠ
acids	 ﾠ (PUFA)	 ﾠ from	 ﾠ the	 ﾠ liver,	 ﾠ the	 ﾠ bulk	 ﾠ of	 ﾠ dietary	 ﾠ essential	 ﾠ fatty	 ﾠ acid	 ﾠ chain	 ﾠ
conversions,	 ﾠby	 ﾠelongation	 ﾠand	 ﾠdesaturation,	 ﾠto	 ﾠPUFA	 ﾠoccur	 ﾠintrahepatically.	 ﾠThe	 ﾠ
essential	 ﾠdietary	 ﾠfatty	 ﾠacids	 ﾠlinolate	 ﾠ(18:2n-ﾭ‐6)	 ﾠand	 ﾠα-ﾭ‐linolenate	 ﾠ(18:3n-ﾭ‐3)	 ﾠtherefore	 ﾠ
can	 ﾠbe	 ﾠconverted	 ﾠby	 ﾠdesaturases	 ﾠto	 ﾠthe	 ﾠpolyunsaturated	 ﾠarachidonate	 ﾠ(20:4n-ﾭ‐6),	 ﾠ 25	 ﾠ
eicosapentaenoate	 ﾠ (20:5n-ﾭ‐3)	 ﾠ and	 ﾠ docosahexaenoate	 ﾠ (22:6n-ﾭ‐3)	 ﾠ (Scott	 ﾠ and	 ﾠ Bazan,	 ﾠ
1989).	 ﾠ
Animal	 ﾠ models	 ﾠ for	 ﾠ extreme	 ﾠ prematurity	 ﾠ at	 ﾠ the	 ﾠ edge	 ﾠ of	 ﾠ viability	 ﾠ are	 ﾠ expensive,	 ﾠ
difficult	 ﾠ to	 ﾠ manage	 ﾠ and	 ﾠ poorly	 ﾠ reflect	 ﾠ the	 ﾠ neonatal	 ﾠ intensive	 ﾠ care	 ﾠ situation.	 ﾠ
Meanwhile	 ﾠ the	 ﾠ introduction	 ﾠ of	 ﾠ clinical	 ﾠ studies	 ﾠ in	 ﾠ the	 ﾠ NICU	 ﾠ environment	 ﾠ
necessitates	 ﾠspecial	 ﾠethical	 ﾠconsideration	 ﾠregarding	 ﾠthe	 ﾠsuitability	 ﾠand	 ﾠtolerability	 ﾠ
of	 ﾠprocedures	 ﾠand	 ﾠinterventions	 ﾠfor	 ﾠinfants	 ﾠand	 ﾠfamilies	 ﾠalike.	 ﾠ
For	 ﾠthese	 ﾠreasons	 ﾠthe	 ﾠmetabolism	 ﾠof	 ﾠphosphatidylcholine	 ﾠin	 ﾠextreme	 ﾠprematurity	 ﾠ
remains	 ﾠvery	 ﾠpoorly	 ﾠunderstood.	 ﾠThis	 ﾠis	 ﾠin	 ﾠcontrast	 ﾠto	 ﾠthe	 ﾠsituation	 ﾠin	 ﾠutero	 ﾠwhere	 ﾠ
the	 ﾠ transfer	 ﾠ of	 ﾠ lipids,	 ﾠ lipoproteins	 ﾠ and	 ﾠ free	 ﾠ fatty	 ﾠ acids	 ﾠ from	 ﾠ the	 ﾠ maternal	 ﾠ
bloodstream	 ﾠto	 ﾠthe	 ﾠfetus	 ﾠvia	 ﾠthe	 ﾠplacenta	 ﾠand	 ﾠtheir	 ﾠvariation	 ﾠthrough	 ﾠgestation	 ﾠhas	 ﾠ
been	 ﾠinvestigated.	 ﾠ
	 ﾠ
1.11.1	 ﾠPlacental	 ﾠlipid	 ﾠand	 ﾠfatty	 ﾠacid	 ﾠtransfer	 ﾠto	 ﾠfetus	 ﾠin	 ﾠnormal	 ﾠpregnancy	 ﾠ
Fetal	 ﾠmetabolism,	 ﾠand	 ﾠconsequently	 ﾠfetal	 ﾠgrowth,	 ﾠdirectly	 ﾠdepends	 ﾠon	 ﾠthe	 ﾠnutrients	 ﾠ
crossing	 ﾠ the	 ﾠ placenta	 ﾠ and	 ﾠ therefore	 ﾠ the	 ﾠ mother	 ﾠ must	 ﾠ adapt	 ﾠ her	 ﾠ metabolism	 ﾠ in	 ﾠ
order	 ﾠto	 ﾠsupport	 ﾠthis	 ﾠcontinuous	 ﾠdraining	 ﾠof	 ﾠsubstrates.	 ﾠ	 ﾠ
More	 ﾠthan	 ﾠ90%	 ﾠof	 ﾠthe	 ﾠfat	 ﾠdeposition	 ﾠin	 ﾠthe	 ﾠfetus	 ﾠoccurs	 ﾠin	 ﾠthe	 ﾠlast	 ﾠ10	 ﾠweeks	 ﾠof	 ﾠ
gestation	 ﾠduring	 ﾠwhich	 ﾠit	 ﾠincreases	 ﾠexponentially	 ﾠto	 ﾠreach	 ﾠa	 ﾠrate	 ﾠof	 ﾠaccretion	 ﾠof	 ﾠ
7g/day	 ﾠby	 ﾠterm	 ﾠ(Figure	 ﾠ7).	 ﾠPreterm	 ﾠinfants	 ﾠmiss	 ﾠout	 ﾠon	 ﾠthis	 ﾠfat	 ﾠdeposition	 ﾠphase	 ﾠof	 ﾠ
development	 ﾠ and	 ﾠ have	 ﾠ very	 ﾠ little	 ﾠ or	 ﾠ no	 ﾠ fat	 ﾠ stores	 ﾠ at	 ﾠ the	 ﾠ time	 ﾠ of	 ﾠ birth.	 ﾠ Fat	 ﾠ
deposition	 ﾠrepresents	 ﾠon	 ﾠaverage	 ﾠover	 ﾠhalf	 ﾠof	 ﾠthe	 ﾠenergy	 ﾠaccretion	 ﾠfrom	 ﾠthe	 ﾠ27th	 ﾠ
week	 ﾠof	 ﾠgestation	 ﾠuntil	 ﾠterm	 ﾠand	 ﾠas	 ﾠmuch	 ﾠas	 ﾠ90%	 ﾠat	 ﾠterm	 ﾠ(Sparks	 ﾠet	 ﾠal.,	 ﾠ1980,	 ﾠ
Sparks,	 ﾠ1984).	 ﾠAll	 ﾠof	 ﾠthe	 ﾠn-ﾭ‐3	 ﾠand	 ﾠn-ﾭ‐6	 ﾠfatty	 ﾠacid	 ﾠstructure	 ﾠacquired	 ﾠby	 ﾠthe	 ﾠfetus	 ﾠhas	 ﾠ  26	 ﾠ
to	 ﾠcross	 ﾠthe	 ﾠplacenta	 ﾠand	 ﾠfetal	 ﾠblood	 ﾠis	 ﾠenriched	 ﾠin	 ﾠlong	 ﾠchain	 ﾠpolyunsaturated	 ﾠ
fatty	 ﾠacids	 ﾠ(Haggarty	 ﾠet	 ﾠal.,	 ﾠ2002).	 ﾠ
	 ﾠ
Figure	 ﾠ7.	 ﾠFetal	 ﾠbody	 ﾠfat	 ﾠaccretion	 ﾠwith	 ﾠgestational	 ﾠage	 ﾠduring	 ﾠthe	 ﾠfetal	 ﾠperiod	 ﾠ
(adapted	 ﾠfrom	 ﾠWiddowson,E.M.	 ﾠ1968	 ﾠGrowth	 ﾠand	 ﾠcomposition	 ﾠof	 ﾠthe	 ﾠfetus	 ﾠ
and	 ﾠnewborn.	 ﾠIn	 ﾠThe	 ﾠBiology	 ﾠof	 ﾠGestation	 ﾠpp.	 ﾠ1-ﾭ‐49.	 ﾠNew	 ﾠYork:	 ﾠAcademic	 ﾠ
Press).	 ﾠ
Fatty	 ﾠacid	 ﾠcan	 ﾠcross	 ﾠthe	 ﾠmicrovillous	 ﾠand	 ﾠbasal	 ﾠmembranes	 ﾠby	 ﾠsimple	 ﾠdiffusion	 ﾠand	 ﾠ
via	 ﾠthe	 ﾠaction	 ﾠof	 ﾠmembrane	 ﾠbound	 ﾠand	 ﾠcytosolic	 ﾠfatty	 ﾠacid	 ﾠbinding	 ﾠproteins	 ﾠ(FABP).	 ﾠ
Direction	 ﾠand	 ﾠmagnitude	 ﾠof	 ﾠFA	 ﾠflux	 ﾠis	 ﾠmainly	 ﾠdictated	 ﾠby	 ﾠthe	 ﾠrelative	 ﾠabundance	 ﾠof	 ﾠ
available	 ﾠbinding	 ﾠsites	 ﾠ(Haggarty	 ﾠet	 ﾠal.,	 ﾠ1997,	 ﾠHull	 ﾠand	 ﾠElphick,	 ﾠ1978).	 ﾠ
The	 ﾠfacilitative	 ﾠdiffusion	 ﾠof	 ﾠglucose	 ﾠaccording	 ﾠto	 ﾠconcentration	 ﾠdependent	 ﾠkinetics	 ﾠ
and	 ﾠthe	 ﾠselective	 ﾠtransporters	 ﾠof	 ﾠamino	 ﾠacids	 ﾠare	 ﾠwell	 ﾠdescribed	 ﾠ(Illsley,	 ﾠ2000).	 ﾠ
Maternal	 ﾠ triglycerides	 ﾠ are	 ﾠ not	 ﾠ transported	 ﾠ intact	 ﾠ as	 ﾠ the	 ﾠ mechanisms	 ﾠ in	 ﾠ the	 ﾠ
placenta	 ﾠ only	 ﾠ allow	 ﾠ transfer	 ﾠ of	 ﾠ their	 ﾠ esterified	 ﾠ fatty	 ﾠ acids	 ﾠ to	 ﾠ the	 ﾠ fetus,	 ﾠ which	 ﾠ






























fulfil	 ﾠthe	 ﾠrequirements	 ﾠof	 ﾠessential	 ﾠfatty	 ﾠacids	 ﾠto	 ﾠthe	 ﾠdeveloping	 ﾠfetus	 ﾠ(Herrera,	 ﾠ
2002a).	 ﾠ
Studies	 ﾠof	 ﾠcord	 ﾠblood	 ﾠobtained	 ﾠthrough	 ﾠgestation	 ﾠand	 ﾠat	 ﾠdelivery	 ﾠshow	 ﾠthat	 ﾠthe	 ﾠmix	 ﾠ
of	 ﾠfatty	 ﾠacids	 ﾠin	 ﾠthe	 ﾠmaternal	 ﾠdiet	 ﾠdetermines	 ﾠthe	 ﾠtype	 ﾠand	 ﾠamount	 ﾠof	 ﾠfatty	 ﾠacids	 ﾠ
available	 ﾠto	 ﾠthe	 ﾠfetus	 ﾠduring	 ﾠpregnancy.	 ﾠHigh	 ﾠintakes	 ﾠof	 ﾠcertain	 ﾠfatty	 ﾠacids	 ﾠact	 ﾠto	 ﾠ
increase	 ﾠthe	 ﾠmaternal-ﾭ‐fetal	 ﾠgradient	 ﾠand	 ﾠincrease	 ﾠlevels	 ﾠin	 ﾠthe	 ﾠfetus	 ﾠ(Bansal	 ﾠet	 ﾠal.,	 ﾠ
2005).	 ﾠ
Lipids	 ﾠare	 ﾠtransferred	 ﾠto	 ﾠthe	 ﾠfetus	 ﾠalong	 ﾠmaternal-ﾭ‐fetal	 ﾠconcentration	 ﾠgradients	 ﾠ
mediated	 ﾠby	 ﾠspecific	 ﾠplacental	 ﾠfatty	 ﾠacid	 ﾠcarriers	 ﾠso	 ﾠthe	 ﾠhyperlipidaemic	 ﾠstate	 ﾠof	 ﾠ
late	 ﾠ pregnancy	 ﾠ significantly	 ﾠ increases	 ﾠ this	 ﾠ concentration	 ﾠ gradient	 ﾠ across	 ﾠ the	 ﾠ
placenta,	 ﾠ aided	 ﾠ by	 ﾠ an	 ﾠ increasing	 ﾠ surface	 ﾠ area	 ﾠ for	 ﾠ exchange	 ﾠ and	 ﾠ a	 ﾠ decreased	 ﾠ
diffusion	 ﾠdistance	 ﾠ(Haggarty,	 ﾠ2002)	 ﾠ
Free	 ﾠfatty	 ﾠacids	 ﾠcross	 ﾠthe	 ﾠplacenta	 ﾠby	 ﾠdiffusion	 ﾠin	 ﾠlimited	 ﾠamounts	 ﾠfrom	 ﾠthe	 ﾠmother	 ﾠ
to	 ﾠ the	 ﾠ fetus,	 ﾠ with	 ﾠ a	 ﾠ net	 ﾠ flux	 ﾠ of	 ﾠ unesterified	 ﾠ fatty	 ﾠ acids.	 ﾠ Maternal	 ﾠ plasma	 ﾠ non-ﾭ‐
esterified	 ﾠfatty	 ﾠacids	 ﾠ(NEFA)	 ﾠprovide	 ﾠan	 ﾠimportant	 ﾠsource	 ﾠof	 ﾠPUFA	 ﾠto	 ﾠthe	 ﾠfetus	 ﾠ
(Herrera,	 ﾠ2002b,	 ﾠHerrera	 ﾠand	 ﾠAmusquivar,	 ﾠ2000).	 ﾠ
1.11.2	 ﾠSelective	 ﾠfatty	 ﾠacid	 ﾠtransfer	 ﾠ
The	 ﾠlikelihood	 ﾠthat	 ﾠthe	 ﾠcomposition	 ﾠof	 ﾠfatty	 ﾠacids	 ﾠdelivered	 ﾠto	 ﾠthe	 ﾠfetus	 ﾠcan	 ﾠaffect	 ﾠ
the	 ﾠ quality	 ﾠ of	 ﾠ fetal	 ﾠ development	 ﾠ is	 ﾠ compelling.	 ﾠ Studies	 ﾠ have	 ﾠ shown	 ﾠ a	 ﾠ selective	 ﾠ
uptake	 ﾠof	 ﾠfatty	 ﾠacids	 ﾠfrom	 ﾠthe	 ﾠmaternal	 ﾠcirculation	 ﾠby	 ﾠthe	 ﾠfetus	 ﾠ(Hull	 ﾠand	 ﾠStammers,	 ﾠ
1985).	 ﾠ There	 ﾠ is	 ﾠ a	 ﾠ preferential	 ﾠ uptake	 ﾠ of	 ﾠ long-ﾭ‐chain	 ﾠ polyunsaturated	 ﾠ fatty	 ﾠ acids	 ﾠ
essential	 ﾠ for	 ﾠ structural	 ﾠ development	 ﾠ in	 ﾠ neural	 ﾠ tissue	 ﾠ such	 ﾠ as	 ﾠ arachidonic	 ﾠ acid	 ﾠ
(20:4n-ﾭ‐6)	 ﾠand	 ﾠdocosahexaenoic	 ﾠacid	 ﾠ(22:6n-ﾭ‐3)	 ﾠwith	 ﾠlower	 ﾠconcentrations	 ﾠof	 ﾠlinoleic	 ﾠ
(18:2n-ﾭ‐6)	 ﾠand	 ﾠα-ﾭ‐linolenic	 ﾠ(18:3n-ﾭ‐3)	 ﾠacid	 ﾠ(De	 ﾠVriese	 ﾠet	 ﾠal.,	 ﾠ2003,	 ﾠRuyle	 ﾠet	 ﾠal.,	 ﾠ1990,	 ﾠ
Larque	 ﾠet	 ﾠal.,	 ﾠ2003,	 ﾠKoletzko	 ﾠand	 ﾠMuller,	 ﾠ1990).	 ﾠEicosapentaenoic	 ﾠacid	 ﾠ(20:5n-ﾭ‐3)	 ﾠ  28	 ﾠ
and	 ﾠ the	 ﾠ sum	 ﾠ of	 ﾠ omega-ﾭ‐6	 ﾠ fatty	 ﾠ acids	 ﾠ in	 ﾠ the	 ﾠ maternal	 ﾠ diet	 ﾠ have	 ﾠ been	 ﾠ found	 ﾠ to	 ﾠ
positively	 ﾠcorrelate	 ﾠwith	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠthese	 ﾠfatty	 ﾠacids	 ﾠin	 ﾠthe	 ﾠcord	 ﾠplasma	 ﾠ(De	 ﾠ
Vriese	 ﾠet	 ﾠal.,	 ﾠ2002).	 ﾠ
Cord	 ﾠ NEFAs	 ﾠ correlate	 ﾠ with	 ﾠ those	 ﾠ in	 ﾠ maternal	 ﾠ plasma.	 ﾠ Total	 ﾠ saturated	 ﾠ and	 ﾠ
monounsaturated	 ﾠfatty	 ﾠacids	 ﾠwere	 ﾠfound	 ﾠat	 ﾠhigher	 ﾠpercentage	 ﾠvalues	 ﾠin	 ﾠcord	 ﾠthan	 ﾠ
maternal	 ﾠ plasma	 ﾠ and	 ﾠ there	 ﾠ exists	 ﾠ a	 ﾠ trend	 ﾠ for	 ﾠ positive	 ﾠ venous	 ﾠ to	 ﾠ arterial	 ﾠ
concentration	 ﾠfor	 ﾠthe	 ﾠsaturated,	 ﾠmonounsaturated	 ﾠand	 ﾠomega-ﾭ‐6	 ﾠPUFAs	 ﾠ(Ruyle	 ﾠet	 ﾠ
al.,	 ﾠ1990).	 ﾠThe	 ﾠtrans-ﾭ‐fatty	 ﾠacids	 ﾠare	 ﾠdetected	 ﾠin	 ﾠevery	 ﾠlipid	 ﾠfraction	 ﾠof	 ﾠmaternal	 ﾠand	 ﾠ
umbilical	 ﾠplasma	 ﾠin	 ﾠsimilar	 ﾠproportions,	 ﾠthus	 ﾠconfirming	 ﾠtheir	 ﾠplacental	 ﾠpassage,	 ﾠ
as	 ﾠthey	 ﾠare	 ﾠnot	 ﾠsynthesised	 ﾠby	 ﾠhuman	 ﾠtissue	 ﾠ(Koletzko	 ﾠand	 ﾠMuller,	 ﾠ1990,	 ﾠBerghaus	 ﾠ
et	 ﾠal.,	 ﾠ1998).	 ﾠ
1.11.3	 ﾠCholine	 ﾠmetabolism	 ﾠand	 ﾠrequirement	 ﾠin	 ﾠutero	 ﾠand	 ﾠafter	 ﾠterm	 ﾠdelivery	 ﾠ
Research	 ﾠindicates	 ﾠthat	 ﾠthe	 ﾠdeveloping	 ﾠhuman	 ﾠfetus	 ﾠhas	 ﾠa	 ﾠvery	 ﾠhigh	 ﾠrequirement	 ﾠ
for	 ﾠcholine.	 ﾠPregnancy	 ﾠis	 ﾠa	 ﾠtime	 ﾠof	 ﾠhigh	 ﾠcholine	 ﾠdemand	 ﾠwith	 ﾠactive	 ﾠtransport	 ﾠof	 ﾠ
choline	 ﾠfrom	 ﾠthe	 ﾠmother	 ﾠto	 ﾠthe	 ﾠfetus	 ﾠ(Sweiry	 ﾠet	 ﾠal.,	 ﾠ1986),	 ﾠwhich	 ﾠdepletes	 ﾠmaternal	 ﾠ
plasma	 ﾠcholine	 ﾠin	 ﾠhumans	 ﾠ(McMahon	 ﾠand	 ﾠFarrell,	 ﾠ1985).	 ﾠThe	 ﾠplacenta	 ﾠcontains	 ﾠ
choline	 ﾠ transport	 ﾠ systems	 ﾠ to	 ﾠ pump	 ﾠ it	 ﾠ against	 ﾠ a	 ﾠ concentration	 ﾠ gradient	 ﾠ and	 ﾠ
subsequently	 ﾠ stores	 ﾠ choline	 ﾠ as	 ﾠ acetylcholine.	 ﾠ Therefore	 ﾠ the	 ﾠ developing	 ﾠ fetus	 ﾠ is	 ﾠ
exposed	 ﾠ to	 ﾠ relatively	 ﾠ high	 ﾠ levels	 ﾠ of	 ﾠ choline	 ﾠ to	 ﾠ ensure	 ﾠ enhanced	 ﾠ availability	 ﾠ of	 ﾠ
choline	 ﾠ to	 ﾠ tissues.	 ﾠ At	 ﾠ birth	 ﾠ the	 ﾠ term	 ﾠ neonate	 ﾠ has	 ﾠ plasma	 ﾠ or	 ﾠ serum	 ﾠ choline	 ﾠ
concentrations	 ﾠthat	 ﾠare	 ﾠsix-ﾭ‐	 ﾠto	 ﾠsevenfold	 ﾠhigher	 ﾠthan	 ﾠthey	 ﾠare	 ﾠin	 ﾠthe	 ﾠadult	 ﾠ(Ozarda	 ﾠ
Ilcol	 ﾠet	 ﾠal.,	 ﾠ2002).	 ﾠAs	 ﾠhuman	 ﾠbreast	 ﾠmilk	 ﾠcontains	 ﾠa	 ﾠhigh	 ﾠconcentration	 ﾠof	 ﾠcholine,	 ﾠ
then	 ﾠlactation	 ﾠfurther	 ﾠincreases	 ﾠmaternal	 ﾠdemand	 ﾠfor	 ﾠcholine,	 ﾠresulting	 ﾠin	 ﾠfurther	 ﾠ
depletion	 ﾠof	 ﾠtissue	 ﾠstores	 ﾠin	 ﾠthe	 ﾠmother	 ﾠand	 ﾠindicating	 ﾠa	 ﾠcontinued	 ﾠhigh	 ﾠdemand	 ﾠ
from	 ﾠthe	 ﾠnewborn	 ﾠterm	 ﾠinfant	 ﾠ(Holmes-ﾭ‐McNary	 ﾠet	 ﾠal.,	 ﾠ1996).	 ﾠIn	 ﾠaddition	 ﾠto	 ﾠthese	 ﾠ 29	 ﾠ
findings	 ﾠ choline	 ﾠ also	 ﾠ appears	 ﾠ to	 ﾠ be	 ﾠ important	 ﾠ specifically	 ﾠ in	 ﾠ later	 ﾠ periods	 ﾠ of	 ﾠ
pregnancy	 ﾠ when	 ﾠ the	 ﾠ fetal	 ﾠ hippocampus	 ﾠ is	 ﾠ developing.	 ﾠ Maternal	 ﾠ dietary	 ﾠ choline	 ﾠ
supplementation	 ﾠ or	 ﾠ choline	 ﾠ deficiency	 ﾠ during	 ﾠ late	 ﾠ pregnancy	 ﾠ in	 ﾠ rodents	 ﾠ was	 ﾠ
associated	 ﾠwith	 ﾠsignificant	 ﾠand	 ﾠirreversible	 ﾠchanges	 ﾠin	 ﾠhippocampal	 ﾠfunction	 ﾠin	 ﾠthe	 ﾠ
adult	 ﾠ rodent,	 ﾠ including	 ﾠ altered	 ﾠ long-ﾭ‐term	 ﾠ potentiation	 ﾠ (Jones	 ﾠ et	 ﾠ al.,	 ﾠ 1999)	 ﾠ and	 ﾠ
altered	 ﾠmemory	 ﾠ(Meck	 ﾠand	 ﾠWilliams,	 ﾠ1999).	 ﾠ	 ﾠ
Choline	 ﾠrequirements	 ﾠfor	 ﾠfetal	 ﾠdevelopment	 ﾠand	 ﾠpostnatal	 ﾠgrowth	 ﾠare	 ﾠtherefore	 ﾠ
different	 ﾠfrom	 ﾠrequirements	 ﾠin	 ﾠadults	 ﾠwith	 ﾠsignificant	 ﾠlong-ﾭ‐term	 ﾠconsequences	 ﾠif	 ﾠ
insufficient	 ﾠcholine	 ﾠis	 ﾠavailable.	 ﾠNewborn	 ﾠpreterm	 ﾠinfants	 ﾠare	 ﾠat	 ﾠincreased	 ﾠrisk	 ﾠof	 ﾠ
neurodevelopmental	 ﾠ problems	 ﾠ and	 ﾠ a	 ﾠ better	 ﾠ understanding	 ﾠ of	 ﾠ their	 ﾠ choline	 ﾠ
metabolism	 ﾠmay	 ﾠimprove	 ﾠthe	 ﾠnutritional	 ﾠcare	 ﾠthat	 ﾠthey	 ﾠreceive.	 ﾠ
	 ﾠ
1.12	 ﾠAims	 ﾠof	 ﾠthesis	 ﾠ
If	 ﾠthe	 ﾠeffects	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠadministration	 ﾠon	 ﾠrecycling	 ﾠor	 ﾠendogenous	 ﾠ
production	 ﾠof	 ﾠsurfactant	 ﾠcan	 ﾠbe	 ﾠquantified	 ﾠthen	 ﾠthe	 ﾠability	 ﾠto	 ﾠdefine	 ﾠthese	 ﾠroutes	 ﾠof	 ﾠ
metabolism	 ﾠin	 ﾠvivo	 ﾠcould	 ﾠallow	 ﾠtreatment	 ﾠtailored	 ﾠto	 ﾠindividuals	 ﾠwith	 ﾠspecifically	 ﾠ
defined	 ﾠproblems	 ﾠin	 ﾠmetabolism,	 ﾠrather	 ﾠthan	 ﾠtreating	 ﾠall	 ﾠpreterm	 ﾠbabies	 ﾠin	 ﾠthe	 ﾠ
same	 ﾠmanner.	 ﾠ	 ﾠ
Additionally	 ﾠanalysis	 ﾠof	 ﾠthe	 ﾠmetabolism	 ﾠof	 ﾠcholine	 ﾠand	 ﾠsubsequent	 ﾠphospholipid	 ﾠ
composition	 ﾠin	 ﾠpreterm	 ﾠinfants,	 ﾠwho	 ﾠhave	 ﾠmissed	 ﾠout	 ﾠon	 ﾠa	 ﾠlarge	 ﾠpart	 ﾠof	 ﾠthe	 ﾠnormal	 ﾠ
in	 ﾠutero	 ﾠselective	 ﾠtransfer	 ﾠof	 ﾠcholine	 ﾠand	 ﾠfatty	 ﾠacids,	 ﾠand	 ﾠdeposition	 ﾠof	 ﾠfat	 ﾠstores	 ﾠ
occurring	 ﾠin	 ﾠthe	 ﾠlast	 ﾠtrimester	 ﾠof	 ﾠpregnancy,	 ﾠit	 ﾠmay	 ﾠbe	 ﾠpossible	 ﾠto	 ﾠquantify	 ﾠthe	 ﾠ
effect	 ﾠthis	 ﾠmetabolism	 ﾠhas	 ﾠon	 ﾠrespiratory	 ﾠand	 ﾠnutritional	 ﾠoutcomes.	 ﾠ
To	 ﾠanswer	 ﾠthese	 ﾠquestions	 ﾠa	 ﾠlarge	 ﾠstudy	 ﾠto	 ﾠcharacterise	 ﾠsurfactant	 ﾠand	 ﾠcholine	 ﾠ
metabolism	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠhuman	 ﾠinfant	 ﾠwas	 ﾠestablished,	 ﾠwith	 ﾠNational	 ﾠInstitute	 ﾠ  30	 ﾠ
for	 ﾠHealth	 ﾠResearch	 ﾠ(NIHR)	 ﾠrespiratory	 ﾠBiomedical	 ﾠResearch	 ﾠUnit	 ﾠ(RBRU)	 ﾠfunding,	 ﾠ
jointly	 ﾠ between	 ﾠ the	 ﾠ University	 ﾠ of	 ﾠ Southampton	 ﾠ (UoS)	 ﾠ and	 ﾠ University	 ﾠ Hospital	 ﾠ
Southampton,	 ﾠNHS	 ﾠFoundation	 ﾠTrust	 ﾠ(UHS).	 ﾠThe	 ﾠpurpose	 ﾠwas	 ﾠto	 ﾠrecruit	 ﾠa	 ﾠnumber	 ﾠ
of	 ﾠ extremely	 ﾠ premature	 ﾠ infants	 ﾠ within	 ﾠ one	 ﾠ or	 ﾠ 2	 ﾠ days	 ﾠ of	 ﾠ birth	 ﾠ and	 ﾠ who	 ﾠ are	 ﾠ at	 ﾠ
particularly	 ﾠhigh-ﾭ‐risk	 ﾠof	 ﾠRDS	 ﾠand	 ﾠsubsequently	 ﾠdeveloping	 ﾠlong-ﾭ‐term	 ﾠpulmonary	 ﾠ
and	 ﾠneurodevelopmental	 ﾠcomplications,	 ﾠto	 ﾠmeasure	 ﾠtheir	 ﾠmetabolism	 ﾠof	 ﾠsurfactant	 ﾠ
and	 ﾠ plasma	 ﾠ phospholipids	 ﾠ and,	 ﾠ later	 ﾠ on,	 ﾠ correlate	 ﾠ the	 ﾠ findings	 ﾠ with	 ﾠ clinical	 ﾠ
information	 ﾠcollected	 ﾠprospectively.	 ﾠ
Unlike	 ﾠthe	 ﾠstudies	 ﾠlimited	 ﾠto	 ﾠa	 ﾠsingle	 ﾠsubstrate	 ﾠand	 ﾠproduct,	 ﾠthe	 ﾠuse	 ﾠof	 ﾠ[methyl-ﾭ‐
D9]choline	 ﾠchloride	 ﾠidentifies	 ﾠall	 ﾠintact	 ﾠPC	 ﾠmolecules	 ﾠand	 ﾠwhen	 ﾠcombined	 ﾠwith	 ﾠESI	 ﾠ
MS/MS	 ﾠis	 ﾠmore	 ﾠsensitive,	 ﾠrapid	 ﾠand	 ﾠuses	 ﾠfewer	 ﾠcorrection	 ﾠfactors.	 ﾠThis	 ﾠrapidity,	 ﾠ
sensitivity	 ﾠand	 ﾠreproducibility	 ﾠcan	 ﾠpotentially	 ﾠmake	 ﾠit	 ﾠa	 ﾠpotent	 ﾠtool	 ﾠin	 ﾠthe	 ﾠclinical	 ﾠ
decision	 ﾠmaking	 ﾠprocess	 ﾠin	 ﾠthe	 ﾠneonatal	 ﾠintensive	 ﾠcare	 ﾠenvironment.	 ﾠ
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Chapter	 ﾠ2.	 ﾠMaterials	 ﾠand	 ﾠMethods	 ﾠ
2.1	 ﾠGeneral	 ﾠclinical	 ﾠstudy	 ﾠmethods	 ﾠ
2.1.1	 ﾠClinical	 ﾠstudy	 ﾠ
A	 ﾠlarge-ﾭ‐scale	 ﾠ“umbrella”	 ﾠstudy	 ﾠwas	 ﾠdesigned	 ﾠto	 ﾠidentify	 ﾠand	 ﾠcorrelate	 ﾠrisk	 ﾠfactors	 ﾠ
for	 ﾠdevelopment	 ﾠof	 ﾠnCLD	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠborn	 ﾠin	 ﾠtwo	 ﾠlarge	 ﾠNeonatal	 ﾠIntensive	 ﾠ
Care	 ﾠUnits	 ﾠ(previously	 ﾠknown	 ﾠas	 ﾠ“Level	 ﾠ3	 ﾠunits”)	 ﾠin	 ﾠthe	 ﾠSouth	 ﾠCentral	 ﾠNeonatal	 ﾠ
Network.	 ﾠThese	 ﾠneonatal	 ﾠunits	 ﾠare	 ﾠlocated	 ﾠin	 ﾠPrincess	 ﾠAnne	 ﾠHospital,	 ﾠSouthampton	 ﾠ
(Lead	 ﾠUnit)	 ﾠand	 ﾠQueen	 ﾠAlexandra	 ﾠHospital,	 ﾠPortsmouth.	 ﾠ
2.1.2	 ﾠLocal	 ﾠresearch	 ﾠethics	 ﾠcommittee	 ﾠapproval	 ﾠ
The	 ﾠ study	 ﾠ known	 ﾠ as	 ﾠ “Interactions	 ﾠ between	 ﾠ abnormalities	 ﾠ of	 ﾠ surfactant	 ﾠ biology,	 ﾠ
nutritive	 ﾠ metabolic	 ﾠ pathways,	 ﾠ pulmonary	 ﾠ microorganism	 ﾠ colonisation	 ﾠ and	 ﾠ the	 ﾠ
development	 ﾠof	 ﾠneonatal	 ﾠchronic	 ﾠlung	 ﾠdisease,”	 ﾠor	 ﾠ“The	 ﾠSurfactant,	 ﾠNutrition	 ﾠand	 ﾠ
Microorganism	 ﾠInteraction	 ﾠstudy	 ﾠin	 ﾠbabies	 ﾠat	 ﾠrisk	 ﾠof	 ﾠdeveloping	 ﾠneonatal	 ﾠchronic	 ﾠ
lung	 ﾠdisease	 ﾠ(TSuNaMI)”,	 ﾠethics	 ﾠcommittee	 ﾠreference	 ﾠnumber	 ﾠ09/H0502/95,	 ﾠwas	 ﾠ
approved	 ﾠfor	 ﾠimplementation	 ﾠin	 ﾠSouthampton	 ﾠand	 ﾠPortsmouth,	 ﾠfollowing	 ﾠa	 ﾠminor	 ﾠ
amendment	 ﾠto	 ﾠthe	 ﾠparent	 ﾠinformation	 ﾠsheet	 ﾠ(see	 ﾠAppendix),	 ﾠby	 ﾠthe	 ﾠSouthampton	 ﾠ
and	 ﾠSouth	 ﾠWest	 ﾠHampshire	 ﾠLocal	 ﾠResearch	 ﾠEthics	 ﾠCommittee	 ﾠin	 ﾠSeptember	 ﾠ2009.	 ﾠ	 ﾠ
A	 ﾠ further	 ﾠ minor	 ﾠ amendment	 ﾠ was	 ﾠ granted	 ﾠ in	 ﾠ March	 ﾠ 2010	 ﾠ with	 ﾠ the	 ﾠ addition	 ﾠ of	 ﾠ
King’s	 ﾠCollege	 ﾠLondon	 ﾠas	 ﾠa	 ﾠsite	 ﾠfor	 ﾠsample	 ﾠanalysis.	 ﾠ
	 ﾠ
2.1.3	 ﾠInclusion	 ﾠand	 ﾠexclusion	 ﾠcriteria	 ﾠ
Preterm	 ﾠinfants	 ﾠborn	 ﾠat	 ﾠhigh	 ﾠrisk	 ﾠof	 ﾠdeveloping	 ﾠRDS	 ﾠand	 ﾠnCLD	 ﾠwere	 ﾠenrolled	 ﾠto	 ﾠ
receive	 ﾠ a	 ﾠ short	 ﾠ infusion	 ﾠ of	 ﾠ [methyl-ﾭ‐D9]choline	 ﾠ chloride	 ﾠ and	 ﾠ have	 ﾠ sequential	 ﾠ  32	 ﾠ
samples	 ﾠof	 ﾠbody	 ﾠfluids	 ﾠcollected,	 ﾠprocessed	 ﾠand	 ﾠanalysed	 ﾠfor	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠnewly	 ﾠ
synthesised	 ﾠPC	 ﾠmolecules.	 ﾠ
i)	 ﾠInclusion	 ﾠCriteria	 ﾠ
•  Infants	 ﾠborn	 ﾠ≤28+6	 ﾠweeks	 ﾠand	 ﾠ≤1250g	 ﾠ
•  Age	 ﾠ≤48	 ﾠhours	 ﾠat	 ﾠtime	 ﾠof	 ﾠrecruitment	 ﾠ
•  Ventilated	 ﾠon	 ﾠNICU	 ﾠ
•  Informed	 ﾠconsent	 ﾠfrom	 ﾠchild’s	 ﾠparents	 ﾠobtained	 ﾠby	 ﾠinvestigator	 ﾠ
ii)	 ﾠExclusion	 ﾠCriteria	 ﾠ
•  Failure	 ﾠto	 ﾠobtain	 ﾠconsent	 ﾠ
•  Extreme	 ﾠ cardiovascular	 ﾠ instability,	 ﾠ for	 ﾠ example	 ﾠ requiring	 ﾠ multiple	 ﾠ
inotropes	 ﾠto	 ﾠmaintain	 ﾠnormal	 ﾠblood	 ﾠpressure	 ﾠ
•  Major	 ﾠ pulmonary	 ﾠ haemorrhage	 ﾠ requiring	 ﾠ active	 ﾠ treatment	 ﾠ and	 ﾠ
resuscitation	 ﾠ
•  Persistent	 ﾠair	 ﾠleak	 ﾠ
•  Unlikely	 ﾠto	 ﾠsurvive	 ﾠthe	 ﾠinitial	 ﾠtime	 ﾠperiod	 ﾠof	 ﾠthe	 ﾠintervention	 ﾠ	 ﾠ
•  Identified	 ﾠmajor	 ﾠcongenital	 ﾠabnormality	 ﾠ
	 ﾠ
2.1.4	 ﾠEntry	 ﾠprocedures	 ﾠ
An	 ﾠ investigator	 ﾠ obtained	 ﾠ informed	 ﾠ consent	 ﾠ from	 ﾠ the	 ﾠ parent	 ﾠ or	 ﾠ the	 ﾠ baby’s	 ﾠ legal	 ﾠ
guardian	 ﾠprior	 ﾠto	 ﾠperforming	 ﾠany	 ﾠof	 ﾠthe	 ﾠstudy’s	 ﾠprocedures.	 ﾠ
	 ﾠ 33	 ﾠ
2.1.5	 ﾠStudy	 ﾠperiod	 ﾠone:	 ﾠSubject	 ﾠrecruitment	 ﾠand	 ﾠscreening	 ﾠ
Pregnant	 ﾠ women	 ﾠ at	 ﾠ risk	 ﾠ of	 ﾠ preterm	 ﾠ delivery	 ﾠ were	 ﾠ identified	 ﾠ on	 ﾠ the	 ﾠ antenatal	 ﾠ
wards.	 ﾠIt	 ﾠis	 ﾠroutine	 ﾠpractice,	 ﾠwhere	 ﾠpossible,	 ﾠfor	 ﾠthese	 ﾠwomen	 ﾠto	 ﾠbe	 ﾠcounselled	 ﾠ
about	 ﾠthe	 ﾠpreterm	 ﾠdelivery	 ﾠby	 ﾠa	 ﾠsenior	 ﾠmember	 ﾠof	 ﾠthe	 ﾠneonatal	 ﾠmedical	 ﾠstaff.	 ﾠAt	 ﾠ
this	 ﾠpoint,	 ﾠthe	 ﾠwomen	 ﾠwere	 ﾠapproached	 ﾠfor	 ﾠinclusion	 ﾠin	 ﾠthe	 ﾠstudy.	 ﾠFollowing	 ﾠfull	 ﾠ
explanation	 ﾠof	 ﾠthe	 ﾠstudy	 ﾠobjectives	 ﾠand	 ﾠprocedures	 ﾠby	 ﾠan	 ﾠinvestigator,	 ﾠthey	 ﾠwere	 ﾠ
asked	 ﾠto	 ﾠconsider	 ﾠparticipating	 ﾠin	 ﾠthe	 ﾠstudy.	 ﾠConsent	 ﾠoccurred	 ﾠonly	 ﾠafter	 ﾠdelivery	 ﾠ
of	 ﾠthe	 ﾠpreterm	 ﾠinfant,	 ﾠits	 ﾠsuccessful	 ﾠresuscitation	 ﾠand	 ﾠadmission	 ﾠto	 ﾠthe	 ﾠneonatal	 ﾠ
intensive	 ﾠcare	 ﾠunit	 ﾠ(NICU).	 ﾠ
Additional	 ﾠinfants	 ﾠwere	 ﾠrecruited	 ﾠwithin	 ﾠ48	 ﾠhours	 ﾠof	 ﾠadmission	 ﾠto	 ﾠthe	 ﾠNICU	 ﾠif	 ﾠthe	 ﾠ
parents	 ﾠwere	 ﾠnot	 ﾠapproached	 ﾠantenatally.	 ﾠ
The	 ﾠstudy	 ﾠwas	 ﾠprospective	 ﾠand	 ﾠnon-ﾭ‐randomised.	 ﾠ	 ﾠ
Study	 ﾠPeriod	 ﾠ1	 ﾠ–	 ﾠScreening	 ﾠof	 ﾠpatient	 ﾠ
•  Clinical	 ﾠassessment	 ﾠ
•  Activities:	 ﾠ consent,	 ﾠ confirm	 ﾠ eligibility	 ﾠ requirements;	 ﾠ record	 ﾠ weight,	 ﾠ
gestation,	 ﾠvital	 ﾠsigns,	 ﾠventilatory	 ﾠrequirement,	 ﾠdosage	 ﾠof	 ﾠroutine	 ﾠexogenous	 ﾠ
surfactant	 ﾠreceived,	 ﾠblood	 ﾠgases	 ﾠand	 ﾠFiO2	 ﾠ
•  Gastric	 ﾠaspirate	 ﾠsample	 ﾠon	 ﾠadmission	 ﾠto	 ﾠNICU	 ﾠ
	 ﾠ
2.1.6	 ﾠStudy	 ﾠperiod	 ﾠtwo:	 ﾠInformed	 ﾠconsent	 ﾠand	 ﾠenrolment	 ﾠ
After	 ﾠinformed	 ﾠconsent	 ﾠhad	 ﾠbeen	 ﾠobtained	 ﾠand	 ﾠinfant	 ﾠwas	 ﾠenrolled	 ﾠto	 ﾠthe	 ﾠstudy	 ﾠ
then	 ﾠthe	 ﾠfollowing	 ﾠsamples	 ﾠand	 ﾠprocedures	 ﾠwere	 ﾠperformed.	 ﾠ
•  Baseline	 ﾠblood	 ﾠsample	 ﾠ
•  Baseline	 ﾠETA	 ﾠsample	 ﾠ
•  Baseline	 ﾠurine	 ﾠsample	 ﾠ  34	 ﾠ
•  [Methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠinfusion	 ﾠ(3.6mg/kg)	 ﾠgiven	 ﾠintravenously	 ﾠover	 ﾠ3	 ﾠ
hours	 ﾠin	 ﾠ10%	 ﾠdextrose	 ﾠ
•  ETA	 ﾠsamples	 ﾠwere	 ﾠtaken	 ﾠat	 ﾠ6	 ﾠhours,	 ﾠ12	 ﾠhours	 ﾠand	 ﾠthen	 ﾠdaily	 ﾠ(starting	 ﾠ24	 ﾠ
hours	 ﾠafter	 ﾠthe	 ﾠstart	 ﾠof	 ﾠthe	 ﾠinfusion)	 ﾠfor	 ﾠ5	 ﾠdays	 ﾠor	 ﾠuntil	 ﾠdiscontinuation	 ﾠof	 ﾠ
mechanical	 ﾠventilation	 ﾠ
•  Blood	 ﾠ and	 ﾠ urine	 ﾠ samples	 ﾠ were	 ﾠ collected	 ﾠ at	 ﾠ the	 ﾠ same	 ﾠ intervals	 ﾠ as	 ﾠ ET	 ﾠ
aspirates	 ﾠ
•  Those	 ﾠ infants	 ﾠ still	 ﾠ ventilated	 ﾠ at	 ﾠ 5	 ﾠ days	 ﾠ received	 ﾠ a	 ﾠ second	 ﾠ infusion	 ﾠ of	 ﾠ
[methyl-ﾭ‐D9]choline	 ﾠ chloride,	 ﾠ with	 ﾠ ET	 ﾠ aspirate,	 ﾠ blood	 ﾠ and	 ﾠ urine	 ﾠ samples	 ﾠ
collected	 ﾠwith	 ﾠthe	 ﾠsame	 ﾠregimen	 ﾠ
•  If	 ﾠre-ﾭ‐ventilated,	 ﾠfor	 ﾠwhatever	 ﾠreason,	 ﾠET	 ﾠaspirate	 ﾠspecimens	 ﾠwere	 ﾠcollected	 ﾠ
once	 ﾠdaily	 ﾠ
•  All	 ﾠ sample	 ﾠ collection	 ﾠ ended	 ﾠ at	 ﾠ hospital	 ﾠ discharge	 ﾠ or	 ﾠ transfer	 ﾠ to	 ﾠ non-ﾭ‐
participating	 ﾠunit	 ﾠ	 ﾠ
•  Activities:	 ﾠ daily	 ﾠ clinical	 ﾠ assessment	 ﾠ of	 ﾠ vital	 ﾠ signs,	 ﾠ ventilatory	 ﾠ settings,	 ﾠ
routine	 ﾠblood	 ﾠparameters;	 ﾠdisease	 ﾠseverity	 ﾠand	 ﾠmortality	 ﾠpredication	 ﾠdata;	 ﾠ
outpatient	 ﾠclinical	 ﾠfollow-ﾭ‐up	 ﾠand	 ﾠinvestigations	 ﾠ
	 ﾠ
2.1.7	 ﾠSample	 ﾠcollection	 ﾠ
The	 ﾠstudy	 ﾠsamples	 ﾠwere	 ﾠcollected	 ﾠat	 ﾠregular	 ﾠtimes	 ﾠfollowing	 ﾠrecruitment	 ﾠto	 ﾠthe	 ﾠ
study	 ﾠ(Table	 ﾠ1).	 ﾠ
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Table	 ﾠ1.	 ﾠThe	 ﾠroutine	 ﾠsamples	 ﾠcollected	 ﾠin	 ﾠTSuNaMI	 ﾠStudy.	 ﾠBaseline	 ﾠsamples	 ﾠ
(time	 ﾠ=	 ﾠ0	 ﾠhours)	 ﾠwere	 ﾠtaken	 ﾠat	 ﾠrecruitment	 ﾠand	 ﾠthen	 ﾠthe	 ﾠtime	 ﾠelapsed	 ﾠwas	 ﾠ
measured	 ﾠfrom	 ﾠthe	 ﾠstart	 ﾠof	 ﾠthe	 ﾠ3	 ﾠhour	 ﾠinfusion	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠ
chloride.	 ﾠ
	 ﾠ
To	 ﾠminimise	 ﾠpotentially	 ﾠnegative	 ﾠimpacts	 ﾠon	 ﾠoverall	 ﾠpatient	 ﾠcare,	 ﾠthe	 ﾠtiming	 ﾠof	 ﾠan	 ﾠ
individual	 ﾠbaby’s	 ﾠsample	 ﾠcollection	 ﾠwas	 ﾠcorrelated	 ﾠas	 ﾠclosely	 ﾠas	 ﾠpossible	 ﾠto	 ﾠtheir	 ﾠ
routine	 ﾠcomfort	 ﾠcares.	 ﾠ
2.1.8	 ﾠIntravenous	 ﾠinfusion	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠinfusion	 ﾠ	 ﾠ
After	 ﾠinformed	 ﾠconsent,	 ﾠventilated	 ﾠpreterm	 ﾠinfants	 ﾠin	 ﾠthe	 ﾠneonatal	 ﾠintensive	 ﾠcare	 ﾠ
unit	 ﾠ (NICU),	 ﾠ with	 ﾠ appropriate	 ﾠ arterial	 ﾠ and	 ﾠ venous	 ﾠ access,	 ﾠ were	 ﾠ given	 ﾠ an	 ﾠ
intravenous	 ﾠinfusion	 ﾠof	 ﾠsterile,	 ﾠpyrogen-ﾭ‐free	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠ3.6mg/kg	 ﾠ
over	 ﾠ 3	 ﾠ hours	 ﾠ made	 ﾠ up	 ﾠ in	 ﾠ 10%	 ﾠ dextrose	 ﾠ to	 ﾠ allow	 ﾠ replacement	 ﾠ of	 ﾠ normal	 ﾠ fluids	 ﾠ
rather	 ﾠthan	 ﾠin	 ﾠaddition	 ﾠto	 ﾠthem.	 ﾠ	 ﾠ
2.2	 ﾠSample	 ﾠcollection	 ﾠmaterials	 ﾠand	 ﾠmethods	 ﾠ
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2.2.1	 ﾠBlood	 ﾠsamples	 ﾠ
Blood	 ﾠ samples	 ﾠ (250µl)	 ﾠ were	 ﾠ collected	 ﾠ using	 ﾠ ethylenediaminetetraacetic	 ﾠ acid	 ﾠ
(EDTA)	 ﾠas	 ﾠanti-ﾭ‐coagulant	 ﾠfrom	 ﾠan	 ﾠindwelling	 ﾠarterial	 ﾠline	 ﾠat	 ﾠbaseline	 ﾠthen	 ﾠ6,	 ﾠ12,	 ﾠ24,	 ﾠ
48,	 ﾠ72,	 ﾠ96	 ﾠand	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠthe	 ﾠstart	 ﾠof	 ﾠthe	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠinfusion	 ﾠ
for	 ﾠmeasurement	 ﾠof	 ﾠlabelled	 ﾠphospholipid	 ﾠwhich	 ﾠwill	 ﾠprovide	 ﾠa	 ﾠmeasure	 ﾠof	 ﾠliver	 ﾠ
lipoprotein	 ﾠphospholipid	 ﾠas	 ﾠa	 ﾠcontrol	 ﾠfor	 ﾠthe	 ﾠET	 ﾠaspirate	 ﾠincorporation	 ﾠanalysis	 ﾠ
and	 ﾠto	 ﾠcharacterise	 ﾠliver	 ﾠPC	 ﾠmetabolism.	 ﾠ	 ﾠ
	 ﾠ	 ﾠ	 ﾠ
2.2.2	 ﾠEndotracheal	 ﾠaspirate	 ﾠspecimens	 ﾠ
Specimens	 ﾠof	 ﾠlung	 ﾠfluid	 ﾠwere	 ﾠcollected	 ﾠby	 ﾠgentle	 ﾠsuctioning	 ﾠafter	 ﾠinstillation	 ﾠof	 ﾠup	 ﾠ
to	 ﾠ0.5	 ﾠto	 ﾠ1ml	 ﾠof	 ﾠsterile	 ﾠsaline	 ﾠdown	 ﾠthe	 ﾠET	 ﾠtube.	 ﾠAs	 ﾠwith	 ﾠblood	 ﾠsamples	 ﾠthis	 ﾠwas	 ﾠ
performed	 ﾠat	 ﾠbaseline	 ﾠthen	 ﾠ6	 ﾠhours	 ﾠafter	 ﾠthe	 ﾠstart	 ﾠof	 ﾠadministration	 ﾠof	 ﾠthe	 ﾠ[methyl-ﾭ‐
D9]choline	 ﾠchloride,	 ﾠat	 ﾠ12	 ﾠhours	 ﾠand	 ﾠthen	 ﾠat	 ﾠdaily	 ﾠintervals	 ﾠfrom	 ﾠ24	 ﾠhours	 ﾠafter	 ﾠ
infusion	 ﾠfor	 ﾠ5	 ﾠdays	 ﾠor	 ﾠuntil	 ﾠventilation	 ﾠis	 ﾠdiscontinued,	 ﾠwhichever	 ﾠwas	 ﾠthe	 ﾠshorter	 ﾠ
period.	 ﾠThis	 ﾠtechnique	 ﾠis	 ﾠa	 ﾠcomponent	 ﾠof	 ﾠroutine	 ﾠendotracheal	 ﾠtoilet	 ﾠin	 ﾠintubated	 ﾠ
neonates.	 ﾠ	 ﾠ
2.2.3	 ﾠUrine	 ﾠspecimens	 ﾠ
Urine	 ﾠsamples	 ﾠwere	 ﾠcollected	 ﾠat	 ﾠsimilar	 ﾠintervals	 ﾠas	 ﾠblood	 ﾠand	 ﾠET	 ﾠaspirate	 ﾠsamples.	 ﾠ	 ﾠ
They	 ﾠ were	 ﾠ analysed	 ﾠ for	 ﾠ choline	 ﾠ metabolites	 ﾠ to	 ﾠ provide	 ﾠ an	 ﾠ assessment	 ﾠ of	 ﾠ the	 ﾠ
enrichment	 ﾠof	 ﾠstable	 ﾠisotope	 ﾠlabel	 ﾠin	 ﾠthe	 ﾠcholine	 ﾠpool.	 ﾠ	 ﾠ
2.2.4	 ﾠStabilisation	 ﾠsolutions	 ﾠ
Once	 ﾠ collected	 ﾠ the	 ﾠ samples	 ﾠ were	 ﾠ stabilised	 ﾠ by	 ﾠ the	 ﾠ addition	 ﾠ of	 ﾠ a	 ﾠ pre-ﾭ‐prepared	 ﾠ
aliquot	 ﾠof	 ﾠstabilisation	 ﾠsolution,	 ﾠdesigned	 ﾠfor	 ﾠeach	 ﾠsample	 ﾠtype.	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i)	 ﾠ Gastric	 ﾠ aspirate,	 ﾠ urine	 ﾠ and	 ﾠ endotracheal	 ﾠ aspirate	 ﾠ stabilisation	 ﾠ solution	 ﾠ
(GUESS)	 ﾠ
For	 ﾠthe	 ﾠgastric	 ﾠaspirate,	 ﾠurine	 ﾠand	 ﾠendotracheal	 ﾠaspirate	 ﾠsamples	 ﾠan	 ﾠeppendorf	 ﾠ
containing	 ﾠ 510µl	 ﾠ of	 ﾠ stabilisation	 ﾠ solution	 ﾠ was	 ﾠ added.	 ﾠ This	 ﾠ contained	 ﾠ 10µl	 ﾠ
butylhydroxytoluene	 ﾠ (BHT)	 ﾠ 20g/l	 ﾠ stock	 ﾠ solution	 ﾠ as	 ﾠ an	 ﾠ antioxidant	 ﾠ and	 ﾠ 500µl	 ﾠ
RNAlater®	 ﾠto	 ﾠprevent	 ﾠdegradation	 ﾠof	 ﾠbacterial	 ﾠor	 ﾠviral	 ﾠDNA/RNA.	 ﾠThis	 ﾠstabilisation	 ﾠ
solution,	 ﾠfor	 ﾠuse	 ﾠwith	 ﾠgastric	 ﾠaspirate,	 ﾠurine	 ﾠand	 ﾠETA	 ﾠ(GUESS),	 ﾠwas	 ﾠrefrigerated	 ﾠ
prior	 ﾠto	 ﾠuse.	 ﾠ
ii)	 ﾠBlood	 ﾠonly	 ﾠstabilisation	 ﾠsolution	 ﾠ(BOSS)	 ﾠ
For	 ﾠblood	 ﾠsamples,	 ﾠmeasuring	 ﾠ250µl	 ﾠin	 ﾠEDTA	 ﾠbottles,	 ﾠa	 ﾠblood-ﾭ‐specific	 ﾠstabilisation	 ﾠ
solution	 ﾠ of	 ﾠ 10µl	 ﾠ BHT	 ﾠ 20g/l	 ﾠ stock	 ﾠ solution	 ﾠ and	 ﾠ 200µl	 ﾠ 0.9%	 ﾠ NaCl	 ﾠ was	 ﾠ added	 ﾠ
immediately	 ﾠ following	 ﾠ collection.	 ﾠ This	 ﾠ blood-ﾭ‐only	 ﾠ stabilisation	 ﾠ solution	 ﾠ (BOSS)	 ﾠ
was	 ﾠrefrigerated	 ﾠprior	 ﾠto	 ﾠuse.	 ﾠ
In	 ﾠall	 ﾠcases	 ﾠthe	 ﾠsamples	 ﾠwere	 ﾠlabelled	 ﾠwith	 ﾠstudy	 ﾠidentification	 ﾠnumbers,	 ﾠsample	 ﾠ
type,	 ﾠ date	 ﾠ and	 ﾠ time	 ﾠ of	 ﾠ collection	 ﾠ and,	 ﾠ after	 ﾠ addition	 ﾠ of	 ﾠ stabilisation	 ﾠ solution,	 ﾠ
refrigerated	 ﾠimmediately	 ﾠusing	 ﾠthe	 ﾠdesignated	 ﾠrefrigerator	 ﾠon	 ﾠthe	 ﾠNICU.	 ﾠ
2.2.5	 ﾠSample	 ﾠcollection	 ﾠ
Samples	 ﾠwere	 ﾠcollected	 ﾠdaily	 ﾠand	 ﾠtransported	 ﾠon	 ﾠice	 ﾠto	 ﾠthe	 ﾠpreparation	 ﾠlaboratory	 ﾠ
in	 ﾠthe	 ﾠWellcome	 ﾠTrust	 ﾠClinical	 ﾠResearch	 ﾠFacility	 ﾠ(WTCRF)	 ﾠin	 ﾠSouthampton	 ﾠGeneral	 ﾠ
Hospital.	 ﾠ
2.2.6	 ﾠSample	 ﾠprocessing	 ﾠ
The	 ﾠsamples	 ﾠwere	 ﾠthen	 ﾠprocessed	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠTSuNaMI	 ﾠSample	 ﾠProcessing	 ﾠ
Protocol	 ﾠ(Appendix	 ﾠIII)	 ﾠbefore	 ﾠfreezing	 ﾠin	 ﾠaliquots	 ﾠdown	 ﾠto	 ﾠ-ﾭ‐80˚C.	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The	 ﾠmethod	 ﾠof	 ﾠprocessing	 ﾠwas	 ﾠadapted	 ﾠslightly	 ﾠfor	 ﾠuse	 ﾠby	 ﾠthe	 ﾠresearch	 ﾠnurses	 ﾠin	 ﾠ
Portsmouth	 ﾠ where	 ﾠ ETA	 ﾠ samples	 ﾠ were	 ﾠ not	 ﾠ spun	 ﾠ prior	 ﾠ to	 ﾠ aliquoting	 ﾠ due	 ﾠ to	 ﾠ
restricted	 ﾠlaboratory	 ﾠspace	 ﾠon	 ﾠthe	 ﾠNICU.	 ﾠPrior	 ﾠto	 ﾠbeing	 ﾠmoved,	 ﾠon	 ﾠdry	 ﾠice,	 ﾠto	 ﾠthe	 ﾠ
WTCRF,	 ﾠPortsmouth	 ﾠsamples	 ﾠwere	 ﾠfrozen	 ﾠat	 ﾠ-ﾭ‐20˚C.	 ﾠ
i)	 ﾠBlood	 ﾠsample	 ﾠprocessing	 ﾠ
Blood	 ﾠsamples	 ﾠof	 ﾠ250µl	 ﾠwere	 ﾠcollected	 ﾠinto	 ﾠstandard	 ﾠpaediatric	 ﾠEDTA	 ﾠblood	 ﾠbottles	 ﾠ
(750µl)	 ﾠ before	 ﾠ addition	 ﾠ of	 ﾠ the	 ﾠ specific	 ﾠ blood	 ﾠ stabilisation	 ﾠ solution,	 ﾠ as	 ﾠ detailed	 ﾠ
above.	 ﾠSamples	 ﾠwere	 ﾠrefrigerated	 ﾠat	 ﾠ4˚C	 ﾠuntil	 ﾠprocessing,	 ﾠmainly	 ﾠ<24	 ﾠhours	 ﾠlater.	 ﾠ
250µl	 ﾠsamples	 ﾠof	 ﾠblood	 ﾠwere	 ﾠcentrifuged	 ﾠat	 ﾠ3000rpm	 ﾠfor	 ﾠ15	 ﾠminutes	 ﾠat	 ﾠ4˚C.	 ﾠThe	 ﾠ
upper	 ﾠ plasma	 ﾠ layer	 ﾠ was	 ﾠ carefully	 ﾠ aspirated	 ﾠ and	 ﾠ separated	 ﾠ into	 ﾠ eppendorfs	 ﾠ as	 ﾠ
100µl	 ﾠaliquots.	 ﾠThe	 ﾠremaining	 ﾠred	 ﾠblood	 ﾠcell	 ﾠpellets	 ﾠwere	 ﾠretained	 ﾠand	 ﾠfrozen.	 ﾠThe	 ﾠ
aliquots	 ﾠ of	 ﾠ plasma	 ﾠ were	 ﾠ labelled	 ﾠ and	 ﾠ frozen	 ﾠ at	 ﾠ -ﾭ‐80˚C	 ﾠ until	 ﾠ lipid	 ﾠ extraction	 ﾠ was	 ﾠ
performed.	 ﾠ	 ﾠ
ii)	 ﾠETA	 ﾠsample	 ﾠprocessing	 ﾠ
ETA	 ﾠ samples	 ﾠ were	 ﾠ processed	 ﾠ by	 ﾠ addition	 ﾠ of	 ﾠ 200µl	 ﾠ of	 ﾠ 0.9%	 ﾠ NaCl	 ﾠ by	 ﾠ Hamilton	 ﾠ
syringe.	 ﾠ This	 ﾠ fluid	 ﾠ could	 ﾠ be	 ﾠ used	 ﾠ to	 ﾠ flush	 ﾠ any	 ﾠ suction	 ﾠ tubing	 ﾠ or	 ﾠ ET	 ﾠ catheters	 ﾠ
provided	 ﾠwith	 ﾠthe	 ﾠsample	 ﾠto	 ﾠensure	 ﾠas	 ﾠmuch	 ﾠresidue	 ﾠas	 ﾠpossible	 ﾠwas	 ﾠremoved.	 ﾠ
Samples	 ﾠwere	 ﾠseparated	 ﾠinto	 ﾠeppendorfs	 ﾠin	 ﾠ300µl	 ﾠaliquots	 ﾠbefore	 ﾠfreezing	 ﾠat	 ﾠ-ﾭ‐80˚C.	 ﾠ
iii)	 ﾠUrine	 ﾠsample	 ﾠprocessing	 ﾠ
Urine	 ﾠwas	 ﾠcollected	 ﾠfrom	 ﾠcotton	 ﾠwool	 ﾠpads	 ﾠplaced	 ﾠtowards	 ﾠthe	 ﾠfront	 ﾠof	 ﾠthe	 ﾠnappies	 ﾠ
of	 ﾠparticipating	 ﾠinfants.	 ﾠAfter	 ﾠstabilisation	 ﾠsolution	 ﾠwas	 ﾠadded	 ﾠthe	 ﾠsamples	 ﾠwere	 ﾠ
separated	 ﾠinto	 ﾠ2x	 ﾠ0.5ml	 ﾠaliquots	 ﾠand	 ﾠ1ml	 ﾠaliquots	 ﾠthereafter.	 ﾠAgain	 ﾠsamples	 ﾠwere	 ﾠ
frozen	 ﾠat	 ﾠ-ﾭ‐80˚C.	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iv)	 ﾠGastric	 ﾠaspirate	 ﾠsample	 ﾠprocessing	 ﾠ
Gastric	 ﾠ aspirates	 ﾠ were	 ﾠ not	 ﾠ separated	 ﾠ into	 ﾠ aliquots	 ﾠ and,	 ﾠ after	 ﾠ addition	 ﾠ of	 ﾠ
stabilisation	 ﾠsolution,	 ﾠwere	 ﾠstored	 ﾠwhole	 ﾠat	 ﾠ-ﾭ‐80˚C.	 ﾠ
	 ﾠ
2.2.7	 ﾠInternal	 ﾠstandards	 ﾠ
Prior	 ﾠto	 ﾠanalysis	 ﾠof	 ﾠlipids	 ﾠextracted	 ﾠfrom	 ﾠsamples	 ﾠa	 ﾠreliable	 ﾠinternal	 ﾠstandard	 ﾠmust	 ﾠ
be	 ﾠprepared	 ﾠwith	 ﾠwhich	 ﾠto	 ﾠcompare.	 ﾠThree	 ﾠinternal	 ﾠstandards	 ﾠwere	 ﾠprepared	 ﾠin	 ﾠ
chloroform	 ﾠwith	 ﾠdifferent	 ﾠconcentrations	 ﾠused	 ﾠin	 ﾠplasma	 ﾠand	 ﾠETA	 ﾠsamples.	 ﾠ	 ﾠ	 ﾠ
For	 ﾠplasma	 ﾠsamples:	 ﾠ
a)  10nmol	 ﾠDMPC	 ﾠ(0.1ml	 ﾠof	 ﾠ100nmol/ml	 ﾠsolution)	 ﾠ
b)  2nmol	 ﾠDMPG	 ﾠ(0.1ml	 ﾠof	 ﾠ20nmol/ml	 ﾠsolution)	 ﾠ
c)  1nmol	 ﾠLHPC	 ﾠ(0.1ml	 ﾠof	 ﾠ10nmol/ml	 ﾠsolution)	 ﾠ
For	 ﾠendotracheal	 ﾠaspirate	 ﾠsamples:	 ﾠ
a)  1nmol	 ﾠDMPC	 ﾠ(0.01ml	 ﾠof	 ﾠ100nmol/ml	 ﾠsolution)	 ﾠ
b)  0.2nmol	 ﾠDMPG	 ﾠ(0.01ml	 ﾠof	 ﾠ20nmol/ml	 ﾠsolution)	 ﾠ
c)  0.1nmol	 ﾠLHPC	 ﾠ(0.01ml	 ﾠof	 ﾠ10nmol/ml	 ﾠsolution)	 ﾠ
DMPC	 ﾠis	 ﾠdimyristoylglycerophosphocholine,	 ﾠ	 ﾠ
DMPG	 ﾠis	 ﾠdimyristoylglycerophosphoglycerol,	 ﾠ
LHPC	 ﾠis	 ﾠ1-ﾭ‐heptadecanoylglycerophosphocholine.	 ﾠ
2.2.8	 ﾠLipid	 ﾠextraction	 ﾠ
Lipids	 ﾠwere	 ﾠextracted	 ﾠand	 ﾠpurified	 ﾠusing	 ﾠa	 ﾠtechnique	 ﾠmodified	 ﾠfrom	 ﾠBligh	 ﾠand	 ﾠDyer	 ﾠ
(Bligh	 ﾠand	 ﾠDyer,	 ﾠ1959)	 ﾠas	 ﾠdescribed	 ﾠbelow.	 ﾠ
Samples	 ﾠ (100µl	 ﾠ plasma	 ﾠ or	 ﾠ 300µl	 ﾠ ETA)	 ﾠ had	 ﾠ volumes	 ﾠ adjusted	 ﾠ to	 ﾠ 800µl	 ﾠ with	 ﾠ
0.9%NaCl.	 ﾠThen	 ﾠ2ml	 ﾠof	 ﾠmethanol	 ﾠwere	 ﾠadded	 ﾠfollowed	 ﾠby	 ﾠ100µl	 ﾠof	 ﾠeach	 ﾠinternal	 ﾠ  40	 ﾠ
standard	 ﾠ (above)	 ﾠ and	 ﾠ 700µl	 ﾠ of	 ﾠ chloroform.	 ﾠ The	 ﾠ samples	 ﾠ were	 ﾠ centrifuged	 ﾠ at	 ﾠ
3000rpm,	 ﾠ4-ﾭ‐10˚C	 ﾠfor	 ﾠ10	 ﾠminutes.	 ﾠThe	 ﾠsupernatant	 ﾠwas	 ﾠcarefully	 ﾠdrawn	 ﾠoff	 ﾠto	 ﾠa	 ﾠnew	 ﾠ
drying	 ﾠtube	 ﾠand	 ﾠthe	 ﾠremaining	 ﾠprotein	 ﾠpellet	 ﾠsealed	 ﾠand	 ﾠfrozen	 ﾠfor	 ﾠfuture	 ﾠprotein	 ﾠ
analysis.	 ﾠTo	 ﾠthe	 ﾠsupernatant	 ﾠ1ml	 ﾠdistilled	 ﾠH2O	 ﾠand	 ﾠ1ml	 ﾠchloroform	 ﾠwere	 ﾠadded	 ﾠand	 ﾠ
centrifugation	 ﾠrepeated.	 ﾠThe	 ﾠlower	 ﾠ(chloroform)	 ﾠlayer	 ﾠwas	 ﾠthen	 ﾠcarefully	 ﾠaspirated,	 ﾠ
placed	 ﾠin	 ﾠa	 ﾠnew	 ﾠdrying	 ﾠtube	 ﾠand	 ﾠdried	 ﾠin	 ﾠa	 ﾠconcentrator	 ﾠat	 ﾠ37˚C	 ﾠunder	 ﾠcontinuous	 ﾠ
low	 ﾠflow	 ﾠof	 ﾠN2	 ﾠgas.	 ﾠOnce	 ﾠdry	 ﾠa	 ﾠfurther	 ﾠ500µl	 ﾠchloroform	 ﾠwas	 ﾠadded,	 ﾠsamples	 ﾠwere	 ﾠ
transferred	 ﾠto	 ﾠbrown-ﾭ‐glass	 ﾠmass	 ﾠspectrometry	 ﾠbottles	 ﾠand	 ﾠthe	 ﾠdrying	 ﾠprocess	 ﾠwas	 ﾠ
repeated.	 ﾠOnce	 ﾠdrying	 ﾠwas	 ﾠcompleted	 ﾠthe	 ﾠbottles	 ﾠwere	 ﾠcapped,	 ﾠlabelled	 ﾠand	 ﾠstored	 ﾠ
at	 ﾠ-ﾭ‐20˚C	 ﾠprior	 ﾠto	 ﾠanalysis	 ﾠby	 ﾠelectrospray	 ﾠionisation	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ
(ESI	 ﾠMS/MS).	 ﾠ
	 ﾠ
2.3	 ﾠAnalysis	 ﾠof	 ﾠprocessed	 ﾠsamples	 ﾠ
2.3.1	 ﾠSurfactant	 ﾠand	 ﾠplasma	 ﾠphospholipid	 ﾠanalysis	 ﾠby	 ﾠESI	 ﾠMS/MS	 ﾠ
The	 ﾠET	 ﾠand	 ﾠplasma	 ﾠsamples	 ﾠwere	 ﾠanalysed	 ﾠusing	 ﾠelectrospray	 ﾠionisation	 ﾠtandem	 ﾠ
mass	 ﾠspectrometry	 ﾠ(ESI	 ﾠMS/MS).	 ﾠ
Mass	 ﾠspectrometry	 ﾠscans	 ﾠof	 ﾠeach	 ﾠlipid	 ﾠextraction	 ﾠwere	 ﾠperformed	 ﾠin	 ﾠpositive	 ﾠand	 ﾠ
negative	 ﾠionisation	 ﾠand	 ﾠthen	 ﾠfor	 ﾠprecursors	 ﾠof	 ﾠm/z	 ﾠ184	 ﾠ(P184)	 ﾠwhich	 ﾠare	 ﾠspecific	 ﾠ
for	 ﾠPC.	 ﾠIn	 ﾠaddition,	 ﾠscans	 ﾠwere	 ﾠperformed	 ﾠfor	 ﾠP187,	 ﾠP190	 ﾠand	 ﾠP193.	 ﾠIn	 ﾠeach,	 ﾠthe	 ﾠ
tests	 ﾠperformed	 ﾠare	 ﾠto	 ﾠdetect	 ﾠmolecules	 ﾠwith	 ﾠmasses	 ﾠ3,	 ﾠ6	 ﾠor	 ﾠ9	 ﾠunits	 ﾠhigher	 ﾠthan	 ﾠthe	 ﾠ
endogenous	 ﾠsurfactant	 ﾠphospholipid	 ﾠmolecules.	 ﾠ	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2.3.2	 ﾠPlasma	 ﾠcholine	 ﾠand	 ﾠbetaine	 ﾠanalysis	 ﾠby	 ﾠliquid	 ﾠchromatography	 ﾠmultiple	 ﾠ
reaction	 ﾠmonitoring	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ
Metabolite	 ﾠanalysis	 ﾠof	 ﾠcholine	 ﾠwas	 ﾠperformed	 ﾠon	 ﾠsamples	 ﾠof	 ﾠplasma	 ﾠusing	 ﾠliquid	 ﾠ
chromatography	 ﾠmultiple	 ﾠreaction	 ﾠmonitoring	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ(LC-ﾭ‐
MRM-ﾭ‐MS/MS).	 ﾠFor	 ﾠthis	 ﾠstudy	 ﾠthe	 ﾠmetabolite	 ﾠanalysis	 ﾠwas	 ﾠperformed	 ﾠon	 ﾠplasma	 ﾠ
samples	 ﾠthat	 ﾠwere	 ﾠtaken	 ﾠup	 ﾠto	 ﾠ24	 ﾠhours	 ﾠfollowing	 ﾠrecruitment.	 ﾠ
i)	 ﾠExtraction	 ﾠof	 ﾠmetabolites	 ﾠfrom	 ﾠplasma	 ﾠ
Plasma	 ﾠfrom	 ﾠthe	 ﾠfirst	 ﾠ24h	 ﾠwere	 ﾠselected	 ﾠfor	 ﾠcholine	 ﾠmetabolite	 ﾠanalysis	 ﾠand	 ﾠ
prepared	 ﾠwith	 ﾠthe	 ﾠsame	 ﾠmodified	 ﾠBligh	 ﾠand	 ﾠDyer	 ﾠtechnique	 ﾠas	 ﾠdescribed	 ﾠin	 ﾠsection	 ﾠ
2.2.8	 ﾠexcept	 ﾠthat,	 ﾠat	 ﾠthe	 ﾠpoint	 ﾠof	 ﾠaspirating	 ﾠthe	 ﾠlower	 ﾠchloroform	 ﾠlayer,	 ﾠ2ml	 ﾠof	 ﾠthe	 ﾠ
upper	 ﾠaqueous	 ﾠlayer	 ﾠwas	 ﾠretained	 ﾠseparately.	 ﾠThis	 ﾠaqueous	 ﾠlayer	 ﾠwas	 ﾠfreeze-ﾭ‐dried	 ﾠ
overnight	 ﾠbefore	 ﾠreconstitution	 ﾠwith	 ﾠ100µl	 ﾠof	 ﾠa	 ﾠ1:1	 ﾠmixture	 ﾠof	 ﾠacetonitrile	 ﾠand	 ﾠ
water.	 ﾠFifty	 ﾠpicomoles	 ﾠof	 ﾠD4-ﾭ‐labelled	 ﾠcholine	 ﾠwere	 ﾠadded	 ﾠas	 ﾠthe	 ﾠinternal	 ﾠstandard	 ﾠ
and	 ﾠ10µl	 ﾠof	 ﾠthis	 ﾠsolution	 ﾠwas	 ﾠinjected	 ﾠinto	 ﾠthe	 ﾠLC-ﾭ‐MRM-ﾭ‐MS/MS.	 ﾠ
ii)	 ﾠ Liquid	 ﾠ chromatography	 ﾠ multiple	 ﾠ reaction	 ﾠ monitoring	 ﾠ tandem	 ﾠ mass	 ﾠ
spectrometry	 ﾠ(LC-ﾭ‐MRM-ﾭ‐MS/MS)	 ﾠ
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Table	 ﾠ2.	 ﾠTable	 ﾠof	 ﾠthe	 ﾠliquid	 ﾠchromatography	 ﾠgradients	 ﾠused	 ﾠto	 ﾠstudy	 ﾠcholine	 ﾠ
and	 ﾠmetabolites	 ﾠ
	 ﾠ
	 ﾠMobile	 ﾠphases	 ﾠfor	 ﾠliquid	 ﾠchromatography	 ﾠwere	 ﾠ500	 ﾠmM	 ﾠammonium	 ﾠformate	 ﾠ(pH	 ﾠ
4.1)	 ﾠfor	 ﾠSolvent	 ﾠA	 ﾠand	 ﾠacetonitrile,	 ﾠ0.05	 ﾠ%	 ﾠformic	 ﾠacid	 ﾠfor	 ﾠSolvent	 ﾠB	 ﾠwith	 ﾠMRM	 ﾠ








Time%(minutes)  Flow%Rate%(ml/min)  %%Composition%of%Solvent%B 
0  0.2  99 
1  0.2  80 
3.5  0.2  60 
4  0.2  30 
4.1  0.2  2 
6.6  0.2  90 
7.6  0.2  90 
8  0.2  99 
8.6  0.2  99 
8.7  0.2  99 
9  0.2  99  43	 ﾠ
Table	 ﾠ3.	 ﾠTable	 ﾠof	 ﾠthe	 ﾠmultiple	 ﾠreaction	 ﾠmonitoring	 ﾠtransitions	 ﾠused	 ﾠto	 ﾠstudy	 ﾠ
choline	 ﾠand	 ﾠmetabolites	 ﾠ
	 ﾠ
	 ﾠ
2.3.3	 ﾠAnalysis	 ﾠof	 ﾠESI	 ﾠMS/MS	 ﾠdata	 ﾠ
The	 ﾠdata	 ﾠoutput	 ﾠfrom	 ﾠthe	 ﾠESI	 ﾠMS/MS	 ﾠwere	 ﾠinitially	 ﾠanalysed	 ﾠin	 ﾠMassLynx	 ﾠ(version	 ﾠ
4.0,	 ﾠWaters	 ﾠCorporation).	 ﾠ	 ﾠ	 ﾠ
MassLynx	 ﾠ raw	 ﾠ data	 ﾠ files	 ﾠ were	 ﾠ extracted	 ﾠ in	 ﾠ Microsoft	 ﾠ Excel	 ﾠ to	 ﾠ give	 ﾠ m/z	 ﾠ versus	 ﾠ
intensity	 ﾠtables	 ﾠand	 ﾠthese	 ﾠwere	 ﾠused	 ﾠto	 ﾠcalculate	 ﾠpercentages,	 ﾠabsolute	 ﾠamounts	 ﾠ
and	 ﾠ incorporation	 ﾠ of	 ﾠ all	 ﾠ and	 ﾠ selected	 ﾠ species.	 ﾠ The	 ﾠ extraction	 ﾠ of	 ﾠ data	 ﾠ and	 ﾠ
subsequent	 ﾠ calculation	 ﾠ analyses	 ﾠ were	 ﾠ undertaken	 ﾠ using	 ﾠ two	 ﾠ purpose-ﾭ‐built	 ﾠ
programmes	 ﾠ(macros)	 ﾠfor	 ﾠMicrosoft	 ﾠExcel	 ﾠwritten	 ﾠby	 ﾠGrielof	 ﾠKoster,	 ﾠPhD.	 ﾠ
Compound  Parent-Mass  Daughter-Mass 
Dimethylglycine  103.8  57.9 
Choline  103.8  59.8 
D67dimethylglycine  109.8  63.9 
D97choline  112.9  68.9 
Betaine  117.9  58.9 
D97betaine  126.9  67.9 
Phosphocholine  183.9  85.9 
D97phosphocholine  192.9  94.9   44	 ﾠ
i)	 ﾠ Extractor	 ﾠ programme	 ﾠ for	 ﾠ conversion	 ﾠ of	 ﾠ raw	 ﾠ MassLynx	 ﾠ data	 ﾠ to	 ﾠ Microsoft	 ﾠ
Excel	 ﾠformat	 ﾠ
MassLynx	 ﾠspectrum	 ﾠfiles	 ﾠwere	 ﾠextracted	 ﾠto	 ﾠMicrosoft	 ﾠExcel	 ﾠto	 ﾠproduce	 ﾠa	 ﾠtable	 ﾠof	 ﾠ
mass/charge	 ﾠratio	 ﾠand	 ﾠintensity	 ﾠfor	 ﾠeach	 ﾠscan	 ﾠof	 ﾠeach	 ﾠsample.	 ﾠ	 ﾠ
The	 ﾠ “extractor”	 ﾠ is	 ﾠ a	 ﾠ macro	 ﾠ programme	 ﾠ written	 ﾠ in	 ﾠ Visual	 ﾠ Basic	 ﾠ for	 ﾠ Applications	 ﾠ
(VBA),	 ﾠwhich	 ﾠruns	 ﾠin	 ﾠMicrosoft	 ﾠExcel	 ﾠthat	 ﾠsummates	 ﾠover	 ﾠthe	 ﾠspectrum	 ﾠpeak	 ﾠareas	 ﾠ
and	 ﾠsubtracts	 ﾠthe	 ﾠbackground	 ﾠnoise	 ﾠto	 ﾠdetermine	 ﾠwhere	 ﾠthe	 ﾠpeak	 ﾠoccurs.	 ﾠ	 ﾠ
The	 ﾠversion	 ﾠof	 ﾠthe	 ﾠextractor	 ﾠprogramme	 ﾠused	 ﾠis	 ﾠ“extractor	 ﾠV1v06	 ﾠ	 ﾠ25may2012.xls”.	 ﾠ
ii)	 ﾠMicrosoft	 ﾠExcel	 ﾠVBA	 ﾠprogramme	 ﾠto	 ﾠanalyse	 ﾠextracted	 ﾠMassLynx	 ﾠtables	 ﾠ
The	 ﾠMicrosoft	 ﾠExcel	 ﾠVBA	 ﾠprogramme	 ﾠcan	 ﾠbe	 ﾠused	 ﾠto	 ﾠanalyse	 ﾠmultiple	 ﾠextracted	 ﾠ
samples	 ﾠ from	 ﾠ different	 ﾠ patients	 ﾠ simultaneously	 ﾠ but	 ﾠ the	 ﾠ sample	 ﾠ type	 ﾠ must	 ﾠ be	 ﾠ
consistent	 ﾠbetween	 ﾠsubjects.	 ﾠ
Using	 ﾠ a	 ﾠ list	 ﾠ of	 ﾠ phospholipid	 ﾠ species	 ﾠ and	 ﾠ their	 ﾠ expected	 ﾠ mass/charge	 ﾠ ratio,	 ﾠ the	 ﾠ
“analyser”	 ﾠmacro	 ﾠprogramme	 ﾠimports	 ﾠthe	 ﾠmatching	 ﾠpoints	 ﾠto	 ﾠan	 ﾠExcel	 ﾠspreadsheet.	 ﾠ
The	 ﾠ species	 ﾠ list	 ﾠ is	 ﾠ used	 ﾠ to	 ﾠ create	 ﾠ a	 ﾠ mass	 ﾠ and	 ﾠ isotopic	 ﾠ distribution	 ﾠ table.	 ﾠ A	 ﾠ
correction	 ﾠfor	 ﾠpotential	 ﾠadduct	 ﾠformation	 ﾠ(e.g.	 ﾠNa+)	 ﾠmay	 ﾠbe	 ﾠperformed	 ﾠat	 ﾠthis	 ﾠtime.	 ﾠ
Following	 ﾠ this,	 ﾠ using	 ﾠ a	 ﾠ “nest	 ﾠ table”	 ﾠ for	 ﾠ isotope	 ﾠ distributions,	 ﾠ a	 ﾠ correction	 ﾠ for	 ﾠ
naturally	 ﾠ occurring	 ﾠ isotopes	 ﾠ is	 ﾠ made;	 ﾠ therefore,	 ﾠ for	 ﾠ example,	 ﾠ 13C	 ﾠ is	 ﾠ taken	 ﾠ into	 ﾠ
account.	 ﾠAfter	 ﾠthe	 ﾠinter-ﾭ‐sheet	 ﾠ(worksheet)	 ﾠand	 ﾠmachine	 ﾠcorrections	 ﾠfor	 ﾠisotopes	 ﾠ
have	 ﾠbeen	 ﾠperformed,	 ﾠa	 ﾠlist	 ﾠis	 ﾠgenerated	 ﾠof	 ﾠindependent	 ﾠor	 ﾠseparate	 ﾠmass/charge	 ﾠ
ratios	 ﾠand	 ﾠtheir	 ﾠintensities.	 ﾠ
The	 ﾠ presence	 ﾠ of	 ﾠ internal	 ﾠ standards	 ﾠ is	 ﾠ taken	 ﾠ into	 ﾠ account	 ﾠ and,	 ﾠ after	 ﾠ they	 ﾠ are	 ﾠ
removed,	 ﾠ a	 ﾠ list	 ﾠ of	 ﾠ the	 ﾠ relative	 ﾠ percentages	 ﾠ of	 ﾠ all	 ﾠ phospholipids	 ﾠ and	 ﾠ any	 ﾠ other	 ﾠ
identified	 ﾠmass/charges	 ﾠcan	 ﾠbe	 ﾠcalculated.	 ﾠ	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Another	 ﾠ set	 ﾠ of	 ﾠ parameters	 ﾠ is	 ﾠ implemented,	 ﾠ such	 ﾠ that	 ﾠ a	 ﾠ subgroup	 ﾠ of	 ﾠ selected	 ﾠ
species	 ﾠof	 ﾠinterest	 ﾠcan	 ﾠbe	 ﾠanalysed	 ﾠseparately.	 ﾠThis	 ﾠsubgroup	 ﾠcan	 ﾠbe	 ﾠdefined	 ﾠby	 ﾠ
individual	 ﾠspecies	 ﾠbut	 ﾠusually	 ﾠis	 ﾠset	 ﾠby	 ﾠselecting	 ﾠthe	 ﾠmost	 ﾠfrequently	 ﾠfound	 ﾠspecies	 ﾠ
in	 ﾠthe	 ﾠanalysis.	 ﾠFor	 ﾠexample,	 ﾠin	 ﾠthis	 ﾠstudy	 ﾠthe	 ﾠspecies	 ﾠwere	 ﾠselected	 ﾠby	 ﾠpercentage	 ﾠ
frequency.	 ﾠ For	 ﾠ plasma	 ﾠ analysis	 ﾠ the	 ﾠ species	 ﾠ were	 ﾠ selected	 ﾠ on	 ﾠ the	 ﾠ basis	 ﾠ of	 ﾠ an	 ﾠ
occurrence	 ﾠ of	 ﾠ more	 ﾠ than	 ﾠ eight	 ﾠ species	 ﾠ representing	 ﾠ at	 ﾠ least	 ﾠ 1.5%.	 ﾠ 	 ﾠ For	 ﾠ
endotracheal	 ﾠ aspirate	 ﾠ analysis	 ﾠ the	 ﾠ species	 ﾠ were	 ﾠ selected	 ﾠ on	 ﾠ the	 ﾠ basis	 ﾠ of	 ﾠ an	 ﾠ
occurrence	 ﾠof	 ﾠmore	 ﾠthan	 ﾠfive	 ﾠspecies	 ﾠrepresenting	 ﾠat	 ﾠleast	 ﾠ1.5%.	 ﾠ	 ﾠ	 ﾠ
In	 ﾠaddition	 ﾠto	 ﾠthe	 ﾠrelative	 ﾠpercentages	 ﾠthe	 ﾠanalyser	 ﾠproduces	 ﾠa	 ﾠtable	 ﾠof	 ﾠabsolute	 ﾠ
amounts	 ﾠof	 ﾠall	 ﾠspecies	 ﾠand	 ﾠselected	 ﾠspecies	 ﾠin	 ﾠeach	 ﾠsample	 ﾠon	 ﾠeach	 ﾠscan,	 ﾠagain	 ﾠ
taking	 ﾠinternal	 ﾠstandards	 ﾠinto	 ﾠaccount.	 ﾠ
At	 ﾠthis	 ﾠpoint	 ﾠthe	 ﾠfractional	 ﾠenrichment	 ﾠor	 ﾠfractional	 ﾠincorporation	 ﾠis	 ﾠcalculated	 ﾠfor	 ﾠ
all	 ﾠspecies	 ﾠand	 ﾠselected	 ﾠspecies	 ﾠusing	 ﾠthe	 ﾠformula:	 ﾠ
	 ﾠ
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 ﾠ𝑖𝑛𝑐𝑜𝑟𝑝𝑜𝑟𝑎𝑡𝑖𝑜𝑛 ﾠ % =
𝑃184
Σ 𝑃184 + 𝑃187 + 𝑃190 + 𝑃193
	 ﾠ
	 ﾠ
If	 ﾠresults	 ﾠfrom	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+187	 ﾠand	 ﾠ+190	 ﾠscans	 ﾠare	 ﾠincluded	 ﾠin	 ﾠthe	 ﾠ
initial	 ﾠset-ﾭ‐up	 ﾠthen	 ﾠthe	 ﾠprogramme	 ﾠwill	 ﾠnow	 ﾠcalculate	 ﾠthe	 ﾠmethionine	 ﾠenrichment,	 ﾠ
which	 ﾠtakes	 ﾠinto	 ﾠaccount	 ﾠthe	 ﾠ13C	 ﾠcoming	 ﾠfrom	 ﾠmethionine	 ﾠusing	 ﾠthe	 ﾠformula:	 ﾠ
	 ﾠ
𝑀𝑒𝑡ℎ𝑖𝑜𝑛𝑖𝑛𝑒 ﾠ𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 ﾠ % =
𝑃190
Σ 𝑃187 + 𝑃190
	 ﾠ
This	 ﾠmethionine	 ﾠenrichment	 ﾠcan	 ﾠthen	 ﾠbe	 ﾠconverted	 ﾠto	 ﾠan	 ﾠabsolute	 ﾠrate	 ﾠof	 ﾠsynthesis	 ﾠ
by	 ﾠS-ﾭ‐adenosylmethionine	 ﾠ(SAMe).	 ﾠ  46	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2.4	 ﾠClinical	 ﾠdata	 ﾠcollection	 ﾠmethods	 ﾠ
2.4.1	 ﾠCase	 ﾠreport	 ﾠforms	 ﾠ
All	 ﾠrecruited	 ﾠinfants,	 ﾠhad	 ﾠongoing	 ﾠclinical	 ﾠdata	 ﾠcollected	 ﾠto	 ﾠpaper	 ﾠcase	 ﾠreport	 ﾠforms	 ﾠ
(CRFs)	 ﾠ(see	 ﾠAppendix	 ﾠII)	 ﾠby	 ﾠthe	 ﾠRespiratory	 ﾠBiomedical	 ﾠResearch	 ﾠUnit’s	 ﾠmedical	 ﾠ
and	 ﾠnursing	 ﾠstaff.	 ﾠThe	 ﾠdata	 ﾠcollected	 ﾠrelates	 ﾠto	 ﾠantenatal,	 ﾠperinatal	 ﾠand	 ﾠpostnatal	 ﾠ
periods.	 ﾠIn	 ﾠaddition	 ﾠto	 ﾠthe	 ﾠinitial	 ﾠdata,	 ﾠinformation	 ﾠwas	 ﾠcollected	 ﾠon	 ﾠa	 ﾠweekly	 ﾠbasis	 ﾠ
until	 ﾠdischarge	 ﾠfrom	 ﾠthe	 ﾠneonatal	 ﾠintensive	 ﾠcare	 ﾠunit.	 ﾠ
2.4.2	 ﾠMicrosoft	 ﾠAccess	 ﾠdatabase	 ﾠ
A	 ﾠMicrosoft	 ﾠAccess	 ﾠdatabase	 ﾠwas	 ﾠdesigned,	 ﾠbuilt	 ﾠand	 ﾠtested	 ﾠwith	 ﾠcooperation	 ﾠfrom	 ﾠ
the	 ﾠ Department	 ﾠ of	 ﾠ Public	 ﾠ Health	 ﾠ Sciences	 ﾠ and	 ﾠ Medical	 ﾠ Statistics	 ﾠ (PHSMS)	 ﾠ in	 ﾠ
Southampton	 ﾠGeneral	 ﾠHospital.	 ﾠ
Data	 ﾠ relating	 ﾠ to	 ﾠ ventilatory	 ﾠ requirements,	 ﾠ infection	 ﾠ status,	 ﾠ nutritional	 ﾠ
supplementation,	 ﾠcurrent	 ﾠmedication	 ﾠand	 ﾠother	 ﾠsignificant	 ﾠevents	 ﾠwas	 ﾠcollected	 ﾠ
prospectively	 ﾠ at	 ﾠ each	 ﾠ data	 ﾠ collection	 ﾠ time	 ﾠ point.	 ﾠ Matching	 ﾠ data	 ﾠ was	 ﾠ therefore	 ﾠ
available	 ﾠfor	 ﾠeach	 ﾠset	 ﾠof	 ﾠspecimens	 ﾠcollected	 ﾠduring	 ﾠthe	 ﾠstudy.	 ﾠ	 ﾠ
2.4.3	 ﾠData	 ﾠmanagement	 ﾠand	 ﾠstatistics	 ﾠ
Following	 ﾠdata	 ﾠentry,	 ﾠmanual	 ﾠchecking	 ﾠand	 ﾠcleaning	 ﾠprogrammes	 ﾠwill	 ﾠbe	 ﾠrun	 ﾠto	 ﾠ
ensure	 ﾠconsistency	 ﾠbetween	 ﾠdouble-ﾭ‐entered	 ﾠrecords	 ﾠand	 ﾠto	 ﾠcheck	 ﾠfor	 ﾠoutlying	 ﾠor	 ﾠ
missing	 ﾠdata.	 ﾠProblems	 ﾠin	 ﾠthe	 ﾠdata	 ﾠwill	 ﾠbe	 ﾠresolved	 ﾠby	 ﾠchecking	 ﾠagainst	 ﾠthe	 ﾠoriginal	 ﾠ
paper	 ﾠrecords.	 ﾠFollowing	 ﾠthis	 ﾠinitial	 ﾠdata	 ﾠcleaning,	 ﾠa	 ﾠstatistician	 ﾠwill	 ﾠreview	 ﾠthe	 ﾠ
data	 ﾠ and	 ﾠ data	 ﾠ will	 ﾠ be	 ﾠ further	 ﾠ checked	 ﾠ and	 ﾠ cleaned	 ﾠ as	 ﾠ needed.	 ﾠ Only	 ﾠ three	 ﾠ
individuals	 ﾠcompleted	 ﾠthe	 ﾠdata	 ﾠcollection	 ﾠonto	 ﾠthe	 ﾠCRFs	 ﾠto	 ﾠensure	 ﾠconsistency	 ﾠin	 ﾠ 47	 ﾠ
coding	 ﾠ decisions.	 ﾠ The	 ﾠ clinical	 ﾠ data	 ﾠ is	 ﾠ not	 ﾠ presented	 ﾠ in	 ﾠ this	 ﾠ thesis	 ﾠ but	 ﾠ will	 ﾠ be	 ﾠ
included	 ﾠin	 ﾠfuture	 ﾠpublications	 ﾠfrom	 ﾠthis	 ﾠstudy.	 ﾠ
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Chapter	 ﾠ3.	 ﾠThe	 ﾠprofile	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠ
plasma	 ﾠwith	 ﾠanalysis	 ﾠof	 ﾠtheir	 ﾠsynthesis	 ﾠfrom	 ﾠcholine	 ﾠvia	 ﾠ
the	 ﾠCDP-ﾭ‐choline	 ﾠpathway	 ﾠin	 ﾠa	 ﾠpreterm	 ﾠpopulation	 ﾠ
3.1	 ﾠIntroduction	 ﾠ
Choline	 ﾠis	 ﾠan	 ﾠessential	 ﾠnutrient	 ﾠin	 ﾠhuman	 ﾠdevelopment	 ﾠ(Zeisel	 ﾠand	 ﾠda	 ﾠCosta,	 ﾠ2009).	 ﾠ
The	 ﾠquaternary	 ﾠammonium	 ﾠsalt	 ﾠcontaining	 ﾠcation	 ﾠappears	 ﾠin	 ﾠthe	 ﾠhead	 ﾠgroup	 ﾠof	 ﾠthe	 ﾠ
phosphatidylcholine	 ﾠphospholipids	 ﾠand	 ﾠsphingomyelin,	 ﾠcholine	 ﾠmetabolites	 ﾠare	 ﾠa	 ﾠ
major	 ﾠ source	 ﾠ of	 ﾠ methyl	 ﾠ groups	 ﾠ in	 ﾠ the	 ﾠ s-ﾭ‐adenosyl	 ﾠ methionine	 ﾠ (SAMe)	 ﾠ synthetic	 ﾠ
pathway	 ﾠ and	 ﾠ choline	 ﾠ is	 ﾠ a	 ﾠ precursor	 ﾠ molecule	 ﾠ for	 ﾠ the	 ﾠ neurotransmitter	 ﾠ
acetylcholine.	 ﾠ
Throughout	 ﾠpregnancy	 ﾠthe	 ﾠmaternal	 ﾠstores	 ﾠof	 ﾠcholine	 ﾠare	 ﾠdepleted	 ﾠas	 ﾠplacental	 ﾠ
choline	 ﾠ concentration	 ﾠ increases	 ﾠ and	 ﾠ the	 ﾠ fetus	 ﾠ is	 ﾠ exposed	 ﾠ to	 ﾠ a	 ﾠ high	 ﾠ choline	 ﾠ
environment	 ﾠ but	 ﾠ preterm	 ﾠ delivery	 ﾠ at	 ﾠ ≤29	 ﾠ weeks	 ﾠ gestation	 ﾠ interrupts	 ﾠ this	 ﾠ
developmental	 ﾠprogression	 ﾠof	 ﾠcholine	 ﾠaccumulation	 ﾠand	 ﾠutilisation.	 ﾠ
Unlike	 ﾠdelivery	 ﾠat	 ﾠterm,	 ﾠthe	 ﾠpreterm	 ﾠbaby	 ﾠhas	 ﾠnot	 ﾠlaid	 ﾠdown	 ﾠfat	 ﾠstores	 ﾠto	 ﾠprepare	 ﾠ
for	 ﾠthe	 ﾠnormal	 ﾠinterruption	 ﾠto	 ﾠthe	 ﾠplacental	 ﾠsupply	 ﾠof	 ﾠmaternally	 ﾠderived	 ﾠnutrients	 ﾠ
and	 ﾠsubsequent	 ﾠconversion	 ﾠto	 ﾠfull	 ﾠnourishment	 ﾠby	 ﾠbreast	 ﾠmilk.	 ﾠDue	 ﾠto	 ﾠimmaturity	 ﾠ
of	 ﾠthe	 ﾠgut	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠis	 ﾠunable	 ﾠto	 ﾠtolerate	 ﾠenteral	 ﾠfeeding	 ﾠfor	 ﾠseveral	 ﾠdays	 ﾠ
after	 ﾠdelivery	 ﾠand	 ﾠmay	 ﾠnot	 ﾠbe	 ﾠfully	 ﾠenterally	 ﾠfed	 ﾠfor	 ﾠmany	 ﾠweeks.	 ﾠInstead	 ﾠthese	 ﾠ
children	 ﾠare	 ﾠdependent	 ﾠupon	 ﾠintravenous	 ﾠnutrition	 ﾠwith	 ﾠa	 ﾠcombination	 ﾠof	 ﾠVamin®	 ﾠ
(a	 ﾠ crystalloid	 ﾠ sugar	 ﾠ solution	 ﾠ with	 ﾠ salts	 ﾠ and	 ﾠ amino	 ﾠ acids)	 ﾠ and	 ﾠ a	 ﾠ separate	 ﾠ lipid	 ﾠ
(colloid)	 ﾠsolution.	 ﾠLittle	 ﾠis	 ﾠknown	 ﾠabout	 ﾠhow	 ﾠthese	 ﾠpreterm	 ﾠinfants	 ﾠmetabolise	 ﾠthe	 ﾠ
choline	 ﾠand	 ﾠlipids	 ﾠthey	 ﾠreceive	 ﾠin	 ﾠTPN.	 ﾠAn	 ﾠunderstanding	 ﾠof	 ﾠthe	 ﾠliver	 ﾠfunction	 ﾠin	 ﾠ
the	 ﾠpreterm	 ﾠinfant	 ﾠand	 ﾠthe	 ﾠin	 ﾠvivo	 ﾠmetabolism	 ﾠof	 ﾠcholine	 ﾠto	 ﾠphosphatidylcholine	 ﾠ
phospholipids	 ﾠwill	 ﾠinform	 ﾠdecisions	 ﾠin	 ﾠthe	 ﾠpreparation	 ﾠand	 ﾠadministration	 ﾠof	 ﾠTPN	 ﾠ
components	 ﾠspecifically	 ﾠdesigned	 ﾠfor	 ﾠpreterm	 ﾠinfants.	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In	 ﾠthis	 ﾠchapter	 ﾠthe	 ﾠresults	 ﾠof	 ﾠthe	 ﾠESI	 ﾠMS/MS	 ﾠanalysis	 ﾠof	 ﾠplasma	 ﾠlipid	 ﾠextracts	 ﾠare	 ﾠ
presented	 ﾠ and	 ﾠ discussed	 ﾠ with	 ﾠ particular	 ﾠ focus	 ﾠ on	 ﾠ the	 ﾠ overall	 ﾠ composition	 ﾠ of	 ﾠ
phosphatidylcholine	 ﾠ phospholipids	 ﾠ and	 ﾠ the	 ﾠ D9-ﾭ‐containing	 ﾠ phosphatidylcholine	 ﾠ
phospholipids	 ﾠderived	 ﾠspecifically	 ﾠfrom	 ﾠthe	 ﾠCDP-ﾭ‐choline	 ﾠpathway.	 ﾠ	 ﾠ	 ﾠ
3.1.1	 ﾠMethodologies	 ﾠused	 ﾠin	 ﾠplasma	 ﾠCDP-ﾭ‐choline	 ﾠinvestigation	 ﾠ
Recruited	 ﾠinfants,	 ﾠin	 ﾠreceipt	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠwithin	 ﾠ48	 ﾠhours	 ﾠof	 ﾠbirth,	 ﾠ
who	 ﾠwere	 ﾠborn	 ﾠat	 ﾠless	 ﾠthan	 ﾠ29	 ﾠweeks	 ﾠgestation	 ﾠwith	 ﾠa	 ﾠbirthweight	 ﾠof	 ﾠ≤1250g	 ﾠhad	 ﾠ
serial	 ﾠ samples	 ﾠ of	 ﾠ blood	 ﾠ collected	 ﾠ from	 ﾠ arterial	 ﾠ lines	 ﾠ for	 ﾠ up	 ﾠ to	 ﾠ 120	 ﾠ hours	 ﾠ after	 ﾠ
administration	 ﾠinfusion.	 ﾠSamples	 ﾠof	 ﾠplasma	 ﾠwere	 ﾠcollected	 ﾠas	 ﾠpreviously	 ﾠdescribed,	 ﾠ
in	 ﾠChapter	 ﾠ2.2	 ﾠMaterials	 ﾠand	 ﾠMethods.	 ﾠBlood	 ﾠsample	 ﾠprocessing	 ﾠis	 ﾠdiscussed	 ﾠin	 ﾠ
Chapter	 ﾠ2.2.5	 ﾠ(i)	 ﾠand	 ﾠthe	 ﾠlipid	 ﾠextraction	 ﾠof	 ﾠplasma	 ﾠaliquots	 ﾠis	 ﾠdescribed	 ﾠin	 ﾠChapter	 ﾠ
2.2.8.	 ﾠ The	 ﾠ theory	 ﾠ and	 ﾠ methodology	 ﾠ of	 ﾠ electrospray	 ﾠ ionisation	 ﾠ tandem	 ﾠ mass	 ﾠ
spectrometry	 ﾠ (ESI	 ﾠ MS/MS)	 ﾠ with	 ﾠ direct	 ﾠ infusion	 ﾠ has	 ﾠ been	 ﾠ discussed	 ﾠ in	 ﾠ the	 ﾠ
introduction	 ﾠChapter	 ﾠ1.8.	 ﾠ
3.2	 ﾠPrecursors	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠscanning	 ﾠ
To	 ﾠexamine	 ﾠthe	 ﾠPC	 ﾠcontent	 ﾠof	 ﾠthe	 ﾠplasma	 ﾠsamples,	 ﾠlipid	 ﾠextracts	 ﾠwere	 ﾠfirst	 ﾠanalysed	 ﾠ
for	 ﾠ precursors	 ﾠ of	 ﾠ mass-ﾭ‐to-ﾭ‐charge	 ﾠ (m/z)	 ﾠ 184	 ﾠ on	 ﾠ ESI	 ﾠ MS/MS.	 ﾠ As	 ﾠ described	 ﾠ in	 ﾠ
Chapter	 ﾠ1.8.2,	 ﾠthis	 ﾠmethod	 ﾠof	 ﾠscanning	 ﾠdetermines	 ﾠthe	 ﾠmass	 ﾠof	 ﾠa	 ﾠmolecule	 ﾠin	 ﾠa	 ﾠ
sample	 ﾠthat,	 ﾠon	 ﾠcollision	 ﾠwith	 ﾠan	 ﾠinert	 ﾠgas,	 ﾠbreaks	 ﾠinto	 ﾠfragments,	 ﾠone	 ﾠof	 ﾠwhich	 ﾠhas	 ﾠ
a	 ﾠm/z	 ﾠof	 ﾠ184.	 ﾠThe	 ﾠphosphatidylcholine	 ﾠhead	 ﾠgroup	 ﾠin	 ﾠPC-ﾭ‐containing	 ﾠphospholipids	 ﾠ
produces	 ﾠthis	 ﾠfragment	 ﾠmolecule	 ﾠand	 ﾠtherefore	 ﾠby	 ﾠscanning	 ﾠfor	 ﾠwhich	 ﾠmolecules	 ﾠ
produce	 ﾠthis	 ﾠfragment	 ﾠthen	 ﾠthe	 ﾠindividual	 ﾠPC	 ﾠmolecules	 ﾠcan	 ﾠbe	 ﾠidentified.	 ﾠ	 ﾠ
For	 ﾠeach	 ﾠpatient	 ﾠand	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠa	 ﾠlipid	 ﾠextract	 ﾠof	 ﾠplasma	 ﾠwas	 ﾠexamined	 ﾠfor	 ﾠ
precursor-ﾭ‐of-ﾭ‐184	 ﾠin	 ﾠESI	 ﾠMS/MS.	 ﾠAn	 ﾠexample	 ﾠfull	 ﾠpositive	 ﾠscan	 ﾠspectrum	 ﾠfrom	 ﾠa	 ﾠ 51	 ﾠ
plasma	 ﾠsample	 ﾠtaken	 ﾠat	 ﾠrecruitment	 ﾠshows	 ﾠall	 ﾠpositively	 ﾠcharged	 ﾠmolecules	 ﾠin	 ﾠthe	 ﾠ
sample	 ﾠ(Figure	 ﾠ8).	 ﾠ
	 ﾠ
Figure	 ﾠ8.	 ﾠAn	 ﾠexample	 ﾠof	 ﾠa	 ﾠfull	 ﾠpositive	 ﾠion	 ﾠscan	 ﾠspectrum.	 ﾠIt	 ﾠillustrates	 ﾠa	 ﾠ
typical	 ﾠplasma	 ﾠlipid	 ﾠextract	 ﾠscan	 ﾠat	 ﾠrecruitment	 ﾠ(time	 ﾠpoint	 ﾠ=	 ﾠ0)	 ﾠless	 ﾠthan	 ﾠ48	 ﾠ
hours	 ﾠafter	 ﾠpreterm	 ﾠbirth.	 ﾠ
However	 ﾠ a	 ﾠ precursor-ﾭ‐of-ﾭ‐184	 ﾠ (P184)	 ﾠ spectrum	 ﾠ with	 ﾠ a	 ﾠ mass/charge	 ﾠ ratio	 ﾠ (m/z)	 ﾠ
range	 ﾠof	 ﾠ650-ﾭ‐850	 ﾠillustrates	 ﾠthe	 ﾠmain	 ﾠPC	 ﾠmolecules	 ﾠdetected	 ﾠon	 ﾠadmission	 ﾠ(Figure	 ﾠ
9).	 ﾠ
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Figure	 ﾠ9.	 ﾠAn	 ﾠexample	 ﾠof	 ﾠa	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠ(P184)	 ﾠscan	 ﾠ
spectrum.	 ﾠIt	 ﾠillustrates	 ﾠa	 ﾠtypical	 ﾠplasma	 ﾠlipid	 ﾠextract	 ﾠscan	 ﾠat	 ﾠrecruitment	 ﾠ
(time	 ﾠpoint	 ﾠ=	 ﾠ0)	 ﾠless	 ﾠthan	 ﾠ48	 ﾠhours	 ﾠafter	 ﾠpreterm	 ﾠbirth.	 ﾠ
Significant	 ﾠpeaks	 ﾠare	 ﾠannotated	 ﾠwith	 ﾠtheir	 ﾠm/z	 ﾠand	 ﾠon	 ﾠthe	 ﾠy-ﾭ‐axis	 ﾠthe	 ﾠpeaks	 ﾠare	 ﾠ
normalised	 ﾠto	 ﾠ100%	 ﾠof	 ﾠthe	 ﾠlargest	 ﾠpeak.	 ﾠIn	 ﾠthis	 ﾠspectrum	 ﾠthe	 ﾠhighest	 ﾠpeak	 ﾠis	 ﾠ760	 ﾠ
which	 ﾠcorresponds	 ﾠwith	 ﾠa	 ﾠconfiguration	 ﾠof	 ﾠPC16:0/18:1.	 ﾠ	 ﾠ
3.2.1	 ﾠConcentration	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠpreterm	 ﾠplasma	 ﾠ
i)	 ﾠOverall	 ﾠchange	 ﾠin	 ﾠphosphatidylcholine	 ﾠconcentration	 ﾠ
Total	 ﾠconcentration	 ﾠof	 ﾠPC	 ﾠchanges	 ﾠwith	 ﾠtime	 ﾠfrom	 ﾠrecruitment	 ﾠ(Figure	 ﾠ10)	 ﾠwith	 ﾠan	 ﾠ
upward	 ﾠtrend	 ﾠin	 ﾠthe	 ﾠmedian	 ﾠvalue	 ﾠto	 ﾠ120	 ﾠhours	 ﾠthat	 ﾠis	 ﾠstatistically	 ﾠsignificant.	 ﾠ	 ﾠ
mass/charge (m/z) 
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Figure	 ﾠ10.	 ﾠConcentrations	 ﾠof	 ﾠphosphatidylcholine	 ﾠphospholipids	 ﾠin	 ﾠpreterm	 ﾠ
plasma	 ﾠincrease	 ﾠwith	 ﾠtime	 ﾠfrom	 ﾠrecruitment.	 ﾠThe	 ﾠerror	 ﾠbars	 ﾠshow	 ﾠthe	 ﾠ
median	 ﾠvalues	 ﾠand	 ﾠinterquartile	 ﾠranges.	 ﾠComparison	 ﾠof	 ﾠdata	 ﾠusing	 ﾠMann-ﾭ‐
Whitney	 ﾠnon-ﾭ‐parametric	 ﾠsignificance	 ﾠtesting	 ﾠshows	 ﾠsignificant	 ﾠincrease	 ﾠwith	 ﾠ
time	 ﾠto	 ﾠ120	 ﾠhours	 ﾠ(*	 ﾠp=0.0158	 ﾠ***	 ﾠp=0.0004)	 ﾠ
Concentration	 ﾠof	 ﾠPC	 ﾠphospholipids	 ﾠis	 ﾠnot	 ﾠnormally	 ﾠdistributed,	 ﾠwith	 ﾠone	 ﾠor	 ﾠmore	 ﾠ
children	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠshowing	 ﾠsignificantly	 ﾠhigher	 ﾠconcentrations.	 ﾠAll	 ﾠof	 ﾠthe	 ﾠ
outliers	 ﾠplotted,	 ﾠexcept	 ﾠat	 ﾠ96	 ﾠhours,	 ﾠrepresent	 ﾠa	 ﾠsingle	 ﾠpatient	 ﾠwho	 ﾠconsistently	 ﾠ
had	 ﾠ high	 ﾠ PC	 ﾠ concentrations.	 ﾠ The	 ﾠ significance	 ﾠ of	 ﾠ this	 ﾠ finding	 ﾠ is	 ﾠ not	 ﾠ clinically	 ﾠ
apparent.	 ﾠ
It	 ﾠis	 ﾠimportant	 ﾠto	 ﾠnote	 ﾠthat	 ﾠall	 ﾠpreterm	 ﾠbabies	 ﾠare	 ﾠexposed	 ﾠto	 ﾠparenteral	 ﾠnutrition	 ﾠ
at	 ﾠan	 ﾠearly	 ﾠstage	 ﾠand	 ﾠthe	 ﾠmajority	 ﾠof	 ﾠpatients	 ﾠreceived	 ﾠTPN	 ﾠprior	 ﾠto	 ﾠenrolment.	 ﾠIt	 ﾠis	 ﾠ
normal	 ﾠ clinical	 ﾠ practice	 ﾠ to	 ﾠ increase	 ﾠ the	 ﾠ amount	 ﾠ of	 ﾠ TPN	 ﾠ given	 ﾠ to	 ﾠ the	 ﾠ babies,	 ﾠ
including	 ﾠthe	 ﾠlipid	 ﾠcomponent,	 ﾠover	 ﾠseveral	 ﾠdays	 ﾠand	 ﾠthis	 ﾠmay	 ﾠcontribute	 ﾠto	 ﾠthe	 ﾠ
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ii)	 ﾠChange	 ﾠin	 ﾠphosphatidylcholine	 ﾠconcentration	 ﾠby	 ﾠspecies	 ﾠ
Rather	 ﾠthan	 ﾠsimply	 ﾠexpressing	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠPC	 ﾠphospholipids	 ﾠin	 ﾠtotal	 ﾠit	 ﾠis	 ﾠ
possible	 ﾠto	 ﾠshow	 ﾠin	 ﾠdetail	 ﾠthe	 ﾠconstituent	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠ(Figure	 ﾠ11).	 ﾠ
	 ﾠ
Figure	 ﾠ11.	 ﾠAverage	 ﾠconcentrations	 ﾠof	 ﾠselected	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠ
preterm	 ﾠplasma.	 ﾠPC16:0/18:1	 ﾠis	 ﾠconsistently	 ﾠthe	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠin	 ﾠ
this	 ﾠpopulation.	 ﾠ	 ﾠ
	 ﾠ
Differences	 ﾠin	 ﾠthe	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠare	 ﾠdemonstrated	 ﾠwith	 ﾠPC16:0/18:1	 ﾠthe	 ﾠ
most	 ﾠabundant	 ﾠspecies	 ﾠthroughout.	 ﾠNote	 ﾠthat	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠmost	 ﾠof	 ﾠthe	 ﾠPC	 ﾠ
species	 ﾠrise	 ﾠfor	 ﾠat	 ﾠleast	 ﾠthe	 ﾠfirst	 ﾠ96	 ﾠhours	 ﾠwith	 ﾠthe	 ﾠexception	 ﾠof	 ﾠthe	 ﾠpolyunsaturated	 ﾠ
fatty	 ﾠacid	 ﾠcontaining	 ﾠspecies	 ﾠ(purple	 ﾠand	 ﾠgreen	 ﾠon	 ﾠthe	 ﾠgraph)	 ﾠthat	 ﾠremain	 ﾠat	 ﾠa	 ﾠ
constant	 ﾠconcentration	 ﾠor	 ﾠeven	 ﾠfall	 ﾠwith	 ﾠtime.	 ﾠEach	 ﾠpatient	 ﾠshows	 ﾠa	 ﾠsteady	 ﾠincrease	 ﾠ
in	 ﾠconcentration	 ﾠwith	 ﾠtime,	 ﾠthough	 ﾠthe	 ﾠstarting	 ﾠpoint	 ﾠvaries	 ﾠfrom	 ﾠpatient	 ﾠto	 ﾠpatient.	 ﾠ	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iii)	 ﾠChange	 ﾠin	 ﾠphosphatidylcholine	 ﾠconcentration	 ﾠby	 ﾠindividual	 ﾠpatient	 ﾠ
As	 ﾠa	 ﾠwhole	 ﾠpopulation	 ﾠthere	 ﾠis	 ﾠan	 ﾠincrease	 ﾠin	 ﾠPC	 ﾠconcentration	 ﾠwith	 ﾠtime	 ﾠbut	 ﾠa	 ﾠ
number	 ﾠ of	 ﾠ factors	 ﾠ may	 ﾠ contribute	 ﾠ to	 ﾠ this	 ﾠ rise.	 ﾠ To	 ﾠ examine	 ﾠ whether	 ﾠ degree	 ﾠ of	 ﾠ
prematurity,	 ﾠ gestation	 ﾠ or	 ﾠ time	 ﾠ from	 ﾠ birth	 ﾠ to	 ﾠ sample	 ﾠ collection	 ﾠ relating	 ﾠ to	 ﾠ an	 ﾠ
individual	 ﾠbaby	 ﾠmay	 ﾠinfluence	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠPC	 ﾠphospholipid	 ﾠmeasured	 ﾠthe	 ﾠ
concentration	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ24	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠfor	 ﾠeach	 ﾠpatient	 ﾠis	 ﾠplotted	 ﾠ
with	 ﾠ correction	 ﾠ to	 ﾠ time	 ﾠ from	 ﾠ birth	 ﾠ (Figure	 ﾠ 12).	 ﾠ The	 ﾠ sample	 ﾠ times	 ﾠ have	 ﾠ been	 ﾠ
adjusted	 ﾠ so	 ﾠ that	 ﾠ they	 ﾠ are	 ﾠ plotted	 ﾠ by	 ﾠ time	 ﾠ from	 ﾠ birth	 ﾠ rather	 ﾠ than	 ﾠ time	 ﾠ from	 ﾠ
recruitment	 ﾠ
	 ﾠ
Figure	 ﾠ12.	 ﾠAbsolute	 ﾠamount	 ﾠof	 ﾠPC	 ﾠmeasured	 ﾠin	 ﾠplasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ24	 ﾠhours	 ﾠ
after	 ﾠrecruitment,	 ﾠcorrected	 ﾠfor	 ﾠtime	 ﾠelapsed	 ﾠsince	 ﾠpreterm	 ﾠbirth.	 ﾠThere	 ﾠis	 ﾠa	 ﾠ
trend	 ﾠtowards	 ﾠan	 ﾠincrease	 ﾠin	 ﾠplasma	 ﾠconcentration	 ﾠwith	 ﾠtime	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ
72	 ﾠhours	 ﾠof	 ﾠlife	 ﾠas	 ﾠindicated	 ﾠby	 ﾠthe	 ﾠtrendline.	 ﾠ
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Gestational	 ﾠage	 ﾠat	 ﾠtime	 ﾠof	 ﾠdelivery	 ﾠdoes	 ﾠnot	 ﾠaffect	 ﾠthe	 ﾠpattern	 ﾠof	 ﾠincreasing	 ﾠPC	 ﾠ
concentration	 ﾠwith	 ﾠtime	 ﾠ(Figure	 ﾠ13)	 ﾠand	 ﾠthe	 ﾠoverall	 ﾠincrease	 ﾠin	 ﾠconcentration	 ﾠwith	 ﾠ
time	 ﾠfrom	 ﾠbirth	 ﾠholds	 ﾠ(R2	 ﾠ=	 ﾠ0.26048).	 ﾠ
	 ﾠ
Figure	 ﾠ13.	 ﾠAbsolute	 ﾠamount	 ﾠof	 ﾠPC	 ﾠmeasured	 ﾠin	 ﾠplasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ24	 ﾠhours	 ﾠ
after	 ﾠrecruitment,	 ﾠcorrected	 ﾠfor	 ﾠtime	 ﾠelapsed	 ﾠsince	 ﾠpreterm	 ﾠbirth.	 ﾠThere	 ﾠis	 ﾠ
no	 ﾠcorrelation	 ﾠbetween	 ﾠgestational	 ﾠage	 ﾠat	 ﾠdelivery	 ﾠand	 ﾠconcentration	 ﾠ
measured.	 ﾠ
3.2.2	 ﾠPhosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠpreterm	 ﾠinfant	 ﾠplasma	 ﾠ
The	 ﾠfollowing	 ﾠmass/charge	 ﾠpeaks	 ﾠare	 ﾠconsistently	 ﾠfound	 ﾠin	 ﾠpreterm	 ﾠplasma	 ﾠlipid	 ﾠ
extracts	 ﾠ and	 ﾠ each	 ﾠ species	 ﾠ represents	 ﾠ ≥1%	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ phospholipid	 ﾠ
measured	 ﾠ(Table	 ﾠ4).	 ﾠ
	 ﾠ 57	 ﾠ
Table	 ﾠ4.	 ﾠTable	 ﾠof	 ﾠthe	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠfound	 ﾠin	 ﾠpreterm	 ﾠplasma.	 ﾠ




The	 ﾠPC	 ﾠspecies	 ﾠlisted	 ﾠwith	 ﾠeach	 ﾠm/z	 ﾠhave	 ﾠbeen	 ﾠselected	 ﾠas	 ﾠthe	 ﾠmost	 ﾠbiologically	 ﾠ
active	 ﾠspecies	 ﾠas	 ﾠin	 ﾠplasma	 ﾠfatty	 ﾠacids	 ﾠcontaining	 ﾠ16:0	 ﾠand	 ﾠ18:0	 ﾠare	 ﾠmore	 ﾠlikely	 ﾠto	 ﾠ
appear	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐1	 ﾠposition	 ﾠthan	 ﾠthe	 ﾠsn-ﾭ‐2	 ﾠposition	 ﾠ(Postle	 ﾠet	 ﾠal.,	 ﾠ1995).	 ﾠ
3.2.3	 ﾠComposition	 ﾠof	 ﾠplasma	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠ
near	 ﾠbirth	 ﾠ
An	 ﾠearly	 ﾠanalysis	 ﾠperformed	 ﾠon	 ﾠthe	 ﾠsamples	 ﾠcollected	 ﾠentailed	 ﾠexamination	 ﾠof	 ﾠthe	 ﾠ
composition	 ﾠ of	 ﾠ PC	 ﾠ species	 ﾠ at	 ﾠ recruitment.	 ﾠ As	 ﾠ a	 ﾠ whole	 ﾠ population	 ﾠ the	 ﾠ average	 ﾠ
composition	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠshowed	 ﾠthat,	 ﾠat	 ﾠless	 ﾠthan	 ﾠ48	 ﾠhours	 ﾠafter	 ﾠpreterm	 ﾠbirth,	 ﾠ
the	 ﾠpredominant	 ﾠPC	 ﾠspecies	 ﾠare	 ﾠmono-ﾭ‐	 ﾠand	 ﾠdi-ﾭ‐unsaturated	 ﾠwith	 ﾠa	 ﾠlarge	 ﾠamount	 ﾠof	 ﾠ
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Figure	 ﾠ14.	 ﾠComposition	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠfound	 ﾠin	 ﾠplasma	 ﾠof	 ﾠ
preterm	 ﾠinfants	 ﾠat	 ﾠrecruitment,	 ﾠwithin	 ﾠ48	 ﾠhours	 ﾠof	 ﾠbirth.	 ﾠSpecies	 ﾠare	 ﾠ
arranged,	 ﾠleft	 ﾠto	 ﾠright,	 ﾠby	 ﾠincreasing	 ﾠmass/charge	 ﾠand	 ﾠare	 ﾠgrouped,	 ﾠusing	 ﾠthe	 ﾠ
colours	 ﾠblue,	 ﾠred,	 ﾠgreen	 ﾠand	 ﾠpurple,	 ﾠby	 ﾠthe	 ﾠincreasing	 ﾠnumber	 ﾠof	 ﾠdouble	 ﾠ
bonds	 ﾠassociated	 ﾠwith	 ﾠthe	 ﾠfatty	 ﾠacid	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐2	 ﾠposition.	 ﾠ	 ﾠError	 ﾠbars	 ﾠ
represent	 ﾠone	 ﾠstandard	 ﾠdeviation.	 ﾠ
However,	 ﾠwhile	 ﾠall	 ﾠbabies	 ﾠshowed	 ﾠthese	 ﾠspecies	 ﾠin	 ﾠtheir	 ﾠplasma	 ﾠat	 ﾠrecruitment,	 ﾠand	 ﾠ
PC16:0/18:1	 ﾠ was	 ﾠ the	 ﾠ dominant	 ﾠ species	 ﾠ seen,	 ﾠ variation	 ﾠ existed	 ﾠ in	 ﾠ the	 ﾠ relative	 ﾠ
proportions	 ﾠof	 ﾠthe	 ﾠother	 ﾠfatty	 ﾠacid	 ﾠgroups.	 ﾠ	 ﾠ
Newborn	 ﾠpreterm	 ﾠinfants	 ﾠcan	 ﾠbe	 ﾠseen	 ﾠto	 ﾠdiffer	 ﾠsignificantly	 ﾠfrom	 ﾠadult	 ﾠvolunteers	 ﾠ
who	 ﾠhave	 ﾠPC16:0/18:2	 ﾠas	 ﾠthe	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠand	 ﾠrelatively	 ﾠlow	 ﾠamounts	 ﾠ
of	 ﾠpolyunsaturated	 ﾠlipids	 ﾠ(Postle	 ﾠet	 ﾠal.,	 ﾠ1995).	 ﾠ
In	 ﾠthis	 ﾠstudy,	 ﾠand	 ﾠfor	 ﾠthe	 ﾠfirst	 ﾠtime,	 ﾠthe	 ﾠprofile	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠfound	 ﾠin	 ﾠplasma	 ﾠwithin	 ﾠ
48	 ﾠhours	 ﾠof	 ﾠpreterm	 ﾠbirth	 ﾠcan	 ﾠbe	 ﾠdescribed.	 ﾠThe	 ﾠprofile	 ﾠis	 ﾠconsistent	 ﾠbut	 ﾠdiffers	 ﾠ














































































3.2.4	 ﾠComposition	 ﾠof	 ﾠplasma	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠ
over	 ﾠtime	 ﾠ
Having	 ﾠ established	 ﾠ the	 ﾠ composition	 ﾠ of	 ﾠ the	 ﾠ PC	 ﾠ phospholipids	 ﾠ for	 ﾠ these	 ﾠ preterm	 ﾠ
infants	 ﾠat	 ﾠrecruitment	 ﾠit	 ﾠis	 ﾠnecessary	 ﾠto	 ﾠconsider	 ﾠthe	 ﾠchanges	 ﾠthat	 ﾠoccur	 ﾠwith	 ﾠtime.	 ﾠ
Serial	 ﾠsamples	 ﾠof	 ﾠplasma	 ﾠwere	 ﾠcollected	 ﾠon	 ﾠall	 ﾠinfants	 ﾠat	 ﾠrecruitment	 ﾠand	 ﾠthen	 ﾠ6,	 ﾠ12,	 ﾠ
24,	 ﾠ48,	 ﾠ72,	 ﾠ96	 ﾠand	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠthe	 ﾠinitiation	 ﾠof	 ﾠthe	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠ
infusion.	 ﾠFurther	 ﾠsamples	 ﾠof	 ﾠplasma	 ﾠwere	 ﾠonly	 ﾠcollected	 ﾠfrom	 ﾠthose	 ﾠinfants	 ﾠwho	 ﾠ
remained	 ﾠintubated	 ﾠand	 ﾠventilated	 ﾠat	 ﾠthat	 ﾠpoint.	 ﾠ
Hence	 ﾠthere	 ﾠexists	 ﾠa	 ﾠseries	 ﾠof	 ﾠsamples	 ﾠto	 ﾠinvestigate	 ﾠthe	 ﾠchanges	 ﾠin	 ﾠcomposition	 ﾠ
with	 ﾠtime	 ﾠpostnatally.	 ﾠ
i)	 ﾠ Composition	 ﾠ of	 ﾠ plasma	 ﾠ phosphatidylcholine	 ﾠ species	 ﾠ in	 ﾠ preterm	 ﾠ infants	 ﾠ to	 ﾠ
120	 ﾠhours	 ﾠpost-ﾭ‐recruitment	 ﾠ
As	 ﾠat	 ﾠrecruitment	 ﾠthe	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠremains	 ﾠPC16:0/18:1	 ﾠwith	 ﾠa	 ﾠrelative	 ﾠ
proportion	 ﾠincreasing	 ﾠover	 ﾠthe	 ﾠstudy	 ﾠperiod	 ﾠ(Figure	 ﾠ15).	 ﾠ
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Figure	 ﾠ15.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠmeasured	 ﾠin	 ﾠplasma	 ﾠ
over	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠSpecies	 ﾠare	 ﾠgrouped	 ﾠby	 ﾠthe	 ﾠdegree	 ﾠ
of	 ﾠsaturation	 ﾠin	 ﾠthe	 ﾠfatty	 ﾠacid	 ﾠesterified	 ﾠto	 ﾠthe	 ﾠsn-ﾭ‐2	 ﾠposition.	 ﾠFully	 ﾠsaturated	 ﾠ
and	 ﾠmonounsaturated	 ﾠ(blue),	 ﾠdiunsaturated	 ﾠ(red),	 ﾠarachidonoyl	 ﾠ(green)	 ﾠand	 ﾠ
docosahexaenoyl	 ﾠ(purple).	 ﾠ
The	 ﾠmajority	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠare	 ﾠfully	 ﾠsaturated	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐1	 ﾠposition	 ﾠbut	 ﾠthere	 ﾠis	 ﾠ
variation	 ﾠin	 ﾠthe	 ﾠdegree	 ﾠof	 ﾠsaturation	 ﾠof	 ﾠthe	 ﾠfatty	 ﾠacid	 ﾠgroups	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐2	 ﾠso	 ﾠif	 ﾠthe	 ﾠ
species	 ﾠare	 ﾠgrouped	 ﾠaccordingly	 ﾠthen	 ﾠsignificant	 ﾠpatterns	 ﾠof	 ﾠchange	 ﾠare	 ﾠseen	 ﾠwhen	 ﾠ
the	 ﾠgroups	 ﾠare	 ﾠcompared.	 ﾠ	 ﾠ
When	 ﾠ the	 ﾠ sn-ﾭ‐1	 ﾠ position	 ﾠ is	 ﾠ fully	 ﾠ saturated	 ﾠ with	 ﾠ 16:0	 ﾠ or	 ﾠ 18:0	 ﾠ the	 ﾠ relative	 ﾠ
composition	 ﾠof	 ﾠdiunsaturated	 ﾠ(18:2)	 ﾠspecies	 ﾠrises	 ﾠsteadily	 ﾠafter	 ﾠthe	 ﾠfirst	 ﾠ12	 ﾠhours	 ﾠ
(Figure	 ﾠ 16)	 ﾠ while	 ﾠ the	 ﾠ arachidonoyl-ﾭ‐containing	 ﾠ (20:4)	 ﾠ species	 ﾠ show	 ﾠ a	 ﾠ drop	 ﾠ in	 ﾠ
relative	 ﾠ abundance.	 ﾠ This	 ﾠ clearly	 ﾠ demonstrates	 ﾠ that	 ﾠ individual	 ﾠ species	 ﾠ are	 ﾠ not	 ﾠ
constant	 ﾠin	 ﾠrelation	 ﾠto	 ﾠeach	 ﾠother	 ﾠand	 ﾠthat	 ﾠoverall	 ﾠincreases	 ﾠin	 ﾠPC	 ﾠconcentration	 ﾠ
with	 ﾠtime	 ﾠare	 ﾠdue	 ﾠto	 ﾠdifferential	 ﾠturnover	 ﾠof	 ﾠPC	 ﾠspecies.	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Figure	 ﾠ16.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠmeasured	 ﾠin	 ﾠplasma	 ﾠ
over	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠThe	 ﾠ18:2	 ﾠcontaining	 ﾠspecies	 ﾠ
increase	 ﾠproportionally	 ﾠwith	 ﾠtime	 ﾠas	 ﾠthe	 ﾠ20:4-ﾭ‐containing	 ﾠspecies	 ﾠfall	 ﾠ
relatively	 ﾠfrom	 ﾠa	 ﾠhigh	 ﾠstarting	 ﾠpoint	 ﾠat	 ﾠrecruitment.	 ﾠ
There	 ﾠ may	 ﾠ be	 ﾠ a	 ﾠ number	 ﾠ of	 ﾠ drivers	 ﾠ for	 ﾠ this	 ﾠ dramatic	 ﾠ change	 ﾠ in	 ﾠ PC	 ﾠ species	 ﾠ
abundance.	 ﾠ The	 ﾠ changes	 ﾠ are	 ﾠ not	 ﾠ related	 ﾠ to	 ﾠ the	 ﾠ degree	 ﾠ of	 ﾠ prematurity	 ﾠ or	 ﾠ
birthweight	 ﾠof	 ﾠthe	 ﾠinfant.	 ﾠHowever	 ﾠone	 ﾠelement	 ﾠthat	 ﾠis	 ﾠcommon	 ﾠto	 ﾠall	 ﾠbabies	 ﾠand	 ﾠ
not	 ﾠto	 ﾠthe	 ﾠpreviously	 ﾠpublished	 ﾠadult	 ﾠvolunteers	 ﾠis	 ﾠtheir	 ﾠsource	 ﾠof	 ﾠnutrition.	 ﾠThe	 ﾠ
adult	 ﾠvolunteers	 ﾠhad	 ﾠaccess	 ﾠto	 ﾠtheir	 ﾠnormal	 ﾠmixed	 ﾠfoodstuffs,	 ﾠwhereas	 ﾠthe	 ﾠpreterm	 ﾠ
infant	 ﾠ in	 ﾠ the	 ﾠ first	 ﾠ days	 ﾠ of	 ﾠ life,	 ﾠ being	 ﾠ unable	 ﾠ to	 ﾠ tolerate	 ﾠ enteral	 ﾠ feeding,	 ﾠ has	 ﾠ
parenteral	 ﾠ nutrition	 ﾠ (PN	 ﾠ or	 ﾠ TPN)	 ﾠ administered	 ﾠ intravenously	 ﾠ to	 ﾠ provide	 ﾠ some	 ﾠ
complex	 ﾠnutrition.	 ﾠ
3.2.5	 ﾠ Effect	 ﾠ of	 ﾠ total	 ﾠ parenteral	 ﾠ nutrition	 ﾠ (TPN)	 ﾠ on	 ﾠ plasma	 ﾠ
phosphatidylcholine	 ﾠspecies	 ﾠ
As	 ﾠdiet	 ﾠis	 ﾠnot	 ﾠcontrolled	 ﾠin	 ﾠthe	 ﾠstudy	 ﾠbut	 ﾠrather	 ﾠis	 ﾠadjusted	 ﾠaccording	 ﾠto	 ﾠclinical	 ﾠ
criteria,	 ﾠ two	 ﾠ infants	 ﾠ happened	 ﾠ to	 ﾠ be	 ﾠ recruited	 ﾠ prior	 ﾠ to	 ﾠ administration	 ﾠ of	 ﾠ total	 ﾠ  62	 ﾠ
parenteral	 ﾠ nutrition	 ﾠ (TPN).	 ﾠ Instead	 ﾠ of	 ﾠ receiving	 ﾠ a	 ﾠ complex	 ﾠ and	 ﾠ tailored	 ﾠ fluid	 ﾠ
regime	 ﾠ consisting	 ﾠ of	 ﾠ Vamin®	 ﾠ (crystalloid	 ﾠ sugar	 ﾠ solution	 ﾠ with	 ﾠ salts	 ﾠ and	 ﾠ amino	 ﾠ
acids)	 ﾠand	 ﾠa	 ﾠseparate	 ﾠlipid	 ﾠ(colloid)	 ﾠsolution,	 ﾠthey	 ﾠhad	 ﾠa	 ﾠsimple	 ﾠ10-ﾭ‐15%	 ﾠdextrose	 ﾠ
infusion	 ﾠ±	 ﾠsodium	 ﾠchloride	 ﾠ±	 ﾠpotassium	 ﾠchloride	 ﾠand	 ﾠno	 ﾠother	 ﾠnutrition	 ﾠat	 ﾠthe	 ﾠtime	 ﾠ
of	 ﾠentry	 ﾠto	 ﾠthe	 ﾠstudy.	 ﾠThe	 ﾠtwo	 ﾠinfants	 ﾠwere	 ﾠsubsequently	 ﾠstarted	 ﾠon	 ﾠTPN,	 ﾠaffording	 ﾠ
a	 ﾠunique	 ﾠinsight	 ﾠinto	 ﾠthe	 ﾠeffects	 ﾠof	 ﾠTPN	 ﾠon	 ﾠthe	 ﾠoverall	 ﾠPC	 ﾠcomposition.	 ﾠ
By	 ﾠplotting	 ﾠthe	 ﾠPC	 ﾠcomposition	 ﾠseen	 ﾠin	 ﾠthis	 ﾠsubgroup	 ﾠof	 ﾠtwo	 ﾠprior	 ﾠto	 ﾠand	 ﾠafter	 ﾠ
administration	 ﾠof	 ﾠTPN	 ﾠthe	 ﾠeffect	 ﾠof	 ﾠnutrition	 ﾠon	 ﾠcomposition	 ﾠis	 ﾠdemonstrated.	 ﾠ
i)	 ﾠPC	 ﾠcomposition	 ﾠin	 ﾠpatients	 ﾠSO02	 ﾠand	 ﾠSO03	 ﾠbefore	 ﾠand	 ﾠafter	 ﾠTPN	 ﾠ
For	 ﾠclarity	 ﾠonly	 ﾠthe	 ﾠdiunsaturated	 ﾠand	 ﾠarachidonoyl-ﾭ‐containing	 ﾠspecies	 ﾠresults	 ﾠare	 ﾠ
discussed.	 ﾠPrior	 ﾠto	 ﾠadministration	 ﾠof	 ﾠTPN	 ﾠthe	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠthe	 ﾠselected	 ﾠ
PC	 ﾠ species	 ﾠ are	 ﾠ either	 ﾠ relatively	 ﾠ constant	 ﾠ (Figure	 ﾠ 17)	 ﾠ or	 ﾠ show	 ﾠ a	 ﾠ falling	 ﾠ
diunsaturated	 ﾠ–	 ﾠrising	 ﾠarachidonoyl-ﾭ‐containing	 ﾠspecies	 ﾠprofile	 ﾠ(Figure	 ﾠ18).	 ﾠ	 ﾠ
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Figure	 ﾠ17.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠmeasured	 ﾠin	 ﾠplasma	 ﾠ
before	 ﾠand	 ﾠafter	 ﾠthe	 ﾠadministration	 ﾠof	 ﾠTPN	 ﾠin	 ﾠpatient	 ﾠSO02.	 ﾠThe	 ﾠproportional	 ﾠ
changes	 ﾠoccur	 ﾠafter	 ﾠthe	 ﾠadministration	 ﾠof	 ﾠTPN,	 ﾠmarked	 ﾠwith	 ﾠan	 ﾠasterisk	 ﾠ(*),	 ﾠ
between	 ﾠthe	 ﾠsamples	 ﾠcollected	 ﾠat	 ﾠ24	 ﾠand	 ﾠ48	 ﾠhours.	 ﾠ
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Figure	 ﾠ18.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠmeasured	 ﾠin	 ﾠplasma	 ﾠ
before	 ﾠand	 ﾠafter	 ﾠthe	 ﾠadministration	 ﾠof	 ﾠTPN	 ﾠin	 ﾠpatient	 ﾠSO03.	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In	 ﾠboth	 ﾠindividuals	 ﾠthe	 ﾠcomposition	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠchanges	 ﾠon	 ﾠadministration	 ﾠof	 ﾠ
TPN	 ﾠ with	 ﾠ the	 ﾠ proportion	 ﾠ of	 ﾠ the	 ﾠ diunsaturated	 ﾠ species	 ﾠ rising	 ﾠ sharply	 ﾠ and	 ﾠ
overtaking	 ﾠthe	 ﾠfalling	 ﾠarachidonoyl-ﾭ‐containing	 ﾠspecies.	 ﾠ
Therefore	 ﾠchanges	 ﾠin	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠPC	 ﾠphospholipids	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ5	 ﾠdays	 ﾠof	 ﾠ
study	 ﾠmust	 ﾠbe	 ﾠconsidered	 ﾠin	 ﾠthe	 ﾠcontext	 ﾠof	 ﾠTPNs	 ﾠinfluence	 ﾠdriving	 ﾠthe	 ﾠproportions	 ﾠ
of	 ﾠdiunsaturated	 ﾠup	 ﾠwhile	 ﾠrelatively	 ﾠdecreasing	 ﾠarachidonoyl	 ﾠspecies.	 ﾠTPN	 ﾠappears	 ﾠ
to	 ﾠaffect	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠthese	 ﾠspecies	 ﾠand,	 ﾠgiven	 ﾠthat	 ﾠall	 ﾠthe	 ﾠpatients	 ﾠreceived	 ﾠ
TPN	 ﾠover	 ﾠthe	 ﾠcourse	 ﾠof	 ﾠthe	 ﾠstudy,	 ﾠat	 ﾠleast	 ﾠsome	 ﾠof	 ﾠthe	 ﾠchanges	 ﾠseen	 ﾠin	 ﾠcomposition	 ﾠ
are	 ﾠdriven	 ﾠby	 ﾠthe	 ﾠTPN	 ﾠdelivered.	 ﾠ
3.2.6	 ﾠOverall	 ﾠchanges	 ﾠin	 ﾠproportions	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠ
Overall	 ﾠthe	 ﾠchanges	 ﾠin	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠcan	 ﾠbe	 ﾠseen	 ﾠas	 ﾠa	 ﾠcombination	 ﾠ
of	 ﾠfactors	 ﾠrelating	 ﾠto	 ﾠthe	 ﾠabrupt	 ﾠinterruption	 ﾠto	 ﾠplacental	 ﾠsupply	 ﾠof	 ﾠcomplex	 ﾠfatty	 ﾠ
acids	 ﾠand	 ﾠphospholipids,	 ﾠthe	 ﾠadaptation	 ﾠof	 ﾠthe	 ﾠpreterm	 ﾠliver	 ﾠto	 ﾠex	 ﾠutero	 ﾠlife	 ﾠand	 ﾠthe	 ﾠ
direct	 ﾠeffect	 ﾠof	 ﾠintravenously	 ﾠadministered	 ﾠTPN.	 ﾠ	 ﾠ
The	 ﾠalteration	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠon	 ﾠthe	 ﾠaddition	 ﾠof	 ﾠTPN	 ﾠeffectively	 ﾠdemonstrates	 ﾠthat	 ﾠ
nutrition	 ﾠaffects	 ﾠthe	 ﾠPC	 ﾠproducts	 ﾠmeasurable	 ﾠin	 ﾠpreterm	 ﾠplasma	 ﾠsamples	 ﾠin	 ﾠthe	 ﾠ
first	 ﾠweeks	 ﾠof	 ﾠlife.	 ﾠ
3.2.7	 ﾠSummary	 ﾠof	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠscanning	 ﾠresults	 ﾠ
In	 ﾠsummary,	 ﾠusing	 ﾠESI	 ﾠMS/MS	 ﾠit	 ﾠis	 ﾠpossible	 ﾠto	 ﾠdescribe	 ﾠthe	 ﾠcomposition	 ﾠof	 ﾠPC	 ﾠ
phospholipids	 ﾠin	 ﾠpreterm	 ﾠplasma,	 ﾠhow	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠPC	 ﾠincreases	 ﾠwith	 ﾠtime	 ﾠ
and	 ﾠhow	 ﾠthe	 ﾠchange	 ﾠis	 ﾠdynamic	 ﾠwith	 ﾠsignificant	 ﾠvariation	 ﾠin	 ﾠindividual	 ﾠPC	 ﾠspecies.	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3.3	 ﾠPrecursors	 ﾠof	 ﾠmass/charge	 ﾠ+193	 ﾠscanning	 ﾠ
To	 ﾠthis	 ﾠpoint	 ﾠthe	 ﾠresults	 ﾠpresented	 ﾠhave	 ﾠshown	 ﾠthe	 ﾠrelative	 ﾠprevalence	 ﾠof	 ﾠthe	 ﾠPC	 ﾠ
species	 ﾠbut	 ﾠhave	 ﾠnot	 ﾠaddressed	 ﾠsynthetic	 ﾠor	 ﾠmetabolic	 ﾠchanges.	 ﾠMeasurement	 ﾠand	 ﾠ
analysis	 ﾠof	 ﾠthe	 ﾠappearance	 ﾠof	 ﾠD9-ﾭ‐containing	 ﾠPC	 ﾠspecies,	 ﾠwhich	 ﾠare	 ﾠsynthesised	 ﾠby	 ﾠ
the	 ﾠCDP-ﾭ‐choline	 ﾠpathway,	 ﾠreveals	 ﾠthe	 ﾠnewly	 ﾠsynthesised	 ﾠPC	 ﾠphospholipids	 ﾠ(Figure	 ﾠ
19).	 ﾠ
	 ﾠ
Figure	 ﾠ19.	 ﾠBottom	 ﾠ-ﾭ‐	 ﾠAn	 ﾠexample	 ﾠof	 ﾠa	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠ(P184)	 ﾠ
scan	 ﾠspectrum.	 ﾠIt	 ﾠillustrates	 ﾠa	 ﾠtypical	 ﾠplasma	 ﾠlipid	 ﾠextract	 ﾠscan	 ﾠafter	 ﾠ72	 ﾠhours.	 ﾠ
Top	 ﾠ-ﾭ‐	 ﾠThe	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+193	 ﾠ(P193)	 ﾠscan	 ﾠof	 ﾠthe	 ﾠsame	 ﾠlipid	 ﾠ
extract.	 ﾠThere	 ﾠis	 ﾠa	 ﾠsimilar	 ﾠpattern	 ﾠof	 ﾠpeaks	 ﾠbut	 ﾠoffset	 ﾠby	 ﾠa	 ﾠmass/charge	 ﾠof	 ﾠ
nine	 ﾠhigher.	 ﾠ	 ﾠ
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3.3.1	 ﾠOverall	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐labelled	 ﾠphosphatidylcholine	 ﾠ	 ﾠ
Examining	 ﾠplasma	 ﾠfrom	 ﾠthe	 ﾠwhole	 ﾠpopulation	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠof	 ﾠstudy	 ﾠ
using	 ﾠprecursor	 ﾠof	 ﾠm/z	 ﾠ193	 ﾠscanning	 ﾠon	 ﾠESI	 ﾠMS/MS	 ﾠwill	 ﾠdetermine	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠ
D9-ﾭ‐containing	 ﾠPC	 ﾠhead	 ﾠgroups	 ﾠ(Figure	 ﾠ20).	 ﾠ
	 ﾠ
Figure	 ﾠ20.	 ﾠThe	 ﾠmean	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐containing	 ﾠPC	 ﾠ
phospholipids	 ﾠin	 ﾠplasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠD9	 ﾠ
enrichment	 ﾠhas	 ﾠbeen	 ﾠexpressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠ
measured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint.	 ﾠThe	 ﾠerror	 ﾠbars	 ﾠrepresent	 ﾠa	 ﾠsingle	 ﾠstandard	 ﾠ
deviation	 ﾠfrom	 ﾠthe	 ﾠmean.	 ﾠ
The	 ﾠ newly	 ﾠ synthesised	 ﾠ D9-ﾭ‐PC	 ﾠ species	 ﾠ appear	 ﾠ rapidly	 ﾠ in	 ﾠ the	 ﾠ plasma	 ﾠ and	 ﾠ are	 ﾠ
detectable	 ﾠwithin	 ﾠ6	 ﾠhours	 ﾠof	 ﾠthe	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠadministration.	 ﾠAs	 ﾠ
anticipated	 ﾠ from	 ﾠ previously	 ﾠ published	 ﾠ adult	 ﾠ work	 ﾠ (Pynn	 ﾠ et	 ﾠ al.,	 ﾠ 2011)	 ﾠ the	 ﾠ D9	 ﾠ
species	 ﾠrepresent	 ﾠa	 ﾠsmall	 ﾠpercentage	 ﾠof	 ﾠthe	 ﾠtotal	 ﾠamount	 ﾠof	 ﾠPC	 ﾠwith	 ﾠthe	 ﾠfractional	 ﾠ
incorporation	 ﾠ of	 ﾠ D9-ﾭ‐labelled	 ﾠ PC	 ﾠ species	 ﾠ showing	 ﾠ an	 ﾠ average	 ﾠ incorporation	 ﾠ of	 ﾠ
0.867%	 ﾠat	 ﾠ12	 ﾠhours	 ﾠpost	 ﾠinfusion	 ﾠor	 ﾠa	 ﾠfractional	 ﾠincorporation	 ﾠrate	 ﾠof	 ﾠ0.072%	 ﾠper	 ﾠ
hour.	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Newborn	 ﾠ preterm	 ﾠ infants	 ﾠ therefore	 ﾠ demonstrate	 ﾠ a	 ﾠ similar	 ﾠ maximal	 ﾠ fractional	 ﾠ
enrichment	 ﾠ of	 ﾠ D9-ﾭ‐PC	 ﾠ to	 ﾠ adults	 ﾠ (0.867%	 ﾠ versus	 ﾠ 0.9%)	 ﾠ but	 ﾠ reach	 ﾠ this	 ﾠ maximum	 ﾠ
incorporation	 ﾠmore	 ﾠthan	 ﾠtwice	 ﾠas	 ﾠfast	 ﾠ(12	 ﾠhours	 ﾠversus	 ﾠ24-ﾭ‐30	 ﾠhours)	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ
2011).	 ﾠ
Following	 ﾠthis	 ﾠ12-ﾭ‐hour	 ﾠpeak	 ﾠthe	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠfalls	 ﾠor	 ﾠdecays	 ﾠin	 ﾠ
a	 ﾠ non-ﾭ‐linear	 ﾠ fashion.	 ﾠ This	 ﾠ decay	 ﾠ may	 ﾠ be	 ﾠ thought	 ﾠ of	 ﾠ as	 ﾠ combination	 ﾠ of	 ﾠ lack	 ﾠ of	 ﾠ
labelled	 ﾠsubstrate,	 ﾠactive	 ﾠmetabolism	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠand	 ﾠuptake	 ﾠfrom	 ﾠthe	 ﾠcirculation	 ﾠby	 ﾠ
cells	 ﾠthroughout	 ﾠthe	 ﾠbody.	 ﾠ
With	 ﾠa	 ﾠsecond	 ﾠdose	 ﾠ(Figure	 ﾠ21)	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride,	 ﾠin	 ﾠthose	 ﾠbabies	 ﾠstill	 ﾠ
intubated	 ﾠat	 ﾠ120	 ﾠhours,	 ﾠproducing	 ﾠthe	 ﾠsame	 ﾠeffect	 ﾠit	 ﾠmay	 ﾠtherefore	 ﾠbe	 ﾠinterpreted	 ﾠ
that	 ﾠthe	 ﾠhigh	 ﾠsynthetic	 ﾠrate	 ﾠseen	 ﾠwithin	 ﾠ48	 ﾠhours	 ﾠof	 ﾠbirth	 ﾠis	 ﾠsustained	 ﾠover	 ﾠat	 ﾠleast	 ﾠ
the	 ﾠfirst	 ﾠweek	 ﾠof	 ﾠlife.	 ﾠ
	 ﾠ
Figure	 ﾠ21.	 ﾠThe	 ﾠmean	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐containing	 ﾠPC	 ﾠ
phospholipids	 ﾠin	 ﾠplasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠD9	 ﾠ
enrichment	 ﾠhas	 ﾠbeen	 ﾠexpressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠ
measured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint.	 ﾠThe	 ﾠerror	 ﾠbars	 ﾠrepresent	 ﾠa	 ﾠsingle	 ﾠstandard	 ﾠ
deviation	 ﾠfrom	 ﾠthe	 ﾠmean.	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For	 ﾠthe	 ﾠfirst	 ﾠtime	 ﾠthis	 ﾠstudy	 ﾠhas	 ﾠdemonstrated	 ﾠthat	 ﾠby	 ﾠconverting	 ﾠcholine	 ﾠavailable	 ﾠ
in	 ﾠthe	 ﾠbloodstream	 ﾠto	 ﾠproduce	 ﾠnew	 ﾠphosphatidylcholine	 ﾠphospholipids	 ﾠthe	 ﾠliver	 ﾠof	 ﾠ
newborn	 ﾠpreterm	 ﾠinfants	 ﾠis	 ﾠmetabolically	 ﾠvery	 ﾠactive.	 ﾠ
This	 ﾠmetabolic	 ﾠactivity	 ﾠwas	 ﾠinvestigated	 ﾠfurther	 ﾠby	 ﾠexamining	 ﾠthe	 ﾠindividual	 ﾠPC	 ﾠ
species	 ﾠproduced	 ﾠby	 ﾠthe	 ﾠCDP-ﾭ‐choline	 ﾠpathway.	 ﾠ	 ﾠ
3.3.2	 ﾠComposition	 ﾠof	 ﾠD9-ﾭ‐phosphatidylcholine	 ﾠspecies	 ﾠ
Results	 ﾠ from	 ﾠ the	 ﾠ P184	 ﾠ scans	 ﾠ (section	 ﾠ 3.2.3)	 ﾠ showed	 ﾠ that	 ﾠ the	 ﾠ composition	 ﾠ of	 ﾠ
individual	 ﾠPC	 ﾠspecies	 ﾠchanged	 ﾠwith	 ﾠtime,	 ﾠbut	 ﾠnot	 ﾠhow	 ﾠmuch	 ﾠof	 ﾠthis	 ﾠcompositional	 ﾠ
change	 ﾠis	 ﾠdue	 ﾠto	 ﾠsynthesis	 ﾠand	 ﾠmetabolism	 ﾠof	 ﾠthe	 ﾠspecies.	 ﾠ
i)	 ﾠ Comparison	 ﾠ of	 ﾠ the	 ﾠ composition	 ﾠ of	 ﾠ unlabelled	 ﾠ and	 ﾠ D9-ﾭ‐phosphatidylcholine	 ﾠ
species	 ﾠat	 ﾠ6	 ﾠhours	 ﾠ
At	 ﾠ6	 ﾠhours	 ﾠthe	 ﾠfirst	 ﾠplasma	 ﾠsample	 ﾠis	 ﾠtaken	 ﾠafter	 ﾠinfusion.	 ﾠThe	 ﾠproportions	 ﾠof	 ﾠthe	 ﾠ
individual	 ﾠD9-ﾭ‐species	 ﾠat	 ﾠ6	 ﾠhours	 ﾠwere	 ﾠcompared	 ﾠwith	 ﾠthe	 ﾠendogenous	 ﾠcomposition	 ﾠ
previously	 ﾠpresented	 ﾠ	 ﾠ(Figure	 ﾠ22).	 ﾠ
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Figure	 ﾠ22.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ6	 ﾠhours	 ﾠ
after	 ﾠrecruitment.	 ﾠFor	 ﾠeach	 ﾠpair	 ﾠof	 ﾠcolumns	 ﾠthe	 ﾠendogenous	 ﾠPC	 ﾠproportions	 ﾠ
are	 ﾠshown	 ﾠas	 ﾠthe	 ﾠleft-ﾭ‐hand	 ﾠcolumn,	 ﾠwhile	 ﾠthe	 ﾠright-ﾭ‐hand	 ﾠcolumn	 ﾠis	 ﾠthe	 ﾠD9-ﾭ‐
labelled	 ﾠspecies.	 ﾠ
	 ﾠ
Proportions	 ﾠ are	 ﾠ found	 ﾠ to	 ﾠ be	 ﾠ similar	 ﾠ with	 ﾠ the	 ﾠ commonest	 ﾠ species	 ﾠ the	 ﾠ
monounsaturated	 ﾠ PC16:0/18:1	 ﾠ and	 ﾠ slightly	 ﾠ less	 ﾠ of	 ﾠ the	 ﾠ arachidonoyl-ﾭ‐containing	 ﾠ
species.	 ﾠHence,	 ﾠat	 ﾠleast	 ﾠinitially,	 ﾠthe	 ﾠphospholipids	 ﾠbeing	 ﾠmade	 ﾠas	 ﾠD9-ﾭ‐containing	 ﾠPC	 ﾠ
species	 ﾠreflect	 ﾠoverall	 ﾠPC	 ﾠcomposition.	 ﾠ
ii)	 ﾠVariation	 ﾠin	 ﾠcomposition	 ﾠof	 ﾠD9-ﾭ‐phosphatidylcholine	 ﾠspecies	 ﾠup	 ﾠto	 ﾠ120	 ﾠhours	 ﾠ
Within	 ﾠthe	 ﾠoverall	 ﾠpattern	 ﾠof	 ﾠincorporation	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠinto	 ﾠPC	 ﾠ
and	 ﾠan	 ﾠinitial	 ﾠpicture	 ﾠof	 ﾠproduction	 ﾠin	 ﾠsimilar	 ﾠproportions	 ﾠto	 ﾠoverall	 ﾠPC	 ﾠspecies	 ﾠby	 ﾠ
48	 ﾠhours	 ﾠ(Figure	 ﾠ23),	 ﾠit	 ﾠis	 ﾠpossible	 ﾠto	 ﾠexamine	 ﾠthe	 ﾠchange	 ﾠin	 ﾠeach	 ﾠPC	 ﾠspecies	 ﾠto	 ﾠ
examine	 ﾠspecificity	 ﾠof	 ﾠliver	 ﾠmetabolism	 ﾠand	 ﾠwhether	 ﾠit	 ﾠchanges	 ﾠover	 ﾠtime	 ﾠ(Figure	 ﾠ
24).	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Figure	 ﾠ23.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ48	 ﾠ
hours	 ﾠafter	 ﾠrecruitment.	 ﾠThe	 ﾠcolumns	 ﾠare	 ﾠnow	 ﾠmore	 ﾠsimilar	 ﾠthan	 ﾠat	 ﾠ6	 ﾠhours.	 ﾠ
For	 ﾠeach	 ﾠpair	 ﾠof	 ﾠcolumns	 ﾠthe	 ﾠendogenous	 ﾠPC	 ﾠproportions	 ﾠare	 ﾠshown	 ﾠas	 ﾠthe	 ﾠ
left-ﾭ‐hand	 ﾠcolumn,	 ﾠwhile	 ﾠthe	 ﾠright-ﾭ‐hand	 ﾠcolumn	 ﾠis	 ﾠthe	 ﾠD9-ﾭ‐labelled	 ﾠspecies.	 ﾠ
	 ﾠ
Figure	 ﾠ24.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠPC	 ﾠspecies	 ﾠup	 ﾠ
to	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	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Again	 ﾠ PC16:0/18:1	 ﾠ is	 ﾠ the	 ﾠ dominant	 ﾠ species	 ﾠ and	 ﾠ proportions	 ﾠ of	 ﾠ diunsaturated	 ﾠ
species	 ﾠrise,	 ﾠas	 ﾠthe	 ﾠarachidonoyl-ﾭ‐containing	 ﾠspecies	 ﾠremain	 ﾠconstant	 ﾠor	 ﾠfall	 ﾠ(Figure	 ﾠ
25).	 ﾠ
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Figure	 ﾠ25.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠdiunsaturated	 ﾠ
and	 ﾠarachidonoyl-ﾭ‐containing	 ﾠPC	 ﾠspecies	 ﾠup	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠ
	 ﾠ
Therefore	 ﾠthe	 ﾠproduction	 ﾠof	 ﾠnewly	 ﾠsynthesised	 ﾠmaterial	 ﾠis	 ﾠmatching	 ﾠthe	 ﾠoverall	 ﾠ
composition	 ﾠas	 ﾠthe	 ﾠcomposition	 ﾠchanges	 ﾠwith	 ﾠtime.	 ﾠ
This	 ﾠ compositional	 ﾠ change	 ﾠ is	 ﾠ driven	 ﾠ by	 ﾠ the	 ﾠ alteration	 ﾠ in	 ﾠ PC	 ﾠ synthesis	 ﾠ in	 ﾠ the	 ﾠ
preterm	 ﾠliver.	 ﾠPreviously	 ﾠit	 ﾠwas	 ﾠdemonstrated	 ﾠthat	 ﾠTPN	 ﾠcould	 ﾠaffect	 ﾠthe	 ﾠoverall	 ﾠ
composition	 ﾠof	 ﾠthe	 ﾠPC	 ﾠphospholipid	 ﾠpool	 ﾠdirectly.	 ﾠA	 ﾠmajor	 ﾠdriver	 ﾠfor	 ﾠthe	 ﾠchanges	 ﾠin	 ﾠ
profile	 ﾠmay	 ﾠtherefore	 ﾠbe	 ﾠnutritional	 ﾠfactors	 ﾠand	 ﾠavailability	 ﾠof	 ﾠfatty	 ﾠacid	 ﾠspecies	 ﾠ
and	 ﾠcholine	 ﾠitself.	 ﾠ
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A	 ﾠdirect	 ﾠlink	 ﾠbetween	 ﾠnutritional	 ﾠintake	 ﾠand	 ﾠPC	 ﾠspecies	 ﾠsynthetic	 ﾠchanges	 ﾠhas	 ﾠnot	 ﾠ
been	 ﾠdemonstrated	 ﾠin	 ﾠthe	 ﾠhuman	 ﾠpreterm	 ﾠinfant	 ﾠbefore	 ﾠnow.	 ﾠ
Further	 ﾠevidence	 ﾠof	 ﾠactive	 ﾠand	 ﾠvariable	 ﾠturnover	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠexists	 ﾠon	 ﾠ
examination	 ﾠof	 ﾠthe	 ﾠD9	 ﾠfractional	 ﾠincorporation	 ﾠdata.	 ﾠ
3.3.3	 ﾠ Turnover	 ﾠ of	 ﾠ newly	 ﾠ synthesised	 ﾠ individual	 ﾠ D9-ﾭ‐phosphatidylcholine	 ﾠ
species	 ﾠ
By	 ﾠnormalising	 ﾠthe	 ﾠfractional	 ﾠenrichment	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠto	 ﾠ1,	 ﾠat	 ﾠtheir	 ﾠ
peak	 ﾠof	 ﾠ12	 ﾠhours	 ﾠand	 ﾠlog	 ﾠtransforming	 ﾠthe	 ﾠy-ﾭ‐axis	 ﾠthen	 ﾠthe	 ﾠdifferences	 ﾠin	 ﾠturnover,	 ﾠ
that	 ﾠis	 ﾠthe	 ﾠrelative	 ﾠloss	 ﾠof	 ﾠlabelled	 ﾠspecies,	 ﾠcan	 ﾠbe	 ﾠseen	 ﾠ(Figure	 ﾠ26).	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Figure	 ﾠ26.	 ﾠTurnover	 ﾠof	 ﾠselected	 ﾠenriched	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma.	 ﾠHigher	 ﾠ
turnover,	 ﾠor	 ﾠrelative	 ﾠloss,	 ﾠof	 ﾠa	 ﾠspecies	 ﾠis	 ﾠreflected	 ﾠin	 ﾠa	 ﾠsteeper	 ﾠslope	 ﾠafter	 ﾠthe	 ﾠ
peak	 ﾠat	 ﾠ12	 ﾠhours.	 ﾠ	 ﾠ
The	 ﾠsteeper	 ﾠthat	 ﾠthe	 ﾠslope	 ﾠappears	 ﾠfrom	 ﾠ12	 ﾠhours	 ﾠthen	 ﾠthe	 ﾠhigher	 ﾠis	 ﾠthe	 ﾠturnover	 ﾠof	 ﾠ
that	 ﾠspecies.	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i)	 ﾠTurnover	 ﾠof	 ﾠD9-ﾭ‐phosphatidylcholine	 ﾠspecies	 ﾠgrouped	 ﾠby	 ﾠsn-ﾭ‐1	 ﾠfatty	 ﾠacid	 ﾠ
By	 ﾠselecting	 ﾠthe	 ﾠspecies	 ﾠwith	 ﾠa	 ﾠ16:0	 ﾠfatty	 ﾠacid	 ﾠat	 ﾠsn-ﾭ‐1	 ﾠthere	 ﾠis	 ﾠclearly	 ﾠa	 ﾠhigher	 ﾠ
turnover	 ﾠ when	 ﾠ the	 ﾠ sn-ﾭ‐2	 ﾠ is	 ﾠ the	 ﾠ monounsaturated	 ﾠ species,	 ﾠ followed	 ﾠ by	 ﾠ the	 ﾠ
diunsaturated	 ﾠand	 ﾠthen	 ﾠdocosahexaenoyl-ﾭ‐containing	 ﾠ(22:6)	 ﾠand	 ﾠthen	 ﾠslowest	 ﾠin	 ﾠ
the	 ﾠarachidonoyl-ﾭ‐containing	 ﾠ(20:4)	 ﾠspecies	 ﾠ(Figure	 ﾠ27).	 ﾠ
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Figure	 ﾠ27.	 ﾠTurnover	 ﾠof	 ﾠenriched	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠwith	 ﾠa	 ﾠ16:0	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐1	 ﾠ
position.	 ﾠHigher	 ﾠturnover,	 ﾠor	 ﾠrelative	 ﾠloss,	 ﾠof	 ﾠa	 ﾠspecies	 ﾠis	 ﾠreflected	 ﾠin	 ﾠa	 ﾠ
steeper	 ﾠslope	 ﾠafter	 ﾠthe	 ﾠpeak	 ﾠat	 ﾠ12	 ﾠhours.	 ﾠ	 ﾠ
This	 ﾠ specificity	 ﾠ of	 ﾠ liver	 ﾠ turnover	 ﾠ is	 ﾠ similar	 ﾠ to	 ﾠ that	 ﾠ found	 ﾠ in	 ﾠ published	 ﾠ rat	 ﾠ
experimental	 ﾠwork	 ﾠ(Burdge	 ﾠet	 ﾠal.,	 ﾠ1994).	 ﾠ
In	 ﾠ contrast,	 ﾠ when	 ﾠ the	 ﾠ sn-ﾭ‐1	 ﾠ is	 ﾠ an	 ﾠ 18:0	 ﾠ there	 ﾠ is	 ﾠ even	 ﾠ slower	 ﾠ turnover	 ﾠ with	 ﾠ the	 ﾠ
polyunsaturated	 ﾠ sn-ﾭ‐2	 ﾠ species	 ﾠ continuing	 ﾠ to	 ﾠ rise	 ﾠ after	 ﾠ 12	 ﾠ hours.	 ﾠ The	 ﾠ highest	 ﾠ
turnover	 ﾠis	 ﾠby	 ﾠthe	 ﾠdiunsaturated	 ﾠspecies,	 ﾠwith	 ﾠthe	 ﾠarachidonoyl-ﾭ‐containing	 ﾠspecies	 ﾠ
the	 ﾠleast	 ﾠ(Figure	 ﾠ28).	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Figure	 ﾠ28.	 ﾠTurnover	 ﾠof	 ﾠenriched	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠwith	 ﾠa	 ﾠ18:0	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐1	 ﾠ
position.	 ﾠHigher	 ﾠturnover,	 ﾠor	 ﾠrelative	 ﾠloss,	 ﾠof	 ﾠa	 ﾠspecies	 ﾠis	 ﾠreflected	 ﾠin	 ﾠa	 ﾠ
steeper	 ﾠslope	 ﾠafter	 ﾠthe	 ﾠpeak	 ﾠat	 ﾠ12	 ﾠhours.	 ﾠ	 ﾠ
	 ﾠ
ii)	 ﾠ Turnover	 ﾠ of	 ﾠ D9-ﾭ‐phosphatidylcholine	 ﾠ species	 ﾠ grouped	 ﾠ by	 ﾠ presence	 ﾠ of	 ﾠ a	 ﾠ
polyunsaturated	 ﾠfatty	 ﾠacid	 ﾠon	 ﾠsn-ﾭ‐2	 ﾠ	 ﾠ
If	 ﾠPUFA-ﾭ‐containing	 ﾠspecies	 ﾠare	 ﾠexamined	 ﾠalone	 ﾠthen	 ﾠthe	 ﾠarachidonoyl-ﾭ‐containing	 ﾠ
and	 ﾠdocosahexaenoyl-ﾭ‐containing	 ﾠshow	 ﾠthe	 ﾠsame	 ﾠpattern	 ﾠof	 ﾠturnover	 ﾠrelative	 ﾠto	 ﾠ
each	 ﾠother.	 ﾠThe	 ﾠ16:0	 ﾠversion	 ﾠof	 ﾠa	 ﾠgiven	 ﾠPC	 ﾠspecies	 ﾠhas	 ﾠa	 ﾠhigher	 ﾠturnover	 ﾠthan	 ﾠthe	 ﾠ
18:0	 ﾠequivalent	 ﾠ(Figure	 ﾠ29).	 ﾠ 75	 ﾠ
	 ﾠ
Figure	 ﾠ29.	 ﾠTurnover	 ﾠof	 ﾠenriched	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠwith	 ﾠa	 ﾠpolyunsaturated	 ﾠ
fatty	 ﾠacid	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐2	 ﾠposition.	 ﾠHigher	 ﾠturnover,	 ﾠor	 ﾠrelative	 ﾠloss,	 ﾠof	 ﾠa	 ﾠspecies	 ﾠ
is	 ﾠreflected	 ﾠin	 ﾠa	 ﾠsteeper	 ﾠslope	 ﾠafter	 ﾠthe	 ﾠpeak	 ﾠat	 ﾠ12	 ﾠhours.	 ﾠ	 ﾠ
The	 ﾠpatterns	 ﾠdescribed	 ﾠare	 ﾠrepeated	 ﾠfrom	 ﾠ120	 ﾠhours	 ﾠto	 ﾠ240	 ﾠhours.	 ﾠ
These	 ﾠdata	 ﾠdemonstrate	 ﾠthe	 ﾠdifferential	 ﾠturnover	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠliver.	 ﾠ
3.4	 ﾠDiscussion	 ﾠ
As	 ﾠCDP-ﾭ‐choline	 ﾠis	 ﾠpresent	 ﾠin	 ﾠall	 ﾠmetabolically	 ﾠactive	 ﾠcells	 ﾠin	 ﾠthe	 ﾠbody	 ﾠand	 ﾠPC	 ﾠis	 ﾠthe	 ﾠ
predominant	 ﾠphospholipid	 ﾠin	 ﾠmost	 ﾠmammals,	 ﾠthe	 ﾠability	 ﾠto	 ﾠproduce	 ﾠand	 ﾠuse	 ﾠPC	 ﾠis	 ﾠ
vital	 ﾠto	 ﾠongoing	 ﾠhealth,	 ﾠnormal	 ﾠfunction	 ﾠand	 ﾠrepair.	 ﾠ	 ﾠ
This	 ﾠis	 ﾠthe	 ﾠfirst	 ﾠstudy	 ﾠperformed	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠto	 ﾠinvestigate	 ﾠthe	 ﾠprofile	 ﾠof	 ﾠPC	 ﾠ
lipids	 ﾠ circulating	 ﾠ in	 ﾠ plasma.	 ﾠ ESI	 ﾠ MS/MS	 ﾠ analysis	 ﾠ of	 ﾠ lipid	 ﾠ extracts	 ﾠ from	 ﾠ plasma	 ﾠ
reveals	 ﾠa	 ﾠsignificant	 ﾠamount	 ﾠof	 ﾠdetail	 ﾠin	 ﾠthe	 ﾠoverall	 ﾠamount	 ﾠof	 ﾠPC	 ﾠphospholipid	 ﾠ
present	 ﾠand	 ﾠtheir	 ﾠspecific	 ﾠfatty	 ﾠacid	 ﾠcomposition.	 ﾠ	 ﾠ
As	 ﾠthe	 ﾠsole	 ﾠsource	 ﾠof	 ﾠnutrition	 ﾠin	 ﾠthe	 ﾠcritical	 ﾠfirst	 ﾠweeks	 ﾠof	 ﾠextreme	 ﾠpreterm	 ﾠlife	 ﾠis	 ﾠ
often	 ﾠparenteral	 ﾠnutrition	 ﾠthis	 ﾠthen	 ﾠraises	 ﾠthe	 ﾠissue	 ﾠof	 ﾠwhether	 ﾠthese	 ﾠchildren	 ﾠare	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receiving	 ﾠsufficient	 ﾠcholine	 ﾠin	 ﾠtheir	 ﾠparenteral	 ﾠnutrition	 ﾠor	 ﾠwhether	 ﾠthe	 ﾠTPN	 ﾠthey	 ﾠ
receive	 ﾠshould	 ﾠbe	 ﾠsupplemented	 ﾠwith	 ﾠextra	 ﾠcholine.	 ﾠ
The	 ﾠD9-ﾭ‐PC	 ﾠdata	 ﾠin	 ﾠthis	 ﾠchapter	 ﾠclearly	 ﾠshows	 ﾠthat	 ﾠthese	 ﾠchildren,	 ﾠas	 ﾠa	 ﾠgroup,	 ﾠare	 ﾠ
able	 ﾠ to	 ﾠ rapidly	 ﾠ metabolise	 ﾠ the	 ﾠ labelled	 ﾠ choline	 ﾠ that	 ﾠ they	 ﾠ receive.	 ﾠ In	 ﾠ fact,	 ﾠ they	 ﾠ
incorporate	 ﾠsubstrate	 ﾠat	 ﾠa	 ﾠrate	 ﾠin	 ﾠexcess	 ﾠof	 ﾠany	 ﾠpreviously	 ﾠexamined	 ﾠpatient	 ﾠor	 ﾠ
volunteer	 ﾠgroup	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ2011).	 ﾠThere	 ﾠis	 ﾠvery	 ﾠclear	 ﾠevidence	 ﾠthat	 ﾠthey	 ﾠare	 ﾠable	 ﾠ
to	 ﾠproduce	 ﾠPC	 ﾠphospholipid	 ﾠrapidly	 ﾠeven	 ﾠa	 ﾠshort	 ﾠtime	 ﾠfollowing	 ﾠpreterm	 ﾠbirth,	 ﾠand	 ﾠ
that	 ﾠwhat	 ﾠthey	 ﾠmake,	 ﾠin	 ﾠterms	 ﾠof	 ﾠfatty	 ﾠacid	 ﾠcomposition	 ﾠand	 ﾠspecificity,	 ﾠchanges	 ﾠ
with	 ﾠtime.	 ﾠ
One	 ﾠ driver	 ﾠ for	 ﾠ this	 ﾠ change	 ﾠ in	 ﾠ specificity	 ﾠ may	 ﾠ be	 ﾠ alteration	 ﾠ in	 ﾠ requirement	 ﾠ –	 ﾠ a	 ﾠ
requirement	 ﾠdriven	 ﾠby	 ﾠthe	 ﾠneed	 ﾠfor	 ﾠspecific	 ﾠPC	 ﾠmolecules,	 ﾠfor	 ﾠexample	 ﾠby	 ﾠthe	 ﾠlung.	 ﾠ
However	 ﾠ there	 ﾠ is	 ﾠ some	 ﾠ evidence,	 ﾠ from	 ﾠ two	 ﾠ babies,	 ﾠ that	 ﾠ the	 ﾠ addition	 ﾠ of	 ﾠ TPN	 ﾠ
markedly	 ﾠalters	 ﾠthe	 ﾠcomposition	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠfound	 ﾠin	 ﾠplasma.	 ﾠThese	 ﾠchanges	 ﾠare	 ﾠ
directly	 ﾠ reflected	 ﾠ in	 ﾠ the	 ﾠ newly	 ﾠ synthesised	 ﾠ PC	 ﾠ phospholipids	 ﾠ with	 ﾠ increasing	 ﾠ
proportions	 ﾠof	 ﾠdiunsaturated	 ﾠspecies	 ﾠat	 ﾠthe	 ﾠexpense	 ﾠof	 ﾠarachidonoyl-ﾭ‐containing	 ﾠ
phospholipids.	 ﾠTherefore	 ﾠthe	 ﾠsuggestion	 ﾠis	 ﾠthat	 ﾠthe	 ﾠTPN	 ﾠthat	 ﾠis	 ﾠprovided	 ﾠto	 ﾠthese	 ﾠ
babies	 ﾠdirectly	 ﾠinfluences	 ﾠtheir	 ﾠability	 ﾠto	 ﾠproduce	 ﾠnew	 ﾠPC	 ﾠphospholipid	 ﾠspecies.	 ﾠ	 ﾠ
It	 ﾠis	 ﾠpossible	 ﾠtherefore	 ﾠalso	 ﾠto	 ﾠsurmise	 ﾠthat	 ﾠthe	 ﾠintake	 ﾠof	 ﾠfatty	 ﾠacids	 ﾠin	 ﾠthe	 ﾠTPN	 ﾠ
alters	 ﾠthe	 ﾠPC	 ﾠmolecules	 ﾠavailable	 ﾠin	 ﾠthe	 ﾠplasma	 ﾠtoo.	 ﾠThis	 ﾠevidence,	 ﾠalongside	 ﾠother	 ﾠ
results	 ﾠfrom	 ﾠthis	 ﾠstudy,	 ﾠleads	 ﾠto	 ﾠquestions	 ﾠabout	 ﾠthe	 ﾠsuitability	 ﾠof	 ﾠthe	 ﾠTPN	 ﾠsupplied	 ﾠ
and	 ﾠthe	 ﾠpossibility	 ﾠof	 ﾠrefinement	 ﾠor	 ﾠtailoring	 ﾠthe	 ﾠfatty	 ﾠacids	 ﾠin	 ﾠTPN	 ﾠfor	 ﾠthis	 ﾠgroup.	 ﾠ	 ﾠ
Equally,	 ﾠmore	 ﾠfully	 ﾠsaturated	 ﾠfatty	 ﾠacids	 ﾠmay	 ﾠbe	 ﾠrequired	 ﾠto	 ﾠsupport	 ﾠsurface-ﾭ‐active	 ﾠ
surfactant	 ﾠproduction	 ﾠin	 ﾠthe	 ﾠlungs	 ﾠ–	 ﾠthough,	 ﾠas	 ﾠevidence	 ﾠpresented	 ﾠin	 ﾠChapter	 ﾠ5	 ﾠof	 ﾠ
this	 ﾠthesis	 ﾠsuggests,	 ﾠit	 ﾠmay	 ﾠbe	 ﾠmore	 ﾠappropriate	 ﾠto	 ﾠsupply	 ﾠthose	 ﾠsubstrates	 ﾠby	 ﾠa	 ﾠ
topical	 ﾠroute	 ﾠdirectly	 ﾠto	 ﾠthe	 ﾠlungs.	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In	 ﾠ the	 ﾠ clinical	 ﾠ environment	 ﾠ changes	 ﾠ are	 ﾠ being	 ﾠ implemented	 ﾠ to	 ﾠ provide	 ﾠ TPN	 ﾠ as	 ﾠ
quickly	 ﾠas	 ﾠpossible	 ﾠto	 ﾠpreterm	 ﾠinfants,	 ﾠdriven	 ﾠby	 ﾠevidence	 ﾠof	 ﾠearly	 ﾠtolerance	 ﾠto	 ﾠ
amino	 ﾠ acids	 ﾠ and	 ﾠ lipids	 ﾠ without	 ﾠ increasing	 ﾠ the	 ﾠ risk	 ﾠ of	 ﾠ metabolic	 ﾠ acidosis,	 ﾠ
hypercholesterolemia,	 ﾠ or	 ﾠ hypertriglyceridemia	 ﾠ (Ibrahim	 ﾠ et	 ﾠ al.,	 ﾠ 2004).	 ﾠ The	 ﾠ goal	 ﾠ
must	 ﾠbe	 ﾠto	 ﾠsupply	 ﾠTPN	 ﾠto	 ﾠevery	 ﾠeligible	 ﾠpreterm	 ﾠinfant	 ﾠwithin	 ﾠ24	 ﾠhours	 ﾠof	 ﾠbirth	 ﾠ
and	 ﾠ as	 ﾠ demonstrated	 ﾠ in	 ﾠ this	 ﾠ chapter	 ﾠ the	 ﾠ newborn	 ﾠ preterm	 ﾠ infant	 ﾠ rapidly	 ﾠ
synthesises	 ﾠ phosphatidylcholine	 ﾠ phospholipids,	 ﾠ in	 ﾠ the	 ﾠ presence	 ﾠ of	 ﾠ available	 ﾠ
substrate,	 ﾠwithin	 ﾠthis	 ﾠ24-ﾭ‐hour	 ﾠwindow.	 ﾠAdditionally	 ﾠthey	 ﾠproduce	 ﾠphospholipids	 ﾠ
with	 ﾠfatty	 ﾠacid	 ﾠprofiles	 ﾠthat	 ﾠare	 ﾠdirectly	 ﾠinfluenced	 ﾠby	 ﾠthe	 ﾠTPN	 ﾠthey	 ﾠreceive.	 ﾠThe	 ﾠ
evidence	 ﾠpoints	 ﾠtowards	 ﾠthe	 ﾠneed	 ﾠto	 ﾠalter	 ﾠthe	 ﾠTPN	 ﾠthese	 ﾠpatients	 ﾠreceive	 ﾠto	 ﾠbetter	 ﾠ
reflect	 ﾠtheir	 ﾠability	 ﾠto	 ﾠsynthesise	 ﾠand	 ﾠuse	 ﾠcholine	 ﾠand	 ﾠfatty	 ﾠacids.	 ﾠFuture	 ﾠstudies	 ﾠ
should	 ﾠaddress	 ﾠthe	 ﾠTPN	 ﾠgiven	 ﾠand	 ﾠthe	 ﾠoutcomes	 ﾠfor	 ﾠthese	 ﾠinfants.	 ﾠ
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Chapter	 ﾠ 4.	 ﾠ The	 ﾠ characterisation	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ
species	 ﾠin	 ﾠplasma	 ﾠsynthesised	 ﾠvia	 ﾠmethyl	 ﾠgroup	 ﾠtransfer	 ﾠ
from	 ﾠcholine	 ﾠto	 ﾠphosphatidylethanolamine	 ﾠin	 ﾠa	 ﾠpreterm	 ﾠ
population	 ﾠ
4.1	 ﾠIntroduction	 ﾠ
In	 ﾠthe	 ﾠprevious	 ﾠchapter	 ﾠthe	 ﾠeffect	 ﾠof	 ﾠthe	 ﾠCDP-ﾭ‐choline	 ﾠpathway	 ﾠon	 ﾠmetabolism	 ﾠof	 ﾠ
phosphatidylcholine	 ﾠin	 ﾠnewborn	 ﾠpreterm	 ﾠinfants	 ﾠwas	 ﾠinvestigated.	 ﾠ
PC	 ﾠ is	 ﾠ synthesised	 ﾠ by	 ﾠ all	 ﾠ nucleated	 ﾠ cell	 ﾠ types	 ﾠ directly	 ﾠ from	 ﾠ choline	 ﾠ and	 ﾠ
diacylglycerol	 ﾠ via	 ﾠ this	 ﾠ pathway,	 ﾠ but	 ﾠ can	 ﾠ also	 ﾠ be	 ﾠ synthesised	 ﾠ in	 ﾠ hepatocytes	 ﾠ by	 ﾠ
three	 ﾠsequential	 ﾠmethylations	 ﾠof	 ﾠphosphatidylethanolamine	 ﾠ(PE)	 ﾠcatalysed	 ﾠby	 ﾠPE-ﾭ‐
N-ﾭ‐methyltransferases	 ﾠ(PEMT).	 ﾠThis	 ﾠpathway	 ﾠuses	 ﾠS-ﾭ‐Adenosyl	 ﾠmethionine	 ﾠ(SAMe)	 ﾠ
as	 ﾠthe	 ﾠmethyl	 ﾠdonor	 ﾠand	 ﾠaccounts	 ﾠfor	 ﾠaround	 ﾠ30%	 ﾠof	 ﾠtotal	 ﾠliver	 ﾠPC	 ﾠsynthesis	 ﾠin	 ﾠthe	 ﾠ
mature	 ﾠ systems	 ﾠ investigated	 ﾠ (Sundler	 ﾠ and	 ﾠ Akesson,	 ﾠ 1975b).	 ﾠ Unlike	 ﾠ the	 ﾠ CDP-ﾭ‐
choline	 ﾠpathway,	 ﾠwhich	 ﾠproduces	 ﾠmainly	 ﾠmonounsaturated	 ﾠand	 ﾠdiunsaturated	 ﾠPC	 ﾠ
species,	 ﾠ in	 ﾠ the	 ﾠ adult	 ﾠ the	 ﾠ PEMT	 ﾠ pathway	 ﾠ synthesises	 ﾠ polyunsaturated	 ﾠ fatty	 ﾠ acid	 ﾠ
(PUFA)-ﾭ‐containing	 ﾠPC	 ﾠspecies.	 ﾠThis	 ﾠenrichment	 ﾠin	 ﾠPUFA	 ﾠis	 ﾠdependent	 ﾠon	 ﾠthe	 ﾠfatty	 ﾠ
acid	 ﾠcomposition	 ﾠof	 ﾠliver	 ﾠphosphatidylethanolamine.	 ﾠ
The	 ﾠimportance	 ﾠof	 ﾠPE-ﾭ‐N-ﾭ‐methylation	 ﾠfor	 ﾠthe	 ﾠsupply	 ﾠof	 ﾠPUFA	 ﾠfrom	 ﾠthe	 ﾠliver	 ﾠto	 ﾠthe	 ﾠ
peripheral	 ﾠ tissues	 ﾠ is	 ﾠ highlighted	 ﾠ in	 ﾠ the	 ﾠ PEMT-ﾭ‐/-ﾭ‐	 ﾠ knockout	 ﾠ mouse,	 ﾠ with	 ﾠ two	 ﾠ
selectively	 ﾠdisrupted	 ﾠalleles	 ﾠof	 ﾠthe	 ﾠPempt-ﾭ‐2	 ﾠgene	 ﾠon	 ﾠexon	 ﾠ2	 ﾠ(Walkey	 ﾠet	 ﾠal.,	 ﾠ1997),	 ﾠ
that	 ﾠhas	 ﾠsubstantially	 ﾠdiminished	 ﾠPUFA-ﾭ‐containing	 ﾠPC	 ﾠspecies,	 ﾠthough	 ﾠfatal	 ﾠliver	 ﾠ
failure	 ﾠis	 ﾠprevented	 ﾠand	 ﾠtotal	 ﾠplasma	 ﾠPC	 ﾠnormalised	 ﾠby	 ﾠcholine	 ﾠsupplementation	 ﾠ
(Zhu	 ﾠet	 ﾠal.,	 ﾠ2003).	 ﾠ
Choline	 ﾠis	 ﾠa	 ﾠsignificant	 ﾠmethyl	 ﾠdonor	 ﾠfor	 ﾠsynthesis	 ﾠof	 ﾠSAMe,	 ﾠso	 ﾠthe	 ﾠuse	 ﾠof	 ﾠa	 ﾠ[methyl-ﾭ‐
D9]choline	 ﾠ chloride,	 ﾠ as	 ﾠ in	 ﾠ this	 ﾠ study	 ﾠ results	 ﾠ in	 ﾠ the	 ﾠ transfer	 ﾠ of	 ﾠ a	 ﾠ single	 ﾠ labelled	 ﾠ
methyl	 ﾠgroup	 ﾠto	 ﾠform	 ﾠmethyl-ﾭ‐D3-ﾭ‐SAMe.	 ﾠConsequently,	 ﾠas	 ﾠin	 ﾠa	 ﾠpreviously	 ﾠpublished	 ﾠ  80	 ﾠ
human	 ﾠvolunteer	 ﾠstudy	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ2011),	 ﾠit	 ﾠis	 ﾠpossible,	 ﾠusing	 ﾠmultiple	 ﾠisotopomer	 ﾠ
distribution	 ﾠ analysis	 ﾠ (MIDA),	 ﾠ to	 ﾠ monitor	 ﾠ flux	 ﾠ through	 ﾠ the	 ﾠ PEMT	 ﾠ pathway	 ﾠ
independently	 ﾠfrom	 ﾠthe	 ﾠincorporation	 ﾠof	 ﾠthe	 ﾠmethyl-ﾭ‐D9	 ﾠlabel.	 ﾠ	 ﾠ
Methyl	 ﾠdonors	 ﾠare	 ﾠvitally	 ﾠimportant	 ﾠin	 ﾠearly	 ﾠmammalian	 ﾠand	 ﾠhuman	 ﾠdevelopment,	 ﾠ
affecting	 ﾠthe	 ﾠmethylation	 ﾠof	 ﾠnucleic	 ﾠacids	 ﾠand	 ﾠdownstream	 ﾠgene	 ﾠexpression.	 ﾠ	 ﾠDNA	 ﾠ
methylation	 ﾠin	 ﾠgene	 ﾠpromoter	 ﾠregions	 ﾠcan	 ﾠresult	 ﾠin	 ﾠgene	 ﾠsilencing	 ﾠand	 ﾠinfluences	 ﾠ
gene	 ﾠ expression.	 ﾠ While	 ﾠ this	 ﾠ form	 ﾠ of	 ﾠ gene	 ﾠ silencing	 ﾠ is	 ﾠ extremely	 ﾠ important	 ﾠ in	 ﾠ
development	 ﾠ and	 ﾠ cellular	 ﾠ differentiation,	 ﾠ aberrant	 ﾠ DNA	 ﾠ methylation	 ﾠ can	 ﾠ be	 ﾠ
detrimental	 ﾠand	 ﾠhas	 ﾠbeen	 ﾠlinked	 ﾠto	 ﾠdisease	 ﾠprocesses,	 ﾠsuch	 ﾠas	 ﾠcancer,	 ﾠin	 ﾠlater	 ﾠlife.	 ﾠ	 ﾠ
4.1.1	 ﾠMethodologies	 ﾠused	 ﾠin	 ﾠplasma	 ﾠPEMT	 ﾠinvestigation	 ﾠ
Infants	 ﾠin	 ﾠreceipt	 ﾠof	 ﾠlabelled	 ﾠD9-ﾭ‐choline	 ﾠwithin	 ﾠ48	 ﾠhours	 ﾠof	 ﾠpreterm	 ﾠbirth	 ﾠhad	 ﾠserial	 ﾠ
samples	 ﾠ of	 ﾠ blood	 ﾠ collected	 ﾠ for	 ﾠ up	 ﾠ to	 ﾠ 120	 ﾠ hours	 ﾠ after	 ﾠ the	 ﾠ administration	 ﾠ of	 ﾠ the	 ﾠ
[methyl-ﾭ‐D9]choline	 ﾠ chloride.	 ﾠ Samples	 ﾠ of	 ﾠ plasma	 ﾠ were	 ﾠ collected	 ﾠ as	 ﾠ previously	 ﾠ
described,	 ﾠ in	 ﾠ Chapter	 ﾠ 2.2	 ﾠ Materials	 ﾠ and	 ﾠ Methods.	 ﾠ Blood	 ﾠ sample	 ﾠ processing	 ﾠ is	 ﾠ
discussed	 ﾠ in	 ﾠ Chapter	 ﾠ 2.2.5	 ﾠ (i),	 ﾠ with	 ﾠ the	 ﾠ lipid	 ﾠ extraction	 ﾠ of	 ﾠ plasma	 ﾠ aliquots	 ﾠ is	 ﾠ
described	 ﾠin	 ﾠChapter	 ﾠ2.2.8.	 ﾠThe	 ﾠtheory	 ﾠand	 ﾠmethodology	 ﾠof	 ﾠelectrospray	 ﾠionisation	 ﾠ
tandem	 ﾠmass	 ﾠspectrometry	 ﾠ(ESI	 ﾠMS/MS)	 ﾠwith	 ﾠdirect	 ﾠinfusion	 ﾠhas	 ﾠbeen	 ﾠdiscussed	 ﾠin	 ﾠ
the	 ﾠintroduction	 ﾠchapter	 ﾠ1.8.	 ﾠ
Liquid	 ﾠchromatography	 ﾠmultiple	 ﾠreaction	 ﾠmonitoring	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ
(LC-ﾭ‐MRM-ﾭ‐MS/MS)	 ﾠwas	 ﾠused	 ﾠfor	 ﾠcholine	 ﾠand	 ﾠbetaine	 ﾠplasma	 ﾠanalysis.	 ﾠThe	 ﾠmethod	 ﾠ
is	 ﾠdescribed	 ﾠin	 ﾠthe	 ﾠmethodology	 ﾠsection	 ﾠ(2.3.2	 ﾠii).	 ﾠ
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4.2	 ﾠPrecursors	 ﾠof	 ﾠmass/charge	 ﾠ+187	 ﾠ&	 ﾠ+190	 ﾠscanning	 ﾠ
The	 ﾠlipid	 ﾠextract	 ﾠfrom	 ﾠplasma	 ﾠwas	 ﾠfirst	 ﾠanalysed	 ﾠfor	 ﾠprecursors	 ﾠof	 ﾠmass-ﾭ‐to-ﾭ‐charge	 ﾠ
(m/z)	 ﾠ 187	 ﾠ on	 ﾠ ESI	 ﾠ MS/MS.	 ﾠ As	 ﾠ previously	 ﾠ outlined	 ﾠ this	 ﾠ method	 ﾠ of	 ﾠ scanning	 ﾠ
determines	 ﾠthe	 ﾠmass	 ﾠof	 ﾠa	 ﾠmolecule	 ﾠin	 ﾠa	 ﾠsample	 ﾠwhich,	 ﾠon	 ﾠcollision	 ﾠwith	 ﾠan	 ﾠinert	 ﾠgas,	 ﾠ
breaks	 ﾠinto	 ﾠfragments,	 ﾠone	 ﾠof	 ﾠwhich	 ﾠhas	 ﾠa	 ﾠm/z	 ﾠof	 ﾠ187.	 ﾠThe	 ﾠphosphatidylcholine	 ﾠ
head	 ﾠgroup	 ﾠin	 ﾠD3-ﾭ‐PC-ﾭ‐containing	 ﾠphospholipids	 ﾠproduces	 ﾠthis	 ﾠfragment	 ﾠmolecule.	 ﾠ
Caution	 ﾠ must	 ﾠ be	 ﾠ exercised	 ﾠ at	 ﾠ this	 ﾠ point	 ﾠ as	 ﾠ the	 ﾠ PEMT	 ﾠ pathway	 ﾠ produces	 ﾠ small	 ﾠ
quantities	 ﾠ of	 ﾠ PC	 ﾠ phospholipid	 ﾠ and	 ﾠ the	 ﾠ spectra	 ﾠ seen	 ﾠ may	 ﾠ be	 ﾠ supplemented	 ﾠ by	 ﾠ
Carbon-ﾭ‐13	 ﾠ (13C),	 ﾠ the	 ﾠ stable	 ﾠ environmental	 ﾠ isotope	 ﾠ of	 ﾠ Carbon	 ﾠ with	 ﾠ a	 ﾠ natural	 ﾠ
abundance	 ﾠof	 ﾠ1.11%.	 ﾠNaturally	 ﾠoccurring	 ﾠCarbon	 ﾠisotopes	 ﾠwill	 ﾠnot	 ﾠinterfere	 ﾠwith	 ﾠ
D9-ﾭ‐PC	 ﾠdetection,	 ﾠas	 ﾠnine	 ﾠ13C	 ﾠatoms	 ﾠare	 ﾠrequired	 ﾠin	 ﾠa	 ﾠsingle	 ﾠmolecule	 ﾠto	 ﾠproduce	 ﾠa	 ﾠ
false	 ﾠ positive	 ﾠ spike	 ﾠ on	 ﾠ MS,	 ﾠ a	 ﾠ likelihood	 ﾠ that	 ﾠ is	 ﾠ statistically	 ﾠ insignificant.	 ﾠ D3-ﾭ‐PC	 ﾠ
analysis	 ﾠhowever	 ﾠcan	 ﾠbe	 ﾠinfluenced	 ﾠby	 ﾠthree	 ﾠ13C	 ﾠmolecules	 ﾠand,	 ﾠwhile	 ﾠsmall	 ﾠit	 ﾠis	 ﾠ
not	 ﾠinsignificant	 ﾠand	 ﾠmust	 ﾠbe	 ﾠtaken	 ﾠinto	 ﾠaccount	 ﾠwhen	 ﾠcalculating	 ﾠthe	 ﾠflux	 ﾠthrough	 ﾠ
the	 ﾠPEMT	 ﾠsystem.	 ﾠ	 ﾠ
This	 ﾠ problem	 ﾠ of	 ﾠ isotope	 ﾠ peaks	 ﾠ exists	 ﾠ throughout	 ﾠ mass	 ﾠ spectrometry	 ﾠ research	 ﾠ
where	 ﾠa	 ﾠsmaller	 ﾠpeak	 ﾠmay	 ﾠbe	 ﾠvisible	 ﾠwith	 ﾠa	 ﾠmass/charge	 ﾠratio	 ﾠlarger	 ﾠthan	 ﾠthe	 ﾠ
molecular	 ﾠ ion	 ﾠ peak.	 ﾠ In	 ﾠ this	 ﾠ study,	 ﾠ for	 ﾠ example,	 ﾠ the	 ﾠ m/z	 ﾠ value	 ﾠ of	 ﾠ 760	 ﾠ for	 ﾠ the	 ﾠ
PC16:0/18:1	 ﾠcorresponds	 ﾠto	 ﾠthe	 ﾠmonoisotopic	 ﾠmass	 ﾠof	 ﾠa	 ﾠmolecule	 ﾠof	 ﾠPC16:0/18:1	 ﾠ
entirely	 ﾠcomposed	 ﾠof	 ﾠthe	 ﾠmost	 ﾠabundant	 ﾠisotopes	 ﾠ(1H	 ﾠand	 ﾠ12C)	 ﾠwhereas	 ﾠthe	 ﾠM+1	 ﾠ
peak	 ﾠ(761)	 ﾠcorresponds	 ﾠto	 ﾠa	 ﾠfraction	 ﾠof	 ﾠthe	 ﾠmolecules	 ﾠwith	 ﾠone	 ﾠhigher	 ﾠisotope	 ﾠ
incorporated	 ﾠ(2H	 ﾠor	 ﾠ13C)	 ﾠand	 ﾠtherefore	 ﾠthe	 ﾠM+2	 ﾠpeak	 ﾠ(762)	 ﾠhas	 ﾠtwo	 ﾠhigher	 ﾠisotopes,	 ﾠ
M+3	 ﾠ has	 ﾠ three	 ﾠ isotopes	 ﾠ and	 ﾠ so	 ﾠ on.	 ﾠ The	 ﾠ natural	 ﾠ background	 ﾠ abundance	 ﾠ of	 ﾠ the	 ﾠ
higher	 ﾠisotopes	 ﾠfor	 ﾠfrequently	 ﾠencountered	 ﾠelements,	 ﾠsuch	 ﾠas	 ﾠhydrogen,	 ﾠcarbon	 ﾠ
and	 ﾠ nitrogen,	 ﾠ is	 ﾠ known	 ﾠ and	 ﾠ therefore	 ﾠ the	 ﾠ chance	 ﾠ of	 ﾠ any	 ﾠ higher	 ﾠ isotope	 ﾠ peak	 ﾠ  82	 ﾠ
occurring	 ﾠnaturally	 ﾠrather	 ﾠthan	 ﾠby	 ﾠincorporation	 ﾠof	 ﾠan	 ﾠintroduced	 ﾠstable	 ﾠisotope	 ﾠ
must	 ﾠbe	 ﾠtaken	 ﾠinto	 ﾠaccount	 ﾠwith	 ﾠany	 ﾠcalculation	 ﾠof	 ﾠenrichment.	 ﾠ
4.2.1	 ﾠMass	 ﾠspectrometry	 ﾠspectra	 ﾠ(P187)	 ﾠ
The	 ﾠP184	 ﾠscan	 ﾠwas	 ﾠpresented	 ﾠin	 ﾠthe	 ﾠprevious	 ﾠchapter	 ﾠand	 ﾠthe	 ﾠP187	 ﾠscan	 ﾠfrom	 ﾠthe	 ﾠ
same	 ﾠsample	 ﾠwas	 ﾠthen	 ﾠexamined.	 ﾠThere	 ﾠis	 ﾠa	 ﾠsimilar	 ﾠpattern	 ﾠof	 ﾠpeaks	 ﾠbut	 ﾠoffset	 ﾠby	 ﾠa	 ﾠ
mass/charge	 ﾠ3	 ﾠhigher	 ﾠ(Figure	 ﾠ30).	 ﾠAs	 ﾠindicated	 ﾠby	 ﾠthe	 ﾠdescriptors	 ﾠon	 ﾠthe	 ﾠspectra	 ﾠ
the	 ﾠsignal	 ﾠstrength	 ﾠis	 ﾠmuch	 ﾠhigher	 ﾠfor	 ﾠP184	 ﾠ(bottom,	 ﾠ5.72x109)	 ﾠthan	 ﾠP187	 ﾠ(top,	 ﾠ
1.32x107),	 ﾠwhich	 ﾠis	 ﾠmasked	 ﾠby	 ﾠthe	 ﾠnormalising	 ﾠof	 ﾠeach	 ﾠspectrum	 ﾠindividually	 ﾠto	 ﾠ
100%	 ﾠof	 ﾠthe	 ﾠhighest	 ﾠpeak.	 ﾠ
	 ﾠ
Figure	 ﾠ30.	 ﾠBottom	 ﾠ-ﾭ‐	 ﾠAn	 ﾠexample	 ﾠof	 ﾠa	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠ(P184)	 ﾠ
scan	 ﾠspectrum.	 ﾠIt	 ﾠillustrates	 ﾠa	 ﾠtypical	 ﾠplasma	 ﾠlipid	 ﾠextract	 ﾠscan	 ﾠafter	 ﾠ72	 ﾠhours.	 ﾠ
Top	 ﾠ-ﾭ‐	 ﾠThe	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+187	 ﾠ(P187)	 ﾠscan	 ﾠof	 ﾠthe	 ﾠsame	 ﾠlipid	 ﾠ
extract.	 ﾠThere	 ﾠis	 ﾠa	 ﾠsimilar	 ﾠpattern	 ﾠof	 ﾠpeaks	 ﾠbut	 ﾠoffset	 ﾠby	 ﾠa	 ﾠmass/charge	 ﾠof	 ﾠ
three	 ﾠhigher.	 ﾠ	 ﾠ
Mass/charge (m/z) 
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It	 ﾠis	 ﾠtechnically	 ﾠpossible	 ﾠfor	 ﾠtwo	 ﾠmethyl	 ﾠgroups	 ﾠto	 ﾠbe	 ﾠdonated	 ﾠsequentially	 ﾠfrom	 ﾠthe	 ﾠ
[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠsubstrate.	 ﾠHowever	 ﾠanalysis	 ﾠof	 ﾠthe	 ﾠprecursor-ﾭ‐of-ﾭ‐190	 ﾠ
(P190)	 ﾠ scans	 ﾠ reveals	 ﾠ a	 ﾠ very	 ﾠ low	 ﾠ recovery	 ﾠ rate	 ﾠ and	 ﾠ the	 ﾠ spectra	 ﾠ become	 ﾠ
uninterpretable.	 ﾠ This	 ﾠ has	 ﾠ implications	 ﾠ for	 ﾠ the	 ﾠ calculation	 ﾠ of	 ﾠ methionine	 ﾠ
enrichment	 ﾠ and	 ﾠ therefore	 ﾠ only	 ﾠ whole	 ﾠ population	 ﾠ data	 ﾠ can	 ﾠ be	 ﾠ used	 ﾠ rather	 ﾠ than	 ﾠ
analysis	 ﾠ from	 ﾠ an	 ﾠ individual	 ﾠ patient.	 ﾠ As	 ﾠ in	 ﾠ the	 ﾠ previous	 ﾠ chapter,	 ﾠ the	 ﾠ D3-ﾭ‐PC	 ﾠ
molecules	 ﾠidentified	 ﾠwill	 ﾠbe	 ﾠpresented	 ﾠby	 ﾠname	 ﾠrather	 ﾠthan	 ﾠmass/charge	 ﾠand	 ﾠby	 ﾠ
colour	 ﾠin	 ﾠgraphs	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠsaturation	 ﾠof	 ﾠthe	 ﾠfatty	 ﾠacid	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐2	 ﾠposition.	 ﾠ
4.2.2	 ﾠComposition	 ﾠof	 ﾠD3-ﾭ‐phosphatidylcholine	 ﾠspecies	 ﾠ
The	 ﾠ proportions	 ﾠ of	 ﾠ D3-ﾭ‐species	 ﾠ vary	 ﾠ markedly	 ﾠ from	 ﾠ the	 ﾠ endogenous	 ﾠ PC	 ﾠ species	 ﾠ
present	 ﾠin	 ﾠplasma	 ﾠat	 ﾠrecruitment	 ﾠ(Figure	 ﾠ31).	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ31.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ12	 ﾠ
hours	 ﾠafter	 ﾠrecruitment.	 ﾠFor	 ﾠeach	 ﾠpair	 ﾠof	 ﾠcolumns	 ﾠthe	 ﾠendogenous	 ﾠPC	 ﾠ
proportions	 ﾠare	 ﾠshown	 ﾠas	 ﾠthe	 ﾠleft-ﾭ‐hand	 ﾠcolumn,	 ﾠwhile	 ﾠthe	 ﾠright-ﾭ‐hand	 ﾠcolumn	 ﾠ
is	 ﾠthe	 ﾠPEMT	 ﾠderived	 ﾠD3-ﾭ‐labelled	 ﾠspecies.	 ﾠError	 ﾠbars	 ﾠrepresent	 ﾠone	 ﾠstandard	 ﾠ
deviation.	 ﾠ  84	 ﾠ
Marked	 ﾠdifferences	 ﾠexist	 ﾠin	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠD3-ﾭ‐PC	 ﾠspecies	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠthe	 ﾠ
unlabelled	 ﾠ endogenous	 ﾠ species	 ﾠ present	 ﾠ in	 ﾠ plasma.	 ﾠ Unlike	 ﾠ in	 ﾠ the	 ﾠ D9-ﾭ‐labelled	 ﾠ
analysis	 ﾠ there	 ﾠ is	 ﾠ a	 ﾠ predominance	 ﾠ of	 ﾠ polyunsaturated	 ﾠ PC	 ﾠ species,	 ﾠ with	 ﾠ
D3PC18:0/20:4	 ﾠthe	 ﾠmost	 ﾠcommonly	 ﾠfound	 ﾠPEMT-ﾭ‐derived	 ﾠspecies.	 ﾠIn	 ﾠcontrast	 ﾠto	 ﾠthe	 ﾠ
CDP-ﾭ‐choline	 ﾠ derived	 ﾠ molecules	 ﾠ the	 ﾠ D3-ﾭ‐PC	 ﾠ molecules	 ﾠ do	 ﾠ not	 ﾠ reflect	 ﾠ the	 ﾠ overall	 ﾠ
abundance	 ﾠpattern	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠat	 ﾠthis	 ﾠearly	 ﾠtime	 ﾠpoint.	 ﾠ
These	 ﾠinitial	 ﾠpatterns	 ﾠof	 ﾠincorporation	 ﾠreflect	 ﾠthe	 ﾠPEMT	 ﾠdata,	 ﾠpublished	 ﾠin	 ﾠ2011,	 ﾠ
that	 ﾠlooked	 ﾠat	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠfrom	 ﾠhuman	 ﾠadult	 ﾠvolunteers	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ
2011).	 ﾠ	 ﾠ
For	 ﾠthe	 ﾠfirst	 ﾠtime	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠit	 ﾠis	 ﾠpossible	 ﾠto	 ﾠreport	 ﾠthe	 ﾠactivity,	 ﾠnear	 ﾠbirth,	 ﾠ
of	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠand	 ﾠthe	 ﾠpathway’s	 ﾠspecificity	 ﾠfor	 ﾠpolyunsaturated	 ﾠspecies.	 ﾠ
4.2.3	 ﾠComposition	 ﾠof	 ﾠD3-ﾭ‐phosphatidylcholine	 ﾠspecies	 ﾠover	 ﾠtime	 ﾠ
In	 ﾠthe	 ﾠadult	 ﾠvolunteer	 ﾠthe	 ﾠinitial	 ﾠpattern	 ﾠwas	 ﾠsimilar	 ﾠto	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠbut	 ﾠthen	 ﾠ
changed	 ﾠwith	 ﾠtime,	 ﾠsuch	 ﾠthat	 ﾠthere	 ﾠwas	 ﾠredistribution	 ﾠof	 ﾠPC	 ﾠto	 ﾠthe	 ﾠ18:2-ﾭ‐containing	 ﾠ
PC	 ﾠspecies.	 ﾠIt	 ﾠis	 ﾠnecessary	 ﾠtherefore,	 ﾠfor	 ﾠcomparison,	 ﾠto	 ﾠinvestigate	 ﾠif	 ﾠthis	 ﾠinitial	 ﾠ
composition	 ﾠof	 ﾠPEMT	 ﾠproduction	 ﾠis	 ﾠmaintained	 ﾠin	 ﾠpreterm	 ﾠchildren	 ﾠthrough	 ﾠthe	 ﾠ
study	 ﾠperiod.	 ﾠ
i)	 ﾠVariation	 ﾠin	 ﾠcomposition	 ﾠof	 ﾠD3-ﾭ‐PC	 ﾠspecies	 ﾠto	 ﾠ120	 ﾠhours	 ﾠ
Plotting	 ﾠthe	 ﾠrelative	 ﾠcomposition	 ﾠchanging	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠof	 ﾠthe	 ﾠstudy	 ﾠfor	 ﾠ
selected	 ﾠspecies	 ﾠ(Figure	 ﾠ32).	 ﾠ 85	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Figure	 ﾠ32.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠD3-ﾭ‐PC	 ﾠspecies,	 ﾠ
from	 ﾠthe	 ﾠPEMT	 ﾠpathway,	 ﾠup	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠ
	 ﾠ
While	 ﾠthe	 ﾠarachidonoyl-ﾭ‐containing	 ﾠ(20:4)	 ﾠand	 ﾠdocosahexaenoyl-ﾭ‐containing	 ﾠ	 ﾠ(22:6)	 ﾠ
species	 ﾠconstitute	 ﾠthe	 ﾠmajority	 ﾠof	 ﾠD3-ﾭ‐containing	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠhours	 ﾠof	 ﾠ
study,	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠthese	 ﾠspecies	 ﾠfall	 ﾠwithin	 ﾠ12	 ﾠhours	 ﾠto	 ﾠplateau	 ﾠaround	 ﾠ72	 ﾠ
hours.	 ﾠ Meanwhile	 ﾠ the	 ﾠ mono-ﾭ‐unsaturated	 ﾠ and	 ﾠ di-ﾭ‐unsaturated	 ﾠ species,	 ﾠ which	 ﾠ are	 ﾠ
more	 ﾠcommonly	 ﾠfound	 ﾠin	 ﾠthe	 ﾠendogenous	 ﾠ(non-ﾭ‐labelled)	 ﾠplasma,	 ﾠrise	 ﾠand	 ﾠagain	 ﾠ
plateau	 ﾠin	 ﾠabundance	 ﾠaround	 ﾠ72	 ﾠhours.	 ﾠThis	 ﾠsignificant	 ﾠproportional	 ﾠincrease	 ﾠin	 ﾠ
18:1-ﾭ‐containing	 ﾠPC	 ﾠspecies	 ﾠwas	 ﾠdifferent	 ﾠfrom	 ﾠthe	 ﾠadult	 ﾠvolunteer	 ﾠgroup.	 ﾠ	 ﾠ
As	 ﾠthe	 ﾠphosphatidylcholine	 ﾠcreated	 ﾠvia	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠderived	 ﾠentirely	 ﾠfrom	 ﾠ
phosphatidylethanolamine,	 ﾠhence	 ﾠthe	 ﾠspecificity	 ﾠof	 ﾠPC	 ﾠderived	 ﾠfrom	 ﾠthis	 ﾠpathway	 ﾠ
and	 ﾠmeasured	 ﾠin	 ﾠplasma	 ﾠis	 ﾠdependent	 ﾠon	 ﾠthe	 ﾠfatty	 ﾠacid	 ﾠcomposition	 ﾠof	 ﾠthe	 ﾠoriginal	 ﾠ
PE	 ﾠ molecule	 ﾠ located	 ﾠ in	 ﾠ hepatocytic	 ﾠ mitochondria-ﾭ‐associated	 ﾠ microsomes.	 ﾠ PE	 ﾠ
composition	 ﾠ is	 ﾠ dependent	 ﾠ on	 ﾠ the	 ﾠ available	 ﾠ substrate	 ﾠ from	 ﾠ free	 ﾠ fatty	 ﾠ acids	 ﾠ and	 ﾠ
diacylglycerol,	 ﾠwhich	 ﾠin	 ﾠthe	 ﾠabsence	 ﾠof	 ﾠplacental	 ﾠsupply	 ﾠmust	 ﾠbe	 ﾠderived	 ﾠfrom	 ﾠthe	 ﾠ  86	 ﾠ
TPN	 ﾠ administered.	 ﾠ Therefore	 ﾠ adjusting	 ﾠ the	 ﾠ TPN	 ﾠ administered	 ﾠ to	 ﾠ the	 ﾠ newborn	 ﾠ
preterm	 ﾠbaby	 ﾠcould	 ﾠaffect	 ﾠthe	 ﾠPC	 ﾠspecies	 ﾠproduced	 ﾠdownstream.	 ﾠ
ii)	 ﾠComparison	 ﾠof	 ﾠunlabelled	 ﾠand	 ﾠD3-ﾭ‐PC	 ﾠspecies	 ﾠat	 ﾠ72	 ﾠhours	 ﾠ
The	 ﾠproportions	 ﾠof	 ﾠnon-ﾭ‐labelled	 ﾠPC	 ﾠspecies	 ﾠand	 ﾠD3-ﾭ‐containing	 ﾠspecies	 ﾠat	 ﾠ72	 ﾠhours	 ﾠ
are	 ﾠnow	 ﾠmuch	 ﾠmore	 ﾠclosely	 ﾠaligned	 ﾠthan	 ﾠat	 ﾠ12	 ﾠhours	 ﾠ(Figure	 ﾠ33).	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ33.	 ﾠComparison	 ﾠof	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ72	 ﾠ
hours	 ﾠafter	 ﾠrecruitment.	 ﾠFor	 ﾠeach	 ﾠpair	 ﾠof	 ﾠcolumns	 ﾠthe	 ﾠendogenous	 ﾠPC	 ﾠ
proportions	 ﾠare	 ﾠshown	 ﾠas	 ﾠthe	 ﾠleft-ﾭ‐hand	 ﾠcolumn,	 ﾠwhile	 ﾠthe	 ﾠright-ﾭ‐hand	 ﾠcolumn	 ﾠ




Overall	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠstill	 ﾠproducing	 ﾠmore	 ﾠPUFA	 ﾠproportionally	 ﾠthan	 ﾠexist	 ﾠ
endogenously	 ﾠ in	 ﾠ the	 ﾠ plasma	 ﾠ but	 ﾠ the	 ﾠ differences	 ﾠ are	 ﾠ smaller	 ﾠ than	 ﾠ at	 ﾠ 12	 ﾠ hours.	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Additionally	 ﾠthe	 ﾠmono-ﾭ‐unsaturated	 ﾠand	 ﾠdi-ﾭ‐unsaturated	 ﾠspecies	 ﾠmore	 ﾠclosely	 ﾠreflect	 ﾠ
the	 ﾠendogenous	 ﾠproportions.	 ﾠ
The	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠchanging	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠit	 ﾠproduces	 ﾠwith	 ﾠtime	 ﾠ
and	 ﾠthey	 ﾠare	 ﾠbecoming	 ﾠcloser	 ﾠto	 ﾠthe	 ﾠoverall	 ﾠpicture	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠthe	 ﾠplasma.	 ﾠ	 ﾠ
Endogenous	 ﾠproportions	 ﾠof	 ﾠPUFA-ﾭ‐containing	 ﾠPC	 ﾠspecies	 ﾠfall	 ﾠover	 ﾠtime	 ﾠin	 ﾠpreterm	 ﾠ
babies,	 ﾠ as	 ﾠ shown	 ﾠ in	 ﾠ the	 ﾠ previous	 ﾠ chapter,	 ﾠ as	 ﾠ the	 ﾠ diunsaturated	 ﾠ species	 ﾠ rise;	 ﾠ a	 ﾠ
change	 ﾠdriven,	 ﾠat	 ﾠleast	 ﾠin	 ﾠpart,	 ﾠby	 ﾠparenteral	 ﾠnutrition.	 ﾠThe	 ﾠimportance	 ﾠof	 ﾠPUFA-ﾭ‐
containing	 ﾠphospholipids	 ﾠto	 ﾠnormal	 ﾠneurodevelopment	 ﾠin	 ﾠfetal	 ﾠand	 ﾠpostnatal	 ﾠlife	 ﾠis	 ﾠ
still	 ﾠdebated	 ﾠwith	 ﾠsome	 ﾠstudies	 ﾠshowing	 ﾠbenefits	 ﾠto	 ﾠpreterm	 ﾠbabies	 ﾠ(Dziechciarz	 ﾠet	 ﾠ
al.,	 ﾠ2010)	 ﾠand	 ﾠfrom	 ﾠthe	 ﾠpreterm	 ﾠPEMT	 ﾠdata	 ﾠalready	 ﾠseen	 ﾠthere	 ﾠis	 ﾠstrong	 ﾠevidence	 ﾠ
that	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠis	 ﾠable	 ﾠto	 ﾠsynthesise	 ﾠPUFA-ﾭ‐containing	 ﾠPC	 ﾠspecies,	 ﾠalbeit	 ﾠin	 ﾠa	 ﾠ
small	 ﾠamount	 ﾠand	 ﾠreflecting	 ﾠthe	 ﾠoverall	 ﾠproportions	 ﾠin	 ﾠthe	 ﾠplasma.	 ﾠ
The	 ﾠraised	 ﾠproportion	 ﾠof	 ﾠPC16:0/18:1	 ﾠin	 ﾠthese	 ﾠchildren,	 ﾠwhich	 ﾠis	 ﾠnot	 ﾠseen	 ﾠin	 ﾠadult	 ﾠ
volunteers,	 ﾠmay	 ﾠbe	 ﾠdriven	 ﾠby	 ﾠthe	 ﾠcomposition	 ﾠof	 ﾠthe	 ﾠTPN	 ﾠadministered	 ﾠin	 ﾠthe	 ﾠNICU.	 ﾠ
A	 ﾠ clinically	 ﾠ relevant	 ﾠ question	 ﾠ for	 ﾠ future	 ﾠ study	 ﾠ would	 ﾠ be	 ﾠ to	 ﾠ consider	 ﾠ whether	 ﾠ
raising	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠPUFA	 ﾠin	 ﾠthe	 ﾠcirculation	 ﾠby	 ﾠaltering	 ﾠthe	 ﾠproportions	 ﾠin	 ﾠ
the	 ﾠTPN	 ﾠreceived	 ﾠwould	 ﾠalso	 ﾠdirectly	 ﾠaffect	 ﾠthe	 ﾠprofile	 ﾠof	 ﾠnewly	 ﾠsynthesised	 ﾠspecies	 ﾠ
seen	 ﾠin	 ﾠplasma	 ﾠtowards	 ﾠPUFA-ﾭ‐containing	 ﾠspecies.	 ﾠ
As	 ﾠ the	 ﾠ proportions	 ﾠ are	 ﾠ changing	 ﾠ then	 ﾠ it	 ﾠ is	 ﾠ important	 ﾠ to	 ﾠ examine	 ﾠ whether	 ﾠ the	 ﾠ
absolute	 ﾠ amount	 ﾠ of	 ﾠ D3-ﾭ‐containing	 ﾠ species	 ﾠ increases	 ﾠ with	 ﾠ time,	 ﾠ like	 ﾠ the	 ﾠ overall	 ﾠ
picture	 ﾠand	 ﾠD9-ﾭ‐containing	 ﾠspecies.	 ﾠ
4.2.4	 ﾠConcentration	 ﾠof	 ﾠD3-ﾭ‐PC	 ﾠspecies	 ﾠin	 ﾠplasma	 ﾠ
The	 ﾠ amount	 ﾠ of	 ﾠ D3-ﾭ‐containing	 ﾠ phosphatidylcholine	 ﾠ does	 ﾠ increase	 ﾠ to	 ﾠ a	 ﾠ maximum	 ﾠ
around	 ﾠ72	 ﾠhours	 ﾠ(Figure	 ﾠ34).	 ﾠ	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Figure	 ﾠ34.	 ﾠConcentrations	 ﾠof	 ﾠD3-ﾭ‐phosphatidylcholine	 ﾠphospholipids	 ﾠin	 ﾠ
preterm	 ﾠplasma	 ﾠincrease	 ﾠwith	 ﾠtime	 ﾠfrom	 ﾠrecruitment	 ﾠto	 ﾠ72	 ﾠhours.	 ﾠThe	 ﾠerror	 ﾠ
bars	 ﾠshow	 ﾠthe	 ﾠmedian	 ﾠvalues	 ﾠand	 ﾠinterquartile	 ﾠranges.	 ﾠComparison	 ﾠof	 ﾠdata	 ﾠ
using	 ﾠMann-ﾭ‐Whitney	 ﾠnon-ﾭ‐parametric	 ﾠsignificance	 ﾠtesting	 ﾠshows	 ﾠsignificant	 ﾠ
increase	 ﾠbetween	 ﾠtimes	 ﾠ12	 ﾠand	 ﾠ72	 ﾠhours	 ﾠ(****	 ﾠp<0.0001)	 ﾠand	 ﾠbetween	 ﾠ12	 ﾠ
and	 ﾠ120	 ﾠhours	 ﾠ(**	 ﾠp=0.0064)	 ﾠ
	 ﾠ
	 ﾠ
Compared	 ﾠ with	 ﾠ the	 ﾠ total	 ﾠ concentration	 ﾠ of	 ﾠ PC	 ﾠ phospholipids	 ﾠ at	 ﾠ the	 ﾠ same	 ﾠ time	 ﾠ
(92.53nmol/100µl)	 ﾠ or	 ﾠ the	 ﾠ median	 ﾠ concentration	 ﾠ of	 ﾠ D9-ﾭ‐labelled	 ﾠ species	 ﾠ
(1.107nmol/100µl),	 ﾠ the	 ﾠ median	 ﾠ absolute	 ﾠ amount	 ﾠ of	 ﾠ D3-ﾭ‐labelled	 ﾠ PEMT-ﾭ‐derived	 ﾠ
species	 ﾠremains	 ﾠvery	 ﾠlow	 ﾠto	 ﾠa	 ﾠmaximum	 ﾠof	 ﾠ0.054nmol/100µl.	 ﾠ	 ﾠ	 ﾠ
In	 ﾠother	 ﾠwords	 ﾠthere	 ﾠis	 ﾠ20.5	 ﾠtimes	 ﾠthe	 ﾠamount	 ﾠof	 ﾠD9-ﾭ‐labelled	 ﾠphospholipid	 ﾠthan	 ﾠD3	 ﾠ
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Although	 ﾠ it	 ﾠ is	 ﾠ not	 ﾠ presented	 ﾠ here	 ﾠ the	 ﾠ P190	 ﾠ scan	 ﾠ for	 ﾠ D6-ﾭ‐labelled	 ﾠ PC	 ﾠ showed	 ﾠ a	 ﾠ
maximum	 ﾠconcentration	 ﾠof	 ﾠ0.0012nmol/100µl	 ﾠor	 ﾠalmost	 ﾠ50	 ﾠtimes	 ﾠless	 ﾠthan	 ﾠthe	 ﾠ
already	 ﾠvery	 ﾠlow	 ﾠD3.	 ﾠ
The	 ﾠ relative	 ﾠ concentrations	 ﾠ of	 ﾠ D3-ﾭ‐labelled	 ﾠ species	 ﾠ show	 ﾠ again	 ﾠ specificity	 ﾠ for	 ﾠ
different	 ﾠ fatty	 ﾠ acid	 ﾠ groups	 ﾠ (Figure	 ﾠ 35).	 ﾠ With	 ﾠ the	 ﾠ concentrations	 ﾠ rising	 ﾠ and	 ﾠ
stabilising	 ﾠ in	 ﾠ groups,	 ﾠ whether	 ﾠ diunsaturated,	 ﾠ arachidonoyl-ﾭ‐containing	 ﾠ or	 ﾠ
docosahexaenoyl-ﾭ‐containing	 ﾠ there	 ﾠ is	 ﾠ strong	 ﾠ evidence	 ﾠ of	 ﾠ PEMT	 ﾠ in	 ﾠ the	 ﾠ preterm	 ﾠ
infant	 ﾠ producing	 ﾠ more	 ﾠ monounsaturated	 ﾠ and	 ﾠ diunsaturated	 ﾠ species	 ﾠ than	 ﾠ PUFA	 ﾠ
species	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠweek	 ﾠof	 ﾠlife.	 ﾠThis	 ﾠfinding	 ﾠcontrasts	 ﾠwith	 ﾠpreviously	 ﾠpublished	 ﾠ
adult	 ﾠdata	 ﾠwhere	 ﾠvery	 ﾠlittle	 ﾠ18:1-ﾭ‐containing	 ﾠPC	 ﾠis	 ﾠproduced	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ2011).	 ﾠ
	 ﾠ
Figure	 ﾠ35.	 ﾠAverage	 ﾠconcentrations	 ﾠof	 ﾠselected	 ﾠD3-ﾭ‐phosphatidylcholine	 ﾠ
species	 ﾠin	 ﾠpreterm	 ﾠplasma.	 ﾠThe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠassociated	 ﾠwith	 ﾠPUFA	 ﾠPC	 ﾠ
species	 ﾠin	 ﾠadults	 ﾠbut	 ﾠPC16:0/18:1	 ﾠis	 ﾠthe	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠproduced	 ﾠby	 ﾠ
this	 ﾠpathway	 ﾠfrom	 ﾠ48	 ﾠhours	 ﾠin	 ﾠthis	 ﾠpopulation.	 ﾠ	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This	 ﾠpattern	 ﾠis	 ﾠcontinued	 ﾠuntil	 ﾠ240	 ﾠhours	 ﾠpost	 ﾠrecruitment	 ﾠ(Figure	 ﾠ36).	 ﾠSo	 ﾠthere	 ﾠ
are	 ﾠdynamic	 ﾠchanges	 ﾠto	 ﾠthe	 ﾠPEMT-ﾭ‐derived	 ﾠD3-ﾭ‐labelled	 ﾠPC	 ﾠspecies	 ﾠfound	 ﾠin	 ﾠpreterm	 ﾠ
infant	 ﾠplasma.	 ﾠ
	 ﾠ
Figure	 ﾠ36.	 ﾠAverage	 ﾠconcentrations	 ﾠof	 ﾠselected	 ﾠD3-ﾭ‐phosphatidylcholine	 ﾠ
species	 ﾠin	 ﾠpreterm	 ﾠplasma.	 ﾠThe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠassociated	 ﾠwith	 ﾠPUFA	 ﾠPC	 ﾠ
species	 ﾠin	 ﾠadults	 ﾠbut	 ﾠPC16:0/18:1	 ﾠis	 ﾠthe	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠproduced	 ﾠby	 ﾠ
this	 ﾠpathway	 ﾠfrom	 ﾠ48	 ﾠhours	 ﾠin	 ﾠthis	 ﾠpopulation	 ﾠand	 ﾠcontinues	 ﾠto	 ﾠbe	 ﾠmost	 ﾠ
abundant	 ﾠuntil	 ﾠthe	 ﾠend	 ﾠof	 ﾠthe	 ﾠstudy	 ﾠat	 ﾠ240	 ﾠhours.	 ﾠ	 ﾠ
It	 ﾠis	 ﾠnow	 ﾠimportant	 ﾠto	 ﾠconsider	 ﾠthe	 ﾠfractional	 ﾠincorporation,	 ﾠin	 ﾠother	 ﾠwords,	 ﾠwhat	 ﾠ
fraction	 ﾠ or	 ﾠ percentage	 ﾠ of	 ﾠ PC	 ﾠ phospholipid	 ﾠ found	 ﾠ in	 ﾠ plasma	 ﾠ is	 ﾠ D3-ﾭ‐labelled	 ﾠ and	 ﾠ
therefore	 ﾠderived	 ﾠfrom	 ﾠthe	 ﾠPEMT	 ﾠpathway.	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4.2.5	 ﾠFractional	 ﾠincorporation	 ﾠof	 ﾠD3-ﾭ‐PC	 ﾠspecies	 ﾠ
i)	 ﾠOverall	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD3-ﾭ‐PC	 ﾠspecies	 ﾠ
The	 ﾠoverall	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD3-ﾭ‐labelled	 ﾠPC	 ﾠphospholipids	 ﾠis	 ﾠmuch	 ﾠlower	 ﾠ
than	 ﾠD9-ﾭ‐labelled	 ﾠand	 ﾠdoes	 ﾠnot	 ﾠshow	 ﾠthe	 ﾠsame	 ﾠsharp	 ﾠrise	 ﾠin	 ﾠincorporation	 ﾠwithin	 ﾠ6-ﾭ‐
12	 ﾠhours	 ﾠof	 ﾠsubstrate	 ﾠinfusion	 ﾠ(Figure	 ﾠ37).	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ37.	 ﾠFractional	 ﾠincorporation	 ﾠof	 ﾠD3-ﾭ‐phosphatidylcholine	 ﾠ
phospholipids	 ﾠin	 ﾠpreterm	 ﾠplasma.	 ﾠThe	 ﾠbox	 ﾠand	 ﾠwhisker	 ﾠplots	 ﾠshow	 ﾠthe	 ﾠ
median	 ﾠvalues,	 ﾠinterquartile	 ﾠranges	 ﾠand	 ﾠoutliers.	 ﾠ
Rather	 ﾠthere	 ﾠis	 ﾠa	 ﾠgradual	 ﾠrise	 ﾠor	 ﾠsteady	 ﾠbuild-ﾭ‐up	 ﾠin	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD3-ﾭ‐
labelled	 ﾠphosphatidylcholine	 ﾠphospholipids	 ﾠto	 ﾠ72	 ﾠhours.	 ﾠThe	 ﾠrise	 ﾠapproximates	 ﾠto	 ﾠ
logarithmic	 ﾠ(Figure	 ﾠ38)	 ﾠas	 ﾠseen	 ﾠwhen	 ﾠa	 ﾠline	 ﾠof	 ﾠbest	 ﾠfit	 ﾠ(R2	 ﾠ=	 ﾠ0.97443)	 ﾠis	 ﾠformulated	 ﾠ
for	 ﾠthe	 ﾠmean	 ﾠdata	 ﾠfrom	 ﾠthe	 ﾠfirst	 ﾠ72	 ﾠhours.	 ﾠ
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Figure	 ﾠ38.	 ﾠThe	 ﾠmean	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠD3-ﾭ‐containing	 ﾠPC	 ﾠ
phospholipids	 ﾠin	 ﾠplasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠD3	 ﾠ
enrichment	 ﾠhas	 ﾠbeen	 ﾠexpressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠ
measured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint.	 ﾠThe	 ﾠerror	 ﾠbars	 ﾠrepresent	 ﾠa	 ﾠsingle	 ﾠstandard	 ﾠ
deviation	 ﾠfrom	 ﾠthe	 ﾠmean.	 ﾠ
	 ﾠ
ii)	 ﾠFractional	 ﾠincorporation	 ﾠof	 ﾠindividual	 ﾠD3-ﾭ‐PC	 ﾠspecies	 ﾠ
In	 ﾠterms	 ﾠof	 ﾠwhich	 ﾠspecies	 ﾠaccount	 ﾠfor	 ﾠthis	 ﾠslowly	 ﾠrising	 ﾠfractional	 ﾠincorporation	 ﾠit	 ﾠ
is	 ﾠpossible,	 ﾠagain,	 ﾠto	 ﾠlook	 ﾠat	 ﾠthe	 ﾠindividual	 ﾠspecies	 ﾠpresent	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠ
of	 ﾠthe	 ﾠstudy	 ﾠ(Figure	 ﾠ39).	 ﾠ 93	 ﾠ
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Figure	 ﾠ39.	 ﾠThe	 ﾠmean	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠselected	 ﾠD3-ﾭ‐containing	 ﾠPC	 ﾠ
phospholipids	 ﾠin	 ﾠplasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠ
Proportionally	 ﾠmore	 ﾠPUFA	 ﾠspecies	 ﾠare	 ﾠsynthesised	 ﾠby	 ﾠthe	 ﾠPEMT	 ﾠpathway.	 ﾠD3	 ﾠ
enrichment	 ﾠhas	 ﾠbeen	 ﾠexpressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠ
measured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint.	 ﾠ
Fractional	 ﾠincorporation	 ﾠis	 ﾠused	 ﾠto	 ﾠillustrate	 ﾠthe	 ﾠamount	 ﾠof	 ﾠa	 ﾠgiven	 ﾠPC	 ﾠspecies	 ﾠthat	 ﾠ
has	 ﾠbeen	 ﾠderived	 ﾠfrom	 ﾠa	 ﾠstable-ﾭ‐isotope	 ﾠlabelled	 ﾠsource,	 ﾠor	 ﾠin	 ﾠother	 ﾠwords,	 ﾠwhat	 ﾠ
proportion	 ﾠof	 ﾠthat	 ﾠwhich	 ﾠhas	 ﾠbeen	 ﾠmeasured	 ﾠis	 ﾠnewly	 ﾠsynthesised.	 ﾠ
From	 ﾠ Figure	 ﾠ 39	 ﾠ it	 ﾠ is	 ﾠ very	 ﾠ clear	 ﾠ to	 ﾠ which	 ﾠ species	 ﾠ types	 ﾠ the	 ﾠ PEMT	 ﾠ pathway	 ﾠ is	 ﾠ
contributing	 ﾠ most	 ﾠ to	 ﾠ the	 ﾠ total	 ﾠ amount	 ﾠ measured.	 ﾠ The	 ﾠ pathway	 ﾠ is	 ﾠ contributing	 ﾠ
relatively	 ﾠmore	 ﾠto	 ﾠPUFA	 ﾠassociated	 ﾠPC	 ﾠspecies,	 ﾠwith	 ﾠdocosahexaenoyl-ﾭ‐containing	 ﾠ
species	 ﾠ consistently	 ﾠ more	 ﾠ so	 ﾠ than	 ﾠ the	 ﾠ arachidonoyl-ﾭ‐containing	 ﾠ species.	 ﾠ The	 ﾠ
diunsaturated	 ﾠand	 ﾠmonounsaturated	 ﾠspecies	 ﾠfollow	 ﾠin	 ﾠfractional	 ﾠincorporation	 ﾠand	 ﾠ
remain	 ﾠin	 ﾠthat	 ﾠrank	 ﾠorder.	 ﾠ
Even	 ﾠwhen	 ﾠthe	 ﾠspecies	 ﾠare	 ﾠexamined	 ﾠto	 ﾠ240	 ﾠhours	 ﾠ(Figure	 ﾠ40)	 ﾠthis	 ﾠgrouping	 ﾠtrend	 ﾠ
holds	 ﾠeven	 ﾠwhile	 ﾠthe	 ﾠfractional	 ﾠincorporation	 ﾠdecreases	 ﾠor	 ﾠplateaus.	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Figure	 ﾠ40.	 ﾠThe	 ﾠmean	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠselected	 ﾠD3-ﾭ‐containing	 ﾠPC	 ﾠ
phospholipids	 ﾠin	 ﾠplasma	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠ
Proportionally	 ﾠmore	 ﾠPUFA	 ﾠspecies	 ﾠare	 ﾠsynthesised	 ﾠby	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠand	 ﾠ
this	 ﾠis	 ﾠmaintained	 ﾠthroughout	 ﾠthe	 ﾠstudy	 ﾠperiod.	 ﾠD3	 ﾠenrichment	 ﾠhas	 ﾠbeen	 ﾠ
expressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠall	 ﾠthe	 ﾠPC	 ﾠphospholipids	 ﾠmeasured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠ
point.	 ﾠ
So	 ﾠby	 ﾠcomparing	 ﾠthe	 ﾠabsolute	 ﾠamount	 ﾠof	 ﾠD3-ﾭ‐PC	 ﾠmeasured	 ﾠin	 ﾠthe	 ﾠplasma,	 ﾠwhere	 ﾠ
there	 ﾠ was	 ﾠ more	 ﾠ monounsaturated	 ﾠ PC,	 ﾠ with	 ﾠ the	 ﾠ fractional	 ﾠ incorporation	 ﾠ of	 ﾠ
individual	 ﾠspecies	 ﾠit	 ﾠis	 ﾠclear	 ﾠthat	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠcontributes	 ﾠproportionally	 ﾠ
more	 ﾠto	 ﾠthe	 ﾠPUFA-ﾭ‐containing	 ﾠspecies	 ﾠbut	 ﾠit	 ﾠactually	 ﾠproduces	 ﾠa	 ﾠgreater	 ﾠquantity	 ﾠof	 ﾠ
monounsaturated	 ﾠ and	 ﾠ some	 ﾠ diunsaturated	 ﾠ species.	 ﾠ However	 ﾠ it	 ﾠ is	 ﾠ not	 ﾠ clear	 ﾠ
whether	 ﾠthis	 ﾠis	 ﾠbecause	 ﾠthe	 ﾠpreterm	 ﾠinfant’s	 ﾠrapid	 ﾠgrowth	 ﾠand	 ﾠdemand	 ﾠfor	 ﾠPUFA	 ﾠ
species	 ﾠis	 ﾠoutstripping	 ﾠsupply	 ﾠof	 ﾠthe	 ﾠnecessary	 ﾠPUFA	 ﾠbuilding	 ﾠblocks.	 ﾠ	 ﾠ
During	 ﾠgestation,	 ﾠPUFAs	 ﾠare	 ﾠsupplied	 ﾠto	 ﾠthe	 ﾠfetus	 ﾠthrough	 ﾠthe	 ﾠplacenta	 ﾠor	 ﾠby	 ﾠfetal	 ﾠ
synthesis,	 ﾠ in	 ﾠ the	 ﾠ liver	 ﾠ through	 ﾠ the	 ﾠ elongation/desaturation	 ﾠ of	 ﾠ the	 ﾠ n–6	 ﾠ and	 ﾠ n–3	 ﾠ
series	 ﾠ fatty	 ﾠ acid	 ﾠ precursors:	 ﾠ linoleic	 ﾠ (18:2n–6)	 ﾠ and	 ﾠ α-ﾭ‐linolenic	 ﾠ (18:3n–3)	 ﾠ acids,	 ﾠ 95	 ﾠ
respectively.	 ﾠ Desaturases	 ﾠ are	 ﾠ key	 ﾠ enzymes	 ﾠ in	 ﾠ the	 ﾠ regulation	 ﾠ of	 ﾠ unsaturated	 ﾠ FA	 ﾠ
biosynthesis	 ﾠand	 ﾠare	 ﾠmainly	 ﾠpresent	 ﾠin	 ﾠliver	 ﾠcell	 ﾠendoplasmic	 ﾠreticulum.	 ﾠ
	 ﾠThe	 ﾠfetal	 ﾠliver	 ﾠis	 ﾠknown	 ﾠto	 ﾠhave	 ﾠ∆5-ﾭ‐	 ﾠand	 ﾠ∆6-ﾭ‐desaturase	 ﾠ(Rodriguez	 ﾠet	 ﾠal.,	 ﾠ1998)	 ﾠ
and	 ﾠit	 ﾠhas	 ﾠbeen	 ﾠshown	 ﾠthat	 ﾠ1-ﾭ‐month-ﾭ‐old	 ﾠpreterm	 ﾠinfants	 ﾠare	 ﾠcapable	 ﾠof	 ﾠconverting	 ﾠ
dietary	 ﾠ linoleic	 ﾠ and	 ﾠ α-ﾭ‐linolenic	 ﾠ acids	 ﾠ to	 ﾠ arachidonic	 ﾠ and	 ﾠ docosahexaenoic	 ﾠ acid	 ﾠ
respectively	 ﾠ(Carnielli	 ﾠet	 ﾠal.,	 ﾠ1996)	 ﾠsuggesting	 ﾠthat	 ﾠlow	 ﾠlevels	 ﾠof	 ﾠpolyunsaturated	 ﾠ
species	 ﾠin	 ﾠlater	 ﾠpreterm	 ﾠbabies	 ﾠis	 ﾠnot	 ﾠdue	 ﾠto	 ﾠreduced	 ﾠdesaturase	 ﾠactivity.	 ﾠTo	 ﾠdate	 ﾠ
however	 ﾠ activity	 ﾠ of	 ﾠ desaturases	 ﾠ in	 ﾠ the	 ﾠ newborn	 ﾠ preterm	 ﾠ infant	 ﾠ has	 ﾠ not	 ﾠ been	 ﾠ
demonstrated.	 ﾠ	 ﾠ
4.3	 ﾠFlux	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠ
As	 ﾠhas	 ﾠbeen	 ﾠdescribed	 ﾠearlier	 ﾠthe	 ﾠsynthesis	 ﾠof	 ﾠPC	 ﾠin	 ﾠadult	 ﾠhepatocytes	 ﾠby	 ﾠthree	 ﾠ
sequential	 ﾠmethylations	 ﾠof	 ﾠPE,	 ﾠusing	 ﾠS-ﾭ‐Adenosyl	 ﾠmethionine	 ﾠ(SAMe)	 ﾠas	 ﾠthe	 ﾠmethyl	 ﾠ
donor,	 ﾠaccounts	 ﾠfor	 ﾠ30%	 ﾠof	 ﾠtotal	 ﾠPC	 ﾠliver	 ﾠsynthesis	 ﾠ(Pynn	 ﾠet	 ﾠal.).	 ﾠ	 ﾠ
However	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠonly	 ﾠa	 ﾠvery	 ﾠsmall	 ﾠamount	 ﾠof	 ﾠPC	 ﾠis	 ﾠproduced	 ﾠby	 ﾠthis	 ﾠ
PEMT	 ﾠpathway	 ﾠas	 ﾠseen	 ﾠby	 ﾠthe	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠP187	 ﾠ(D3)	 ﾠand	 ﾠP190	 ﾠ(D6),	 ﾠ
where	 ﾠD3	 ﾠis	 ﾠmaximal	 ﾠat	 ﾠ72	 ﾠhours	 ﾠwith	 ﾠ0.06%	 ﾠand	 ﾠD6	 ﾠat	 ﾠ12	 ﾠhours	 ﾠand	 ﾠ0.0012%.	 ﾠ
If	 ﾠit	 ﾠis	 ﾠassumed	 ﾠthat	 ﾠthe	 ﾠsystem	 ﾠwas	 ﾠat	 ﾠsteady	 ﾠstate,	 ﾠthen	 ﾠusing	 ﾠthe	 ﾠformula:	 ﾠ
SAMe % =
Σ(siP190)
Σ siP187 + siP190
∗ 100	 ﾠ
The	 ﾠflux	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠcan	 ﾠbe	 ﾠcalculated	 ﾠusing	 ﾠmultiple	 ﾠisotopomer	 ﾠ
distribution	 ﾠanalysis	 ﾠ(MIDA)	 ﾠ(Hellerstein	 ﾠand	 ﾠNeese,	 ﾠ1992,	 ﾠHellerstein	 ﾠand	 ﾠNeese,	 ﾠ
1999)	 ﾠto	 ﾠfirst	 ﾠdetermine	 ﾠthe	 ﾠenrichment	 ﾠof	 ﾠthe	 ﾠmethyl-ﾭ‐D3-ﾭ‐SAMe	 ﾠpool	 ﾠin	 ﾠthe	 ﾠliver	 ﾠ
(Figure	 ﾠ41)	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint.	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Figure	 ﾠ41.	 ﾠEnrichment	 ﾠby	 ﾠS-ﾭ‐Adenosyl	 ﾠ[methyl-ﾭ‐D3]methionine	 ﾠin	 ﾠpreterm	 ﾠ
plasma	 ﾠshowing	 ﾠmedian	 ﾠvalues	 ﾠand	 ﾠinterquartile	 ﾠrange	 ﾠplus	 ﾠoutliers	 ﾠ
Then	 ﾠ use	 ﾠ these	 ﾠ estimates	 ﾠ of	 ﾠ enrichment	 ﾠ in	 ﾠ methyl-ﾭ‐D3-ﾭ‐SAMe	 ﾠ to	 ﾠ correct	 ﾠ
corresponding	 ﾠmethyl-ﾭ‐D3-ﾭ‐PC	 ﾠenrichment	 ﾠto	 ﾠprovide	 ﾠestimates	 ﾠ(Figure	 ﾠ42)	 ﾠof	 ﾠtotal	 ﾠ
























































Figure	 ﾠ42.	 ﾠFractional	 ﾠsynthesis	 ﾠby	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠto	 ﾠ
240	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠshowing	 ﾠmedian	 ﾠvalues	 ﾠwith	 ﾠinterquartile	 ﾠrange	 ﾠ
and	 ﾠoutliers.	 ﾠ
At	 ﾠ72	 ﾠhours	 ﾠthe	 ﾠmaximally	 ﾠobserved	 ﾠmedian	 ﾠfractional	 ﾠsynthesis	 ﾠor	 ﾠflux	 ﾠin	 ﾠplasma	 ﾠ
measured	 ﾠin	 ﾠextremely	 ﾠpreterm	 ﾠinfants,	 ﾠis	 ﾠsignificantly	 ﾠlower	 ﾠat	 ﾠ2%,	 ﾠthan	 ﾠthe	 ﾠ30%	 ﾠ
reported	 ﾠin	 ﾠadults.	 ﾠPrevious	 ﾠpublications	 ﾠhave	 ﾠreported	 ﾠthe	 ﾠfractional	 ﾠsynthesis	 ﾠas	 ﾠ
a	 ﾠmean	 ﾠvalue	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ2011)	 ﾠand	 ﾠtherefore,	 ﾠwhile	 ﾠpreterm	 ﾠdata	 ﾠis	 ﾠnot	 ﾠnormally	 ﾠ
distributed,	 ﾠ for	 ﾠ direct	 ﾠ comparison	 ﾠ with	 ﾠ adult	 ﾠ data	 ﾠ the	 ﾠ rest	 ﾠ of	 ﾠ this	 ﾠ section	 ﾠ will	 ﾠ
report	 ﾠ mean	 ﾠ values.	 ﾠ The	 ﾠ mean	 ﾠ fractional	 ﾠ synthesis	 ﾠ observed	 ﾠ at	 ﾠ 72	 ﾠ hours	 ﾠ in	 ﾠ
preterm	 ﾠinfants	 ﾠis	 ﾠ4.55%	 ﾠand	 ﾠas	 ﾠthe	 ﾠmean	 ﾠinitial	 ﾠincorporation	 ﾠphase	 ﾠis	 ﾠnear	 ﾠlinear	 ﾠ
it	 ﾠis	 ﾠpossible	 ﾠto	 ﾠestimate	 ﾠflux	 ﾠthrough	 ﾠthis	 ﾠpathway	 ﾠ(Figure	 ﾠ43).	 ﾠThe	 ﾠprevious	 ﾠstudy	 ﾠ
on	 ﾠ adult	 ﾠ volunteers	 ﾠ showed	 ﾠ a	 ﾠ mean	 ﾠ synthetic	 ﾠ flux	 ﾠ rate	 ﾠ of	 ﾠ 0.53%/hour,	 ﾠ while	 ﾠ
mouse	 ﾠ plasma	 ﾠ was	 ﾠ 4.71%/hour	 ﾠ (Pynn	 ﾠ et	 ﾠ al.,	 ﾠ 2011).	 ﾠ These	 ﾠ preterm	 ﾠ infants	 ﾠ
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Figure	 ﾠ43.	 ﾠSynthetic	 ﾠrate	 ﾠof	 ﾠflux	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠin	 ﾠpreterm	 ﾠ
infants	 ﾠto	 ﾠpeak	 ﾠat	 ﾠ72	 ﾠhours	 ﾠafter	 ﾠinfusion	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline.	 ﾠOverall	 ﾠrate	 ﾠ
of	 ﾠsynthetic	 ﾠflux	 ﾠis	 ﾠ0.06%,	 ﾠsignificantly	 ﾠlower	 ﾠthan	 ﾠadult	 ﾠvolunteer	 ﾠvalues	 ﾠof	 ﾠ
0.53%	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ2011)	 ﾠ
Further	 ﾠ analysis	 ﾠ of	 ﾠ the	 ﾠ specificity	 ﾠ for	 ﾠ specific	 ﾠ examples	 ﾠ of	 ﾠ D3PC	 ﾠ species	 ﾠ
representative	 ﾠof	 ﾠeach	 ﾠgroup	 ﾠ(Figure	 ﾠ44)	 ﾠshows	 ﾠthat	 ﾠsynthesis	 ﾠrates	 ﾠvaried	 ﾠfrom	 ﾠa	 ﾠ
high	 ﾠ of	 ﾠ 0.32%	 ﾠ for	 ﾠ 18:0/22:6	 ﾠ to	 ﾠ a	 ﾠ low	 ﾠ of	 ﾠ 0.027%	 ﾠ for	 ﾠ 16:0/16:0	 ﾠ or	 ﾠ a	 ﾠ ten-ﾭ‐fold	 ﾠ
difference	 ﾠin	 ﾠmagnitude.	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Figure	 ﾠ44.	 ﾠSynthetic	 ﾠrate	 ﾠof	 ﾠflux	 ﾠfor	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠ
pathway	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠup	 ﾠto	 ﾠ24	 ﾠhours	 ﾠafter	 ﾠinfusion	 ﾠof	 ﾠ[methyl-ﾭ‐
D9]choline.	 ﾠSynthetic	 ﾠflux	 ﾠvaries	 ﾠfrom	 ﾠ0.325%	 ﾠfor	 ﾠPC18:0/22:6	 ﾠto	 ﾠ0.027%	 ﾠfor	 ﾠ
the	 ﾠsurface-ﾭ‐active	 ﾠPC16:0/16:0	 ﾠ
Identical	 ﾠrank	 ﾠorders	 ﾠof	 ﾠgroups	 ﾠof	 ﾠspecies	 ﾠhave	 ﾠbeen	 ﾠseen	 ﾠin	 ﾠthe	 ﾠadult	 ﾠhuman	 ﾠbut	 ﾠ
the	 ﾠrange	 ﾠof	 ﾠflux	 ﾠseen	 ﾠwas	 ﾠfrom	 ﾠ2.76%	 ﾠto	 ﾠ0.25%	 ﾠor	 ﾠten	 ﾠtimes	 ﾠhigher	 ﾠthan	 ﾠthat	 ﾠseen	 ﾠ
in	 ﾠthe	 ﾠpreterm	 ﾠinfant.	 ﾠ
This	 ﾠis	 ﾠthe	 ﾠfirst	 ﾠtime	 ﾠthat	 ﾠMIDA	 ﾠestimation	 ﾠof	 ﾠmethyl-ﾭ‐D3-ﾭ‐SAMe	 ﾠenrichment	 ﾠenabling	 ﾠ
calculation	 ﾠof	 ﾠabsolute	 ﾠrates	 ﾠof	 ﾠsynthetic	 ﾠflux	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠhas	 ﾠbeen	 ﾠ
used	 ﾠin	 ﾠvivo	 ﾠin	 ﾠpatients	 ﾠto	 ﾠdetermine	 ﾠnon-ﾭ‐invasively	 ﾠthe	 ﾠliver	 ﾠPEMT	 ﾠactivity.	 ﾠThe	 ﾠ
preterm	 ﾠ infant	 ﾠ population	 ﾠ show	 ﾠ significant	 ﾠ differences	 ﾠ from	 ﾠ the	 ﾠ previously	 ﾠ
published	 ﾠwork	 ﾠin	 ﾠadult	 ﾠvolunteers	 ﾠwith	 ﾠa	 ﾠdifferent	 ﾠspecificity	 ﾠfor	 ﾠPC	 ﾠspecies	 ﾠand	 ﾠa	 ﾠ
mean	 ﾠrate	 ﾠof	 ﾠflux	 ﾠabout	 ﾠ1/10th	 ﾠthe	 ﾠadults.	 ﾠ
The	 ﾠflux	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠof	 ﾠpreterm	 ﾠinfants	 ﾠis	 ﾠvery	 ﾠlow	 ﾠwhen	 ﾠcompared	 ﾠ
to	 ﾠthat	 ﾠof	 ﾠan	 ﾠadult	 ﾠand	 ﾠtherefore	 ﾠthe	 ﾠimpact	 ﾠof	 ﾠthe	 ﾠadministration	 ﾠof	 ﾠthe	 ﾠ[methyl-ﾭ‐
D9]choline	 ﾠchloride	 ﾠto	 ﾠthe	 ﾠinfant	 ﾠpool	 ﾠof	 ﾠcholine	 ﾠmust	 ﾠbe	 ﾠexamined	 ﾠas	 ﾠthe	 ﾠlow	 ﾠflux	 ﾠ  100	 ﾠ
demonstrated	 ﾠmay	 ﾠbe	 ﾠdue	 ﾠto	 ﾠlow	 ﾠlevels	 ﾠof	 ﾠsubstrate,	 ﾠfor	 ﾠexample,	 ﾠor	 ﾠthe	 ﾠmethyl	 ﾠ
transfer	 ﾠsystem	 ﾠmay	 ﾠbe	 ﾠimmature.	 ﾠ	 ﾠ
4.3	 ﾠCholine,	 ﾠD9-ﾭ‐choline	 ﾠand	 ﾠD9-ﾭ‐betaine	 ﾠmeasurement	 ﾠin	 ﾠplasma	 ﾠ
To	 ﾠlook	 ﾠat	 ﾠthe	 ﾠimpact	 ﾠof	 ﾠthe	 ﾠD9-ﾭ‐choline	 ﾠadministered	 ﾠon	 ﾠthe	 ﾠwhole	 ﾠbody	 ﾠpool	 ﾠit	 ﾠis	 ﾠ
necessary	 ﾠ to	 ﾠ measure	 ﾠ the	 ﾠ total	 ﾠ amount	 ﾠ of	 ﾠ choline	 ﾠ in	 ﾠ the	 ﾠ plasma	 ﾠ samples,	 ﾠ the	 ﾠ
amount	 ﾠof	 ﾠenrichment	 ﾠby	 ﾠD9-ﾭ‐choline	 ﾠand	 ﾠthe	 ﾠamount	 ﾠof	 ﾠD9-ﾭ‐enrichment	 ﾠin	 ﾠplasma	 ﾠ
betaine.	 ﾠThe	 ﾠmethods	 ﾠused	 ﾠin	 ﾠthis	 ﾠsection	 ﾠto	 ﾠinvestigate	 ﾠcholine	 ﾠand	 ﾠbetaine	 ﾠin	 ﾠ
plasma	 ﾠ were	 ﾠ devised	 ﾠ by	 ﾠ Dr	 ﾠ Victoria	 ﾠ Goss,	 ﾠ who	 ﾠ also	 ﾠ did	 ﾠ the	 ﾠ majority	 ﾠ of	 ﾠ the	 ﾠ
laboratory	 ﾠwork	 ﾠto	 ﾠproduce	 ﾠthe	 ﾠdata.	 ﾠ
These	 ﾠmeasurements	 ﾠhave	 ﾠimportant	 ﾠclinical	 ﾠimplications	 ﾠas	 ﾠthey	 ﾠcould	 ﾠbe	 ﾠused	 ﾠto	 ﾠ
determine	 ﾠranges	 ﾠfor	 ﾠsupplementation	 ﾠof	 ﾠcholine	 ﾠin	 ﾠthe	 ﾠextreme	 ﾠpreterm	 ﾠinfant.	 ﾠ
4.3.1	 ﾠMethodology	 ﾠ
Liquid	 ﾠchromatography	 ﾠmultiple	 ﾠreaction	 ﾠmonitoring	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ
(LC-ﾭ‐MRM-ﾭ‐MS/MS)	 ﾠ was	 ﾠ used	 ﾠ for	 ﾠ this	 ﾠ part	 ﾠ of	 ﾠ the	 ﾠ experiment.	 ﾠ The	 ﾠ method	 ﾠ is	 ﾠ
described	 ﾠin	 ﾠthe	 ﾠmethodology	 ﾠsection	 ﾠ(2.3.2	 ﾠii).	 ﾠ
4.3.2	 ﾠPhosphatidylethanolamine	 ﾠN-ﾭ‐methyltransferase	 ﾠ(PEMT)	 ﾠactivity	 ﾠ
As	 ﾠ described	 ﾠ in	 ﾠ detail	 ﾠ in	 ﾠ section	 ﾠ 4.1,	 ﾠ the	 ﾠ activity	 ﾠ of	 ﾠ the	 ﾠ PEMT	 ﾠ pathway	 ﾠ in	 ﾠ the	 ﾠ
presence	 ﾠof	 ﾠlabelled	 ﾠsubstrate,	 ﾠmethyl-ﾭ‐D9-ﾭ‐choline	 ﾠis	 ﾠconverted	 ﾠto	 ﾠmethyl-ﾭ‐D9-ﾭ‐betaine,	 ﾠ
by	 ﾠ the	 ﾠ action	 ﾠ of	 ﾠ choline	 ﾠ dehydrogenase	 ﾠ (CDH)	 ﾠ and/or	 ﾠ betaine	 ﾠ aldehyde	 ﾠ
dehydrogenase	 ﾠ(BADH).	 ﾠFrom	 ﾠthis	 ﾠpoint	 ﾠmethyl-ﾭ‐D9-ﾭ‐betaine	 ﾠand	 ﾠhomocysteine,	 ﾠin	 ﾠ
the	 ﾠpresence	 ﾠof	 ﾠbetaine-ﾭ‐homocysteine	 ﾠmethyltransferase	 ﾠ(BHMT),	 ﾠare	 ﾠconverted,	 ﾠ
respectively,	 ﾠto	 ﾠmethyl-ﾭ‐D6-ﾭ‐dimethylglycine	 ﾠand	 ﾠmethyl-ﾭ‐D3-ﾭ‐methionine.	 ﾠUsing	 ﾠATP	 ﾠ
the	 ﾠmethyl-ﾭ‐D3-ﾭ‐methionine	 ﾠthen	 ﾠis	 ﾠconverted	 ﾠto	 ﾠS-ﾭ‐Adenosyl-ﾭ‐methyl-ﾭ‐D3-ﾭ‐methionine	 ﾠ  101	 ﾠ
(D3-ﾭ‐SAMe).	 ﾠIt	 ﾠthen	 ﾠtransfers	 ﾠits	 ﾠmethyl-ﾭ‐D3	 ﾠgroup	 ﾠto	 ﾠphosphatidylethanolamine,	 ﾠin	 ﾠ
the	 ﾠany	 ﾠof	 ﾠthe	 ﾠthree	 ﾠsequential	 ﾠmethyl	 ﾠtransfers	 ﾠunder	 ﾠthe	 ﾠinfluence	 ﾠof	 ﾠthe	 ﾠenzyme	 ﾠ
phosphatidylethanolamine	 ﾠN-ﾭ‐methyltransferase	 ﾠ(PEMT),	 ﾠthat	 ﾠresult	 ﾠin	 ﾠmethyl-ﾭ‐D3-ﾭ‐
phosphatidylcholine.	 ﾠThere	 ﾠis	 ﾠa	 ﾠvery	 ﾠsmall	 ﾠchance	 ﾠthat	 ﾠanother	 ﾠD3-ﾭ‐SAMe	 ﾠmolecule	 ﾠ
could	 ﾠ donate	 ﾠ to	 ﾠ a	 ﾠ second	 ﾠ methyl	 ﾠ transfer	 ﾠ and	 ﾠ that	 ﾠ could	 ﾠ therefore	 ﾠ result	 ﾠ in	 ﾠ a	 ﾠ
methyl-ﾭ‐D6-ﾭ‐phosphatidylcholine	 ﾠproduced	 ﾠby	 ﾠPEMT.	 ﾠ
4.3.3	 ﾠConcentration	 ﾠof	 ﾠcholine	 ﾠin	 ﾠplasma	 ﾠ
Examination	 ﾠof	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠcholine	 ﾠpresent	 ﾠin	 ﾠplasma	 ﾠimmediately	 ﾠbefore	 ﾠ
and	 ﾠafter	 ﾠinfusion	 ﾠof	 ﾠlabelled	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠreveals	 ﾠthat	 ﾠthere	 ﾠis	 ﾠa	 ﾠ
short	 ﾠlived,	 ﾠbut	 ﾠnot	 ﾠstatistically	 ﾠsignificant,	 ﾠrise	 ﾠin	 ﾠtotal	 ﾠcholine	 ﾠconcentration	 ﾠfrom	 ﾠ
0	 ﾠto	 ﾠ6	 ﾠhours	 ﾠ(Figure	 ﾠ45).	 ﾠ
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Figure	 ﾠ45.	 ﾠConcentration	 ﾠof	 ﾠcholine	 ﾠin	 ﾠplasma	 ﾠof	 ﾠpreterm	 ﾠinfants	 ﾠover	 ﾠfirst	 ﾠ24	 ﾠ
hours	 ﾠof	 ﾠstudy.	 ﾠAdministration	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠat	 ﾠt=0	 ﾠ
produced	 ﾠa	 ﾠsmall,	 ﾠbut	 ﾠstatistically	 ﾠnot	 ﾠsignificant,	 ﾠrise	 ﾠin	 ﾠplasma	 ﾠcholine	 ﾠat	 ﾠ6	 ﾠ
hours.	 ﾠ	 ﾠ
The	 ﾠcholine	 ﾠconcentration	 ﾠthen	 ﾠfalls	 ﾠback	 ﾠto	 ﾠsimilar	 ﾠlevels	 ﾠby	 ﾠ12	 ﾠhours.	 ﾠThis	 ﾠmay	 ﾠ
reflect	 ﾠan	 ﾠoverall	 ﾠinsufficient	 ﾠsupply	 ﾠof	 ﾠcholine	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠdays	 ﾠof	 ﾠlife	 ﾠwith	 ﾠrapid	 ﾠ
uptake	 ﾠand	 ﾠmetabolism	 ﾠof	 ﾠany	 ﾠavailable	 ﾠcholine.	 ﾠHowever	 ﾠit	 ﾠis	 ﾠalso	 ﾠpossible	 ﾠthat	 ﾠ
the	 ﾠ amount	 ﾠ of	 ﾠ D9-ﾭ‐choline	 ﾠ given	 ﾠ was	 ﾠ sufficient	 ﾠ to	 ﾠ decrease	 ﾠ the	 ﾠ catabolism	 ﾠ and	 ﾠ
turnover	 ﾠ of	 ﾠ non-ﾭ‐labelled	 ﾠ choline.	 ﾠ It	 ﾠ may	 ﾠ be	 ﾠ that	 ﾠ these	 ﾠ infants	 ﾠ are	 ﾠ deficient	 ﾠ in	 ﾠ
choline	 ﾠand	 ﾠmay	 ﾠbenefit	 ﾠfrom	 ﾠenhanced	 ﾠsupplementation.	 ﾠ
Importantly	 ﾠthe	 ﾠadministration	 ﾠof	 ﾠ3.6mg/kg	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠdoes	 ﾠ
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i)	 ﾠCholine	 ﾠconcentration	 ﾠby	 ﾠpatient	 ﾠ
While	 ﾠthere	 ﾠis	 ﾠa	 ﾠsignificant	 ﾠspread	 ﾠof	 ﾠconcentrations	 ﾠover	 ﾠthe	 ﾠwhole	 ﾠpopulation	 ﾠ
there	 ﾠis	 ﾠno	 ﾠcorrelation	 ﾠbetween	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠcholine	 ﾠmeasured	 ﾠin	 ﾠplasma	 ﾠ
and	 ﾠthe	 ﾠgestational	 ﾠage	 ﾠof	 ﾠthe	 ﾠbaby	 ﾠwhen	 ﾠthe	 ﾠindividual	 ﾠinfants	 ﾠresults	 ﾠare	 ﾠplotted	 ﾠ
(Figure	 ﾠ46).	 ﾠSpecifically	 ﾠthe	 ﾠspread	 ﾠof	 ﾠconcentrations	 ﾠat	 ﾠtime	 ﾠof	 ﾠrecruitment	 ﾠis	 ﾠ2.82	 ﾠ
to	 ﾠ51.35µM/100µl.	 ﾠ	 ﾠ
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Figure	 ﾠ46.	 ﾠConcentration	 ﾠof	 ﾠcholine	 ﾠin	 ﾠplasma	 ﾠof	 ﾠindividual	 ﾠpreterm	 ﾠinfants	 ﾠ
over	 ﾠfirst	 ﾠ24	 ﾠhours	 ﾠof	 ﾠstudy.	 ﾠIndividual	 ﾠbabies	 ﾠare	 ﾠarranged	 ﾠin	 ﾠthe	 ﾠlegend	 ﾠby	 ﾠ
gestation	 ﾠfrom	 ﾠ23	 ﾠweeks	 ﾠ(blue)	 ﾠto	 ﾠ28	 ﾠweeks	 ﾠ(grey).	 ﾠThere	 ﾠis	 ﾠno	 ﾠmeasured	 ﾠ
correlation	 ﾠbetween	 ﾠcholine	 ﾠlevel	 ﾠand	 ﾠgestational	 ﾠage.	 ﾠ
To	 ﾠhelp	 ﾠvisualise	 ﾠthe	 ﾠdata,	 ﾠthe	 ﾠy-ﾭ‐axis	 ﾠhas	 ﾠbeen	 ﾠlog	 ﾠconverted	 ﾠto	 ﾠseparate	 ﾠthe	 ﾠfigures	 ﾠ
after	 ﾠ12	 ﾠhours	 ﾠand	 ﾠthe	 ﾠindividual	 ﾠpatients	 ﾠhave	 ﾠbeen	 ﾠarranged	 ﾠby	 ﾠgestation	 ﾠin	 ﾠthe	 ﾠ
legend.	 ﾠPrevious	 ﾠstudies	 ﾠhave	 ﾠshown	 ﾠthat	 ﾠthere	 ﾠis	 ﾠlarge	 ﾠvariation	 ﾠin	 ﾠnormal	 ﾠcholine	 ﾠ
levels	 ﾠ and	 ﾠ requirements	 ﾠ within	 ﾠ a	 ﾠ population	 ﾠ (Zeisel,	 ﾠ 2006a)	 ﾠ and	 ﾠ this	 ﾠ data	 ﾠ
reinforces	 ﾠthe	 ﾠfindings	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠgroup	 ﾠstudied.	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4.3.4	 ﾠEnrichment	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠ
Measurement	 ﾠ of	 ﾠ the	 ﾠ enrichment	 ﾠ of	 ﾠ plasma	 ﾠ choline	 ﾠ by	 ﾠ the	 ﾠ methyl-ﾭ‐D9	 ﾠ choline	 ﾠ is	 ﾠ
important	 ﾠbecause	 ﾠit	 ﾠdemonstrates	 ﾠthe	 ﾠcontribution	 ﾠthat	 ﾠthe	 ﾠinfusion	 ﾠmakes	 ﾠto	 ﾠthe	 ﾠ
total	 ﾠamount	 ﾠof	 ﾠcholine	 ﾠin	 ﾠthe	 ﾠplasma	 ﾠ(Figure	 ﾠ47).	 ﾠ
	 ﾠ
Figure	 ﾠ47.	 ﾠEnrichment	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠin	 ﾠplasma.	 ﾠThe	 ﾠproportion	 ﾠof	 ﾠcholine	 ﾠ
measured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠenriched	 ﾠwith	 ﾠnine	 ﾠdeuterium	 ﾠatoms.	 ﾠ
The	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠcontributed	 ﾠa	 ﾠmaximum	 ﾠof	 ﾠ4.83%	 ﾠof	 ﾠthe	 ﾠtotal	 ﾠcholine	 ﾠby	 ﾠ
the	 ﾠtime	 ﾠof	 ﾠthe	 ﾠfirst	 ﾠmeasurement,	 ﾠ6	 ﾠhours	 ﾠafter	 ﾠthe	 ﾠstart	 ﾠof	 ﾠthe	 ﾠinfusion.	 ﾠIt	 ﾠis	 ﾠ
possible	 ﾠ that	 ﾠ the	 ﾠ true	 ﾠ maximum	 ﾠ may	 ﾠ be	 ﾠ at	 ﾠ 3	 ﾠ hours	 ﾠ at	 ﾠ the	 ﾠ completion	 ﾠ of	 ﾠ the	 ﾠ
infusion	 ﾠbut	 ﾠsamples	 ﾠwere	 ﾠnot	 ﾠcollected	 ﾠat	 ﾠthat	 ﾠtime	 ﾠpoint.	 ﾠThe	 ﾠD9-ﾭ‐choline	 ﾠthen	 ﾠ
rapidly	 ﾠdisappears,	 ﾠfalling	 ﾠto	 ﾠ2.42%	 ﾠof	 ﾠthe	 ﾠtotal	 ﾠby	 ﾠ12	 ﾠhours	 ﾠand	 ﾠthen	 ﾠ1.86%	 ﾠby	 ﾠ24	 ﾠ
hours.	 ﾠ
The	 ﾠ amount	 ﾠ of	 ﾠ choline	 ﾠ supplied,	 ﾠ as	 ﾠ a	 ﾠ label,	 ﾠ to	 ﾠ these	 ﾠ babies	 ﾠ is	 ﾠ determined	 ﾠ by	 ﾠ
birthweight	 ﾠ and	 ﾠ each	 ﾠ child	 ﾠ receives	 ﾠ 3.6mg/kg.	 ﾠ This	 ﾠ amount	 ﾠ can	 ﾠ be	 ﾠ seen	 ﾠ to	 ﾠ
contribute	 ﾠless	 ﾠthan	 ﾠ5%	 ﾠof	 ﾠthe	 ﾠmeasured	 ﾠcholine	 ﾠin	 ﾠplasma	 ﾠand	 ﾠit’s	 ﾠproportion	 ﾠfalls	 ﾠ  105	 ﾠ
as	 ﾠ the	 ﾠ total	 ﾠ amount	 ﾠ of	 ﾠ plasma	 ﾠ choline	 ﾠ decreases	 ﾠ over	 ﾠ the	 ﾠ first	 ﾠ 24	 ﾠ hours	 ﾠ of	 ﾠ
recruitment.	 ﾠThe	 ﾠaddition	 ﾠof	 ﾠthis	 ﾠsmall	 ﾠamount	 ﾠof	 ﾠlabelled	 ﾠcholine	 ﾠhas	 ﾠnot	 ﾠaffected	 ﾠ
significantly	 ﾠthe	 ﾠmetabolism	 ﾠseen	 ﾠand	 ﾠevidence	 ﾠpoints	 ﾠto	 ﾠinsufficiency	 ﾠin	 ﾠpreterm	 ﾠ
infants	 ﾠas	 ﾠcholine	 ﾠrapidly	 ﾠfalls	 ﾠin	 ﾠplasma	 ﾠ6	 ﾠhours	 ﾠafter	 ﾠthe	 ﾠlabelled	 ﾠinfusion.	 ﾠThis	 ﾠ
evidence	 ﾠ supports	 ﾠ enhanced	 ﾠ nutritional	 ﾠ supplementation	 ﾠ with	 ﾠ choline	 ﾠ in	 ﾠ the	 ﾠ
extreme	 ﾠpreterm	 ﾠinfant,	 ﾠwith	 ﾠearlier	 ﾠTPN	 ﾠand	 ﾠpotentially	 ﾠsupports	 ﾠthe	 ﾠinclusion	 ﾠof	 ﾠ
increased	 ﾠamounts	 ﾠof	 ﾠcholine	 ﾠin	 ﾠTPN.	 ﾠ
4.3.5	 ﾠVariation	 ﾠin	 ﾠD9-ﾭ‐choline	 ﾠenrichment	 ﾠby	 ﾠindividual	 ﾠpatient	 ﾠ
Individual	 ﾠ patient	 ﾠ analysis	 ﾠ (Figure	 ﾠ 48)	 ﾠ reveals	 ﾠ no	 ﾠ clinical	 ﾠ correlation	 ﾠ with	 ﾠ
gestation	 ﾠor	 ﾠbirthweight	 ﾠand	 ﾠD9-ﾭ‐choline	 ﾠenrichment.	 ﾠ	 ﾠ
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Figure	 ﾠ48.	 ﾠEnrichment	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠin	 ﾠplasma	 ﾠplotted	 ﾠfor	 ﾠeach	 ﾠpatient.	 ﾠ
Individual	 ﾠbabies	 ﾠare	 ﾠarranged	 ﾠin	 ﾠthe	 ﾠlegend	 ﾠby	 ﾠgestation	 ﾠfrom	 ﾠ23	 ﾠweeks	 ﾠ
(blue)	 ﾠto	 ﾠ28	 ﾠweeks	 ﾠ(grey).	 ﾠThere	 ﾠis	 ﾠno	 ﾠmeasured	 ﾠcorrelation	 ﾠbetween	 ﾠD9-ﾭ‐
choline	 ﾠenrichment	 ﾠand	 ﾠgestational	 ﾠage.	 ﾠ	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The	 ﾠ y-ﾭ‐axis	 ﾠ has	 ﾠ been	 ﾠ log5	 ﾠtransformed	 ﾠ to	 ﾠ aid	 ﾠ visualisation	 ﾠ and	 ﾠ the	 ﾠ infants	 ﾠ are	 ﾠ
colour-ﾭ‐coded	 ﾠ as	 ﾠ before.	 ﾠ All	 ﾠ but	 ﾠ one	 ﾠ infant	 ﾠ (20.1%)	 ﾠ demonstrated	 ﾠ enrichment	 ﾠ
between	 ﾠ0.5	 ﾠand	 ﾠ10%	 ﾠwithin	 ﾠ6	 ﾠhours.	 ﾠThose	 ﾠthat	 ﾠstarted	 ﾠlower	 ﾠthan	 ﾠ1%	 ﾠshowed	 ﾠa	 ﾠ
rise	 ﾠto	 ﾠ12	 ﾠhours	 ﾠshowing	 ﾠa	 ﾠvariation	 ﾠin	 ﾠhandling	 ﾠD9-ﾭ‐choline	 ﾠbetween	 ﾠpatients.	 ﾠ
Again	 ﾠ the	 ﾠ evidence	 ﾠ points	 ﾠ to	 ﾠ rapid	 ﾠ metabolism	 ﾠ and	 ﾠ hence	 ﾠ the	 ﾠ clinical	 ﾠ need	 ﾠ to	 ﾠ
supplement	 ﾠthis	 ﾠimportant	 ﾠsubstrate.	 ﾠ
Following	 ﾠ the	 ﾠ progression	 ﾠ of	 ﾠ metabolism	 ﾠ in	 ﾠ the	 ﾠ PEMT	 ﾠ pathway,	 ﾠ D9-ﾭ‐choline	 ﾠ is	 ﾠ
metabolised	 ﾠ to	 ﾠ D9-ﾭ‐betaine	 ﾠ by	 ﾠ CDH	 ﾠ and	 ﾠ BADH.	 ﾠ Measurement	 ﾠ of	 ﾠ D9-ﾭ‐betaine	 ﾠ
enrichment	 ﾠ can	 ﾠ therefore	 ﾠ demonstrate	 ﾠ activity	 ﾠ by	 ﾠ these	 ﾠ enzymes	 ﾠ in	 ﾠ this	 ﾠ
hepatocellular	 ﾠpathway.	 ﾠ
4.3.6	 ﾠBetaine	 ﾠconcentration	 ﾠin	 ﾠplasma	 ﾠ
Looking	 ﾠat	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠbetaine	 ﾠpresent	 ﾠin	 ﾠplasma	 ﾠimmediately	 ﾠbefore	 ﾠand	 ﾠ
after	 ﾠinfusion	 ﾠof	 ﾠlabelled	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠ(Figure	 ﾠ49)	 ﾠreveals	 ﾠthat	 ﾠthere	 ﾠ
is	 ﾠno	 ﾠstatistically	 ﾠsignificant	 ﾠdifference	 ﾠin	 ﾠtotal	 ﾠbetaine	 ﾠconcentration	 ﾠfrom	 ﾠ0	 ﾠto	 ﾠ24	 ﾠ
hours.	 ﾠ
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Figure	 ﾠ49.	 ﾠConcentration	 ﾠof	 ﾠbetaine	 ﾠin	 ﾠplasma	 ﾠof	 ﾠpreterm	 ﾠinfants	 ﾠover	 ﾠfirst	 ﾠ24	 ﾠ
hours	 ﾠof	 ﾠstudy.	 ﾠAdministration	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠat	 ﾠt=0	 ﾠ
produced	 ﾠno	 ﾠstatistically	 ﾠsignificant	 ﾠrise	 ﾠin	 ﾠplasma	 ﾠbetaine	 ﾠover	 ﾠ24	 ﾠhours.	 ﾠ	 ﾠ
4.3.7	 ﾠD9-ﾭ‐betaine	 ﾠenrichment	 ﾠin	 ﾠplasma	 ﾠ
The	 ﾠD9-ﾭ‐betaine	 ﾠenrichment	 ﾠ(Figure	 ﾠ50)	 ﾠshows	 ﾠa	 ﾠlower	 ﾠpeak	 ﾠat	 ﾠ6	 ﾠhours	 ﾠin	 ﾠresponse	 ﾠ
to	 ﾠthe	 ﾠload	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠat	 ﾠtime	 ﾠof	 ﾠrecruitment.	 ﾠThe	 ﾠaverage	 ﾠD9-ﾭ‐betaine	 ﾠ
maximum	 ﾠof	 ﾠ3.01%	 ﾠat	 ﾠ6	 ﾠhours	 ﾠgradually	 ﾠfalls	 ﾠto	 ﾠ2.87%	 ﾠat	 ﾠ12	 ﾠhours	 ﾠand	 ﾠ2.57%	 ﾠby	 ﾠ
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Figure	 ﾠ50.	 ﾠEnrichment	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠand	 ﾠD9-ﾭ‐betaine	 ﾠin	 ﾠplasma.	 ﾠ
4.3.8	 ﾠ Comparison	 ﾠ of	 ﾠ D9-ﾭ‐choline,	 ﾠ D9-ﾭ‐betaine	 ﾠ and	 ﾠ D9-ﾭ‐phosphatidylcholine	 ﾠ
enrichment	 ﾠ
Both	 ﾠ D9-ﾭ‐choline	 ﾠ and	 ﾠ D9-ﾭ‐betaine	 ﾠ show	 ﾠ peak	 ﾠ enrichment	 ﾠ with	 ﾠ the	 ﾠ first	 ﾠ sample	 ﾠ
collected	 ﾠafter	 ﾠinfusion	 ﾠwith	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠwhereas	 ﾠthe	 ﾠpeak	 ﾠenrichment	 ﾠof	 ﾠ
D9-ﾭ‐PC	 ﾠ is	 ﾠ reached	 ﾠ at	 ﾠ 12	 ﾠ hours.	 ﾠ There	 ﾠ is	 ﾠ a	 ﾠ weak	 ﾠ inverse	 ﾠ correlation	 ﾠ (Figure	 ﾠ 51)	 ﾠ
between	 ﾠpeak	 ﾠincorporation	 ﾠseen	 ﾠin	 ﾠcholine	 ﾠor	 ﾠbetaine	 ﾠand	 ﾠphosphatidylcholine	 ﾠ
showing	 ﾠthat	 ﾠcholine	 ﾠis	 ﾠrapidly	 ﾠconverted	 ﾠto	 ﾠbetaine	 ﾠvia	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠwhere	 ﾠ
it	 ﾠ subsequently	 ﾠ is	 ﾠ demethylated	 ﾠ in	 ﾠ the	 ﾠ presence	 ﾠ of	 ﾠ homocysteine	 ﾠ to	 ﾠ
dimethylglycine	 ﾠand	 ﾠmethionine	 ﾠor	 ﾠthat	 ﾠit	 ﾠcontributes	 ﾠto	 ﾠPC	 ﾠproduction	 ﾠvia	 ﾠCDP-ﾭ‐
choline	 ﾠpathway.	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Figure	 ﾠ51.	 ﾠPeak	 ﾠenrichment	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠand	 ﾠD9-ﾭ‐betaine	 ﾠat	 ﾠ6	 ﾠhours	 ﾠin	 ﾠ
plasma	 ﾠplotted	 ﾠagainst	 ﾠcorresponding	 ﾠpeak	 ﾠenrichment	 ﾠvalue	 ﾠof	 ﾠD9-ﾭ‐
phosphatidylcholine	 ﾠat	 ﾠ12	 ﾠhours.	 ﾠThe	 ﾠtrendlines	 ﾠshow	 ﾠthat	 ﾠthere	 ﾠis	 ﾠa	 ﾠweak	 ﾠ
correlation	 ﾠbetween	 ﾠa	 ﾠlower	 ﾠpeak	 ﾠD9-ﾭ‐choline	 ﾠor	 ﾠD9-ﾭ‐betaine	 ﾠenrichment	 ﾠand	 ﾠ
a	 ﾠhigher	 ﾠpeak	 ﾠD9-ﾭ‐PC	 ﾠenrichment.	 ﾠ	 ﾠ
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4.4	 ﾠDiscussion	 ﾠ	 ﾠ
The	 ﾠ hepatocellular	 ﾠ conversion	 ﾠ of	 ﾠ choline	 ﾠ and	 ﾠ homocysteine	 ﾠ to	 ﾠ S-ﾭ‐adenosyl	 ﾠ
methionine	 ﾠ(SAMe)	 ﾠby	 ﾠmethyl	 ﾠtransfer	 ﾠ(BHMT)	 ﾠand	 ﾠthe	 ﾠsubsequent	 ﾠconversion	 ﾠof	 ﾠ
phosphatidylethanolamine	 ﾠ(PE)	 ﾠby	 ﾠthree	 ﾠsequential	 ﾠmethylations	 ﾠusing	 ﾠSAMe	 ﾠto	 ﾠ
phosphatidylcholine	 ﾠ (PC)	 ﾠ by	 ﾠ PE-ﾭ‐N-ﾭ‐methyltransferase	 ﾠ (PEMT)	 ﾠ is	 ﾠ an	 ﾠ important	 ﾠ
route	 ﾠfor	 ﾠpolyunsaturated	 ﾠPC	 ﾠsynthesis	 ﾠin	 ﾠthe	 ﾠadult	 ﾠhuman,	 ﾠaccounting	 ﾠfor	 ﾠalmost	 ﾠa	 ﾠ
third	 ﾠof	 ﾠall	 ﾠliver	 ﾠPC	 ﾠoutput	 ﾠ(Vance	 ﾠet	 ﾠal.,	 ﾠ1997,	 ﾠLi	 ﾠand	 ﾠVance,	 ﾠ2008).	 ﾠ	 ﾠ
In	 ﾠ this	 ﾠ study,	 ﾠ for	 ﾠ the	 ﾠ first	 ﾠ time,	 ﾠ the	 ﾠ liver-ﾭ‐specific	 ﾠ PEMT	 ﾠ pathway	 ﾠ has	 ﾠ been	 ﾠ
investigated	 ﾠin	 ﾠthe	 ﾠnewborn	 ﾠpreterm	 ﾠbaby.	 ﾠ	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Through	 ﾠthe	 ﾠanalysis,	 ﾠpresented	 ﾠearlier,	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠin	 ﾠcirculating	 ﾠplasma	 ﾠit	 ﾠhas	 ﾠbeen	 ﾠ
established	 ﾠthat	 ﾠthese	 ﾠinfants	 ﾠare	 ﾠable	 ﾠto	 ﾠrapidly	 ﾠsynthesise	 ﾠnew	 ﾠPC	 ﾠmolecules	 ﾠvia	 ﾠ
the	 ﾠCDP-ﾭ‐choline	 ﾠpathway.	 ﾠTurning	 ﾠinstead	 ﾠto	 ﾠthe	 ﾠD3-ﾭ‐,	 ﾠand	 ﾠto	 ﾠa	 ﾠmuch	 ﾠsmaller	 ﾠextent	 ﾠ
the	 ﾠD6-ﾭ‐phosphatidylcholine	 ﾠspecies,	 ﾠit	 ﾠis	 ﾠpossible	 ﾠto	 ﾠexamine	 ﾠthe	 ﾠPEMT	 ﾠpathway.	 ﾠ
It	 ﾠ can	 ﾠ be	 ﾠ stated	 ﾠ at	 ﾠ the	 ﾠ outset	 ﾠ that	 ﾠ the	 ﾠ PEMT	 ﾠ pathway	 ﾠ is	 ﾠ active	 ﾠ in	 ﾠ the	 ﾠ preterm	 ﾠ
newborn,	 ﾠproviding	 ﾠclear	 ﾠevidence	 ﾠof	 ﾠspecific	 ﾠliver	 ﾠsynthesis	 ﾠin	 ﾠthis	 ﾠpopulation	 ﾠand	 ﾠ
rapidly	 ﾠproduces	 ﾠnew	 ﾠD3-ﾭ‐PC	 ﾠspecies	 ﾠwithin	 ﾠ6	 ﾠto	 ﾠ48	 ﾠhours	 ﾠof	 ﾠbirth,	 ﾠalthough	 ﾠat	 ﾠa	 ﾠ
lower	 ﾠ overall	 ﾠ concentration	 ﾠ than	 ﾠ seen	 ﾠ in	 ﾠ the	 ﾠ CDP-ﾭ‐choline	 ﾠ pathway	 ﾠ equating	 ﾠ to	 ﾠ
around	 ﾠ5%.	 ﾠ
Unlike	 ﾠin	 ﾠadults	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ2011)	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠin	 ﾠpreterm	 ﾠinfants	 ﾠproduces	 ﾠ
more	 ﾠmono-ﾭ‐	 ﾠand	 ﾠdi-ﾭ‐unsaturated	 ﾠspecies	 ﾠthan	 ﾠpolyunsaturated	 ﾠPC	 ﾠspecies	 ﾠas	 ﾠan	 ﾠ
absolute	 ﾠ amount	 ﾠ but	 ﾠ importantly	 ﾠ contributes	 ﾠ a	 ﾠ higher	 ﾠ proportion	 ﾠ of	 ﾠ newly	 ﾠ
synthesised	 ﾠPUFA-ﾭ‐containing	 ﾠspecies	 ﾠby	 ﾠfractional	 ﾠincorporation.	 ﾠ
When	 ﾠ compared	 ﾠ to	 ﾠ the	 ﾠ adult	 ﾠ the	 ﾠ flux	 ﾠ calculated	 ﾠ by	 ﾠ MIDA	 ﾠ through	 ﾠ the	 ﾠ PEMT	 ﾠ
pathway	 ﾠis	 ﾠlow	 ﾠ(Pynn	 ﾠet	 ﾠal.,	 ﾠ2011).	 ﾠThis	 ﾠis	 ﾠperhaps	 ﾠto	 ﾠbe	 ﾠexpected	 ﾠas	 ﾠlow	 ﾠflux	 ﾠhas	 ﾠ
previously	 ﾠ been	 ﾠ described	 ﾠ in	 ﾠ proliferating	 ﾠ liver	 ﾠ states	 ﾠ such	 ﾠ as	 ﾠ partially	 ﾠ
hepatectomised	 ﾠrodents	 ﾠ(Houweling	 ﾠet	 ﾠal.,	 ﾠ1997)	 ﾠand	 ﾠthese	 ﾠchildren	 ﾠshould	 ﾠbe	 ﾠin	 ﾠa	 ﾠ
period	 ﾠof	 ﾠrapid	 ﾠgrowth	 ﾠin	 ﾠutero.	 ﾠ
There	 ﾠis	 ﾠno	 ﾠpublished	 ﾠdata	 ﾠlooking	 ﾠat	 ﾠabsolute	 ﾠrates	 ﾠof	 ﾠsynthetic	 ﾠflux	 ﾠthrough	 ﾠthe	 ﾠ
PEMT	 ﾠpathway	 ﾠin	 ﾠpatients.	 ﾠThe	 ﾠresults	 ﾠfrom	 ﾠadult	 ﾠvolunteer	 ﾠdata	 ﾠshows	 ﾠa	 ﾠvery	 ﾠ
different	 ﾠpicture	 ﾠwith	 ﾠflux	 ﾠrate	 ﾠup	 ﾠto	 ﾠ10	 ﾠtimes	 ﾠgreater	 ﾠthan	 ﾠthat	 ﾠmeasured	 ﾠin	 ﾠthese	 ﾠ
children.	 ﾠ	 ﾠ
The	 ﾠ implications	 ﾠ for	 ﾠ future	 ﾠ investigation	 ﾠ and	 ﾠ clinical	 ﾠ care	 ﾠ are	 ﾠ two-ﾭ‐fold.	 ﾠ Firstly,	 ﾠ
preterm	 ﾠbabies	 ﾠare	 ﾠable	 ﾠto	 ﾠsynthesise	 ﾠPC	 ﾠvia	 ﾠPEMT	 ﾠpathway	 ﾠrapidly	 ﾠbut	 ﾠat	 ﾠa	 ﾠlevel	 ﾠ
much	 ﾠlower	 ﾠthan	 ﾠin	 ﾠadults	 ﾠand	 ﾠlower	 ﾠthan	 ﾠin	 ﾠCDP-ﾭ‐choline	 ﾠpathway.	 ﾠAs	 ﾠthe	 ﾠPEMT	 ﾠ
pathway	 ﾠis	 ﾠthe	 ﾠmajor	 ﾠroute	 ﾠfor	 ﾠsynthesising	 ﾠPUFA-ﾭ‐containing	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠadults,	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it	 ﾠ is	 ﾠ easy	 ﾠ to	 ﾠ suggest	 ﾠ that	 ﾠ these	 ﾠ children	 ﾠ are	 ﾠ significantly	 ﾠ more	 ﾠ dependent	 ﾠ on	 ﾠ
nutritional	 ﾠ sources	 ﾠ of	 ﾠ polyunsaturated	 ﾠ fatty	 ﾠ acids	 ﾠ to	 ﾠ make	 ﾠ PUFA-ﾭ‐containing	 ﾠ
phospholipids.	 ﾠFailure	 ﾠto	 ﾠprovide	 ﾠenough	 ﾠPUFA	 ﾠcould	 ﾠtherefore	 ﾠhave	 ﾠa	 ﾠsignificant	 ﾠ
impact	 ﾠon	 ﾠtheir	 ﾠneurodevelopment	 ﾠduring	 ﾠa	 ﾠperiod	 ﾠof	 ﾠrapid	 ﾠgrowth.	 ﾠAdequate	 ﾠand	 ﾠ
early	 ﾠsupply	 ﾠof	 ﾠthe	 ﾠfatty	 ﾠacids	 ﾠis	 ﾠneeded.	 ﾠSecondly,	 ﾠSAMe	 ﾠis	 ﾠan	 ﾠimportant	 ﾠmethyl	 ﾠ
donor,	 ﾠnot	 ﾠjust	 ﾠin	 ﾠthe	 ﾠlipid	 ﾠspecific	 ﾠPEMT	 ﾠpathway	 ﾠas	 ﾠillustrated	 ﾠbut	 ﾠin	 ﾠseveral	 ﾠ
other	 ﾠmethyl	 ﾠtransfer	 ﾠreactions	 ﾠinvolving	 ﾠproteins	 ﾠand	 ﾠnucleic	 ﾠacids.	 ﾠMethylation	 ﾠ
patterns	 ﾠ in	 ﾠ promoter	 ﾠ regions	 ﾠ of	 ﾠ DNA	 ﾠ play	 ﾠ a	 ﾠ vital	 ﾠ role	 ﾠ in	 ﾠ influencing	 ﾠ gene	 ﾠ
expression	 ﾠ and	 ﾠ therefore	 ﾠ alter,	 ﾠ by	 ﾠ epigenetics,	 ﾠ future	 ﾠ disease	 ﾠ development	 ﾠ and	 ﾠ
health	 ﾠ(Burdge	 ﾠand	 ﾠLillycrop,	 ﾠ2010).	 ﾠ	 ﾠ
By	 ﾠidentifying	 ﾠlow	 ﾠflux	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠit	 ﾠmay	 ﾠindicate	 ﾠlow	 ﾠactivity	 ﾠin	 ﾠ
methyl	 ﾠtransfer	 ﾠmore	 ﾠgenerally.	 ﾠFurther	 ﾠstudy	 ﾠis	 ﾠrequired	 ﾠto	 ﾠlook	 ﾠat	 ﾠthe	 ﾠconnection	 ﾠ
between	 ﾠ PEMT	 ﾠ activity,	 ﾠ homocysteine	 ﾠ and	 ﾠ choline	 ﾠ bioavailability,	 ﾠ general	 ﾠ
methylation	 ﾠactivity	 ﾠand	 ﾠepigenetics	 ﾠof	 ﾠdisease	 ﾠdevelopment	 ﾠin	 ﾠpreterm	 ﾠinfants.	 ﾠA	 ﾠ
potential	 ﾠextension	 ﾠof	 ﾠthe	 ﾠmethod	 ﾠcould	 ﾠbe	 ﾠto	 ﾠuse	 ﾠa	 ﾠlabelled	 ﾠL-ﾭ‐serine	 ﾠas	 ﾠa	 ﾠsubstrate	 ﾠ
for	 ﾠphosphatidylethanolamine,	 ﾠfrom	 ﾠphosphatidyl-ﾭ‐L-ﾭ‐serine	 ﾠusing	 ﾠphosphatidyl-ﾭ‐L-ﾭ‐
serine	 ﾠdecarboxylase.	 ﾠPS	 ﾠis	 ﾠmade	 ﾠin	 ﾠthe	 ﾠendoplasmic	 ﾠreticulum	 ﾠand	 ﾠtransported	 ﾠto	 ﾠ
the	 ﾠinner	 ﾠmitochondrial	 ﾠmembrane	 ﾠwhere	 ﾠPS	 ﾠdecarboxylase	 ﾠacts	 ﾠto	 ﾠproduce	 ﾠPE.	 ﾠPE	 ﾠ
is	 ﾠnot	 ﾠnormally	 ﾠmeasured	 ﾠdirectly	 ﾠas	 ﾠit	 ﾠremains	 ﾠintracellular	 ﾠbut	 ﾠnewly	 ﾠsynthesised	 ﾠ
PE	 ﾠsubsequently	 ﾠconverted	 ﾠto	 ﾠPC	 ﾠcould	 ﾠbe	 ﾠidentified.	 ﾠ
In	 ﾠsummary,	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠan	 ﾠimportant	 ﾠsource	 ﾠof	 ﾠPUFA	 ﾠPC	 ﾠspecies	 ﾠthough	 ﾠ
there	 ﾠis	 ﾠvery	 ﾠlow	 ﾠflux	 ﾠthrough	 ﾠthis	 ﾠpathway	 ﾠin	 ﾠnewborn	 ﾠpreterm	 ﾠinfants.	 ﾠLow	 ﾠflux	 ﾠ
has	 ﾠbeen	 ﾠpreviously	 ﾠassociated	 ﾠwith	 ﾠproliferating	 ﾠliver	 ﾠstates.	 ﾠ
There	 ﾠis	 ﾠevidence	 ﾠthat	 ﾠthe	 ﾠpathway	 ﾠis	 ﾠusing	 ﾠcholine	 ﾠwhere	 ﾠavailable	 ﾠand	 ﾠthat	 ﾠthe	 ﾠ
choline	 ﾠ is	 ﾠ converted	 ﾠ by	 ﾠ CDH/BADH	 ﾠ to	 ﾠ betaine	 ﾠ readily.	 ﾠ It	 ﾠ is	 ﾠ not	 ﾠ clear	 ﾠ however	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whether	 ﾠthe	 ﾠlow	 ﾠflux	 ﾠlater	 ﾠin	 ﾠthe	 ﾠpathway	 ﾠis	 ﾠdue	 ﾠto	 ﾠa	 ﾠlow	 ﾠactivity	 ﾠin	 ﾠBHMT	 ﾠor	 ﾠPEMT	 ﾠ
itself,	 ﾠor	 ﾠdue	 ﾠto	 ﾠan	 ﾠabsence	 ﾠor	 ﾠlow	 ﾠlevels	 ﾠof	 ﾠhomocysteine.	 ﾠ	 ﾠ
Of	 ﾠparticular	 ﾠimportance	 ﾠto	 ﾠthis	 ﾠgroup	 ﾠis	 ﾠthe	 ﾠrole	 ﾠof	 ﾠPEMT	 ﾠpathway	 ﾠin	 ﾠcholine	 ﾠ
synthesis.	 ﾠThe	 ﾠmajority	 ﾠof	 ﾠcholine	 ﾠis	 ﾠobtained	 ﾠfrom	 ﾠdietary	 ﾠsources	 ﾠbut	 ﾠthere	 ﾠexists	 ﾠ
the	 ﾠability	 ﾠto	 ﾠsynthesise	 ﾠcholine	 ﾠde	 ﾠnovo	 ﾠin	 ﾠhepatocytes	 ﾠusing	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠ
(Jacobs	 ﾠet	 ﾠal.,	 ﾠ2010).	 ﾠReduced	 ﾠactivity	 ﾠand	 ﾠflux	 ﾠthrough	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠin	 ﾠthese	 ﾠ
preterm	 ﾠinfants	 ﾠplaces	 ﾠthem	 ﾠat	 ﾠparticular	 ﾠrisk	 ﾠof	 ﾠcholine	 ﾠdeficiency,	 ﾠas	 ﾠthey	 ﾠare	 ﾠ
primarily	 ﾠdependent	 ﾠon	 ﾠdietary	 ﾠsources	 ﾠof	 ﾠcholine.	 ﾠ
In	 ﾠ the	 ﾠ next	 ﾠ chapter	 ﾠ the	 ﾠ importance	 ﾠ and	 ﾠ role	 ﾠ of	 ﾠ PC	 ﾠ in	 ﾠ pulmonary	 ﾠ surfactant	 ﾠ is	 ﾠ
considered,	 ﾠespecially	 ﾠthe	 ﾠfully	 ﾠsaturated	 ﾠspecies	 ﾠpredominantly	 ﾠproduced	 ﾠby	 ﾠCDP-ﾭ‐
choline.	 ﾠ
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Chapter	 ﾠ5.	 ﾠThe	 ﾠprofile	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠ
endotracheal	 ﾠ aspirates	 ﾠ with	 ﾠ analysis	 ﾠ of	 ﾠ their	 ﾠ synthesis	 ﾠ
from	 ﾠcholine	 ﾠin	 ﾠa	 ﾠpreterm	 ﾠpopulation	 ﾠ
5.1	 ﾠIntroduction	 ﾠ
As	 ﾠoutlined	 ﾠin	 ﾠthe	 ﾠintroduction	 ﾠchapter	 ﾠthe	 ﾠinfants	 ﾠin	 ﾠthis	 ﾠstudy	 ﾠwere	 ﾠdelivered	 ﾠ
prematurely	 ﾠ with	 ﾠ underdeveloped	 ﾠ lungs.	 ﾠ Through	 ﾠ the	 ﾠ analysis	 ﾠ of	 ﾠ plasma	 ﾠ lipid	 ﾠ
extracts	 ﾠthe	 ﾠmetabolic	 ﾠactivity	 ﾠof	 ﾠboth	 ﾠCDP-ﾭ‐choline	 ﾠand	 ﾠPEMT	 ﾠpathways	 ﾠfor	 ﾠthe	 ﾠ
production	 ﾠ of	 ﾠ distinct	 ﾠ phosphatidylcholine	 ﾠ phospholipids	 ﾠ has	 ﾠ been	 ﾠ outlined	 ﾠ in	 ﾠ
Chapters	 ﾠ3	 ﾠand	 ﾠ4.	 ﾠThe	 ﾠmeasurement	 ﾠof	 ﾠde	 ﾠnovo	 ﾠplasma	 ﾠphospholipids	 ﾠreflects	 ﾠthe	 ﾠ
liver	 ﾠactivity	 ﾠin	 ﾠthese	 ﾠinfants	 ﾠand	 ﾠthe	 ﾠphospholipids	 ﾠproduced	 ﾠreflect	 ﾠthe	 ﾠavailable	 ﾠ
fatty	 ﾠacid	 ﾠsubstrate	 ﾠand	 ﾠthe	 ﾠdemands	 ﾠof	 ﾠthe	 ﾠbody,	 ﾠwhich	 ﾠchange	 ﾠwith	 ﾠtime.	 ﾠ	 ﾠ
Surfactant	 ﾠproduction	 ﾠand	 ﾠmetabolism	 ﾠin	 ﾠthe	 ﾠlung	 ﾠis	 ﾠclosely	 ﾠlinked	 ﾠto	 ﾠthe	 ﾠliver	 ﾠ
metabolism	 ﾠof	 ﾠphospholipids	 ﾠand	 ﾠthe	 ﾠCDP-ﾭ‐choline	 ﾠpathway	 ﾠis	 ﾠpresent	 ﾠin	 ﾠtype-ﾭ‐II	 ﾠ
alveolar	 ﾠcells.	 ﾠPreterm	 ﾠinfants	 ﾠare	 ﾠdependent	 ﾠon	 ﾠthe	 ﾠadministration	 ﾠof	 ﾠexogenously	 ﾠ
derived	 ﾠ surfactant	 ﾠ phospholipids	 ﾠ at	 ﾠ birth	 ﾠ but	 ﾠ little	 ﾠ is	 ﾠ known	 ﾠ about	 ﾠ how	 ﾠ the	 ﾠ
exogenous	 ﾠ surfactant	 ﾠ is	 ﾠ metabolised	 ﾠ and	 ﾠ how	 ﾠ long	 ﾠ it	 ﾠ takes	 ﾠ for	 ﾠ the	 ﾠ child	 ﾠ to	 ﾠ
synthesise	 ﾠ new	 ﾠ phospholipids.	 ﾠ The	 ﾠ dominant	 ﾠ phosphatidylcholine	 ﾠ phospholipid	 ﾠ
species	 ﾠ in	 ﾠ exogenous	 ﾠ surfactant	 ﾠ are	 ﾠ fully	 ﾠ saturated,	 ﾠ which	 ﾠ constitutes	 ﾠ a	 ﾠ small	 ﾠ
percentage	 ﾠof	 ﾠthe	 ﾠliver	 ﾠoutput	 ﾠof	 ﾠphospholipids.	 ﾠ
By	 ﾠusing	 ﾠthe	 ﾠsame	 ﾠtechniques	 ﾠof	 ﾠlipid	 ﾠextraction	 ﾠand	 ﾠanalysis	 ﾠof	 ﾠthe	 ﾠincorporation	 ﾠ
of	 ﾠthe	 ﾠlabelled	 ﾠcholine	 ﾠin	 ﾠto	 ﾠthe	 ﾠphospholipid	 ﾠpool	 ﾠit	 ﾠis	 ﾠpossible	 ﾠto	 ﾠidentify	 ﾠand	 ﾠ
quantify	 ﾠthe	 ﾠmetabolic	 ﾠactivity	 ﾠof	 ﾠthe	 ﾠCDP–choline	 ﾠpathway	 ﾠin	 ﾠthe	 ﾠlungs	 ﾠand,	 ﾠwith	 ﾠ
sequential	 ﾠsample	 ﾠanalysis,	 ﾠshow	 ﾠhow	 ﾠthis	 ﾠactivity	 ﾠchanges	 ﾠwith	 ﾠtime.	 ﾠEnhanced	 ﾠ
understanding	 ﾠ of	 ﾠ how	 ﾠ these	 ﾠ infants	 ﾠ metabolise	 ﾠ the	 ﾠ exogenous	 ﾠ surfactant	 ﾠ they	 ﾠ
receive	 ﾠ and	 ﾠ how	 ﾠ they	 ﾠ synthesise	 ﾠ their	 ﾠ own	 ﾠ surface-ﾭ‐active	 ﾠ phospholipids	 ﾠ will	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provide	 ﾠinsights	 ﾠinto	 ﾠfuture	 ﾠstudies	 ﾠand	 ﾠinterventions	 ﾠto	 ﾠchange	 ﾠhow	 ﾠclinicians	 ﾠ
manage	 ﾠthe	 ﾠsmallest	 ﾠand	 ﾠsickest	 ﾠinfants.	 ﾠ
A	 ﾠtotal	 ﾠof	 ﾠtwenty-ﾭ‐six	 ﾠbabies	 ﾠwere	 ﾠrecruited	 ﾠto	 ﾠthe	 ﾠstudy	 ﾠand	 ﾠthe	 ﾠresults	 ﾠpresented	 ﾠ
in	 ﾠthis	 ﾠchapter	 ﾠare	 ﾠfor	 ﾠtwenty-ﾭ‐three	 ﾠpatients	 ﾠrecruited	 ﾠin	 ﾠPrincess	 ﾠAnne	 ﾠHospital,	 ﾠ
Southampton	 ﾠwho	 ﾠprovided	 ﾠat	 ﾠleast	 ﾠtwo	 ﾠETA	 ﾠsamples	 ﾠduring	 ﾠthe	 ﾠstudy	 ﾠperiod.	 ﾠ
The	 ﾠother	 ﾠthree	 ﾠbabies	 ﾠrecruited	 ﾠto	 ﾠthe	 ﾠstudy,	 ﾠwere	 ﾠsuccessfully	 ﾠextubated	 ﾠearly	 ﾠin	 ﾠ
the	 ﾠcourse	 ﾠof	 ﾠtheir	 ﾠclinical	 ﾠstay	 ﾠon	 ﾠthe	 ﾠneonatal	 ﾠintensive	 ﾠcare	 ﾠunit	 ﾠbut	 ﾠhave	 ﾠhad	 ﾠ
their	 ﾠ blood	 ﾠ samples	 ﾠ included	 ﾠ in	 ﾠ the	 ﾠ plasma	 ﾠ analysis	 ﾠ in	 ﾠ the	 ﾠ previous	 ﾠ results	 ﾠ
chapters.	 ﾠ
5.1.1	 ﾠMethodologies	 ﾠused	 ﾠin	 ﾠthe	 ﾠETA	 ﾠresults	 ﾠchapter	 ﾠ
As	 ﾠ described	 ﾠ previously	 ﾠ the	 ﾠ specimens	 ﾠ of	 ﾠ lung	 ﾠ fluid	 ﾠ were	 ﾠ collected	 ﾠ by	 ﾠ gentle	 ﾠ
suctioning	 ﾠafter	 ﾠinstillation	 ﾠof	 ﾠup	 ﾠto	 ﾠ1ml	 ﾠof	 ﾠsterile	 ﾠsaline	 ﾠdown	 ﾠthe	 ﾠET	 ﾠtube.	 ﾠAs	 ﾠwith	 ﾠ
blood	 ﾠ samples	 ﾠ this	 ﾠ was	 ﾠ performed	 ﾠ at	 ﾠ baseline	 ﾠ then	 ﾠ 6	 ﾠ hours	 ﾠ after	 ﾠ the	 ﾠ start	 ﾠ of	 ﾠ
administration	 ﾠof	 ﾠthe	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠchloride,	 ﾠat	 ﾠ12	 ﾠhours	 ﾠand	 ﾠthen	 ﾠat	 ﾠdaily	 ﾠ
intervals	 ﾠ from	 ﾠ 24	 ﾠ hours	 ﾠ after	 ﾠ infusion	 ﾠ for	 ﾠ 5	 ﾠ days	 ﾠ or	 ﾠ until	 ﾠ ventilation	 ﾠ is	 ﾠ
discontinued,	 ﾠwhichever	 ﾠwas	 ﾠthe	 ﾠshorter	 ﾠperiod.	 ﾠThis	 ﾠtechnique	 ﾠis	 ﾠa	 ﾠcomponent	 ﾠof	 ﾠ
routine	 ﾠendotracheal	 ﾠtoilet	 ﾠin	 ﾠintubated	 ﾠneonates.	 ﾠ	 ﾠ
The	 ﾠtheory	 ﾠand	 ﾠmethodology	 ﾠof	 ﾠsample	 ﾠprocessing,	 ﾠlipid	 ﾠextraction,	 ﾠelectrospray	 ﾠ
ionisation	 ﾠtandem	 ﾠmass	 ﾠspectrometry	 ﾠ(ESI	 ﾠMS/MS)	 ﾠand	 ﾠprecursor	 ﾠscanning	 ﾠhave	 ﾠ
been	 ﾠdescribed	 ﾠin	 ﾠprevious	 ﾠchapters.	 ﾠ
5.2	 ﾠPrecursors	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠscanning	 ﾠ
As	 ﾠa	 ﾠstarting	 ﾠpoint	 ﾠwith	 ﾠthese	 ﾠpreterm	 ﾠinfants	 ﾠit	 ﾠis	 ﾠimportant	 ﾠto	 ﾠask	 ﾠwhat	 ﾠis	 ﾠthe	 ﾠPC	 ﾠ
species	 ﾠcomposition	 ﾠof	 ﾠthe	 ﾠETA	 ﾠaspirates	 ﾠwithin	 ﾠ48	 ﾠhours	 ﾠof	 ﾠbirth	 ﾠand	 ﾠreceipt	 ﾠof	 ﾠ  115	 ﾠ
Curosurf®	 ﾠ100-ﾭ‐200mg/kg?	 ﾠLipid	 ﾠextracts	 ﾠfrom	 ﾠthe	 ﾠbaseline	 ﾠsamples	 ﾠwere	 ﾠscanned	 ﾠ
for	 ﾠthe	 ﾠprecursors	 ﾠof	 ﾠ184,	 ﾠby	 ﾠESI	 ﾠMS/MS.	 ﾠ
5.2.1	 ﾠMass	 ﾠspectrometry	 ﾠspectra	 ﾠ(P184)	 ﾠ
ETA	 ﾠsamples,	 ﾠobtained	 ﾠfrom	 ﾠpreterm	 ﾠventilated	 ﾠinfants,	 ﾠwere	 ﾠanalysed	 ﾠfor	 ﾠtotal	 ﾠPC	 ﾠ
by	 ﾠprecursor	 ﾠof	 ﾠ184	 ﾠ(P184)	 ﾠscanning	 ﾠon	 ﾠESI	 ﾠMS/MS	 ﾠ(Figure	 ﾠ52).	 ﾠ
	 ﾠ
Figure	 ﾠ52.	 ﾠAn	 ﾠexample	 ﾠof	 ﾠa	 ﾠprecursor	 ﾠof	 ﾠmass/charge	 ﾠ+184	 ﾠ(P184)	 ﾠscan	 ﾠ
spectrum.	 ﾠIt	 ﾠillustrates	 ﾠa	 ﾠtypical	 ﾠendotracheal	 ﾠaspirate	 ﾠ(ETA)	 ﾠlipid	 ﾠextract	 ﾠ
scan	 ﾠat	 ﾠrecruitment	 ﾠ(time	 ﾠpoint	 ﾠ=	 ﾠ0)	 ﾠless	 ﾠthan	 ﾠ48	 ﾠhours	 ﾠafter	 ﾠpreterm	 ﾠbirth.	 ﾠ
	 ﾠ
The	 ﾠ highest	 ﾠ peak	 ﾠ represents	 ﾠ the	 ﾠ most	 ﾠ abundant	 ﾠ species	 ﾠ and	 ﾠ this	 ﾠ spectrum	 ﾠ is	 ﾠ
normalised	 ﾠwith	 ﾠthis	 ﾠpeak	 ﾠat	 ﾠ100%.	 ﾠ	 ﾠ
The	 ﾠmost	 ﾠcommonly	 ﾠfound	 ﾠspecies	 ﾠin	 ﾠETA	 ﾠsamples	 ﾠare	 ﾠlisted	 ﾠin	 ﾠthe	 ﾠtable	 ﾠbelow.	 ﾠ
mass/charge (m/z) 
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In	 ﾠ the	 ﾠ table	 ﾠ the	 ﾠ species	 ﾠ are	 ﾠ arranged	 ﾠ by	 ﾠ m/z	 ﾠ but	 ﾠ it	 ﾠ is	 ﾠ also	 ﾠ appropriate	 ﾠ to	 ﾠ be	 ﾠ
classified	 ﾠaccording	 ﾠto	 ﾠtotal	 ﾠfatty	 ﾠacid	 ﾠchain	 ﾠlength	 ﾠinto	 ﾠshort,	 ﾠmedium	 ﾠand	 ﾠPUFA-ﾭ‐
containing	 ﾠPC	 ﾠspecies	 ﾠ(Table	 ﾠ5).	 ﾠNote	 ﾠthat	 ﾠthis	 ﾠgrouping	 ﾠis	 ﾠdifferent	 ﾠthan	 ﾠin	 ﾠthe	 ﾠ
plasma	 ﾠchapters	 ﾠwhere	 ﾠthe	 ﾠspecies	 ﾠwere	 ﾠgrouped	 ﾠby	 ﾠthe	 ﾠdegree	 ﾠof	 ﾠsaturation	 ﾠon	 ﾠ
the	 ﾠfatty	 ﾠacid	 ﾠon	 ﾠthe	 ﾠsn-ﾭ‐2	 ﾠposition.	 ﾠThe	 ﾠpeak	 ﾠfound	 ﾠat	 ﾠmass/charge	 ﾠof	 ﾠ678	 ﾠis	 ﾠthe	 ﾠ
internal	 ﾠstandard	 ﾠused	 ﾠin	 ﾠthe	 ﾠanalysis	 ﾠas	 ﾠexplained	 ﾠin	 ﾠthe	 ﾠMethods	 ﾠchapter.	 ﾠ
Table	 ﾠ5.	 ﾠTable	 ﾠof	 ﾠthe	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠfound	 ﾠin	 ﾠpreterm	 ﾠ
endotracheal	 ﾠaspirate.	 ﾠThe	 ﾠspecies	 ﾠare	 ﾠordered	 ﾠby	 ﾠmass/charge	 ﾠratio	 ﾠand	 ﾠ
colour	 ﾠcoded	 ﾠaccording	 ﾠto	 ﾠthe	 ﾠtotal	 ﾠfatty	 ﾠacid	 ﾠesterified	 ﾠlength	 ﾠ(sn-ﾭ‐1	 ﾠ+	 ﾠsn-ﾭ‐2).	 ﾠ
	 ﾠ
	 ﾠThe	 ﾠPC	 ﾠspecies	 ﾠwill	 ﾠbe	 ﾠcoloured	 ﾠaccording	 ﾠto	 ﾠthis	 ﾠclassification	 ﾠin	 ﾠthe	 ﾠbar	 ﾠcharts	 ﾠ
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5.2.2	 ﾠComposition	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠat	 ﾠrecruitment	 ﾠ
As	 ﾠ a	 ﾠ whole	 ﾠ population	 ﾠ the	 ﾠ average	 ﾠ composition	 ﾠ or	 ﾠ proportions	 ﾠ of	 ﾠ PC	 ﾠ species	 ﾠ
showed	 ﾠ that,	 ﾠ at	 ﾠ recruitment,	 ﾠ which	 ﾠ is	 ﾠ less	 ﾠ than	 ﾠ 48	 ﾠ hours	 ﾠ after	 ﾠ preterm	 ﾠ birth,	 ﾠ
PC16:0/16:0	 ﾠmakes	 ﾠup	 ﾠto	 ﾠ45%	 ﾠof	 ﾠall	 ﾠPC	 ﾠspecies	 ﾠseen	 ﾠ(Figure	 ﾠ53).	 ﾠThe	 ﾠnext	 ﾠmost	 ﾠ
abundant	 ﾠPC	 ﾠspecies,	 ﾠPC16:0/18:1,	 ﾠconstitutes	 ﾠonly	 ﾠ15%.	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ53.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠmeasured	 ﾠin	 ﾠ
baseline	 ﾠ(t=0)	 ﾠendotracheal	 ﾠaspirate	 ﾠsamples.	 ﾠPC16:0/16:0	 ﾠconstitutes	 ﾠthe	 ﾠ
largest	 ﾠpercentage	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠmeasured.	 ﾠError	 ﾠbar	 ﾠdemonstrates	 ﾠone	 ﾠ
standard	 ﾠdeviation.	 ﾠ
	 ﾠ
5.2.3	 ﾠDirect	 ﾠcomparison	 ﾠof	 ﾠthe	 ﾠcompositions	 ﾠof	 ﾠrecruitment	 ﾠET	 ﾠsamples	 ﾠand	 ﾠ
Curosurf®	 ﾠ
All	 ﾠinfants	 ﾠwere	 ﾠtreated	 ﾠat	 ﾠdelivery	 ﾠwith	 ﾠthe	 ﾠsame	 ﾠexogenous	 ﾠsurfactant	 ﾠtherefore	 ﾠa	 ﾠ
sample	 ﾠ of	 ﾠ this	 ﾠ Curosurf®	 ﾠ preparation	 ﾠ was	 ﾠ analysed	 ﾠ by	 ﾠ the	 ﾠ same	 ﾠ ESI	 ﾠ MS/MS	 ﾠ
technique,	 ﾠwith	 ﾠthe	 ﾠresulting	 ﾠspectra	 ﾠfor	 ﾠdirect	 ﾠcomparison	 ﾠ(Figure	 ﾠ54).	 ﾠ  118	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Figure	 ﾠ54.	 ﾠComparison	 ﾠof	 ﾠP+184	 ﾠscans	 ﾠfrom	 ﾠETA	 ﾠand	 ﾠCurosurf®	 ﾠshowing	 ﾠ
similar	 ﾠspecies	 ﾠand	 ﾠproportions	 ﾠof	 ﾠpeaks.	 ﾠ
Again	 ﾠ m/z=734	 ﾠ (PC16:0/16:0	 ﾠ or	 ﾠ dipalmitoylphosphatidylcholine)	 ﾠ is	 ﾠ the	 ﾠ most	 ﾠ
abundant	 ﾠ PC	 ﾠ species.	 ﾠ Other	 ﾠ species	 ﾠ measured	 ﾠ in	 ﾠ the	 ﾠ Curosurf®	 ﾠ sample	 ﾠ
demonstrate	 ﾠ comparable	 ﾠ proportions	 ﾠ when	 ﾠ measured	 ﾠ against	 ﾠ the	 ﾠ ETA	 ﾠ at	 ﾠ
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Figure	 ﾠ55.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠmeasured	 ﾠin	 ﾠ
baseline	 ﾠ(t=0)	 ﾠendotracheal	 ﾠaspirate	 ﾠsamples	 ﾠ(left)	 ﾠcompared	 ﾠwith	 ﾠmeasured	 ﾠ
proportions	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠCurosurf®	 ﾠ(right).	 ﾠThe	 ﾠproportions	 ﾠare	 ﾠvery	 ﾠ
similar	 ﾠwith	 ﾠPC16:0/16:0	 ﾠconstituting	 ﾠthe	 ﾠlargest	 ﾠpercentage	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠ
measured	 ﾠin	 ﾠboth	 ﾠsample	 ﾠtypes.	 ﾠError	 ﾠbars	 ﾠdemonstrate	 ﾠone	 ﾠstandard	 ﾠ
deviation	 ﾠfor	 ﾠthe	 ﾠETA	 ﾠsamples.	 ﾠ
For	 ﾠ the	 ﾠ first	 ﾠ time	 ﾠ the	 ﾠ profile	 ﾠ of	 ﾠ phosphatidylcholine	 ﾠ species	 ﾠ in	 ﾠ endotracheal	 ﾠ
aspirates	 ﾠ have	 ﾠ been	 ﾠ described	 ﾠ following	 ﾠ the	 ﾠ therapeutic	 ﾠ administration	 ﾠ of	 ﾠ
exogenous	 ﾠsurfactant	 ﾠtherapy.	 ﾠPrevious	 ﾠstudies	 ﾠhave	 ﾠdescribed	 ﾠonly	 ﾠhow	 ﾠthe	 ﾠfully	 ﾠ
disaturated	 ﾠPC	 ﾠ(16:0/14:0	 ﾠand	 ﾠ16:0/16:0)	 ﾠare	 ﾠpresent	 ﾠin	 ﾠthe	 ﾠET	 ﾠsecretions	 ﾠ(Cogo	 ﾠ
et	 ﾠal.,	 ﾠ1999,	 ﾠCogo	 ﾠet	 ﾠal.,	 ﾠ2005b,	 ﾠCogo	 ﾠet	 ﾠal.,	 ﾠ2007,	 ﾠCogo	 ﾠet	 ﾠal.,	 ﾠ2004)	 ﾠbut	 ﾠthis	 ﾠanalysis	 ﾠ
demonstrates	 ﾠthat	 ﾠa	 ﾠsignificant	 ﾠamount	 ﾠof	 ﾠother	 ﾠPC	 ﾠspecies	 ﾠare	 ﾠpresent	 ﾠboth	 ﾠin	 ﾠ
samples	 ﾠand	 ﾠthe	 ﾠCurosurf®.	 ﾠFrom	 ﾠa	 ﾠclinical	 ﾠperspective	 ﾠit	 ﾠshows	 ﾠthat	 ﾠthe	 ﾠCurosurf®	 ﾠ
effectively	 ﾠprovides	 ﾠthe	 ﾠmost	 ﾠsurface	 ﾠactive	 ﾠPC16:0/16:0	 ﾠin	 ﾠlarge	 ﾠquantities	 ﾠand	 ﾠ
that	 ﾠis	 ﾠstill	 ﾠmeasurable	 ﾠup	 ﾠto	 ﾠ48	 ﾠhours	 ﾠafter	 ﾠadministration.	 ﾠ
Having	 ﾠestablished	 ﾠthat	 ﾠthe	 ﾠPC	 ﾠcomposition	 ﾠnear	 ﾠpreterm	 ﾠbirth	 ﾠreflects	 ﾠexogenous	 ﾠ
surfactant	 ﾠit	 ﾠis	 ﾠnecessary	 ﾠto	 ﾠconsider	 ﾠwhether	 ﾠthis	 ﾠcomposition	 ﾠchanges	 ﾠwith	 ﾠtime.	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5.2.4	 ﾠComposition	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠover	 ﾠtime	 ﾠ
Serial	 ﾠETA	 ﾠsamples	 ﾠwere	 ﾠcollected	 ﾠon	 ﾠall	 ﾠeligible	 ﾠinfants	 ﾠat	 ﾠrecruitment	 ﾠand	 ﾠthen	 ﾠat	 ﾠ
6,	 ﾠ12,	 ﾠ24,	 ﾠ48,	 ﾠ72,	 ﾠ96	 ﾠand	 ﾠ120	 ﾠhours	 ﾠfollowing	 ﾠadministration	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠ
chloride	 ﾠ as	 ﾠ long	 ﾠ as	 ﾠ the	 ﾠ baby	 ﾠ remained	 ﾠ intubated.	 ﾠ A	 ﾠ second	 ﾠ administration	 ﾠ of	 ﾠ
[methyl-ﾭ‐D9]choline	 ﾠchloride	 ﾠthen	 ﾠfollowed	 ﾠat	 ﾠ120	 ﾠhours	 ﾠif	 ﾠthe	 ﾠinfant	 ﾠwas	 ﾠintubated	 ﾠ
and	 ﾠthe	 ﾠsampling	 ﾠregimen	 ﾠrepeated.	 ﾠNo	 ﾠfurther	 ﾠlabelled	 ﾠcholine	 ﾠwas	 ﾠgiven	 ﾠafter	 ﾠ
this	 ﾠperiod	 ﾠand	 ﾠfurther	 ﾠsamples	 ﾠbeyond	 ﾠ240	 ﾠhours	 ﾠwere	 ﾠcollected	 ﾠonly	 ﾠif	 ﾠbaby	 ﾠwas	 ﾠ
intubated	 ﾠat	 ﾠany	 ﾠtime	 ﾠto	 ﾠdischarge.	 ﾠ
The	 ﾠcomposition	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠETA	 ﾠ(Figure	 ﾠ56)	 ﾠshows	 ﾠminimal	 ﾠvariation	 ﾠin	 ﾠthe	 ﾠ
relative	 ﾠproportions	 ﾠof	 ﾠthe	 ﾠcommonest	 ﾠspecies	 ﾠwith	 ﾠtime.	 ﾠ
	 ﾠ
Figure	 ﾠ56.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠETA	 ﾠ
measured	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠto	 ﾠ240	 ﾠhours.	 ﾠThe	 ﾠproportions	 ﾠof	 ﾠmajor	 ﾠPC	 ﾠ
species	 ﾠremain	 ﾠsteady	 ﾠthroughout	 ﾠthe	 ﾠstudy	 ﾠperiod.	 ﾠError	 ﾠbars	 ﾠdemonstrate	 ﾠ
one	 ﾠstandard	 ﾠdeviation	 ﾠfor	 ﾠthe	 ﾠtwo	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠshown.	 ﾠ
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As	 ﾠat	 ﾠrecruitment	 ﾠthe	 ﾠdominant	 ﾠspecies	 ﾠis	 ﾠand	 ﾠremains,	 ﾠthe	 ﾠsurface-ﾭ‐active	 ﾠfully-ﾭ‐
saturated,	 ﾠ PC16:0/16:0	 ﾠ (DPPC).	 ﾠ The	 ﾠ two	 ﾠ most	 ﾠ abundant	 ﾠ PC	 ﾠ species	 ﾠ remain	 ﾠ in	 ﾠ
approximately	 ﾠthe	 ﾠsame	 ﾠproportions	 ﾠthroughout	 ﾠthe	 ﾠstudy	 ﾠperiod	 ﾠup	 ﾠto	 ﾠ240	 ﾠhours.	 ﾠ
The	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠthe	 ﾠless	 ﾠabundant	 ﾠspecies	 ﾠare	 ﾠeasier	 ﾠto	 ﾠsee	 ﾠwhen	 ﾠthe	 ﾠy-ﾭ‐
axis	 ﾠis	 ﾠlog	 ﾠtransformed	 ﾠ(Figure	 ﾠ57).	 ﾠIt	 ﾠis	 ﾠclear	 ﾠthat	 ﾠthe	 ﾠaverage	 ﾠproportions	 ﾠof	 ﾠPC	 ﾠ
species	 ﾠare	 ﾠgenerally	 ﾠconsistent	 ﾠbut	 ﾠfrom	 ﾠ120	 ﾠhours	 ﾠthe	 ﾠproportion	 ﾠof	 ﾠPC18:1/18:2	 ﾠ
rises	 ﾠas	 ﾠthe	 ﾠproportion	 ﾠof	 ﾠPC16:0/14:0	 ﾠfalls.	 ﾠ
	 ﾠ
Figure	 ﾠ57.	 ﾠLog	 ﾠtransformation	 ﾠgraph	 ﾠshowing	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠ
phosphatidylcholine	 ﾠspecies	 ﾠmeasured	 ﾠin	 ﾠETA	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠto	 ﾠ240	 ﾠ
hours.	 ﾠThe	 ﾠproportions	 ﾠof	 ﾠmajor	 ﾠPC	 ﾠspecies	 ﾠremain	 ﾠsteady	 ﾠthroughout	 ﾠthe	 ﾠ
study	 ﾠperiod	 ﾠbut	 ﾠPC18:1/18:2	 ﾠrises	 ﾠproportionally	 ﾠfrom	 ﾠ120	 ﾠhours	 ﾠwhile	 ﾠ
PC16:0/14:0	 ﾠfalls	 ﾠin	 ﾠthe	 ﾠsame	 ﾠperiod.	 ﾠError	 ﾠbars	 ﾠdemonstrate	 ﾠone	 ﾠstandard	 ﾠ
deviation	 ﾠfor	 ﾠthe	 ﾠtwo	 ﾠmost	 ﾠabundant	 ﾠspecies	 ﾠshown.	 ﾠ
It	 ﾠ is	 ﾠ now	 ﾠ necessary	 ﾠ to	 ﾠ consider	 ﾠ whether	 ﾠ the	 ﾠ actual	 ﾠ measurable	 ﾠ amount	 ﾠ of	 ﾠ
phosphatidylcholine	 ﾠ changes	 ﾠ with	 ﾠ time	 ﾠ intubated	 ﾠ because	 ﾠ from	 ﾠ a	 ﾠ clinical	 ﾠ  122	 ﾠ
viewpoint	 ﾠ the	 ﾠ babies	 ﾠ require	 ﾠ sufficient	 ﾠ DPPC	 ﾠ to	 ﾠ maintain	 ﾠ their	 ﾠ surface-ﾭ‐active	 ﾠ
surfactant	 ﾠlayer	 ﾠand	 ﾠprevent	 ﾠatelectasis	 ﾠor	 ﾠalveolar	 ﾠcollapse.	 ﾠ
5.2.5	 ﾠConcentration	 ﾠof	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠin	 ﾠendotracheal	 ﾠaspirates	 ﾠ
i)	 ﾠOverall	 ﾠconcentration	 ﾠ
The	 ﾠ measured	 ﾠ concentration	 ﾠ of	 ﾠ recovered	 ﾠ PC	 ﾠ phospholipid	 ﾠ in	 ﾠ preterm	 ﾠ
endotracheal	 ﾠaspirates	 ﾠ(Figure	 ﾠ58)	 ﾠdemonstrated	 ﾠsample-ﾭ‐to-ﾭ‐sample	 ﾠvariation.	 ﾠ
	 ﾠ
Figure	 ﾠ58.	 ﾠConcentration	 ﾠof	 ﾠphosphatidylcholine	 ﾠmeasured	 ﾠin	 ﾠendotracheal	 ﾠ
aspirates	 ﾠover	 ﾠthe	 ﾠ120	 ﾠhours	 ﾠof	 ﾠstudy.	 ﾠThere	 ﾠis	 ﾠno	 ﾠsignificant	 ﾠdifference	 ﾠ
between	 ﾠmeasurements.	 ﾠ
There	 ﾠ was	 ﾠ no	 ﾠ statistically	 ﾠ significant	 ﾠ difference	 ﾠ however	 ﾠ in	 ﾠ the	 ﾠ concentration	 ﾠ
measured	 ﾠbetween	 ﾠbaseline	 ﾠsample	 ﾠand	 ﾠsubsequent	 ﾠtime	 ﾠpoints.	 ﾠThese	 ﾠare	 ﾠthe	 ﾠ
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data	 ﾠfrom	 ﾠall	 ﾠsamples	 ﾠcollected.	 ﾠExamination	 ﾠup	 ﾠto	 ﾠ240	 ﾠhours	 ﾠ(Figure	 ﾠ59),	 ﾠwhich	 ﾠ
contains	 ﾠsamples	 ﾠfrom	 ﾠall	 ﾠrecruited	 ﾠinfants,	 ﾠshows	 ﾠthe	 ﾠsame	 ﾠinformation.	 ﾠ
	 ﾠ
Figure	 ﾠ59.	 ﾠConcentration	 ﾠof	 ﾠphosphatidylcholine	 ﾠmeasured	 ﾠin	 ﾠendotracheal	 ﾠ
aspirates	 ﾠover	 ﾠthe	 ﾠ240	 ﾠhours	 ﾠof	 ﾠstudy.	 ﾠThere	 ﾠis	 ﾠno	 ﾠsignificant	 ﾠdifference	 ﾠ
between	 ﾠmeasurements.	 ﾠ
The	 ﾠnumber	 ﾠof	 ﾠsamples	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint	 ﾠvaries	 ﾠ(Table	 ﾠ6),	 ﾠdependent	 ﾠupon	 ﾠthe	 ﾠ
clinical	 ﾠcondition	 ﾠof	 ﾠthe	 ﾠindividual	 ﾠinfants	 ﾠinvolved	 ﾠso	 ﾠthat	 ﾠfewer	 ﾠsamples	 ﾠaccount	 ﾠ
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Table	 ﾠ6.	 ﾠTable	 ﾠof	 ﾠthe	 ﾠtotal	 ﾠnumber	 ﾠof	 ﾠpatient	 ﾠendotracheal	 ﾠsamples	 ﾠavailable	 ﾠ
at	 ﾠeach	 ﾠtime	 ﾠpoint.	 ﾠ
	 ﾠ
In	 ﾠthe	 ﾠprolonged	 ﾠintubation	 ﾠgroup,	 ﾠthat	 ﾠis	 ﾠthe	 ﾠchildren	 ﾠin	 ﾠreceipt	 ﾠof	 ﾠthe	 ﾠsecond	 ﾠdose	 ﾠ
of	 ﾠ [methyl-ﾭ‐D9]choline	 ﾠ chloride,	 ﾠ there	 ﾠ is	 ﾠ no	 ﾠ noticeable	 ﾠ drop	 ﾠ in	 ﾠ recovery	 ﾠ of	 ﾠ PC	 ﾠ
phospholipid	 ﾠ(Figure	 ﾠ60).	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ60.	 ﾠConcentration	 ﾠof	 ﾠphosphatidylcholine	 ﾠmeasured	 ﾠin	 ﾠendotracheal	 ﾠ
aspirates	 ﾠover	 ﾠthe	 ﾠ240	 ﾠhours	 ﾠof	 ﾠstudy	 ﾠfor	 ﾠthe	 ﾠ10	 ﾠchildren	 ﾠwho	 ﾠremained	 ﾠ
intubated	 ﾠand	 ﾠventilated	 ﾠat	 ﾠ120	 ﾠhours	 ﾠand	 ﾠreceived	 ﾠa	 ﾠsecond	 ﾠdose	 ﾠof	 ﾠ[methyl-ﾭ‐
D9]choline.	 ﾠThere	 ﾠis	 ﾠno	 ﾠsignificant	 ﾠdifference	 ﾠbetween	 ﾠmeasurements	 ﾠin	 ﾠthis	 ﾠ
subgroup.	 ﾠ
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 ﾠ
Some	 ﾠsamples	 ﾠhave	 ﾠbeen	 ﾠmissed,	 ﾠsome	 ﾠsamples	 ﾠare	 ﾠof	 ﾠinsufficient	 ﾠquality	 ﾠto	 ﾠhave	 ﾠ
measurable	 ﾠPC	 ﾠand	 ﾠthe	 ﾠmajority	 ﾠof	 ﾠinfants	 ﾠwere	 ﾠsuccessfully	 ﾠextubated	 ﾠand	 ﾠwere	 ﾠ
therefore	 ﾠunable	 ﾠto	 ﾠprovide	 ﾠa	 ﾠsample	 ﾠat	 ﾠeach	 ﾠtime	 ﾠpoint.	 ﾠThis	 ﾠdata	 ﾠhowever	 ﾠshows	 ﾠ
that	 ﾠ measurement	 ﾠ of	 ﾠ PC	 ﾠ concentration	 ﾠ is	 ﾠ feasible	 ﾠ in	 ﾠ ET	 ﾠ aspirates	 ﾠ and	 ﾠ that	 ﾠ the	 ﾠ
concentration	 ﾠmeasured	 ﾠearly	 ﾠdoes	 ﾠnot	 ﾠpredict	 ﾠwhich	 ﾠbabies	 ﾠwill	 ﾠbe	 ﾠintubated	 ﾠat	 ﾠ5	 ﾠ
or	 ﾠ10	 ﾠdays.	 ﾠ
ii)	 ﾠConcentration	 ﾠof	 ﾠindividual	 ﾠspecies	 ﾠ
The	 ﾠ average	 ﾠ concentration	 ﾠ of	 ﾠ individual	 ﾠ species	 ﾠ correlates	 ﾠ to	 ﾠ the	 ﾠ approximate	 ﾠ
proportions	 ﾠseen	 ﾠbefore	 ﾠ(Figure	 ﾠ61).	 ﾠ
	 ﾠ
Figure	 ﾠ61.	 ﾠAverage	 ﾠconcentration	 ﾠof	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠfrom	 ﾠpreterm	 ﾠ
endotracheal	 ﾠaspirates	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠ
In	 ﾠthis	 ﾠinstance	 ﾠthe	 ﾠconcentration	 ﾠis	 ﾠshown	 ﾠto	 ﾠ120	 ﾠhours	 ﾠfor	 ﾠclarity.	 ﾠAs	 ﾠexpected	 ﾠ
there	 ﾠis	 ﾠsignificantly	 ﾠmore	 ﾠPC16:0/16:0	 ﾠfound	 ﾠat	 ﾠevery	 ﾠtime	 ﾠpoint.	 ﾠ  126	 ﾠ
Plotting	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠPC	 ﾠrecovered	 ﾠfrom	 ﾠETA	 ﾠfor	 ﾠeach	 ﾠpatient	 ﾠreveals	 ﾠlarge	 ﾠ
sample-ﾭ‐to-ﾭ‐sample	 ﾠvariation.	 ﾠIt	 ﾠis	 ﾠworth	 ﾠlooking	 ﾠat	 ﾠthe	 ﾠeffect	 ﾠof	 ﾠtime	 ﾠfrom	 ﾠdelivery,	 ﾠ
or	 ﾠtime	 ﾠfrom	 ﾠCurosurf®,	 ﾠon	 ﾠconcentration	 ﾠin	 ﾠeach	 ﾠbaby.	 ﾠ
iii)	 ﾠConcentration	 ﾠof	 ﾠPC	 ﾠrecovered,	 ﾠgestation	 ﾠof	 ﾠinfant	 ﾠand	 ﾠtime	 ﾠfrom	 ﾠbirth	 ﾠ
Plotting	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠPC	 ﾠin	 ﾠthe	 ﾠETA	 ﾠsamples	 ﾠcollected	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ24	 ﾠ
hours	 ﾠof	 ﾠeach	 ﾠinfant’s	 ﾠparticipation	 ﾠin	 ﾠthe	 ﾠstudy	 ﾠcorrected	 ﾠto	 ﾠtime	 ﾠfrom	 ﾠbirth	 ﾠrather	 ﾠ
than	 ﾠ time	 ﾠ of	 ﾠ recruitment	 ﾠ (Figure	 ﾠ 62)	 ﾠ demonstrates	 ﾠ that	 ﾠ there	 ﾠ is	 ﾠ no	 ﾠ trend	 ﾠ in	 ﾠ
concentration	 ﾠassociated	 ﾠwith	 ﾠgestation	 ﾠor	 ﾠtime	 ﾠfrom	 ﾠbirth.	 ﾠThe	 ﾠuse	 ﾠof	 ﾠdefining	 ﾠPC	 ﾠ
concentration	 ﾠ in	 ﾠ ETA	 ﾠ alone	 ﾠ is	 ﾠ not	 ﾠ helpful	 ﾠ for	 ﾠ clinically	 ﾠ stratifying	 ﾠ the	 ﾠ newborn	 ﾠ
preterm	 ﾠinfant	 ﾠwho	 ﾠhas	 ﾠreceived	 ﾠexogenous	 ﾠsurfactant.	 ﾠ	 ﾠ
	 ﾠ
Figure	 ﾠ62.	 ﾠAverage	 ﾠconcentration	 ﾠof	 ﾠPC	 ﾠfrom	 ﾠpreterm	 ﾠendotracheal	 ﾠaspirates	 ﾠ
up	 ﾠto	 ﾠ24	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠand	 ﾠcorrected	 ﾠfor	 ﾠtime	 ﾠfrom	 ﾠbirth.	 ﾠNeither	 ﾠ
the	 ﾠtime	 ﾠfrom	 ﾠbirth	 ﾠof	 ﾠsample	 ﾠcollection	 ﾠnor	 ﾠgestation	 ﾠaffect	 ﾠconcentration	 ﾠof	 ﾠ
PC	 ﾠcollected	 ﾠfrom	 ﾠETA.	 ﾠ  127	 ﾠ
5.3	 ﾠSummary	 ﾠof	 ﾠm/z	 ﾠ+184	 ﾠresults	 ﾠ
In	 ﾠsummary,	 ﾠit	 ﾠhas	 ﾠbeen	 ﾠpossible	 ﾠto	 ﾠestablish	 ﾠ1)	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠ
ETA	 ﾠat	 ﾠthe	 ﾠearliest	 ﾠtime	 ﾠpoints,	 ﾠ2)	 ﾠthat	 ﾠthese	 ﾠproportions	 ﾠclosely	 ﾠreflect	 ﾠCurosurf®	 ﾠ
and	 ﾠ3)	 ﾠthat	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠthe	 ﾠPC	 ﾠspecies	 ﾠdo	 ﾠnot	 ﾠvary	 ﾠgreatly	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ5	 ﾠ
days	 ﾠof	 ﾠstudy.	 ﾠ
To	 ﾠfully	 ﾠinterpret	 ﾠthese	 ﾠfindings	 ﾠmore	 ﾠinformation	 ﾠis	 ﾠrequired	 ﾠon	 ﾠPC	 ﾠsynthesis	 ﾠand	 ﾠ
its	 ﾠincorporation	 ﾠinto	 ﾠsurfactant.	 ﾠIt	 ﾠis	 ﾠappropriate	 ﾠto	 ﾠlook	 ﾠat	 ﾠthe	 ﾠincorporation	 ﾠof	 ﾠ
newly	 ﾠsynthesised	 ﾠD9-ﾭ‐PC	 ﾠspecies	 ﾠinto	 ﾠthe	 ﾠphospholipids	 ﾠmeasured	 ﾠin	 ﾠETA,	 ﾠwhich	 ﾠ
will	 ﾠ allow	 ﾠ monitoring	 ﾠ of	 ﾠ new	 ﾠ synthesis.	 ﾠ Clinically	 ﾠ the	 ﾠ synthesis	 ﾠ of	 ﾠ new	 ﾠ surface	 ﾠ
active	 ﾠPC	 ﾠis	 ﾠimportant	 ﾠbecause	 ﾠit	 ﾠcan	 ﾠinform	 ﾠa	 ﾠpoint	 ﾠin	 ﾠtime	 ﾠwhen	 ﾠthe	 ﾠpreterm	 ﾠ
infant	 ﾠbegins	 ﾠto	 ﾠmanufacture	 ﾠnew	 ﾠmaterial	 ﾠand	 ﾠthe	 ﾠrate	 ﾠat	 ﾠwhich	 ﾠit	 ﾠis	 ﾠproduced.	 ﾠ
This	 ﾠinformation	 ﾠin	 ﾠturn	 ﾠcan	 ﾠthen	 ﾠinform	 ﾠpotential	 ﾠtherapeutic	 ﾠinterventions	 ﾠsuch	 ﾠ
as	 ﾠsupplementary	 ﾠexogenous	 ﾠsurfactant	 ﾠtherapy.	 ﾠ
5.4	 ﾠ Precursors	 ﾠ of	 ﾠ mass/charge	 ﾠ +193	 ﾠ scanning	 ﾠ of	 ﾠ endotracheal	 ﾠ
aspirates	 ﾠ
Examining	 ﾠendotracheal	 ﾠaspirates	 ﾠfrom	 ﾠthe	 ﾠwhole	 ﾠpopulation	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠ
hours	 ﾠ of	 ﾠ the	 ﾠ study,	 ﾠ using	 ﾠ precursor	 ﾠ of	 ﾠ m/z	 ﾠ 193	 ﾠ scanning	 ﾠ on	 ﾠ ESI	 ﾠ MS/MS,	 ﾠ
determines	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠD9-ﾭ‐containing	 ﾠPC	 ﾠmolecules.	 ﾠ
	 ﾠ
5.4.1	 ﾠMass	 ﾠspectrometry	 ﾠspectra	 ﾠ(P193)	 ﾠ
The	 ﾠ P193	 ﾠ spectrum	 ﾠ taken	 ﾠ from	 ﾠ an	 ﾠ ETA	 ﾠ sample	 ﾠ 72	 ﾠ hours	 ﾠ after	 ﾠ recruitment	 ﾠ
demonstrates	 ﾠthe	 ﾠappearance	 ﾠof	 ﾠnewly	 ﾠsynthesised	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠa	 ﾠpreterm	 ﾠinfant	 ﾠ
(Figure	 ﾠ63).	 ﾠBoth	 ﾠspectra	 ﾠin	 ﾠthe	 ﾠfigure	 ﾠare	 ﾠplotted	 ﾠwith	 ﾠthe	 ﾠmost	 ﾠabundant	 ﾠsignal	 ﾠat	 ﾠ  128	 ﾠ
100%	 ﾠon	 ﾠthe	 ﾠy-ﾭ‐axis.	 ﾠNote	 ﾠthat	 ﾠin	 ﾠfact	 ﾠthe	 ﾠP193	 ﾠspectrum	 ﾠrepresents	 ﾠ<1%	 ﾠof	 ﾠthe	 ﾠ
total	 ﾠsignal	 ﾠabundance	 ﾠseen	 ﾠin	 ﾠP184.	 ﾠ
	 ﾠ
Figure	 ﾠ63.	 ﾠComparison	 ﾠof	 ﾠP+184	 ﾠand	 ﾠP+193	 ﾠscans	 ﾠfrom	 ﾠan	 ﾠETA	 ﾠsample	 ﾠ(at	 ﾠ
time	 ﾠ72	 ﾠhours)	 ﾠshowing	 ﾠincorporation	 ﾠof	 ﾠdeuterated	 ﾠcholine	 ﾠas	 ﾠthe	 ﾠ
displacement	 ﾠof	 ﾠnine	 ﾠmass	 ﾠunits	 ﾠon	 ﾠthe	 ﾠP+193	 ﾠscan.	 ﾠ
5.4.2	 ﾠConcentration	 ﾠof	 ﾠD9-ﾭ‐labelled	 ﾠphosphatidylcholine	 ﾠspecies	 ﾠ
i)	 ﾠOverall	 ﾠconcentration	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠin	 ﾠETA	 ﾠ
The	 ﾠ concentration	 ﾠ of	 ﾠ D9-ﾭ‐labelled	 ﾠ PC	 ﾠ rises	 ﾠ slowly	 ﾠ over	 ﾠ the	 ﾠ first	 ﾠ 120	 ﾠ hours	 ﾠ to	 ﾠ a	 ﾠ
median	 ﾠvalue	 ﾠof	 ﾠ4nmol/300µl	 ﾠ(Figure	 ﾠ64).	 ﾠD9-ﾭ‐PC	 ﾠspecies	 ﾠare	 ﾠnot	 ﾠstatistically	 ﾠraised	 ﾠ
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 ﾠ
Figure	 ﾠ64.	 ﾠConcentration	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠpreterm	 ﾠendotracheal	 ﾠ
aspirates	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠThe	 ﾠrise	 ﾠin	 ﾠconcentration	 ﾠbecomes	 ﾠ
statistically	 ﾠsignificant	 ﾠabove	 ﾠbackground	 ﾠlevels	 ﾠat	 ﾠ48	 ﾠhours.	 ﾠ
After	 ﾠ 120	 ﾠ hours	 ﾠ the	 ﾠ concentration	 ﾠ appears	 ﾠ to	 ﾠ plateau	 ﾠ when	 ﾠ the	 ﾠ whole	 ﾠ study	 ﾠ






























































































** p=0.0034  130	 ﾠ
	 ﾠ
Figure	 ﾠ65.	 ﾠConcentration	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠpreterm	 ﾠendotracheal	 ﾠ
aspirates	 ﾠto	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠA	 ﾠstatistically	 ﾠsignificant	 ﾠrise	 ﾠfrom	 ﾠ
baseline	 ﾠoccurs	 ﾠto	 ﾠ120	 ﾠhours	 ﾠbut	 ﾠvariation	 ﾠin	 ﾠconcentration	 ﾠafter	 ﾠ120	 ﾠhours	 ﾠ
is	 ﾠnot	 ﾠstatistically	 ﾠsignificant.	 ﾠ
Variation	 ﾠ is	 ﾠ seen	 ﾠ after	 ﾠ 120	 ﾠ hours	 ﾠ but	 ﾠ given	 ﾠ the	 ﾠ small	 ﾠ number	 ﾠ of	 ﾠ samples	 ﾠ the	 ﾠ
differences	 ﾠin	 ﾠconcentration	 ﾠdo	 ﾠnot	 ﾠreach	 ﾠstatistical	 ﾠsignificance.	 ﾠThe	 ﾠpopulation	 ﾠof	 ﾠ
babies	 ﾠafter	 ﾠ120	 ﾠhours	 ﾠis	 ﾠa	 ﾠsubset	 ﾠof	 ﾠten	 ﾠinfants	 ﾠwho	 ﾠwere	 ﾠintubated	 ﾠat	 ﾠ5	 ﾠdays	 ﾠand	 ﾠ
received	 ﾠa	 ﾠsecond	 ﾠdose	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠso	 ﾠby	 ﾠplotting	 ﾠthem	 ﾠas	 ﾠgroup	 ﾠit	 ﾠis	 ﾠ
possible	 ﾠto	 ﾠconfirm	 ﾠthat	 ﾠthe	 ﾠvalues	 ﾠprior	 ﾠto	 ﾠ120	 ﾠhours	 ﾠare	 ﾠnot	 ﾠstatistically	 ﾠdifferent	 ﾠ
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 ﾠ
Figure	 ﾠ66.	 ﾠConcentration	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠpreterm	 ﾠendotracheal	 ﾠ
aspirates	 ﾠto	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠin	 ﾠthe	 ﾠ10	 ﾠchildren	 ﾠwho	 ﾠreceived	 ﾠa	 ﾠ
second	 ﾠdose	 ﾠof	 ﾠcholine	 ﾠat	 ﾠ120	 ﾠhours.	 ﾠA	 ﾠstatistically	 ﾠsignificant	 ﾠrise	 ﾠfrom	 ﾠ
baseline	 ﾠoccurs	 ﾠto	 ﾠ120	 ﾠhours	 ﾠbut	 ﾠvariation	 ﾠin	 ﾠconcentration	 ﾠafter	 ﾠ120	 ﾠhours	 ﾠ
is	 ﾠnot	 ﾠstatistically	 ﾠsignificant.	 ﾠ
ii)	 ﾠConcentration	 ﾠof	 ﾠindividual	 ﾠD9-ﾭ‐PC	 ﾠspecies	 ﾠ
The	 ﾠaverage	 ﾠconcentration	 ﾠof	 ﾠall	 ﾠspecies	 ﾠis	 ﾠvery	 ﾠlow	 ﾠinitially	 ﾠ(Figure	 ﾠ67),	 ﾠbut	 ﾠfrom	 ﾠ
24	 ﾠ hours	 ﾠ there	 ﾠ is	 ﾠ a	 ﾠ significant	 ﾠ output	 ﾠ of	 ﾠ the	 ﾠ surface-ﾭ‐active	 ﾠ saturated	 ﾠ
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Figure	 ﾠ67.	 ﾠAverage	 ﾠconcentration	 ﾠof	 ﾠindividual	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠ
preterm	 ﾠendotracheal	 ﾠaspirates	 ﾠto	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠSignificant	 ﾠ
differences	 ﾠbetween	 ﾠnewly	 ﾠsynthesised	 ﾠspecies	 ﾠdemonstrated	 ﾠfrom	 ﾠ24	 ﾠto	 ﾠ48	 ﾠ
hours	 ﾠwith	 ﾠconcentration	 ﾠof	 ﾠD9PC16:0/16:0	 ﾠrising	 ﾠmost	 ﾠrapidly.	 ﾠThe	 ﾠfall	 ﾠin	 ﾠ
concentration	 ﾠafter	 ﾠ120	 ﾠhours	 ﾠis	 ﾠnot	 ﾠstatistically	 ﾠsignificant	 ﾠand	 ﾠreflects	 ﾠ
smaller	 ﾠpatient	 ﾠnumbers.	 ﾠImportantly	 ﾠthe	 ﾠrelative	 ﾠabundance	 ﾠof	 ﾠspecies	 ﾠdoes	 ﾠ
not	 ﾠchange	 ﾠafter	 ﾠ120	 ﾠhours.	 ﾠ
iii)	 ﾠConcentration	 ﾠof	 ﾠindividual	 ﾠspecies	 ﾠover	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠ
By	 ﾠlog	 ﾠtransforming	 ﾠthe	 ﾠy-ﾭ‐axis	 ﾠit	 ﾠis	 ﾠpossible	 ﾠto	 ﾠdifferentiate	 ﾠthe	 ﾠconcentrations	 ﾠof	 ﾠ
individual	 ﾠ species	 ﾠ even	 ﾠ back	 ﾠ to	 ﾠ 6	 ﾠ hours	 ﾠ after	 ﾠ starting	 ﾠ the	 ﾠ [methyl-ﾭ‐D9]choline	 ﾠ
chloride	 ﾠinfusion	 ﾠ(Figure	 ﾠ68).	 ﾠThere	 ﾠis	 ﾠa	 ﾠtenfold	 ﾠdifference	 ﾠin	 ﾠconcentration	 ﾠof	 ﾠthe	 ﾠ
species	 ﾠand	 ﾠthis	 ﾠis	 ﾠmaintained	 ﾠthroughout	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours.	 ﾠNewly	 ﾠsynthesised	 ﾠ
D9PC16:0/14:0,	 ﾠknown	 ﾠto	 ﾠbe	 ﾠa	 ﾠsurface	 ﾠdisaturated	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠother	 ﾠmammals,	 ﾠ
shows	 ﾠa	 ﾠconcentration	 ﾠin	 ﾠthe	 ﾠET	 ﾠsecretions	 ﾠequivalent	 ﾠto	 ﾠthe	 ﾠnon-ﾭ‐surface	 ﾠactive	 ﾠ
phospholipids	 ﾠ D9PC16:0/18:2	 ﾠ and	 ﾠ D9PC16:0/20:4.	 ﾠ The	 ﾠ mono-ﾭ‐unsaturated	 ﾠ
D9PC16:0/18:1	 ﾠ has	 ﾠ a	 ﾠ concentration	 ﾠ equivalent	 ﾠ to	 ﾠ the	 ﾠ dominant	 ﾠ surface-ﾭ‐active	 ﾠ
species	 ﾠuntil	 ﾠ24	 ﾠhours	 ﾠwhen	 ﾠdifferentiation	 ﾠof	 ﾠthe	 ﾠspecies	 ﾠoccurs.	 ﾠIt	 ﾠis	 ﾠnot	 ﾠclear	 ﾠ  133	 ﾠ
whether	 ﾠ the	 ﾠ non-ﾭ‐disaturated	 ﾠ species	 ﾠ mentioned	 ﾠ originate	 ﾠ in	 ﾠ the	 ﾠ lung	 ﾠ or	 ﾠ were	 ﾠ
synthesised	 ﾠelsewhere	 ﾠand	 ﾠleaked	 ﾠinto	 ﾠthe	 ﾠlung	 ﾠfrom	 ﾠplasma.	 ﾠ
	 ﾠ
Figure	 ﾠ68.	 ﾠAverage	 ﾠconcentration	 ﾠof	 ﾠindividual	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠ
preterm	 ﾠendotracheal	 ﾠaspirates	 ﾠto	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠLog	 ﾠ
transformation	 ﾠof	 ﾠy-ﾭ‐axis	 ﾠto	 ﾠallow	 ﾠcomparison	 ﾠof	 ﾠspecies	 ﾠback	 ﾠto	 ﾠ6	 ﾠhours.	 ﾠ
5.5	 ﾠ Fractional	 ﾠ incorporation	 ﾠ of	 ﾠ D9-ﾭ‐phosphatidylcholine	 ﾠ species	 ﾠ
into	 ﾠETA	 ﾠ
The	 ﾠmean	 ﾠfractional	 ﾠincorporation	 ﾠfor	 ﾠall	 ﾠbabies	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ10	 ﾠdays	 ﾠof	 ﾠthe	 ﾠstudy	 ﾠ
(Figure	 ﾠ69)	 ﾠconfirms	 ﾠthat	 ﾠthere	 ﾠwas	 ﾠlittle	 ﾠnewly	 ﾠsynthesised	 ﾠmaterial	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠ24	 ﾠ
hours	 ﾠand	 ﾠthereafter	 ﾠa	 ﾠsteady	 ﾠincrease	 ﾠis	 ﾠseen	 ﾠto	 ﾠ96	 ﾠto	 ﾠ120	 ﾠhours.	 ﾠ	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Figure	 ﾠ69.	 ﾠAverage	 ﾠenrichment	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠphospholipids	 ﾠfrom	 ﾠpreterm	 ﾠ
endotracheal	 ﾠaspirates	 ﾠto	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment.	 ﾠ
Unlike	 ﾠ in	 ﾠ plasma	 ﾠ the	 ﾠ D9-ﾭ‐containing	 ﾠ PC	 ﾠ species	 ﾠ do	 ﾠ not	 ﾠ appear	 ﾠ rapidly.	 ﾠ As	 ﾠ the	 ﾠ
associated	 ﾠfigure	 ﾠindicates	 ﾠthere	 ﾠis	 ﾠa	 ﾠlow	 ﾠbut	 ﾠmeasurable	 ﾠfractional	 ﾠincorporation	 ﾠ
measurable	 ﾠwithin	 ﾠ6	 ﾠto	 ﾠ12	 ﾠhours	 ﾠpost	 ﾠinfusion.	 ﾠ
The	 ﾠaverage	 ﾠamount	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠin	 ﾠETA	 ﾠthen	 ﾠrises	 ﾠslowly	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ10	 ﾠdays	 ﾠof	 ﾠ
study	 ﾠat	 ﾠthe	 ﾠequivalent	 ﾠof	 ﾠ0.003%	 ﾠrise	 ﾠper	 ﾠhour	 ﾠto	 ﾠa	 ﾠmaximum	 ﾠof	 ﾠ0.722%.	 ﾠThis	 ﾠ
contrasts	 ﾠ markedly	 ﾠ with	 ﾠ the	 ﾠ pattern	 ﾠ of	 ﾠ incorporation	 ﾠ in	 ﾠ plasma	 ﾠ where	 ﾠ a	 ﾠ peak	 ﾠ
incorporation	 ﾠ of	 ﾠ almost	 ﾠ 0.9%	 ﾠ is	 ﾠ seen	 ﾠ within	 ﾠ 12	 ﾠ hours	 ﾠ of	 ﾠ [methyl-ﾭ‐D9]choline	 ﾠ
chloride	 ﾠadministration	 ﾠ(section	 ﾠ3.3.1).	 ﾠThe	 ﾠsecond	 ﾠadministration	 ﾠat	 ﾠ120	 ﾠhours	 ﾠ
produces	 ﾠa	 ﾠsmall	 ﾠbut	 ﾠtemporary	 ﾠincrease	 ﾠin	 ﾠincorporation.	 ﾠ
This	 ﾠETA	 ﾠincorporation	 ﾠis	 ﾠmuch	 ﾠlower	 ﾠthan	 ﾠpreviously	 ﾠpublished	 ﾠadult	 ﾠvolunteer	 ﾠ
data	 ﾠlooking	 ﾠat	 ﾠinduced	 ﾠsputum	 ﾠ(Bernhard	 ﾠet	 ﾠal.,	 ﾠ2004).	 ﾠThis	 ﾠis	 ﾠa	 ﾠvery	 ﾠsignificant	 ﾠ
finding,	 ﾠ when	 ﾠ examined	 ﾠ in	 ﾠ conjunction	 ﾠ with	 ﾠ the	 ﾠ plasma	 ﾠ analysis	 ﾠ previously	 ﾠ
described,	 ﾠbecause	 ﾠthe	 ﾠchildren	 ﾠare	 ﾠcapable	 ﾠof	 ﾠsynthesising	 ﾠnew	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠthe	 ﾠ
liver	 ﾠrapidly	 ﾠbut	 ﾠthey	 ﾠare	 ﾠnot	 ﾠseen	 ﾠin	 ﾠthe	 ﾠET	 ﾠsecretions	 ﾠfor	 ﾠa	 ﾠsignificant	 ﾠperiod	 ﾠand	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then	 ﾠ slowly	 ﾠ build	 ﾠ up	 ﾠ over	 ﾠ several	 ﾠ days.	 ﾠ Active	 ﾠ monitoring	 ﾠ of	 ﾠ this	 ﾠ process	 ﾠ in	 ﾠ
individual	 ﾠpatients	 ﾠmay	 ﾠreveal	 ﾠthose	 ﾠwho	 ﾠare	 ﾠfailing	 ﾠto	 ﾠproduce	 ﾠnewly	 ﾠsynthesised	 ﾠ
PC	 ﾠphospholipids	 ﾠat	 ﾠthe	 ﾠtime	 ﾠof	 ﾠclinical	 ﾠimprovement	 ﾠthereby	 ﾠindicating	 ﾠa	 ﾠfuture	 ﾠ
failure	 ﾠof	 ﾠrespiratory	 ﾠfunction.	 ﾠ
Having	 ﾠestablished	 ﾠthat	 ﾠthe	 ﾠoverall	 ﾠproportions	 ﾠof	 ﾠPC	 ﾠin	 ﾠETA	 ﾠdo	 ﾠnot	 ﾠchange	 ﾠover	 ﾠ
the	 ﾠfirst	 ﾠ10	 ﾠdays	 ﾠof	 ﾠpreterm	 ﾠlife	 ﾠand	 ﾠthat	 ﾠnewly	 ﾠsynthesised	 ﾠPC	 ﾠis	 ﾠproduced,	 ﾠalbeit	 ﾠ
at	 ﾠa	 ﾠlow	 ﾠrate,	 ﾠit	 ﾠis	 ﾠimportant	 ﾠto	 ﾠlook	 ﾠin	 ﾠmore	 ﾠdetail	 ﾠat	 ﾠthis	 ﾠnewly	 ﾠproduced	 ﾠmaterial.	 ﾠ
Does	 ﾠits	 ﾠmake-ﾭ‐up	 ﾠreflect	 ﾠthe	 ﾠoverall	 ﾠproportions	 ﾠof	 ﾠPC	 ﾠmeasured?	 ﾠIs	 ﾠit	 ﾠthe	 ﾠsame	 ﾠas	 ﾠ
the	 ﾠexogenous	 ﾠPC	 ﾠadministered	 ﾠprophylactically	 ﾠat	 ﾠbirth	 ﾠor	 ﾠis	 ﾠthere	 ﾠevidence	 ﾠof	 ﾠ
plasma-ﾭ‐derived	 ﾠnon-ﾭ‐surface	 ﾠactive	 ﾠspecies?	 ﾠ
5.6	 ﾠComposition	 ﾠof	 ﾠunlabelled	 ﾠand	 ﾠD9-ﾭ‐phosphatidylcholine	 ﾠin	 ﾠETA	 ﾠ
5.6.1	 ﾠComposition	 ﾠat	 ﾠ12	 ﾠhours	 ﾠ
At	 ﾠ 12	 ﾠ hours	 ﾠ post	 ﾠ recruitment	 ﾠ there	 ﾠ is	 ﾠ a	 ﾠ measurable	 ﾠ and	 ﾠ reliable	 ﾠ signal	 ﾠ in	 ﾠ the	 ﾠ
precursor-ﾭ‐of-ﾭ‐mass/charge	 ﾠ193	 ﾠscanning.	 ﾠLooking	 ﾠat	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠthe	 ﾠD9-ﾭ‐PC	 ﾠ
molecules	 ﾠin	 ﾠthis	 ﾠsample	 ﾠwill	 ﾠgive	 ﾠthe	 ﾠearliest	 ﾠmeasurement	 ﾠof	 ﾠthe	 ﾠoutput	 ﾠof	 ﾠnewly	 ﾠ
synthesised	 ﾠsurfactant	 ﾠphospholipids	 ﾠand	 ﾠis	 ﾠa	 ﾠpotential	 ﾠclinical	 ﾠtool	 ﾠfor	 ﾠmonitoring	 ﾠ
surfactant	 ﾠsystem	 ﾠsynthetic	 ﾠactivation/recovery.	 ﾠ
The	 ﾠproportions	 ﾠof	 ﾠthe	 ﾠindividual	 ﾠD9-ﾭ‐PC	 ﾠspecies	 ﾠat	 ﾠ12	 ﾠhours	 ﾠcan	 ﾠbe	 ﾠcompared	 ﾠto	 ﾠ
the	 ﾠunlabelled	 ﾠPC	 ﾠpresent	 ﾠat	 ﾠthe	 ﾠsame	 ﾠtime	 ﾠpoint	 ﾠ(Figure	 ﾠ70).	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Figure	 ﾠ70.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ12	 ﾠhours	 ﾠafter	 ﾠ
recruitment.	 ﾠColumns	 ﾠon	 ﾠthe	 ﾠleft	 ﾠare	 ﾠendogenous	 ﾠ(non-ﾭ‐labelled)	 ﾠand	 ﾠcolumns	 ﾠ
on	 ﾠthe	 ﾠright	 ﾠare	 ﾠthe	 ﾠnewly-ﾭ‐synthesised	 ﾠ(D9-ﾭ‐labelled)	 ﾠPC	 ﾠspecies.	 ﾠ
It	 ﾠis	 ﾠimmediately	 ﾠapparent	 ﾠthat	 ﾠthe	 ﾠnewly	 ﾠsynthesised	 ﾠPC	 ﾠis	 ﾠmade	 ﾠand	 ﾠsecreted	 ﾠin	 ﾠa	 ﾠ
significantly	 ﾠdifferent	 ﾠcomposition	 ﾠwhen	 ﾠcompared	 ﾠdirectly	 ﾠwith	 ﾠthe	 ﾠunlabelled	 ﾠPC	 ﾠ
in	 ﾠthe	 ﾠpreterm	 ﾠETA.	 ﾠ
In	 ﾠterms	 ﾠof	 ﾠfatty	 ﾠacid	 ﾠchain	 ﾠlength	 ﾠthere	 ﾠis	 ﾠa	 ﾠsignificantly	 ﾠhigher	 ﾠproportion	 ﾠof	 ﾠ
medium	 ﾠ(red)	 ﾠand	 ﾠPUFA-ﾭ‐containing	 ﾠ(blue)	 ﾠPC	 ﾠspecies	 ﾠcoupled	 ﾠwith	 ﾠfew	 ﾠsurface-ﾭ‐
active	 ﾠ short	 ﾠ (green)	 ﾠ species.	 ﾠ D9PC16:0/18:1	 ﾠ is	 ﾠ the	 ﾠ most	 ﾠ abundant	 ﾠ newly	 ﾠ
synthesised	 ﾠPC	 ﾠphospholipid.	 ﾠOf	 ﾠpossible	 ﾠsignificance	 ﾠthis	 ﾠis	 ﾠalso	 ﾠthe	 ﾠpredominant	 ﾠ
PC	 ﾠspecies	 ﾠfound	 ﾠin	 ﾠplasma.	 ﾠ
5.6.2	 ﾠComposition	 ﾠat	 ﾠ48	 ﾠhours	 ﾠ
By	 ﾠ48	 ﾠhours	 ﾠthe	 ﾠproportions	 ﾠare	 ﾠmore	 ﾠclosely	 ﾠaligned	 ﾠbetween	 ﾠthe	 ﾠunlabelled	 ﾠand	 ﾠ
newly	 ﾠ synthesised	 ﾠ PC,	 ﾠ with	 ﾠ surface-ﾭ‐active	 ﾠ D9PC16:0/16:0	 ﾠ (DPPC)	 ﾠ now	 ﾠ
predominant	 ﾠamongst	 ﾠthe	 ﾠnewly	 ﾠsynthesised	 ﾠspecies	 ﾠfor	 ﾠthe	 ﾠfirst	 ﾠtime	 ﾠ(Figure	 ﾠ71).	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Figure	 ﾠ71.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ48	 ﾠhours	 ﾠafter	 ﾠ
recruitment.	 ﾠColumns	 ﾠon	 ﾠthe	 ﾠleft	 ﾠare	 ﾠendogenous	 ﾠ(non-ﾭ‐labelled)	 ﾠand	 ﾠcolumns	 ﾠ
on	 ﾠthe	 ﾠright	 ﾠare	 ﾠthe	 ﾠnewly-ﾭ‐synthesised	 ﾠ(D9-ﾭ‐labelled)	 ﾠPC	 ﾠspecies.	 ﾠ
There	 ﾠstill	 ﾠdiscrepancy	 ﾠbetween	 ﾠwhat	 ﾠis	 ﾠnewly	 ﾠsynthesised	 ﾠand	 ﾠthe	 ﾠoverall	 ﾠprofile.	 ﾠ
	 ﾠ
5.6.3	 ﾠComposition	 ﾠat	 ﾠ120	 ﾠhours	 ﾠ
However	 ﾠby	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠthe	 ﾠD9-ﾭ‐PC	 ﾠand	 ﾠunlabelled	 ﾠPC	 ﾠproportions	 ﾠ
are	 ﾠvery	 ﾠsimilar	 ﾠ(Figure	 ﾠ72)	 ﾠand	 ﾠthe	 ﾠpattern	 ﾠis	 ﾠnow	 ﾠsuggestive	 ﾠof	 ﾠmore	 ﾠcomplete	 ﾠ
synthesis,	 ﾠselection	 ﾠand	 ﾠpackaging	 ﾠof	 ﾠPC	 ﾠby	 ﾠthe	 ﾠlamellar	 ﾠbodies	 ﾠin	 ﾠthe	 ﾠalveolar	 ﾠtype	 ﾠ
II	 ﾠcells..	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Figure	 ﾠ72.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠselected	 ﾠPC	 ﾠspecies	 ﾠat	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠ
recruitment.	 ﾠColumns	 ﾠon	 ﾠthe	 ﾠleft	 ﾠare	 ﾠendogenous	 ﾠ(non-ﾭ‐labelled)	 ﾠand	 ﾠcolumns	 ﾠ
on	 ﾠthe	 ﾠright	 ﾠare	 ﾠthe	 ﾠnewly-ﾭ‐synthesised	 ﾠ(D9-ﾭ‐labelled)	 ﾠPC	 ﾠspecies.	 ﾠ
	 ﾠ
5.7	 ﾠFractional	 ﾠincorporation	 ﾠof	 ﾠindividual	 ﾠD9-ﾭ‐phosphatidylcholine	 ﾠ
species	 ﾠ
Having	 ﾠestablished	 ﾠthat	 ﾠthe	 ﾠnewly	 ﾠsynthesised	 ﾠD9-ﾭ‐PC	 ﾠphospholipid	 ﾠmakes	 ﾠup	 ﾠonly	 ﾠa	 ﾠ
small	 ﾠ proportion	 ﾠ of	 ﾠ the	 ﾠ total	 ﾠ PC	 ﾠ material	 ﾠ seen	 ﾠ in	 ﾠ the	 ﾠ ETA,	 ﾠ that	 ﾠ the	 ﾠ fraction	 ﾠ
increases	 ﾠgradually	 ﾠwith	 ﾠtime	 ﾠand	 ﾠthat	 ﾠthe	 ﾠproportions	 ﾠchange	 ﾠto	 ﾠeventually	 ﾠmatch	 ﾠ
the	 ﾠunlabelled	 ﾠPC	 ﾠphospholipids,	 ﾠit	 ﾠis	 ﾠnecessary	 ﾠto	 ﾠexamine	 ﾠthe	 ﾠoverall	 ﾠfractional	 ﾠ
incorporation	 ﾠpattern	 ﾠof	 ﾠD9-ﾭ‐PC	 ﾠspecies	 ﾠproduction	 ﾠand	 ﾠits	 ﾠchange	 ﾠwith	 ﾠtime.	 ﾠ
5.7.1	 ﾠFractional	 ﾠincorporation	 ﾠto	 ﾠ240	 ﾠhours	 ﾠ
The	 ﾠaveraged	 ﾠfractional	 ﾠincorporation	 ﾠinto	 ﾠETA	 ﾠof	 ﾠindividual	 ﾠselected	 ﾠPC	 ﾠspecies	 ﾠ
(Figure	 ﾠ73)	 ﾠwith	 ﾠa	 ﾠpattern	 ﾠof	 ﾠsynthesis	 ﾠchanging	 ﾠwith	 ﾠtime	 ﾠso	 ﾠthat	 ﾠit	 ﾠis	 ﾠpossible	 ﾠto	 ﾠ  139	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determine	 ﾠthat	 ﾠthe	 ﾠD9-ﾭ‐PC	 ﾠspecies	 ﾠsynthesised	 ﾠdid	 ﾠnot	 ﾠreflect	 ﾠthe	 ﾠPC	 ﾠspecies	 ﾠalready	 ﾠ
present	 ﾠin	 ﾠthe	 ﾠETA.	 ﾠ	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Figure	 ﾠ73.	 ﾠFractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐label	 ﾠinto	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠ
over	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠto	 ﾠstudy.	 ﾠ
Of	 ﾠnote	 ﾠis	 ﾠthat	 ﾠthe	 ﾠD9-ﾭ‐PC	 ﾠspecies	 ﾠwith	 ﾠthe	 ﾠlargest	 ﾠfractional	 ﾠincorporation	 ﾠover	 ﾠthe	 ﾠ
first	 ﾠ5	 ﾠdays	 ﾠwas	 ﾠa	 ﾠPUFA-ﾭ‐containing	 ﾠPC,	 ﾠspecifically	 ﾠD9PC18:1/20:4.	 ﾠ
5.7.2	 ﾠFractional	 ﾠincorporation	 ﾠover	 ﾠ120	 ﾠhours	 ﾠ
Over	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠthe	 ﾠpattern	 ﾠis	 ﾠmore	 ﾠclearly	 ﾠdemonstrated	 ﾠ(Figure	 ﾠ74).	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Figure	 ﾠ74.	 ﾠFractional	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐label	 ﾠinto	 ﾠindividual	 ﾠPC	 ﾠspecies	 ﾠ
over	 ﾠthe	 ﾠfirst	 ﾠ120	 ﾠhours	 ﾠafter	 ﾠrecruitment	 ﾠto	 ﾠstudy.	 ﾠ
New	 ﾠ PC	 ﾠ synthesis	 ﾠ contributes	 ﾠ most,	 ﾠ in	 ﾠ terms	 ﾠ of	 ﾠ the	 ﾠ amount	 ﾠ that	 ﾠ is	 ﾠ newly	 ﾠ
synthesised	 ﾠexpressed	 ﾠas	 ﾠa	 ﾠpercentage	 ﾠof	 ﾠthe	 ﾠtotal	 ﾠamount	 ﾠmeasured,	 ﾠto	 ﾠthe	 ﾠPUFA-ﾭ‐
containing	 ﾠ PC18:1/20:4.	 ﾠ However	 ﾠ this	 ﾠ species	 ﾠ exists	 ﾠ in	 ﾠ very	 ﾠ small	 ﾠ quantities	 ﾠ
overall	 ﾠso	 ﾠa	 ﾠsmall	 ﾠamount	 ﾠmade	 ﾠwill	 ﾠcontribute	 ﾠa	 ﾠlarge	 ﾠfractional	 ﾠincorporation.	 ﾠ
Meanwhile	 ﾠthe	 ﾠlowest	 ﾠfractional	 ﾠincorporations	 ﾠare	 ﾠin	 ﾠthe	 ﾠshort	 ﾠ(green)	 ﾠand	 ﾠfully	 ﾠ
saturated	 ﾠ(PC16:0/18:0)	 ﾠPC	 ﾠspecies	 ﾠbecause	 ﾠthese	 ﾠare	 ﾠpresent	 ﾠin	 ﾠrelatively	 ﾠlarger	 ﾠ
amounts.	 ﾠ
5.8	 ﾠComposition	 ﾠof	 ﾠD9-ﾭ‐phosphatidylcholine	 ﾠspecies	 ﾠchanges	 ﾠover	 ﾠ
time	 ﾠ
While	 ﾠPC16:0/16:0	 ﾠwas	 ﾠthe	 ﾠpredominant	 ﾠspecies	 ﾠseen	 ﾠthroughout	 ﾠsampling	 ﾠit	 ﾠwas	 ﾠ
not	 ﾠthe	 ﾠpredominant	 ﾠspecies	 ﾠproduced	 ﾠ(as	 ﾠD9PC16:0/16:0)	 ﾠin	 ﾠthe	 ﾠlungs	 ﾠuntil	 ﾠover	 ﾠ
24	 ﾠ hours	 ﾠ (Figure	 ﾠ 75)	 ﾠ and	 ﾠ did	 ﾠ not	 ﾠ match	 ﾠ the	 ﾠ endogenous	 ﾠ composition	 ﾠ until	 ﾠ 96	 ﾠ
hours.	 ﾠ	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Figure	 ﾠ75.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠnewly	 ﾠsynthesised	 ﾠPC	 ﾠspecies	 ﾠin	 ﾠ
endotracheal	 ﾠaspirates	 ﾠfrom	 ﾠpreterm	 ﾠinfants	 ﾠover	 ﾠ240	 ﾠhours	 ﾠafter	 ﾠ
recruitment	 ﾠto	 ﾠthe	 ﾠstudy.	 ﾠ
It	 ﾠtakes	 ﾠtime	 ﾠfor	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠlung	 ﾠto	 ﾠchange	 ﾠproduction	 ﾠand	 ﾠsynthesis	 ﾠfrom	 ﾠa	 ﾠ
situation	 ﾠwhere	 ﾠthere	 ﾠexisted	 ﾠsimilar	 ﾠproportions	 ﾠof	 ﾠeach	 ﾠdifferent	 ﾠPC	 ﾠspecies	 ﾠto	 ﾠa	 ﾠ
more	 ﾠ differentiated	 ﾠ pattern	 ﾠ of	 ﾠ production	 ﾠ that	 ﾠ more	 ﾠ closely	 ﾠ resembles	 ﾠ the	 ﾠ
proportions	 ﾠ seen	 ﾠ in	 ﾠ exogenous	 ﾠ or	 ﾠ mature	 ﾠ lung	 ﾠ surfactant.	 ﾠ Even	 ﾠ then	 ﾠ the	 ﾠ
composition	 ﾠof	 ﾠde	 ﾠnovo	 ﾠPC	 ﾠspecies	 ﾠdoes	 ﾠnot	 ﾠreflect	 ﾠthe	 ﾠproportions	 ﾠseen	 ﾠin	 ﾠtotal	 ﾠPC	 ﾠ
measurements.	 ﾠ
The	 ﾠrelative	 ﾠincrease	 ﾠin	 ﾠincorporation	 ﾠinto	 ﾠDPPC	 ﾠ(D9PC16:0/16:0),	 ﾠwhile	 ﾠshowing	 ﾠ
inter-ﾭ‐patient	 ﾠvariability,	 ﾠwas	 ﾠseen	 ﾠconsistently.	 ﾠ
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5.9	 ﾠ Interpretation	 ﾠ of	 ﾠ the	 ﾠ pulmonary	 ﾠ surfactant	 ﾠ
phosphatidylcholine	 ﾠmetabolism	 ﾠdata	 ﾠ
The	 ﾠconstant	 ﾠtotal	 ﾠcomposition	 ﾠand	 ﾠlow	 ﾠinitial	 ﾠrate	 ﾠof	 ﾠsynthesis	 ﾠare	 ﾠconsistent	 ﾠwith	 ﾠ
the	 ﾠpresence	 ﾠof	 ﾠa	 ﾠlarge	 ﾠamount	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠpresent	 ﾠin	 ﾠthe	 ﾠairways.	 ﾠ
There	 ﾠis	 ﾠevidence	 ﾠthat	 ﾠonly	 ﾠlow	 ﾠamounts	 ﾠof	 ﾠPC	 ﾠcome	 ﾠfrom	 ﾠde	 ﾠnovo	 ﾠsynthesis	 ﾠin	 ﾠthis	 ﾠ
situation	 ﾠ as	 ﾠ the	 ﾠ composition	 ﾠ of	 ﾠ the	 ﾠ de	 ﾠnovo	 ﾠ PC	 ﾠ species	 ﾠ does	 ﾠ not	 ﾠ reflect	 ﾠ the	 ﾠ PC	 ﾠ
species	 ﾠproportions	 ﾠseen	 ﾠin	 ﾠtotal	 ﾠPC	 ﾠmeasurements.	 ﾠ
This	 ﾠis	 ﾠthe	 ﾠfirst	 ﾠtime	 ﾠthat	 ﾠactive	 ﾠmetabolism	 ﾠof	 ﾠPC	 ﾠspecies	 ﾠhas	 ﾠbeen	 ﾠreported	 ﾠin	 ﾠ
preterm	 ﾠinfants	 ﾠand	 ﾠthe	 ﾠknowledge	 ﾠgained	 ﾠopens	 ﾠavenues	 ﾠfor	 ﾠfuture	 ﾠtreatment	 ﾠin	 ﾠ
these	 ﾠchildren.	 ﾠ
5.10	 ﾠPulmonary	 ﾠsurfactant	 ﾠacidic	 ﾠphospholipid	 ﾠspecies	 ﾠanalysis	 ﾠ
Having	 ﾠnoted	 ﾠthat	 ﾠlarge	 ﾠamounts	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠmust	 ﾠbe	 ﾠpresent	 ﾠin	 ﾠthe	 ﾠ
airways	 ﾠto	 ﾠaccount	 ﾠfor	 ﾠthe	 ﾠvery	 ﾠlow	 ﾠPC	 ﾠsynthetic	 ﾠrates	 ﾠit	 ﾠis	 ﾠimportant	 ﾠto	 ﾠinvestigate	 ﾠ
the	 ﾠ other,	 ﾠ acidic	 ﾠ phospholipid,	 ﾠ species	 ﾠ present	 ﾠ in	 ﾠ Curosurf®,	 ﾠ which	 ﾠ may	 ﾠ be	 ﾠ
metabolised	 ﾠdifferently.	 ﾠ
5.10.1	 ﾠPhosphatidylglycerol	 ﾠ(PG)	 ﾠand	 ﾠphosphatidylinositol	 ﾠ(PI)	 ﾠanalysis	 ﾠ
i)	 ﾠRatio	 ﾠof	 ﾠPG	 ﾠto	 ﾠPI	 ﾠin	 ﾠexogenous	 ﾠsurfactant	 ﾠanalysis	 ﾠ
Unlike	 ﾠ endogenous	 ﾠ surfactant	 ﾠ produced	 ﾠ by	 ﾠ immature	 ﾠ mammalian	 ﾠ AT-ﾭ‐II	 ﾠ cells,	 ﾠ
Curosurf®	 ﾠcontains	 ﾠa	 ﾠsignificant	 ﾠproportion	 ﾠof	 ﾠPG	 ﾠrelative	 ﾠto	 ﾠPI	 ﾠ(Figure	 ﾠ76).	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Figure	 ﾠ76.	 ﾠA	 ﾠmass	 ﾠspectrum	 ﾠnegative	 ﾠionisation	 ﾠscan	 ﾠ(MS-ﾭ‐)	 ﾠof	 ﾠCurosurf®	 ﾠ
illustrating	 ﾠthe	 ﾠmajor	 ﾠacidic	 ﾠphospholipid	 ﾠspecies.	 ﾠ	 ﾠThree	 ﾠmajor	 ﾠ
phosphatidylglycerol	 ﾠ(PG)	 ﾠspecies	 ﾠand	 ﾠthree	 ﾠmajor	 ﾠphosphatidylinositol	 ﾠ(PI)	 ﾠ
species	 ﾠare	 ﾠlabelled.	 ﾠ	 ﾠOf	 ﾠthe	 ﾠacidic	 ﾠphospholipids,	 ﾠPG	 ﾠspecies	 ﾠare	 ﾠ
predominant	 ﾠin	 ﾠCurosurf®	 ﾠpreparations.	 ﾠ
The	 ﾠ highest	 ﾠ peak,	 ﾠ m/z	 ﾠ =	 ﾠ 747,	 ﾠ is	 ﾠ a	 ﾠ common	 ﾠ PG	 ﾠ species	 ﾠ (PG16:0/18:1).	 ﾠ The	 ﾠ PI	 ﾠ
species	 ﾠare	 ﾠseen	 ﾠas	 ﾠpeaks	 ﾠof	 ﾠm/z	 ﾠ=	 ﾠ835,	 ﾠ861	 ﾠand	 ﾠ885.	 ﾠ
ii)	 ﾠRatio	 ﾠof	 ﾠPG	 ﾠto	 ﾠPI	 ﾠin	 ﾠpreterm	 ﾠendotracheal	 ﾠaspirates	 ﾠ
However	 ﾠESI	 ﾠMS/MS	 ﾠnegative	 ﾠionisation	 ﾠscans	 ﾠof	 ﾠthe	 ﾠETA	 ﾠsamples	 ﾠshow	 ﾠa	 ﾠmore	 ﾠ
complicated	 ﾠprofile.	 ﾠPG	 ﾠand	 ﾠPI	 ﾠspecies	 ﾠin	 ﾠthe	 ﾠET	 ﾠsample	 ﾠrapidly	 ﾠchange	 ﾠin	 ﾠrelative	 ﾠ
abundance.	 ﾠThe	 ﾠPG	 ﾠspecies	 ﾠdisappear	 ﾠrapidly	 ﾠfrom	 ﾠETA	 ﾠafter	 ﾠadministration	 ﾠof	 ﾠ
Curosurf®	 ﾠand	 ﾠthis	 ﾠdisappearance	 ﾠis	 ﾠmeasurable	 ﾠin	 ﾠsamples	 ﾠtaken	 ﾠwithin	 ﾠ7	 ﾠhours	 ﾠ
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Figure	 ﾠ77.	 ﾠRelative	 ﾠproportions	 ﾠof	 ﾠphosphatidylglycerol	 ﾠspecies	 ﾠand	 ﾠ
phosphatidylinositol	 ﾠspecies	 ﾠchange	 ﾠfrom	 ﾠa	 ﾠmature	 ﾠto	 ﾠan	 ﾠimmature	 ﾠratio	 ﾠ
with	 ﾠtime	 ﾠfrom	 ﾠadministration	 ﾠof	 ﾠCurosurf®.	 ﾠThis	 ﾠprovides	 ﾠvery	 ﾠearly	 ﾠ
evidence	 ﾠof	 ﾠactive	 ﾠmetabolism	 ﾠof	 ﾠCurosurf®	 ﾠfrom	 ﾠthe	 ﾠET	 ﾠaspirates	 ﾠof	 ﾠpreterm	 ﾠ
infants	 ﾠdespite	 ﾠrelatively	 ﾠslow	 ﾠphosphatidylcholine	 ﾠmetabolism.	 ﾠ	 ﾠ
This	 ﾠ finding	 ﾠ could	 ﾠ be	 ﾠ combined	 ﾠ with	 ﾠ fractional	 ﾠ incorporation	 ﾠ data	 ﾠ to	 ﾠ clinically	 ﾠ
assess	 ﾠhow	 ﾠrapidly	 ﾠthe	 ﾠCurosurf®	 ﾠis	 ﾠmetabolised	 ﾠby	 ﾠthe	 ﾠlung.	 ﾠ
5.11	 ﾠDiscussion	 ﾠ
The	 ﾠwork	 ﾠpresented	 ﾠin	 ﾠthis	 ﾠchapter	 ﾠillustrates	 ﾠthat	 ﾠa	 ﾠcombination	 ﾠof	 ﾠESI	 ﾠMS/MS	 ﾠ
analysis	 ﾠ of	 ﾠ endotracheal	 ﾠ secretions	 ﾠ and	 ﾠ the	 ﾠ administration	 ﾠ of	 ﾠ a	 ﾠ stable	 ﾠ isotope	 ﾠ
labelled	 ﾠphospholipid	 ﾠsubstrate	 ﾠcan	 ﾠallow	 ﾠinvestigation	 ﾠof	 ﾠsurfactant	 ﾠproduction,	 ﾠ
metabolism	 ﾠand	 ﾠturnover	 ﾠin	 ﾠextremely	 ﾠpreterm	 ﾠinfants	 ﾠin	 ﾠa	 ﾠtimeframe	 ﾠthat,	 ﾠunlike	 ﾠ
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This	 ﾠ is	 ﾠ the	 ﾠ first	 ﾠ study	 ﾠ to	 ﾠ examine	 ﾠ in	 ﾠ detail	 ﾠ the	 ﾠ composition	 ﾠ of	 ﾠ surfactant	 ﾠ
phosphatidylcholine-ﾭ‐containing	 ﾠphospholipids	 ﾠpresent	 ﾠin	 ﾠthe	 ﾠtrachea	 ﾠof	 ﾠinfants,	 ﾠin	 ﾠ
receipt	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠfollowing	 ﾠpreterm	 ﾠbirth,	 ﾠand	 ﾠthen	 ﾠtrack	 ﾠchanges	 ﾠto	 ﾠ
those	 ﾠphospholipids	 ﾠwith	 ﾠtime.	 ﾠ	 ﾠThrough	 ﾠthe	 ﾠexamination	 ﾠof	 ﾠPI/PG	 ﾠratios	 ﾠin	 ﾠET	 ﾠ
aspirates	 ﾠthe	 ﾠstudy	 ﾠhas	 ﾠdemonstrated	 ﾠthat	 ﾠthe	 ﾠadministered	 ﾠexogenous	 ﾠsurfactant	 ﾠ
is	 ﾠactively	 ﾠmetabolised	 ﾠbut	 ﾠthat	 ﾠit	 ﾠtakes	 ﾠtime	 ﾠfor	 ﾠthe	 ﾠinfant	 ﾠto	 ﾠnewly	 ﾠsynthesise	 ﾠPC	 ﾠ
phospholipids	 ﾠde	 ﾠnovo.	 ﾠ
Not	 ﾠonly	 ﾠis	 ﾠthe	 ﾠtechnique	 ﾠable	 ﾠto	 ﾠexamine	 ﾠphosphatidylcholine	 ﾠphospholipids	 ﾠas	 ﾠa	 ﾠ
whole	 ﾠand	 ﾠmonitor	 ﾠthe	 ﾠfatty	 ﾠacid	 ﾠcomposition	 ﾠof	 ﾠthe	 ﾠsame	 ﾠmolecules	 ﾠbut	 ﾠalso	 ﾠit	 ﾠcan	 ﾠ
discriminate	 ﾠbetween	 ﾠthe	 ﾠendogenous	 ﾠmolecules	 ﾠand	 ﾠthe	 ﾠnewly	 ﾠsynthesised	 ﾠD9-ﾭ‐
containing	 ﾠ molecules	 ﾠ in	 ﾠ each	 ﾠ sample	 ﾠ and	 ﾠ hence	 ﾠ offer	 ﾠ an	 ﾠ insight	 ﾠ to	 ﾠ surfactant	 ﾠ
production	 ﾠand	 ﾠmetabolism	 ﾠchanges	 ﾠwith	 ﾠtime.	 ﾠ	 ﾠ
Endotracheal	 ﾠaspirate	 ﾠsample	 ﾠcollection	 ﾠis	 ﾠtolerated	 ﾠby	 ﾠthe	 ﾠpatients	 ﾠand	 ﾠis	 ﾠmore	 ﾠ
acceptable	 ﾠthan	 ﾠbronchoalveolar	 ﾠlavage	 ﾠto	 ﾠparents	 ﾠand	 ﾠstaff.	 ﾠThe	 ﾠsimple	 ﾠfact	 ﾠthat	 ﾠ
these	 ﾠsamples	 ﾠcan	 ﾠbe	 ﾠobtained	 ﾠeasily	 ﾠfrom	 ﾠany	 ﾠpreterm	 ﾠventilated	 ﾠpatient,	 ﾠthen	 ﾠ
processed	 ﾠand	 ﾠanalysed	 ﾠwith	 ﾠresults	 ﾠavailable	 ﾠwithin	 ﾠa	 ﾠfew	 ﾠhours	 ﾠoffers	 ﾠenormous	 ﾠ
scope	 ﾠfor	 ﾠongoing	 ﾠmonitoring	 ﾠof	 ﾠsurfactant	 ﾠmetabolism	 ﾠand	 ﾠtherefore	 ﾠpotentially	 ﾠ
an	 ﾠ area	 ﾠ for	 ﾠ intervention	 ﾠ in	 ﾠ ventilated	 ﾠ patients	 ﾠ if	 ﾠ biomarkers	 ﾠ for	 ﾠ disease	 ﾠ
development	 ﾠor	 ﾠventilation	 ﾠfailure	 ﾠcan	 ﾠbe	 ﾠidentified	 ﾠin	 ﾠfuture	 ﾠstudies.	 ﾠ
This	 ﾠpilot	 ﾠstudy	 ﾠshows	 ﾠthat	 ﾠthe	 ﾠtechniques	 ﾠpreviously	 ﾠonly	 ﾠused	 ﾠin	 ﾠvolunteers	 ﾠare	 ﾠ
possible	 ﾠand	 ﾠeffective	 ﾠin	 ﾠa	 ﾠclinical	 ﾠintensive	 ﾠcare	 ﾠenvironment.	 ﾠ	 ﾠ
	 ﾠ
The	 ﾠ study	 ﾠ demonstrates	 ﾠ that	 ﾠ the	 ﾠ preterm	 ﾠ infant,	 ﾠ ventilated	 ﾠ on	 ﾠ the	 ﾠ neonatal	 ﾠ
intensive	 ﾠ care	 ﾠ unit	 ﾠ has	 ﾠ a	 ﾠ measureable	 ﾠ quantity	 ﾠ of	 ﾠ PC	 ﾠ phospholipids	 ﾠ in	 ﾠ the	 ﾠ
endotracheal	 ﾠaspirates	 ﾠwithin	 ﾠ48	 ﾠhours	 ﾠof	 ﾠbirth	 ﾠand	 ﾠthat	 ﾠthe	 ﾠconcentration	 ﾠof	 ﾠthe	 ﾠ
phospholipids	 ﾠretrieved	 ﾠis	 ﾠrelatively	 ﾠsteady	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠweek	 ﾠor	 ﾠso	 ﾠof	 ﾠlife.	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note,	 ﾠthe	 ﾠrelative	 ﾠproportions	 ﾠof	 ﾠthe	 ﾠdifferent	 ﾠmajor	 ﾠPC	 ﾠspecies	 ﾠare	 ﾠmaintained	 ﾠ
over	 ﾠ the	 ﾠ same	 ﾠ time	 ﾠ period.	 ﾠ As	 ﾠ expected,	 ﾠ given	 ﾠ the	 ﾠ composition	 ﾠ of	 ﾠ exogenous	 ﾠ
surfactant	 ﾠ administered	 ﾠ to	 ﾠ the	 ﾠ children,	 ﾠ the	 ﾠ dominant	 ﾠ PC	 ﾠ species	 ﾠ is	 ﾠ the	 ﾠ fully	 ﾠ
saturated	 ﾠand	 ﾠsurface-ﾭ‐active	 ﾠPC16:0/16:0.	 ﾠ
However	 ﾠthis	 ﾠstudy	 ﾠhas	 ﾠdemonstrated	 ﾠfor	 ﾠthe	 ﾠfirst	 ﾠtime	 ﾠthat	 ﾠthe	 ﾠcomposition	 ﾠof	 ﾠ
newly	 ﾠ synthesised	 ﾠ D9-ﾭ‐containing	 ﾠ PC	 ﾠ species	 ﾠ is	 ﾠ markedly	 ﾠ different	 ﾠ initially	 ﾠ with	 ﾠ
increased	 ﾠamounts	 ﾠof	 ﾠmono-ﾭ‐	 ﾠand	 ﾠdi-ﾭ‐unsaturated	 ﾠspecies	 ﾠproduced.	 ﾠNot	 ﾠonly	 ﾠis	 ﾠit	 ﾠ
different	 ﾠinitially	 ﾠbut	 ﾠalso	 ﾠit	 ﾠtakes	 ﾠalmost	 ﾠ120	 ﾠhours	 ﾠfor	 ﾠthe	 ﾠcomposition	 ﾠof	 ﾠnewly	 ﾠ
synthesised	 ﾠPC	 ﾠto	 ﾠreflect	 ﾠthe	 ﾠoverall	 ﾠcomposition.	 ﾠThere	 ﾠexists	 ﾠa	 ﾠperiod	 ﾠin	 ﾠearly	 ﾠ
preterm	 ﾠ life	 ﾠ where	 ﾠ the	 ﾠ baby	 ﾠ is	 ﾠ dependent	 ﾠ on	 ﾠ PC	 ﾠ obtained	 ﾠ from	 ﾠ the	 ﾠ exogenous	 ﾠ
surfactant	 ﾠbefore	 ﾠit	 ﾠproduces	 ﾠappropriate	 ﾠsurface-ﾭ‐active	 ﾠPC	 ﾠvia	 ﾠit’s	 ﾠown	 ﾠsynthetic	 ﾠ
pathways.	 ﾠ
Unlike	 ﾠthe	 ﾠCDP-ﾭ‐choline	 ﾠderived	 ﾠPC	 ﾠmeasured	 ﾠin	 ﾠthe	 ﾠplasma	 ﾠit	 ﾠtakes	 ﾠa	 ﾠmuch	 ﾠlonger	 ﾠ
time	 ﾠfor	 ﾠthe	 ﾠfractional	 ﾠincorporation	 ﾠof	 ﾠnewly	 ﾠsynthesised	 ﾠPC	 ﾠto	 ﾠbuild	 ﾠup	 ﾠin	 ﾠthe	 ﾠ
surfactant	 ﾠsystem.	 ﾠIn	 ﾠplasma	 ﾠthe	 ﾠpeak	 ﾠincorporation	 ﾠof	 ﾠD9-ﾭ‐derived	 ﾠPC	 ﾠis	 ﾠalmost	 ﾠ1%	 ﾠ
measured	 ﾠwithin	 ﾠ12	 ﾠhours	 ﾠof	 ﾠD9-ﾭ‐choline	 ﾠadministration	 ﾠbefore	 ﾠrapidly	 ﾠsubsiding	 ﾠ
whereas	 ﾠin	 ﾠendotracheal	 ﾠaspirates	 ﾠthe	 ﾠbuild	 ﾠup	 ﾠin	 ﾠincorporation	 ﾠis	 ﾠmuch	 ﾠslower	 ﾠ
gradually	 ﾠ increasing	 ﾠ over	 ﾠ 96	 ﾠ hours.	 ﾠ 	 ﾠ There	 ﾠ is	 ﾠ a	 ﾠ measurable	 ﾠ variation	 ﾠ in	 ﾠ the	 ﾠ
incorporation	 ﾠbetween	 ﾠpatients.	 ﾠ
In	 ﾠthe	 ﾠfuture	 ﾠthis	 ﾠvariation	 ﾠin	 ﾠindividual	 ﾠincorporation	 ﾠrate	 ﾠis	 ﾠan	 ﾠavenue	 ﾠfor	 ﾠthe	 ﾠ
potential	 ﾠ tailoring	 ﾠ of	 ﾠ treatment	 ﾠ from	 ﾠ a	 ﾠ clinical	 ﾠ perspective,	 ﾠ as	 ﾠ it	 ﾠ offers	 ﾠ the	 ﾠ
opportunity	 ﾠto	 ﾠmonitor	 ﾠan	 ﾠindividual	 ﾠpatient’s	 ﾠincorporation	 ﾠrate,	 ﾠcompare	 ﾠit	 ﾠwith	 ﾠ
an	 ﾠideal	 ﾠrate,	 ﾠwhich	 ﾠwill	 ﾠneed	 ﾠto	 ﾠbe	 ﾠdefined,	 ﾠand	 ﾠadjust	 ﾠtreatment	 ﾠaccordingly	 ﾠby	 ﾠ
adding	 ﾠ more	 ﾠ exogenous	 ﾠ surfactant	 ﾠ to	 ﾠ those	 ﾠ failing	 ﾠ to	 ﾠ manufacture	 ﾠ sufficient	 ﾠ
endogenous	 ﾠsurfactant.	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More	 ﾠwork	 ﾠis	 ﾠneeded	 ﾠto	 ﾠexamine	 ﾠthe	 ﾠindividual	 ﾠpatient	 ﾠresponse,	 ﾠtheir	 ﾠsubsequent	 ﾠ
outcome	 ﾠ and	 ﾠ the	 ﾠ impact	 ﾠ of	 ﾠ treatment	 ﾠ such	 ﾠ as	 ﾠ extra	 ﾠ surfactant	 ﾠ exogenously	 ﾠ
administered.	 ﾠ
	 ﾠ
It	 ﾠis	 ﾠimportant	 ﾠto	 ﾠnote	 ﾠthat	 ﾠthere	 ﾠare	 ﾠlimitations	 ﾠto	 ﾠthe	 ﾠinterpretation	 ﾠof	 ﾠthe	 ﾠresults.	 ﾠ
It	 ﾠwas	 ﾠnot	 ﾠpossible	 ﾠto	 ﾠcreate	 ﾠa	 ﾠsuitable	 ﾠcontrol	 ﾠgroup	 ﾠfor	 ﾠthe	 ﾠextremely	 ﾠpremature	 ﾠ
infant	 ﾠ and	 ﾠ it	 ﾠ would	 ﾠ not	 ﾠ be	 ﾠ appropriate	 ﾠ to	 ﾠ withhold	 ﾠ lifesaving	 ﾠ surfactant	 ﾠ
replacement	 ﾠ in	 ﾠ any	 ﾠ preterm	 ﾠ infant.	 ﾠ The	 ﾠ dataset	 ﾠ for	 ﾠ individual	 ﾠ patients	 ﾠ is	 ﾠ
incomplete	 ﾠ as	 ﾠ a	 ﾠ small	 ﾠ number	 ﾠ of	 ﾠ the	 ﾠ collected	 ﾠ samples	 ﾠ were	 ﾠ not	 ﾠ suitable	 ﾠ for	 ﾠ
analysis	 ﾠdue	 ﾠto	 ﾠpoor	 ﾠlipid	 ﾠrecovery	 ﾠor	 ﾠheavy	 ﾠoxidation	 ﾠin	 ﾠsamples	 ﾠaccidentally	 ﾠleft	 ﾠ
without	 ﾠstabilisation	 ﾠsolution.	 ﾠ
	 ﾠ
Future	 ﾠwork	 ﾠwill	 ﾠinclude	 ﾠspecific	 ﾠprecursor	 ﾠscans	 ﾠof	 ﾠm/z	 ﾠ153	 ﾠ(PG	 ﾠand	 ﾠPI)	 ﾠand	 ﾠ241	 ﾠ
(PI)	 ﾠto	 ﾠidentify	 ﾠthe	 ﾠPI	 ﾠand	 ﾠPG	 ﾠmolecules	 ﾠand	 ﾠthen	 ﾠcompare	 ﾠthem	 ﾠto	 ﾠthe	 ﾠratio	 ﾠfound	 ﾠ
in	 ﾠCurosurf®.	 ﾠHallman	 ﾠshowed	 ﾠthat	 ﾠPG	 ﾠrapidly	 ﾠdisappeared	 ﾠfrom	 ﾠpreterm	 ﾠinfants	 ﾠin	 ﾠ
receipt	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠand	 ﾠused	 ﾠthis	 ﾠphenomenon	 ﾠto	 ﾠcalculate	 ﾠpool	 ﾠsize	 ﾠ
and	 ﾠhalf-ﾭ‐life	 ﾠof	 ﾠsurfactant	 ﾠphospholipid	 ﾠ(Hallman	 ﾠet	 ﾠal.,	 ﾠ1986).	 ﾠThis	 ﾠwas	 ﾠinterpreted	 ﾠ
as	 ﾠrapid	 ﾠmetabolism	 ﾠand	 ﾠdisappearance	 ﾠof	 ﾠexogenous	 ﾠsurfactant.	 ﾠSmall	 ﾠamounts	 ﾠof	 ﾠ
PG	 ﾠrelative	 ﾠto	 ﾠPI	 ﾠoccurred	 ﾠthroughout	 ﾠsampling.	 ﾠThe	 ﾠrelatively	 ﾠhigh	 ﾠlevels	 ﾠof	 ﾠPI	 ﾠ
despite	 ﾠendogenous	 ﾠsurfactant	 ﾠpresence	 ﾠsuggested	 ﾠthat,	 ﾠwhile	 ﾠthere	 ﾠwas	 ﾠvery	 ﾠlittle	 ﾠ
PC	 ﾠsynthesis,	 ﾠthe	 ﾠPI	 ﾠwas	 ﾠsynthesised	 ﾠin	 ﾠlarge	 ﾠamounts.	 ﾠ	 ﾠ
This	 ﾠdata	 ﾠwas	 ﾠconsistent	 ﾠwith	 ﾠa	 ﾠscenario	 ﾠof	 ﾠCurosurf®	 ﾠacting	 ﾠas	 ﾠa	 ﾠsubstrate	 ﾠfor	 ﾠ
recycling,	 ﾠdisassembly	 ﾠand	 ﾠreassembly	 ﾠand	 ﾠnot	 ﾠde	 ﾠnovo	 ﾠsynthesis.	 ﾠ
The	 ﾠlow	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠincorporation	 ﾠoffers	 ﾠlittle	 ﾠinformation	 ﾠon	 ﾠendogenous	 ﾠ
synthetic	 ﾠrate	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠ48	 ﾠhours	 ﾠof	 ﾠthe	 ﾠstudy	 ﾠbut	 ﾠthere	 ﾠwas	 ﾠsignificant	 ﾠevidence	 ﾠ
of	 ﾠrecycling	 ﾠof	 ﾠCurosurf®	 ﾠin	 ﾠthis	 ﾠperiod.	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Chapter	 ﾠ6.	 ﾠConcluding	 ﾠRemarks	 ﾠ
Newborn	 ﾠextreme	 ﾠpreterm	 ﾠinfants	 ﾠpresent	 ﾠa	 ﾠunique	 ﾠset	 ﾠof	 ﾠchallenges	 ﾠto	 ﾠboth	 ﾠthe	 ﾠ
clinician	 ﾠ and	 ﾠ the	 ﾠ research	 ﾠ scientist,	 ﾠ as	 ﾠ they	 ﾠ are	 ﾠ different	 ﾠ from	 ﾠ more	 ﾠ mature	 ﾠ
patients	 ﾠ as	 ﾠ a	 ﾠ result	 ﾠ of	 ﾠ their	 ﾠ incomplete	 ﾠ physiological	 ﾠ development	 ﾠ during	 ﾠ
pregnancy.	 ﾠWhile	 ﾠclinical	 ﾠadvances	 ﾠwith	 ﾠthe	 ﾠuse	 ﾠof	 ﾠantenatal	 ﾠsteroids	 ﾠ(Crowley,	 ﾠ
1995,	 ﾠLiggins	 ﾠand	 ﾠHowie,	 ﾠ1972,	 ﾠLiggins	 ﾠand	 ﾠHowie,	 ﾠ1971),	 ﾠventilation	 ﾠstrategies	 ﾠto	 ﾠ
reduce	 ﾠvolutrauma	 ﾠand	 ﾠbarotrauma	 ﾠ(Morley,	 ﾠ2012,	 ﾠWheeler	 ﾠet	 ﾠal.,	 ﾠ2011,	 ﾠOwen	 ﾠet	 ﾠ
al.,	 ﾠ 2011,	 ﾠ Klingenberg	 ﾠ et	 ﾠ al.,	 ﾠ 2011,	 ﾠ Allison	 ﾠ et	 ﾠ al.,	 ﾠ 2008,	 ﾠ McCallion	 ﾠ et	 ﾠ al.,	 ﾠ 2005,	 ﾠ
Henderson-ﾭ‐Smart	 ﾠ et	 ﾠ al.,	 ﾠ 2002,	 ﾠ Tarnow-ﾭ‐Mordi	 ﾠ et	 ﾠ al.,	 ﾠ 1986,	 ﾠ Tarnow-ﾭ‐Mordi	 ﾠ and	 ﾠ
Wilkinson,	 ﾠ1986,	 ﾠSouth	 ﾠand	 ﾠMorley,	 ﾠ1986,	 ﾠGreenough	 ﾠet	 ﾠal.,	 ﾠ1983),	 ﾠimproved	 ﾠfluid	 ﾠ
and	 ﾠnutritional	 ﾠsupport	 ﾠ(Gross	 ﾠand	 ﾠSlagle,	 ﾠ1993,	 ﾠBrownlee	 ﾠet	 ﾠal.,	 ﾠ1993,	 ﾠGilbertson	 ﾠ
et	 ﾠal.,	 ﾠ1991,	 ﾠLucas	 ﾠet	 ﾠal.,	 ﾠ1989),	 ﾠand	 ﾠtemperature	 ﾠmanagement	 ﾠ(Johanson	 ﾠet	 ﾠal.,	 ﾠ
1992,	 ﾠPinter	 ﾠet	 ﾠal.,	 ﾠ1971)	 ﾠhave	 ﾠgreatly	 ﾠimproved	 ﾠmortality	 ﾠto	 ﾠ24	 ﾠweeks	 ﾠgestation	 ﾠ
and	 ﾠeven	 ﾠpushed	 ﾠthe	 ﾠedge	 ﾠof	 ﾠviability	 ﾠback	 ﾠto	 ﾠthe	 ﾠ23rd	 ﾠweek	 ﾠof	 ﾠgestation	 ﾠ(Costeloe	 ﾠ
et	 ﾠal.,	 ﾠ2012,	 ﾠDoyle	 ﾠet	 ﾠal.,	 ﾠ2011),	 ﾠthis	 ﾠincreased	 ﾠsurvival	 ﾠto	 ﾠdischarge	 ﾠcomes	 ﾠat	 ﾠa	 ﾠprice	 ﾠ
with	 ﾠthe	 ﾠrisk	 ﾠof	 ﾠassociated	 ﾠsignificant	 ﾠlong-ﾭ‐term	 ﾠmorbidities.	 ﾠThe	 ﾠrisk	 ﾠof	 ﾠdeveloping	 ﾠ
serious	 ﾠhealth	 ﾠproblems	 ﾠsuch	 ﾠas	 ﾠsevere	 ﾠneurodevelopmental	 ﾠdelay	 ﾠ(Wood	 ﾠet	 ﾠal.,	 ﾠ
2005)	 ﾠ encompassing	 ﾠ cerebral	 ﾠ palsy,	 ﾠ blindness	 ﾠ or	 ﾠ deafness	 ﾠ (Moore	 ﾠ et	 ﾠ al.,	 ﾠ 2012,	 ﾠ
Costeloe	 ﾠ et	 ﾠ al.,	 ﾠ 2012,	 ﾠ Doyle	 ﾠ et	 ﾠ al.,	 ﾠ 2011),	 ﾠ chronic	 ﾠ lung	 ﾠ disease	 ﾠ and	 ﾠ oxygen	 ﾠ
dependence	 ﾠ (Bolton	 ﾠ et	 ﾠ al.,	 ﾠ 2012,	 ﾠ Fawke	 ﾠ et	 ﾠ al.,	 ﾠ 2010),	 ﾠ hyperreactive	 ﾠ airways	 ﾠ
(Northway	 ﾠet	 ﾠal.,	 ﾠ1990)	 ﾠand	 ﾠsusceptibility	 ﾠto	 ﾠrespiratory	 ﾠinfection	 ﾠ(Bolton	 ﾠet	 ﾠal.,	 ﾠ
2012,	 ﾠManktelow	 ﾠet	 ﾠal.,	 ﾠ2001,	 ﾠBancalari,	 ﾠ2001)	 ﾠand	 ﾠincreased	 ﾠenergy	 ﾠrequirement	 ﾠ
and	 ﾠgrowth	 ﾠfailure	 ﾠ(Kurzner	 ﾠet	 ﾠal.,	 ﾠ1988)	 ﾠincreases	 ﾠrapidly	 ﾠfor	 ﾠthose	 ﾠbabies	 ﾠborn	 ﾠ
most	 ﾠpreterm.	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For	 ﾠthese	 ﾠchildren	 ﾠthe	 ﾠnormal	 ﾠpatterns	 ﾠof	 ﾠin	 ﾠutero	 ﾠdevelopment	 ﾠhave	 ﾠbeen	 ﾠarrested	 ﾠ
by	 ﾠtheir	 ﾠpremature	 ﾠbirth,	 ﾠwhich	 ﾠthen	 ﾠaffects	 ﾠmultiple	 ﾠbody	 ﾠsystems.	 ﾠThey	 ﾠhave	 ﾠhad	 ﾠ
insufficient	 ﾠtime	 ﾠto	 ﾠlay	 ﾠdown	 ﾠthe	 ﾠnecessary	 ﾠfat	 ﾠand	 ﾠenergy	 ﾠstores	 ﾠto	 ﾠtolerate	 ﾠthe	 ﾠ
normal	 ﾠ postnatal	 ﾠ transition	 ﾠ from	 ﾠ a	 ﾠ continuous	 ﾠ placental	 ﾠ nutrient	 ﾠ supply	 ﾠ to	 ﾠ an	 ﾠ
intermittent	 ﾠ enteric	 ﾠ feeding	 ﾠ pattern	 ﾠ (Larque	 ﾠ et	 ﾠ al.,	 ﾠ 2011,	 ﾠ Haggarty	 ﾠ et	 ﾠ al.,	 ﾠ 2002,	 ﾠ
Sparks	 ﾠet	 ﾠal.,	 ﾠ1980)	 ﾠwhile	 ﾠtheir	 ﾠbowel	 ﾠis	 ﾠunable	 ﾠto	 ﾠtolerate	 ﾠfeeding	 ﾠfor	 ﾠa	 ﾠprolonged	 ﾠ
period	 ﾠafter	 ﾠbirth	 ﾠ(Hunter	 ﾠet	 ﾠal.,	 ﾠ2008).	 ﾠThey	 ﾠhave	 ﾠimmature	 ﾠbrains	 ﾠ(Costello	 ﾠet	 ﾠal.,	 ﾠ
1988)	 ﾠand	 ﾠthey	 ﾠhave	 ﾠunderdeveloped	 ﾠand	 ﾠonly	 ﾠpartially	 ﾠalveolarised	 ﾠlungs	 ﾠwith	 ﾠa	 ﾠ
deficiency	 ﾠof	 ﾠsurfactant	 ﾠ(Lucey,	 ﾠ1991,	 ﾠShapiro	 ﾠet	 ﾠal.,	 ﾠ1985,	 ﾠFujiwara	 ﾠand	 ﾠAdams,	 ﾠ
1980).	 ﾠ
Previously	 ﾠeffort	 ﾠhas	 ﾠfocused,	 ﾠrightly,	 ﾠon	 ﾠreducing	 ﾠmortality	 ﾠthrough	 ﾠthe	 ﾠuse	 ﾠof	 ﾠ
interventions,	 ﾠ such	 ﾠ as	 ﾠ exogenous	 ﾠ surfactant	 ﾠ replacement	 ﾠ to	 ﾠ correct	 ﾠ surfactant	 ﾠ
deficiency,	 ﾠbut	 ﾠa	 ﾠbetter	 ﾠunderstanding	 ﾠof	 ﾠthe	 ﾠmetabolic	 ﾠchanges	 ﾠundergone	 ﾠin	 ﾠthe	 ﾠ
first	 ﾠhours	 ﾠand	 ﾠdays	 ﾠof	 ﾠlife	 ﾠcan	 ﾠinform	 ﾠour	 ﾠunderstanding	 ﾠof	 ﾠhow	 ﾠthese	 ﾠchildren	 ﾠ
develop	 ﾠ long-ﾭ‐term	 ﾠ morbidities	 ﾠ and	 ﾠ can	 ﾠ drive	 ﾠ advances	 ﾠ in	 ﾠ correcting	 ﾠ and	 ﾠ
preventing	 ﾠthose	 ﾠproblems.	 ﾠ
The	 ﾠtranslational	 ﾠresearch	 ﾠundertaken	 ﾠin	 ﾠthis	 ﾠthesis	 ﾠhas	 ﾠopened	 ﾠup	 ﾠnew	 ﾠavenues	 ﾠ
for	 ﾠthe	 ﾠadvancement	 ﾠof	 ﾠneonatal	 ﾠcare	 ﾠby	 ﾠcombining	 ﾠadvances	 ﾠin	 ﾠthe	 ﾠrefinement	 ﾠ
and	 ﾠ power	 ﾠ of	 ﾠ mass	 ﾠ spectrometric	 ﾠ techniques	 ﾠ with	 ﾠ pioneering	 ﾠ stable	 ﾠ isotope	 ﾠ
labelling	 ﾠto	 ﾠproduce	 ﾠa	 ﾠmethodology	 ﾠthat	 ﾠis	 ﾠrapid,	 ﾠsensitive	 ﾠand	 ﾠaccurate,	 ﾠand	 ﾠwhich	 ﾠ
can	 ﾠ address	 ﾠ some	 ﾠ of	 ﾠ these	 ﾠ underlying	 ﾠ metabolic	 ﾠ questions	 ﾠ relating	 ﾠ to	 ﾠ the	 ﾠ
development	 ﾠof	 ﾠlong	 ﾠterm	 ﾠproblems.	 ﾠPrevious	 ﾠtechniques	 ﾠemployed	 ﾠto	 ﾠinvestigate	 ﾠ
surfactant	 ﾠand	 ﾠcholine	 ﾠmetabolism	 ﾠin	 ﾠthe	 ﾠneonatal	 ﾠclinical	 ﾠenvironment	 ﾠwere	 ﾠless	 ﾠ
sensitive,	 ﾠ relied	 ﾠ on	 ﾠ continuous	 ﾠ infusions	 ﾠ of	 ﾠ stable	 ﾠ isotope	 ﾠ preparations,	 ﾠ took	 ﾠ
several	 ﾠ steps	 ﾠ to	 ﾠ process	 ﾠ in	 ﾠ the	 ﾠ laboratory	 ﾠ and	 ﾠ required	 ﾠ complex	 ﾠ mathematical	 ﾠ
modelling	 ﾠto	 ﾠinterpret	 ﾠ(Carnielli	 ﾠet	 ﾠal.,	 ﾠ2009,	 ﾠCogo	 ﾠet	 ﾠal.,	 ﾠ1999,	 ﾠTorresin	 ﾠet	 ﾠal.,	 ﾠ2000,	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Bohlin	 ﾠet	 ﾠal.,	 ﾠ2005).	 ﾠAs	 ﾠa	 ﾠconsequence	 ﾠthese	 ﾠtechniques,	 ﾠunlike	 ﾠthe	 ﾠcombination	 ﾠof	 ﾠ
ESI-ﾭ‐MS/MS	 ﾠ and	 ﾠ [methyl-ﾭ‐D9]choline	 ﾠ as	 ﾠ presented	 ﾠ in	 ﾠ this	 ﾠ thesis,	 ﾠ have	 ﾠ no	 ﾠ
translational	 ﾠapplication	 ﾠin	 ﾠthe	 ﾠneonatal	 ﾠclinical	 ﾠenvironment.	 ﾠ
Choline	 ﾠ and	 ﾠ phospholipid	 ﾠ metabolism	 ﾠ do	 ﾠ not	 ﾠ exist	 ﾠ in	 ﾠ isolation	 ﾠ and	 ﾠ their	 ﾠ
investigation	 ﾠinforms	 ﾠseveral	 ﾠsystems	 ﾠof	 ﾠcritical	 ﾠimportance	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠ
including	 ﾠ respiratory	 ﾠ function	 ﾠ [phosphatidylcholine	 ﾠ phospholipids]	 ﾠ (Batenburg,	 ﾠ
1992,	 ﾠPost	 ﾠet	 ﾠal.,	 ﾠ1983,	 ﾠRebello	 ﾠet	 ﾠal.,	 ﾠ1996),	 ﾠnutrition	 ﾠ[choline,	 ﾠphospholipids	 ﾠand	 ﾠ
fatty	 ﾠ acids]	 ﾠ (Dziechciarz	 ﾠ et	 ﾠ al.,	 ﾠ 2010,	 ﾠ Lucas	 ﾠ et	 ﾠ al.,	 ﾠ 1989,	 ﾠ Shoji	 ﾠ et	 ﾠ al.,	 ﾠ 2006),	 ﾠ
neurodevelopment	 ﾠ[choline,	 ﾠacetylcholine	 ﾠand	 ﾠPUFA	 ﾠspecies]	 ﾠ(Simopoulos,	 ﾠ2011,	 ﾠ
Zeisel,	 ﾠ 2006b,	 ﾠ Zeisel	 ﾠ and	 ﾠ Niculescu,	 ﾠ 2006),	 ﾠ retinal	 ﾠ development	 ﾠ [PUFA	 ﾠ
phospholipid	 ﾠspecies]	 ﾠ(Aveldano	 ﾠde	 ﾠCaldironi	 ﾠet	 ﾠal.,	 ﾠ1981,	 ﾠBerdeaux	 ﾠet	 ﾠal.,	 ﾠ2010,	 ﾠ
Hoffman	 ﾠet	 ﾠal.,	 ﾠ1993)	 ﾠand	 ﾠmethyl	 ﾠtransfer	 ﾠ[PEMT	 ﾠpathway	 ﾠfunction]	 ﾠ(DeLong	 ﾠet	 ﾠal.,	 ﾠ
2002,	 ﾠSundler	 ﾠand	 ﾠAkesson,	 ﾠ1975a).	 ﾠ
The	 ﾠresults	 ﾠoutlined	 ﾠin	 ﾠChapter	 ﾠ3	 ﾠdemonstrated	 ﾠfor	 ﾠthe	 ﾠfirst	 ﾠtime	 ﾠthe	 ﾠimportant	 ﾠ
differences	 ﾠin	 ﾠthe	 ﾠmetabolism	 ﾠof	 ﾠcholine	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠinfant	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠ
published	 ﾠ adult	 ﾠ volunteer	 ﾠ (Pynn	 ﾠ et	 ﾠ al.,	 ﾠ 2011)	 ﾠ and	 ﾠ paediatric	 ﾠ acute	 ﾠ lung	 ﾠ injury	 ﾠ
population	 ﾠdata	 ﾠ(Goss	 ﾠet	 ﾠal.,	 ﾠ2010a).	 ﾠAdult	 ﾠvolunteers	 ﾠshowed	 ﾠa	 ﾠgradual	 ﾠde	 ﾠnovo	 ﾠ
synthesis	 ﾠof	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠcontaining	 ﾠPC	 ﾠspecies	 ﾠto	 ﾠa	 ﾠsimilar	 ﾠpeak	 ﾠenrichment	 ﾠ
of	 ﾠ0.9%,	 ﾠhowever	 ﾠthe	 ﾠtime	 ﾠtaken	 ﾠto	 ﾠreach	 ﾠthis	 ﾠpeak	 ﾠwas	 ﾠtwice	 ﾠas	 ﾠlong	 ﾠ(24	 ﾠhours)	 ﾠas	 ﾠ
that	 ﾠ demonstrated	 ﾠ in	 ﾠ the	 ﾠ preterm	 ﾠ population.	 ﾠ The	 ﾠ paediatric	 ﾠ acute	 ﾠ lung	 ﾠ injury	 ﾠ
population,	 ﾠunlike	 ﾠthe	 ﾠpreterm	 ﾠinfants,	 ﾠalso	 ﾠtook	 ﾠaround	 ﾠ24	 ﾠhours	 ﾠto	 ﾠreach	 ﾠpeak	 ﾠ
enrichment	 ﾠ(Goss	 ﾠet	 ﾠal.,	 ﾠ2010b,	 ﾠGoss	 ﾠet	 ﾠal.,	 ﾠ2010a).	 ﾠ
This	 ﾠis	 ﾠthe	 ﾠfirst	 ﾠstudy	 ﾠto	 ﾠdemonstrate	 ﾠthat	 ﾠthese	 ﾠinfants,	 ﾠwithin	 ﾠhours	 ﾠof	 ﾠpreterm	 ﾠ
birth,	 ﾠ have	 ﾠ the	 ﾠ ability	 ﾠ to	 ﾠ manufacture	 ﾠ essential	 ﾠ de	 ﾠnovo	 ﾠPC	 ﾠ phospholipids	 ﾠ from	 ﾠ
available	 ﾠ substrate,	 ﾠ via	 ﾠ the	 ﾠ CDP-ﾭ‐choline	 ﾠ pathway,	 ﾠ and	 ﾠ move	 ﾠ these	 ﾠ newly	 ﾠ
synthesised	 ﾠspecies	 ﾠinto	 ﾠplasma,	 ﾠpossibly	 ﾠby	 ﾠlow	 ﾠdensity	 ﾠlipoproteins,	 ﾠat	 ﾠa	 ﾠrate	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twice	 ﾠas	 ﾠrapid	 ﾠas	 ﾠany	 ﾠpreviously	 ﾠpublished	 ﾠhuman	 ﾠstudies.	 ﾠPlasma	 ﾠmeasurements	 ﾠ
of	 ﾠde	 ﾠnovo	 ﾠPC	 ﾠspecies	 ﾠare	 ﾠa	 ﾠreflection	 ﾠof	 ﾠliver	 ﾠactivity	 ﾠ(Postle	 ﾠand	 ﾠHunt,	 ﾠ2009)	 ﾠand	 ﾠ
therefore	 ﾠthe	 ﾠpreterm	 ﾠhuman	 ﾠliver	 ﾠdemonstrates	 ﾠvery	 ﾠhigh	 ﾠactivity	 ﾠin	 ﾠthe	 ﾠCDP-ﾭ‐
choline	 ﾠpathway.	 ﾠ
	 ﾠAdditionally	 ﾠChapter	 ﾠ3	 ﾠhighlights	 ﾠthat	 ﾠthe	 ﾠPC	 ﾠlipid	 ﾠspecies	 ﾠproduced	 ﾠby	 ﾠthe	 ﾠCDP-ﾭ‐
choline	 ﾠpathway	 ﾠare	 ﾠaffected	 ﾠby	 ﾠthe	 ﾠadministration	 ﾠof	 ﾠTPN,	 ﾠwith	 ﾠa	 ﾠmeasurable	 ﾠshift	 ﾠ
towards	 ﾠthe	 ﾠproduction	 ﾠof	 ﾠmono-ﾭ‐	 ﾠand	 ﾠdiunsaturated	 ﾠspecies	 ﾠonce	 ﾠTPN	 ﾠis	 ﾠstarted.	 ﾠ
This	 ﾠevidence	 ﾠfor	 ﾠthe	 ﾠphospholipid	 ﾠsynthetic	 ﾠability	 ﾠof	 ﾠthe	 ﾠpreterm	 ﾠliver	 ﾠand	 ﾠthe	 ﾠ
dependence	 ﾠ of	 ﾠ the	 ﾠ system	 ﾠ on	 ﾠ nutritional	 ﾠ sources	 ﾠ of	 ﾠ fatty	 ﾠ acids	 ﾠ should	 ﾠ inform	 ﾠ
decisions	 ﾠregarding	 ﾠthe	 ﾠappropriateness	 ﾠof	 ﾠusing	 ﾠpredominantly	 ﾠ18:1/oleic	 ﾠacid-ﾭ‐
based	 ﾠTPN	 ﾠlipid	 ﾠin	 ﾠthese	 ﾠchildren.	 ﾠIt	 ﾠis	 ﾠpossible	 ﾠthat	 ﾠthe	 ﾠuse	 ﾠof	 ﾠa	 ﾠthird	 ﾠgeneration	 ﾠ
lipid	 ﾠ emulsion	 ﾠ in	 ﾠ TPN	 ﾠ with	 ﾠ a	 ﾠ higher	 ﾠ polyunsaturated	 ﾠ fatty	 ﾠ acid	 ﾠ content	 ﾠ called	 ﾠ
SMOFlipid®	 ﾠ(soybean	 ﾠoil,	 ﾠmedium	 ﾠchain	 ﾠtriglycerides	 ﾠ(MCT),	 ﾠolive	 ﾠoil	 ﾠand	 ﾠfish	 ﾠoil),	 ﾠ
which	 ﾠhas	 ﾠbeen	 ﾠintroduced	 ﾠinto	 ﾠthe	 ﾠneonatal	 ﾠunit	 ﾠin	 ﾠSouthampton	 ﾠsince	 ﾠthis	 ﾠstudy	 ﾠ
completed	 ﾠrecruitment,	 ﾠhas	 ﾠhad	 ﾠmeasurable	 ﾠdifferences	 ﾠin	 ﾠthe	 ﾠPC	 ﾠphospholipid	 ﾠ
profile	 ﾠ of	 ﾠ the	 ﾠ children	 ﾠ who	 ﾠ have	 ﾠ received	 ﾠ it.	 ﾠ Future	 ﾠ studies,	 ﾠ using	 ﾠ the	 ﾠ same	 ﾠ
technique	 ﾠ of	 ﾠ incorporation	 ﾠ of	 ﾠ a	 ﾠ labelled	 ﾠ substrate	 ﾠ with	 ﾠ mass	 ﾠ spectrometry	 ﾠ of	 ﾠ
clinical	 ﾠsamples,	 ﾠshould	 ﾠcompare	 ﾠthe	 ﾠeffect	 ﾠof	 ﾠvaried	 ﾠTPN	 ﾠlipid	 ﾠpreparations	 ﾠon	 ﾠ
preterm	 ﾠplasma	 ﾠPC	 ﾠphospholipid	 ﾠprofile.	 ﾠ
In	 ﾠChapter	 ﾠ4,	 ﾠand	 ﾠagain	 ﾠfor	 ﾠthe	 ﾠfirst	 ﾠtime,	 ﾠthe	 ﾠactivity	 ﾠof	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠhas	 ﾠ
been	 ﾠdescribed	 ﾠin	 ﾠthe	 ﾠpreterm	 ﾠhuman	 ﾠpopulation.	 ﾠThe	 ﾠidentification	 ﾠof	 ﾠvery	 ﾠlow	 ﾠ
flux	 ﾠ through	 ﾠ this	 ﾠ pathway	 ﾠ when	 ﾠ compared	 ﾠ to	 ﾠ adults	 ﾠ (Pynn	 ﾠ et	 ﾠ al.,	 ﾠ 2011),	 ﾠ has	 ﾠ
significant	 ﾠclinical	 ﾠimplications.	 ﾠPEMT	 ﾠis	 ﾠthe	 ﾠprimary	 ﾠsource	 ﾠof	 ﾠPUFA-ﾭ‐containing	 ﾠ
phosphatidylcholine	 ﾠ phospholipids	 ﾠ in	 ﾠ adults	 ﾠ (Watkins	 ﾠ et	 ﾠ al.,	 ﾠ 2003,	 ﾠ Waite	 ﾠ et	 ﾠ al.,	 ﾠ
2002)	 ﾠ but	 ﾠ the	 ﾠ newborn	 ﾠ preterm	 ﾠ infant	 ﾠ is	 ﾠ capable	 ﾠ of	 ﾠ only	 ﾠ limited	 ﾠ PUFA	 ﾠ PC	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production	 ﾠvia	 ﾠthe	 ﾠvery	 ﾠactive	 ﾠCDP-ﾭ‐choline	 ﾠpathway,	 ﾠas	 ﾠshown	 ﾠin	 ﾠChapter	 ﾠ3,	 ﾠto	 ﾠ
partially	 ﾠaddress	 ﾠthis	 ﾠdeficit	 ﾠin	 ﾠPEMT	 ﾠproduction.	 ﾠ
Also	 ﾠas	 ﾠthe	 ﾠPEMT	 ﾠpathway	 ﾠis	 ﾠthe	 ﾠonly	 ﾠsource	 ﾠof	 ﾠde	 ﾠnovo	 ﾠcholine	 ﾠsynthesis	 ﾠ(Jacobs	 ﾠ
et	 ﾠal.,	 ﾠ2010),	 ﾠthe	 ﾠnewborn	 ﾠpreterm	 ﾠinfant	 ﾠis	 ﾠcompletely	 ﾠdependent	 ﾠon	 ﾠthe	 ﾠdietary	 ﾠ
supply	 ﾠ of	 ﾠ choline	 ﾠ from	 ﾠ TPN.	 ﾠ Research	 ﾠ is	 ﾠ now	 ﾠ underway	 ﾠ in	 ﾠ Southampton	 ﾠ to	 ﾠ
investigate	 ﾠ the	 ﾠ supply	 ﾠ of	 ﾠ choline	 ﾠ in	 ﾠ TPN	 ﾠ to	 ﾠ these	 ﾠ children	 ﾠ with	 ﾠ comparison	 ﾠ to	 ﾠ
recommended	 ﾠintake.	 ﾠPreliminary	 ﾠreports	 ﾠshow	 ﾠthat	 ﾠthese	 ﾠpreterm	 ﾠchildren	 ﾠfail	 ﾠto	 ﾠ
meet	 ﾠthe	 ﾠtargets	 ﾠfor	 ﾠseveral	 ﾠdays	 ﾠor	 ﾠeven	 ﾠweeks	 ﾠafter	 ﾠdelivery	 ﾠ[unpublished	 ﾠdata].	 ﾠ
Inadequate	 ﾠsupply	 ﾠof	 ﾠcholine	 ﾠin	 ﾠthese	 ﾠfirst	 ﾠcritical	 ﾠdays	 ﾠmay	 ﾠhave	 ﾠprofound	 ﾠeffects,	 ﾠ
not	 ﾠjust	 ﾠon	 ﾠphospholipid	 ﾠand	 ﾠcholine	 ﾠmetabolite	 ﾠproduction	 ﾠbut	 ﾠalso	 ﾠon	 ﾠan	 ﾠeffective	 ﾠ
methyl	 ﾠtransfer	 ﾠsystem	 ﾠand	 ﾠhence	 ﾠpotentially	 ﾠaffect	 ﾠgenomic	 ﾠimprinting	 ﾠand	 ﾠfuture	 ﾠ
health	 ﾠ(Barnes	 ﾠand	 ﾠOzanne,	 ﾠ2011,	 ﾠBurdge	 ﾠand	 ﾠLillycrop,	 ﾠ2010).	 ﾠ
Very	 ﾠrecently	 ﾠpublished	 ﾠresearch	 ﾠfrom	 ﾠCanada	 ﾠ(Wu	 ﾠet	 ﾠal.,	 ﾠ2012)	 ﾠhas	 ﾠshown,	 ﾠin	 ﾠ
PEMT-ﾭ‐/-ﾭ‐	 ﾠknockout	 ﾠmice,	 ﾠthat	 ﾠde	 ﾠnovo	 ﾠcholine	 ﾠsynthesis	 ﾠplays	 ﾠa	 ﾠrole	 ﾠin	 ﾠregulating	 ﾠ
whole	 ﾠbody	 ﾠenergy	 ﾠmetabolism,	 ﾠpossibly	 ﾠthrough	 ﾠmodulation	 ﾠof	 ﾠplasma	 ﾠglucagon	 ﾠ
and	 ﾠ its	 ﾠ action	 ﾠ in	 ﾠ liver.	 ﾠ It	 ﾠ is	 ﾠ too	 ﾠ early	 ﾠ to	 ﾠ say	 ﾠ whether	 ﾠ this	 ﾠ applies	 ﾠ in	 ﾠ newborn	 ﾠ
humans	 ﾠbut	 ﾠfuture	 ﾠstudies	 ﾠcould	 ﾠinclude	 ﾠinsulin	 ﾠand	 ﾠglucagon	 ﾠmeasurements	 ﾠin	 ﾠ
addition	 ﾠto	 ﾠlipid	 ﾠprofiles.	 ﾠ
Finally	 ﾠthe	 ﾠresearch	 ﾠpresented	 ﾠin	 ﾠChapter	 ﾠ5	 ﾠprovides	 ﾠthe	 ﾠfirst	 ﾠevidence	 ﾠthat	 ﾠthe	 ﾠ
preterm	 ﾠ lung	 ﾠ takes	 ﾠ several	 ﾠ days	 ﾠ to	 ﾠ synthesise	 ﾠ de	 ﾠ novo	 ﾠ phosphatidylcholine	 ﾠ
phospholipids	 ﾠfrom	 ﾠcholine,	 ﾠeventually	 ﾠreaching	 ﾠan	 ﾠaverage	 ﾠenrichment	 ﾠof	 ﾠ0.3%	 ﾠby	 ﾠ
120	 ﾠhours.	 ﾠImportantly	 ﾠthis	 ﾠdata	 ﾠis	 ﾠavailable	 ﾠfrom	 ﾠthe	 ﾠlaboratory	 ﾠwithin	 ﾠa	 ﾠclinically	 ﾠ
relevant	 ﾠtimeframe.	 ﾠA	 ﾠ2004	 ﾠstudy	 ﾠexamined	 ﾠinduced	 ﾠsputum	 ﾠfrom	 ﾠadult	 ﾠvolunteers	 ﾠ
and	 ﾠdemonstrated	 ﾠa	 ﾠrapid	 ﾠ[methyl-ﾭ‐D9]choline	 ﾠenrichment	 ﾠto	 ﾠ0.6%	 ﾠwithin	 ﾠ24	 ﾠhours	 ﾠ
(Bernhard	 ﾠet	 ﾠal.,	 ﾠ2004).	 ﾠIt	 ﾠtook	 ﾠ48	 ﾠhours	 ﾠfor	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠde	 ﾠnovo	 ﾠadult	 ﾠPC	 ﾠ
phospholipids	 ﾠto	 ﾠreflect	 ﾠoverall	 ﾠproportions.	 ﾠThe	 ﾠPC	 ﾠspecies	 ﾠthat	 ﾠare	 ﾠsynthesised	 ﾠin	 ﾠ  154	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the	 ﾠpreterm	 ﾠinfant	 ﾠhowever	 ﾠtake	 ﾠupwards	 ﾠof	 ﾠ96	 ﾠhours	 ﾠto	 ﾠreflect	 ﾠthe	 ﾠproportions	 ﾠof	 ﾠ
the	 ﾠ total	 ﾠ pool	 ﾠ of	 ﾠ surfactant	 ﾠ species	 ﾠ and	 ﾠ show	 ﾠ a	 ﾠ different	 ﾠ specificity	 ﾠ from	 ﾠ the	 ﾠ
plasma-ﾭ‐derived	 ﾠspecies.	 ﾠThe	 ﾠproduction,	 ﾠproportion	 ﾠand	 ﾠspecificity	 ﾠof	 ﾠindividual	 ﾠ
PC	 ﾠ phospholipid	 ﾠ species	 ﾠ in	 ﾠ preterm	 ﾠ surfactant	 ﾠ has	 ﾠ never	 ﾠ been	 ﾠ demonstrated	 ﾠ
before.	 ﾠPrevious	 ﾠstudies	 ﾠhave	 ﾠonly	 ﾠbeen	 ﾠable	 ﾠto	 ﾠlook	 ﾠmore	 ﾠgenerally	 ﾠat	 ﾠdisaturated	 ﾠ
phosphatidylcholine	 ﾠ(DSPC)	 ﾠspecies	 ﾠin	 ﾠsurfactant	 ﾠ(Cogo	 ﾠet	 ﾠal.,	 ﾠ2005a,	 ﾠTorresin	 ﾠet	 ﾠal.,	 ﾠ
2000,	 ﾠBunt	 ﾠet	 ﾠal.,	 ﾠ2000)	 ﾠleading	 ﾠto	 ﾠan	 ﾠunderestimation	 ﾠof	 ﾠthe	 ﾠquantity	 ﾠof	 ﾠnon-ﾭ‐DSPC	 ﾠ
species	 ﾠin	 ﾠpreterm	 ﾠsurfactant	 ﾠsystems	 ﾠin	 ﾠvivo.	 ﾠ
Meanwhile	 ﾠ the	 ﾠ acidic	 ﾠ phospholipids,	 ﾠ phosphatidylglycerol	 ﾠ and	 ﾠ
phosphatidylinositol	 ﾠshow	 ﾠdramatic	 ﾠchanges	 ﾠwith	 ﾠtime,	 ﾠconsistent	 ﾠwith	 ﾠpreviously	 ﾠ
published	 ﾠ data	 ﾠ on	 ﾠ immature	 ﾠ and	 ﾠ injured	 ﾠ mature	 ﾠ lung	 ﾠ phospholipid	 ﾠ profiles	 ﾠ
(Hallman	 ﾠ et	 ﾠ al.,	 ﾠ 1982,	 ﾠ Hallman	 ﾠ et	 ﾠ al.,	 ﾠ 1977,	 ﾠ Hallman	 ﾠ and	 ﾠ Gluck,	 ﾠ 1975)	 ﾠ
demonstrating	 ﾠactive	 ﾠsurfactant	 ﾠmetabolism.	 ﾠThe	 ﾠconsistent	 ﾠPC	 ﾠprofile	 ﾠsuggests	 ﾠ
selective	 ﾠreuptake	 ﾠand	 ﾠrepackaging	 ﾠof	 ﾠthe	 ﾠexogenously	 ﾠderived	 ﾠPC	 ﾠphospholipids	 ﾠ
by	 ﾠthe	 ﾠalveolar	 ﾠtype	 ﾠII	 ﾠcells	 ﾠrather	 ﾠthan	 ﾠnew	 ﾠsynthesis	 ﾠbeing	 ﾠthe	 ﾠmajor	 ﾠfactor	 ﾠin	 ﾠ
determining	 ﾠtotal	 ﾠPC	 ﾠphospholipid	 ﾠprofile	 ﾠin	 ﾠthe	 ﾠlungs.	 ﾠFrom	 ﾠthis	 ﾠstudy	 ﾠtherefore	 ﾠit	 ﾠ
can	 ﾠ be	 ﾠ clearly	 ﾠ stated	 ﾠ that	 ﾠ the	 ﾠ preterm	 ﾠ infant	 ﾠ is	 ﾠ dependent	 ﾠ on	 ﾠ the	 ﾠ exogenously	 ﾠ
derived	 ﾠ surfactant	 ﾠ for	 ﾠ a	 ﾠ variable	 ﾠ timeframe	 ﾠ after	 ﾠ delivery	 ﾠ until	 ﾠ the	 ﾠ de	 ﾠ novo	 ﾠ
synthesis	 ﾠhas	 ﾠstarted	 ﾠto	 ﾠproduce	 ﾠnew	 ﾠPC	 ﾠspecies.	 ﾠIn	 ﾠthe	 ﾠlonger	 ﾠterm	 ﾠit	 ﾠmay	 ﾠbe	 ﾠ
important	 ﾠ to	 ﾠ enhance	 ﾠ the	 ﾠ nutrition	 ﾠ for	 ﾠ these	 ﾠ infants	 ﾠ to	 ﾠ support	 ﾠ AT-ﾭ‐II	 ﾠ cell	 ﾠ
phospholipid	 ﾠsynthesis	 ﾠrather	 ﾠthan	 ﾠsimply	 ﾠreplacing	 ﾠthe	 ﾠsurfactant	 ﾠthey	 ﾠreceive	 ﾠas	 ﾠ
previous	 ﾠstudies	 ﾠhave	 ﾠdemonstrated	 ﾠthat	 ﾠnutrition	 ﾠaffects	 ﾠsurfactant	 ﾠphospholipid	 ﾠ
composition	 ﾠ(Hunt	 ﾠet	 ﾠal.,	 ﾠ1996).	 ﾠ
A	 ﾠfurther	 ﾠstudy	 ﾠis	 ﾠalready	 ﾠunderway	 ﾠin	 ﾠSouthampton	 ﾠinvestigating	 ﾠthe	 ﾠsubset	 ﾠof	 ﾠ
preterm	 ﾠpatients	 ﾠwho	 ﾠrequire	 ﾠprolonged	 ﾠventilation	 ﾠas	 ﾠthere	 ﾠis	 ﾠsome	 ﾠevidence	 ﾠof	 ﾠ
short-ﾭ‐term	 ﾠbenefit	 ﾠin	 ﾠpatients	 ﾠwhen	 ﾠgiven	 ﾠadditional	 ﾠdoses	 ﾠof	 ﾠexogenous	 ﾠsurfactant	 ﾠ  155	 ﾠ
(Pandit	 ﾠet	 ﾠal.,	 ﾠ1995).	 ﾠThey	 ﾠwill	 ﾠreceive	 ﾠa	 ﾠfurther	 ﾠdose	 ﾠof	 ﾠsurfactant	 ﾠat	 ﾠ5	 ﾠdays	 ﾠof	 ﾠlife	 ﾠ
and	 ﾠ the	 ﾠ impact	 ﾠ on	 ﾠ PC	 ﾠ synthesis	 ﾠ will	 ﾠ be	 ﾠ monitored	 ﾠ using	 ﾠ the	 ﾠ labelled	 ﾠ choline	 ﾠ
techniques	 ﾠas	 ﾠin	 ﾠthis	 ﾠresearch	 ﾠproject.	 ﾠ
Further	 ﾠ research	 ﾠ in	 ﾠ Southampton	 ﾠ will	 ﾠ look	 ﾠ at	 ﾠ clinical	 ﾠ correlations	 ﾠ for	 ﾠ these	 ﾠ
preterm	 ﾠ children	 ﾠ with	 ﾠ the	 ﾠ observed	 ﾠ metabolic	 ﾠ changes	 ﾠ measured	 ﾠ plus	 ﾠ their	 ﾠ
dietary	 ﾠintake	 ﾠthroughout	 ﾠtheir	 ﾠstay	 ﾠon	 ﾠthe	 ﾠNICU	 ﾠto	 ﾠbe	 ﾠexamined	 ﾠto	 ﾠdetermine	 ﾠ
biomarkers	 ﾠpredictive	 ﾠfor	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠmorbidity	 ﾠin	 ﾠthe	 ﾠfuture.	 ﾠ
Importantly	 ﾠthis	 ﾠstudy	 ﾠhas	 ﾠshown	 ﾠthat	 ﾠthe	 ﾠtechnique	 ﾠof	 ﾠusing	 ﾠa	 ﾠshort	 ﾠinfusion	 ﾠof	 ﾠa	 ﾠ
stable	 ﾠ isotope	 ﾠ labelled	 ﾠ choline	 ﾠ combined	 ﾠ with	 ﾠ electrospray	 ﾠ ionisation	 ﾠ tandem	 ﾠ
mass	 ﾠspectrometry	 ﾠis	 ﾠfeasible,	 ﾠsafe	 ﾠand	 ﾠpractical	 ﾠin	 ﾠthe	 ﾠneonatal	 ﾠintensive	 ﾠcare	 ﾠ
environment.	 ﾠThe	 ﾠdata	 ﾠgenerated	 ﾠusing	 ﾠthis	 ﾠtechnique	 ﾠwould	 ﾠneed	 ﾠto	 ﾠbe	 ﾠrefined	 ﾠfor	 ﾠ
interpretation	 ﾠ by	 ﾠ clinicians	 ﾠ or	 ﾠ in	 ﾠ the	 ﾠ chemical	 ﾠ pathology	 ﾠ laboratory	 ﾠ but	 ﾠ the	 ﾠ
timeframe	 ﾠfor	 ﾠgetting	 ﾠresults	 ﾠis	 ﾠwithin	 ﾠa	 ﾠclinically	 ﾠrelevant	 ﾠtimeframe	 ﾠopening	 ﾠthe	 ﾠ
possibility	 ﾠof	 ﾠdiagnostic	 ﾠtesting.	 ﾠ
Taken	 ﾠtogether	 ﾠthe	 ﾠresults	 ﾠfrom	 ﾠthis	 ﾠstudy	 ﾠhave	 ﾠfurther	 ﾠextended	 ﾠour	 ﾠknowledge	 ﾠof	 ﾠ
choline	 ﾠ and	 ﾠ phospholipid	 ﾠ metabolism	 ﾠ and	 ﾠ turnover	 ﾠ in	 ﾠ the	 ﾠ preterm	 ﾠ infant.	 ﾠ This	 ﾠ
data	 ﾠ is	 ﾠ already	 ﾠ informing	 ﾠ further	 ﾠ studies	 ﾠ that	 ﾠ could	 ﾠ be	 ﾠ of	 ﾠ rapid	 ﾠ translational	 ﾠ
benefit	 ﾠto	 ﾠimprove	 ﾠfuture	 ﾠcare	 ﾠfor	 ﾠthese	 ﾠvulnerable	 ﾠpatients.	 ﾠ
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 ﾠtime	 ﾠto	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 ﾠimportant	 ﾠstudy.	 ﾠ
	 ﾠ
This	 ﾠleaflet	 ﾠis	 ﾠto	 ﾠtell	 ﾠyou	 ﾠabout	 ﾠour	 ﾠstudy	 ﾠwhich	 ﾠis	 ﾠcalled:	 ﾠ
“Investigation	 ﾠof	 ﾠthe	 ﾠRisk	 ﾠFactors	 ﾠfor	 ﾠNeonatal	 ﾠChronic	 ﾠLung	 ﾠDisease	 ﾠ(nCLD)”	 ﾠ
or	 ﾠ	 ﾠ
“The	 ﾠSurfactant,	 ﾠNutrition	 ﾠand	 ﾠMicroorganism	 ﾠInteractions	 ﾠStudy,	 ﾠin	 ﾠinfants	 ﾠ
at	 ﾠrisk	 ﾠof	 ﾠneonatal	 ﾠChronic	 ﾠLung	 ﾠDisease”.	 ﾠ	 ﾠ
This	 ﾠstudy	 ﾠis	 ﾠcontributing	 ﾠto	 ﾠmy	 ﾠPhD	 ﾠin	 ﾠneonatal	 ﾠchronic	 ﾠlung	 ﾠdisease	 ﾠwith	 ﾠthe	 ﾠ
University	 ﾠof	 ﾠSouthampton’s	 ﾠSchool	 ﾠof	 ﾠMedicine.	 ﾠ
	 ﾠ
We	 ﾠare	 ﾠinviting	 ﾠparents	 ﾠof	 ﾠall	 ﾠbabies	 ﾠborn	 ﾠprematurely,	 ﾠin	 ﾠPrincess	 ﾠAnne	 ﾠHospital,	 ﾠ
Southampton	 ﾠand	 ﾠQueen	 ﾠAlexandra	 ﾠHospital,	 ﾠPortsmouth	 ﾠwith	 ﾠa	 ﾠbirth	 ﾠweight	 ﾠof	 ﾠ
less	 ﾠthan	 ﾠ1250	 ﾠgrams,	 ﾠto	 ﾠhelp	 ﾠwith	 ﾠthis	 ﾠstudy.	 ﾠ
This	 ﾠ study	 ﾠ is	 ﾠ trying	 ﾠ to	 ﾠ find	 ﾠ if	 ﾠ infection,	 ﾠ nutrition	 ﾠ and	 ﾠ how	 ﾠ infants	 ﾠ produce	 ﾠ
surfactant	 ﾠplay	 ﾠa	 ﾠrole	 ﾠin	 ﾠthe	 ﾠbabies	 ﾠwho	 ﾠgo	 ﾠon	 ﾠto	 ﾠdevelop	 ﾠChronic	 ﾠLung	 ﾠDisease.	 ﾠ
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What	 ﾠis	 ﾠSurfactant?	 ﾠ
Surfactant	 ﾠis	 ﾠa	 ﾠnaturally	 ﾠoccurring	 ﾠdetergent,	 ﾠproduced	 ﾠin	 ﾠthe	 ﾠlungs,	 ﾠwhich	 ﾠhelps	 ﾠ
prevent	 ﾠ the	 ﾠ lungs	 ﾠ collapsing.	 ﾠ It	 ﾠ also	 ﾠ has	 ﾠ a	 ﾠ role	 ﾠ in	 ﾠ protecting	 ﾠ the	 ﾠ lungs	 ﾠ from	 ﾠ
infection	 ﾠand	 ﾠinflammation.	 ﾠVery	 ﾠpremature	 ﾠbabies	 ﾠhave	 ﾠlungs	 ﾠthat	 ﾠdo	 ﾠnot	 ﾠproduce	 ﾠ
surfactant	 ﾠor	 ﾠonly	 ﾠin	 ﾠsmall	 ﾠquantities.	 ﾠPremature	 ﾠbabies	 ﾠare	 ﾠgiven	 ﾠextra	 ﾠsurfactant,	 ﾠ
directly	 ﾠto	 ﾠtheir	 ﾠlungs,	 ﾠsoon	 ﾠafter	 ﾠbirth.	 ﾠThis	 ﾠtreatment	 ﾠhas	 ﾠgreatly	 ﾠimproved	 ﾠthe	 ﾠ
survival	 ﾠof	 ﾠthe	 ﾠsmallest	 ﾠbabies	 ﾠover	 ﾠthe	 ﾠlast	 ﾠdecade.	 ﾠ
	 ﾠ
What	 ﾠis	 ﾠChronic	 ﾠLung	 ﾠDisease	 ﾠ(CLD)?	 ﾠ
CLD	 ﾠis	 ﾠa	 ﾠrecognised	 ﾠproblem	 ﾠof	 ﾠbabies	 ﾠborn	 ﾠprematurely,	 ﾠin	 ﾠwhich	 ﾠthey	 ﾠcontinue	 ﾠto	 ﾠ
need	 ﾠoxygen	 ﾠfor	 ﾠa	 ﾠlong	 ﾠtime	 ﾠafter	 ﾠthey	 ﾠare	 ﾠborn.	 ﾠThe	 ﾠreason	 ﾠfor	 ﾠthis	 ﾠis	 ﾠnot	 ﾠclear.	 ﾠ
Nearly	 ﾠa	 ﾠthird	 ﾠof	 ﾠall	 ﾠextremely	 ﾠpremature	 ﾠgo	 ﾠon	 ﾠto	 ﾠdevelop	 ﾠchronic	 ﾠlung	 ﾠdisease.	 ﾠ
Although	 ﾠ most	 ﾠ of	 ﾠ these	 ﾠ babies	 ﾠ eventually	 ﾠ get	 ﾠ better	 ﾠ they	 ﾠ are	 ﾠ particularly	 ﾠ
vulnerable	 ﾠto	 ﾠother	 ﾠproblems	 ﾠat	 ﾠthis	 ﾠtime.	 ﾠ
	 ﾠ
Why	 ﾠAre	 ﾠWe	 ﾠDoing	 ﾠThis	 ﾠStudy?	 ﾠ
We	 ﾠ do	 ﾠ not	 ﾠ know	 ﾠ why	 ﾠ certain	 ﾠ premature	 ﾠ babies	 ﾠ develop	 ﾠ Chronic	 ﾠ Lung	 ﾠ Disease	 ﾠ
(CLD)	 ﾠand	 ﾠothers	 ﾠdo	 ﾠnot.	 ﾠIt	 ﾠis	 ﾠknown	 ﾠthat	 ﾠcertain	 ﾠfactors,	 ﾠlike	 ﾠbeing	 ﾠborn	 ﾠtoo	 ﾠearly,	 ﾠ
make	 ﾠit	 ﾠmore	 ﾠlikely	 ﾠfor	 ﾠa	 ﾠbaby	 ﾠto	 ﾠdevelop	 ﾠthis	 ﾠtype	 ﾠof	 ﾠlung	 ﾠdisease.	 ﾠIn	 ﾠthis	 ﾠstudy	 ﾠwe	 ﾠ
want	 ﾠto	 ﾠlook	 ﾠat	 ﾠhow	 ﾠsome	 ﾠof	 ﾠthe	 ﾠknown	 ﾠrisk	 ﾠfactors	 ﾠinteract	 ﾠto	 ﾠcause	 ﾠbabies	 ﾠto	 ﾠ
have	 ﾠCLD.	 ﾠ
	 ﾠ
Why	 ﾠAre	 ﾠWe	 ﾠStudying	 ﾠSurfactant?	 ﾠ
Surfactant	 ﾠ has	 ﾠ a	 ﾠ role	 ﾠ in	 ﾠ protecting	 ﾠ the	 ﾠ lungs	 ﾠ from	 ﾠ damage.	 ﾠ Damage	 ﾠ can	 ﾠ be	 ﾠ by	 ﾠ
collapse	 ﾠof	 ﾠthe	 ﾠlungs	 ﾠor	 ﾠas	 ﾠa	 ﾠconsequence	 ﾠof	 ﾠinfection	 ﾠor	 ﾠinflammation.	 ﾠ	 ﾠ
We	 ﾠknow	 ﾠthat	 ﾠpremature	 ﾠbabies	 ﾠdo	 ﾠnot	 ﾠproduce	 ﾠtheir	 ﾠown	 ﾠsurfactant	 ﾠproperly.	 ﾠ
What	 ﾠwe	 ﾠdo	 ﾠnot	 ﾠknow	 ﾠis	 ﾠhow	 ﾠthe	 ﾠsurfactant	 ﾠwe	 ﾠgive	 ﾠthe	 ﾠbabies	 ﾠis	 ﾠused	 ﾠup	 ﾠand	 ﾠ
recycled.	 ﾠ
It	 ﾠis	 ﾠpossible	 ﾠthat	 ﾠthere	 ﾠare	 ﾠdifferences	 ﾠbetween	 ﾠindividual	 ﾠbabies,	 ﾠhow	 ﾠthey	 ﾠuse	 ﾠ
and	 ﾠrecycle	 ﾠthe	 ﾠsurfactant	 ﾠthey	 ﾠare	 ﾠgiven	 ﾠand	 ﾠwhether	 ﾠthey	 ﾠneed	 ﾠextra	 ﾠdoses	 ﾠof	 ﾠ
surfactant	 ﾠuntil	 ﾠthey	 ﾠcan	 ﾠmake	 ﾠtheir	 ﾠown.	 ﾠ
If	 ﾠwe	 ﾠcould	 ﾠidentify	 ﾠhow	 ﾠthe	 ﾠbabies	 ﾠdiffer,	 ﾠit	 ﾠmay	 ﾠbe	 ﾠpossible	 ﾠto	 ﾠimprove	 ﾠtreatment	 ﾠ
of	 ﾠthe	 ﾠsicker	 ﾠinfants	 ﾠand	 ﾠprevent	 ﾠchronic	 ﾠlung	 ﾠdisease	 ﾠdeveloping	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠplace.	 ﾠ
	 ﾠ
Why	 ﾠAre	 ﾠWe	 ﾠStudying	 ﾠNutrition?	 ﾠ
Nutrition	 ﾠplays	 ﾠa	 ﾠvery	 ﾠimportant	 ﾠpart	 ﾠin	 ﾠthe	 ﾠdevelopment	 ﾠof	 ﾠthese	 ﾠpreterm	 ﾠinfants.	 ﾠ
Due	 ﾠto	 ﾠtheir	 ﾠpremature	 ﾠdelivery,	 ﾠthey	 ﾠare	 ﾠnot	 ﾠable	 ﾠto	 ﾠfeed	 ﾠproperly	 ﾠfor	 ﾠdays	 ﾠor	 ﾠeven	 ﾠ
weeks	 ﾠafterwards.	 ﾠDuring	 ﾠthe	 ﾠfirst	 ﾠperiod	 ﾠin	 ﾠthe	 ﾠneonatal	 ﾠunit	 ﾠthe	 ﾠbabies	 ﾠreceive	 ﾠ
the	 ﾠnutrition	 ﾠand	 ﾠwater	 ﾠthey	 ﾠneed	 ﾠfrom	 ﾠfluid	 ﾠgiven	 ﾠdirectly	 ﾠinto	 ﾠtheir	 ﾠbloodstream.	 ﾠ
Surfactant	 ﾠproduction	 ﾠand	 ﾠability	 ﾠto	 ﾠfight	 ﾠinfection	 ﾠis	 ﾠinfluenced	 ﾠby	 ﾠthe	 ﾠnutritional	 ﾠ
status	 ﾠof	 ﾠthe	 ﾠpremature	 ﾠbaby.	 ﾠ
	 ﾠ
Why	 ﾠAre	 ﾠWe	 ﾠStudying	 ﾠInfection?	 ﾠ
Infection	 ﾠhas	 ﾠalways	 ﾠbeen	 ﾠconsidered	 ﾠto	 ﾠbe	 ﾠa	 ﾠreason	 ﾠwhy	 ﾠcertain	 ﾠpremature	 ﾠbabies	 ﾠ
develop	 ﾠCLD	 ﾠand	 ﾠothers	 ﾠdo	 ﾠnot.	 ﾠPremature	 ﾠbabies	 ﾠhave	 ﾠa	 ﾠreduced	 ﾠability	 ﾠto	 ﾠfight	 ﾠ
bacteria	 ﾠand	 ﾠviruses	 ﾠwhen	 ﾠcompared	 ﾠto	 ﾠolder	 ﾠchildren	 ﾠand	 ﾠadults.	 ﾠThe	 ﾠpremature	 ﾠ
babies	 ﾠneed	 ﾠto	 ﾠbe	 ﾠtreated	 ﾠwith	 ﾠantibiotics	 ﾠmore	 ﾠoften	 ﾠand	 ﾠfor	 ﾠa	 ﾠlonger	 ﾠtime	 ﾠuntil	 ﾠ
their	 ﾠimmune	 ﾠsystem	 ﾠhas	 ﾠmatured.	 ﾠ
We	 ﾠplan	 ﾠto	 ﾠdetect	 ﾠmicroorganisms	 ﾠby	 ﾠa	 ﾠnew	 ﾠtechnique,	 ﾠwhich	 ﾠidentifies	 ﾠthem	 ﾠby	 ﾠ
looking	 ﾠat	 ﾠtheir	 ﾠDNA	 ﾠ–	 ﾠthe	 ﾠgenetic	 ﾠbar	 ﾠcode	 ﾠthat	 ﾠmakes	 ﾠeach	 ﾠorganism	 ﾠdifferent.	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The	 ﾠextraction	 ﾠand	 ﾠidentification	 ﾠof	 ﾠbacterial	 ﾠDNA	 ﾠwould	 ﾠbe	 ﾠdone	 ﾠin	 ﾠa	 ﾠspecialist	 ﾠlab.	 ﾠ
This	 ﾠ method	 ﾠ has	 ﾠ been	 ﾠ shown	 ﾠ to	 ﾠ be	 ﾠ more	 ﾠ accurate	 ﾠ and	 ﾠ sensitive	 ﾠ in	 ﾠ detecting	 ﾠ
infections	 ﾠin	 ﾠchildren	 ﾠwith	 ﾠother	 ﾠchronic	 ﾠlung	 ﾠproblems.	 ﾠ
What	 ﾠDoes	 ﾠThis	 ﾠStudy	 ﾠInvolve?	 ﾠ
1.	 ﾠBlood	 ﾠTests	 ﾠ
All	 ﾠpremature	 ﾠbabies	 ﾠrequire	 ﾠregular	 ﾠblood	 ﾠtests,	 ﾠespecially	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠweek	 ﾠof	 ﾠlife.	 ﾠ
All	 ﾠof	 ﾠthe	 ﾠsmallest	 ﾠbabies	 ﾠwill	 ﾠrequire	 ﾠclose	 ﾠmonitoring	 ﾠof	 ﾠtheir	 ﾠblood	 ﾠpressure.	 ﾠ	 ﾠ
To	 ﾠallow	 ﾠmonitoring	 ﾠof	 ﾠblood	 ﾠpressure	 ﾠand	 ﾠblood	 ﾠtests,	 ﾠas	 ﾠwell	 ﾠas	 ﾠto	 ﾠgive	 ﾠfluid,	 ﾠthe	 ﾠ
majority	 ﾠof	 ﾠthe	 ﾠsmallest	 ﾠbabies	 ﾠwill	 ﾠhave	 ﾠsmall	 ﾠtubes	 ﾠor	 ﾠcatheters	 ﾠinserted	 ﾠinto	 ﾠthe	 ﾠ
large	 ﾠblood	 ﾠvessels	 ﾠpresent	 ﾠin	 ﾠtheir	 ﾠumbilical	 ﾠcord	 ﾠsoon	 ﾠafter	 ﾠthey	 ﾠare	 ﾠadmitted	 ﾠto	 ﾠ
the	 ﾠneonatal	 ﾠunit.	 ﾠ	 ﾠ
They	 ﾠare	 ﾠcalled	 ﾠUmbilical	 ﾠArterial	 ﾠand	 ﾠVenous	 ﾠCatheters	 ﾠ(UACs	 ﾠ&	 ﾠUVCs).	 ﾠIf	 ﾠthey	 ﾠare	 ﾠ
not	 ﾠable	 ﾠto	 ﾠhave	 ﾠthis	 ﾠkind	 ﾠof	 ﾠtube	 ﾠinserted	 ﾠthen	 ﾠthey	 ﾠwill	 ﾠhave	 ﾠa	 ﾠdrip	 ﾠplaced	 ﾠin	 ﾠthe	 ﾠ
smaller	 ﾠvessels	 ﾠof	 ﾠthe	 ﾠarm	 ﾠor	 ﾠleg.	 ﾠThese	 ﾠare	 ﾠknown	 ﾠas	 ﾠcannulas.	 ﾠ	 ﾠ
All	 ﾠpremature	 ﾠbabies	 ﾠrequire	 ﾠfluids,	 ﾠinitially	 ﾠas	 ﾠa	 ﾠstandard	 ﾠsugar	 ﾠsolution,	 ﾠgiven	 ﾠvia	 ﾠ
a	 ﾠcannula	 ﾠor	 ﾠUVC.	 ﾠ
In	 ﾠthis	 ﾠstudy	 ﾠwe	 ﾠwill	 ﾠgive	 ﾠthe	 ﾠbabies	 ﾠwho	 ﾠneed	 ﾠhelp	 ﾠwith	 ﾠtheir	 ﾠbreathing,	 ﾠsome	 ﾠof	 ﾠ
the	 ﾠstandard	 ﾠsugar	 ﾠsolution	 ﾠwith	 ﾠan	 ﾠadded	 ﾠnutrient	 ﾠ(choline).	 ﾠThe	 ﾠnutrient	 ﾠwill	 ﾠbe	 ﾠ
marked	 ﾠor	 ﾠlabelled	 ﾠ(to	 ﾠmake	 ﾠmethyl-ﾭ‐D9	 ﾠcholine	 ﾠchloride)	 ﾠso	 ﾠthat	 ﾠit	 ﾠcan	 ﾠbe	 ﾠdetected	 ﾠ
on	 ﾠ laboratory	 ﾠ testing	 ﾠ of	 ﾠ blood	 ﾠ and	 ﾠ lung	 ﾠ secretions.	 ﾠ The	 ﾠ amount	 ﾠ of	 ﾠ fluid	 ﾠ they	 ﾠ
receive	 ﾠwill	 ﾠbe	 ﾠexactly	 ﾠthe	 ﾠsame	 ﾠwhether	 ﾠthey	 ﾠare	 ﾠin	 ﾠthe	 ﾠstudy	 ﾠor	 ﾠnot.	 ﾠThe	 ﾠonly	 ﾠ
difference	 ﾠis	 ﾠthe	 ﾠpresence	 ﾠof	 ﾠthis	 ﾠmarked	 ﾠnutrient.	 ﾠThe	 ﾠfluid	 ﾠwill	 ﾠbe	 ﾠgiven	 ﾠover	 ﾠ3	 ﾠ
hours	 ﾠat	 ﾠthe	 ﾠstart	 ﾠof	 ﾠthe	 ﾠstudy.	 ﾠImmediately	 ﾠafterwards	 ﾠthe	 ﾠbaby	 ﾠwill	 ﾠreturn	 ﾠto	 ﾠ
their	 ﾠnormal	 ﾠfluid	 ﾠregime.	 ﾠ	 ﾠ
Then	 ﾠsmall	 ﾠblood	 ﾠsamples	 ﾠwill	 ﾠbe	 ﾠtaken	 ﾠat	 ﾠregular	 ﾠintervals	 ﾠover	 ﾠthe	 ﾠfirst	 ﾠ24	 ﾠhours,	 ﾠ
every	 ﾠ6	 ﾠhours,	 ﾠfollowed	 ﾠby	 ﾠonce	 ﾠa	 ﾠday	 ﾠuntil	 ﾠthe	 ﾠfifth	 ﾠday.	 ﾠ	 ﾠ
If	 ﾠthe	 ﾠbaby	 ﾠis	 ﾠstill	 ﾠrequiring	 ﾠthe	 ﾠhelp	 ﾠof	 ﾠa	 ﾠventilator	 ﾠon	 ﾠthe	 ﾠfifth	 ﾠday	 ﾠthe	 ﾠbaby	 ﾠwill	 ﾠ
receive	 ﾠa	 ﾠfurther	 ﾠinfusion	 ﾠof	 ﾠthe	 ﾠmarked	 ﾠnutrient	 ﾠin	 ﾠthe	 ﾠsugar	 ﾠsolution	 ﾠand	 ﾠmore	 ﾠ
blood	 ﾠtests	 ﾠtaken	 ﾠuntil	 ﾠthe	 ﾠtenth	 ﾠday.	 ﾠ
The	 ﾠblood	 ﾠsamples	 ﾠwill	 ﾠbe	 ﾠvery	 ﾠsmall;	 ﾠit	 ﾠwould	 ﾠtake	 ﾠ20	 ﾠof	 ﾠthese	 ﾠblood	 ﾠsamples	 ﾠto	 ﾠ
fill	 ﾠ a	 ﾠ teaspoon.	 ﾠ The	 ﾠ baby	 ﾠ will	 ﾠ not	 ﾠ need	 ﾠ extra	 ﾠ blood	 ﾠ transfusions	 ﾠ because	 ﾠ of	 ﾠ
participation	 ﾠin	 ﾠthe	 ﾠstudy.	 ﾠ
Samples	 ﾠwill	 ﾠbe	 ﾠtaken,	 ﾠwhen	 ﾠpossible,	 ﾠat	 ﾠthe	 ﾠsame	 ﾠtime	 ﾠas	 ﾠthe	 ﾠroutine	 ﾠblood	 ﾠtests.	 ﾠ
	 ﾠ
2.	 ﾠLung	 ﾠSecretions	 ﾠ
A	 ﾠbaby	 ﾠwho	 ﾠneeds	 ﾠhelp	 ﾠwith	 ﾠbreathing	 ﾠfrom	 ﾠa	 ﾠventilator	 ﾠwill	 ﾠhave	 ﾠa	 ﾠtube,	 ﾠcalled	 ﾠan	 ﾠ
endotracheal	 ﾠtube	 ﾠ(ET	 ﾠtube),	 ﾠwhich	 ﾠconnects	 ﾠthe	 ﾠventilator	 ﾠto	 ﾠthe	 ﾠbaby’s	 ﾠlungs.	 ﾠThe	 ﾠ
ET	 ﾠtube	 ﾠsits	 ﾠin	 ﾠthe	 ﾠthroat,	 ﾠat	 ﾠthe	 ﾠentrance	 ﾠto	 ﾠthe	 ﾠbaby’s	 ﾠlarge	 ﾠairways.	 ﾠTo	 ﾠallow	 ﾠthe	 ﾠ
ventilator	 ﾠto	 ﾠwork	 ﾠproperly	 ﾠthis	 ﾠtube	 ﾠand	 ﾠthe	 ﾠbaby’s	 ﾠlarge	 ﾠairway	 ﾠare	 ﾠregularly	 ﾠ
cleared	 ﾠof	 ﾠsecretions	 ﾠby	 ﾠsuctioning.	 ﾠNormally	 ﾠthese	 ﾠsecretions	 ﾠwould	 ﾠsimply	 ﾠbe	 ﾠ
thrown	 ﾠaway.	 ﾠWe	 ﾠintend	 ﾠto	 ﾠuse	 ﾠthese	 ﾠsecretions	 ﾠfor	 ﾠour	 ﾠinvestigations.	 ﾠ
Lung	 ﾠsecretions	 ﾠwill	 ﾠbe	 ﾠcollected	 ﾠonce	 ﾠeach	 ﾠdaily	 ﾠfrom	 ﾠday	 ﾠ1	 ﾠuntil	 ﾠthe	 ﾠbaby	 ﾠno	 ﾠ
longer	 ﾠrequires	 ﾠa	 ﾠventilator	 ﾠto	 ﾠhelp	 ﾠwith	 ﾠbreathing.	 ﾠThe	 ﾠsecretions	 ﾠwill	 ﾠbe	 ﾠtaken	 ﾠto	 ﾠ
our	 ﾠ labs	 ﾠ in	 ﾠ either	 ﾠ Southampton	 ﾠ or	 ﾠ Portsmouth	 ﾠ where	 ﾠ they	 ﾠ will	 ﾠ be	 ﾠ frozen	 ﾠ (to	 ﾠ
preserve	 ﾠthe	 ﾠspecimen)	 ﾠand	 ﾠthen	 ﾠtransported	 ﾠto	 ﾠspecialist	 ﾠlabs,	 ﾠin	 ﾠthe	 ﾠUniversity	 ﾠof	 ﾠ
Southampton	 ﾠand	 ﾠKing’s	 ﾠCollege	 ﾠLondon,	 ﾠwhere	 ﾠthey	 ﾠwill	 ﾠbe	 ﾠanalysed.	 ﾠ	 ﾠ
	 ﾠ
3.	 ﾠStomach	 ﾠSecretions	 ﾠ	 ﾠ
All	 ﾠpremature	 ﾠbabies	 ﾠadmitted	 ﾠto	 ﾠthe	 ﾠunit	 ﾠhave	 ﾠa	 ﾠplastic	 ﾠtube	 ﾠpassed	 ﾠinto	 ﾠtheir	 ﾠ
stomach	 ﾠfrom	 ﾠtheir	 ﾠnose	 ﾠcalled	 ﾠa	 ﾠnaso-ﾭ‐gastric	 ﾠ(NG)	 ﾠtube.	 ﾠThe	 ﾠpurpose	 ﾠof	 ﾠthis	 ﾠtube	 ﾠ
is	 ﾠto	 ﾠremove	 ﾠair	 ﾠand	 ﾠsecretions	 ﾠfrom	 ﾠthe	 ﾠstomach	 ﾠand	 ﾠlater	 ﾠto	 ﾠgive	 ﾠmilk	 ﾠfeeds.	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When	 ﾠthe	 ﾠNG	 ﾠtube	 ﾠis	 ﾠfirst	 ﾠpassed	 ﾠwe	 ﾠroutinely	 ﾠclear	 ﾠthe	 ﾠstomach	 ﾠof	 ﾠany	 ﾠsecretions,	 ﾠ
usually	 ﾠconsisting	 ﾠof	 ﾠfluid	 ﾠfrom	 ﾠthe	 ﾠwomb	 ﾠand	 ﾠsend	 ﾠit	 ﾠto	 ﾠthe	 ﾠlab	 ﾠto	 ﾠlook	 ﾠfor	 ﾠany	 ﾠ
infection.	 ﾠAgain	 ﾠthese	 ﾠsecretions	 ﾠwould	 ﾠnormally	 ﾠbe	 ﾠdiscarded.	 ﾠWe	 ﾠintend	 ﾠto	 ﾠuse	 ﾠa	 ﾠ
portion	 ﾠof	 ﾠthis	 ﾠsecretion	 ﾠfor	 ﾠour	 ﾠresearch	 ﾠas	 ﾠwell,	 ﾠto	 ﾠtry	 ﾠand	 ﾠmore	 ﾠsensitively	 ﾠdetect	 ﾠ
any	 ﾠinfection	 ﾠthe	 ﾠbaby	 ﾠmight	 ﾠhave	 ﾠbeen	 ﾠexposed	 ﾠto	 ﾠbefore	 ﾠbirth.	 ﾠ	 ﾠ	 ﾠ
	 ﾠ
4.	 ﾠUrine	 ﾠ
In	 ﾠaddition	 ﾠsamples	 ﾠof	 ﾠurine	 ﾠwill	 ﾠbe	 ﾠcollected	 ﾠfrom	 ﾠthe	 ﾠbabies’	 ﾠnappies	 ﾠeach	 ﾠday	 ﾠfor	 ﾠ
the	 ﾠfirst	 ﾠ2	 ﾠweeks.	 ﾠ
	 ﾠ
Will	 ﾠIt	 ﾠBe	 ﾠPossible	 ﾠTo	 ﾠIdentify	 ﾠMy	 ﾠBaby	 ﾠin	 ﾠReports	 ﾠof	 ﾠthe	 ﾠStudy?	 ﾠ
	 ﾠ
It	 ﾠ will	 ﾠ not	 ﾠ be	 ﾠ possible	 ﾠ to	 ﾠ identify	 ﾠ any	 ﾠ individual	 ﾠ baby	 ﾠ in	 ﾠ the	 ﾠ presentations	 ﾠ or	 ﾠ
reports	 ﾠarising	 ﾠfrom	 ﾠthis	 ﾠstudy.	 ﾠThe	 ﾠdata	 ﾠsent	 ﾠto	 ﾠthe	 ﾠlab	 ﾠwill	 ﾠalso	 ﾠbe	 ﾠanonymised	 ﾠso	 ﾠ
the	 ﾠresearchers	 ﾠthere	 ﾠwill	 ﾠnot	 ﾠbe	 ﾠable	 ﾠto	 ﾠidentify	 ﾠindividual	 ﾠbabies.	 ﾠ
	 ﾠ
What	 ﾠDo	 ﾠWe	 ﾠNeed	 ﾠTo	 ﾠDo	 ﾠNow?	 ﾠ
You	 ﾠneed	 ﾠto	 ﾠconsider	 ﾠwhether	 ﾠyou	 ﾠare	 ﾠhappy	 ﾠfor	 ﾠyour	 ﾠbaby	 ﾠto	 ﾠparticipate	 ﾠin	 ﾠthis	 ﾠ
study.	 ﾠYou	 ﾠmust	 ﾠunderstand	 ﾠthat:	 ﾠ
	 ﾠ
•  The	 ﾠresults	 ﾠof	 ﾠthis	 ﾠstudy	 ﾠwill	 ﾠonly	 ﾠbe	 ﾠavailable	 ﾠafter	 ﾠa	 ﾠminimum	 ﾠof	 ﾠone	 ﾠyear	 ﾠ
and	 ﾠtherefore	 ﾠwould	 ﾠbe	 ﾠbeneficial	 ﾠonly	 ﾠto	 ﾠa	 ﾠfuture	 ﾠgeneration	 ﾠof	 ﾠpremature	 ﾠ
babies.	 ﾠ	 ﾠ
•  Participation	 ﾠ in	 ﾠ the	 ﾠ study	 ﾠ will	 ﾠ result	 ﾠ in	 ﾠ your	 ﾠ baby	 ﾠ receiving	 ﾠ an	 ﾠ extra,	 ﾠ
labelled	 ﾠnutrient.	 ﾠ
•  Participation	 ﾠin	 ﾠthe	 ﾠstudy	 ﾠwill	 ﾠrequire	 ﾠyour	 ﾠbaby	 ﾠto	 ﾠhave	 ﾠextra	 ﾠblood	 ﾠtests	 ﾠ
in	 ﾠthe	 ﾠtwo	 ﾠweeks	 ﾠof	 ﾠlife.	 ﾠ
•  You	 ﾠare	 ﾠfree	 ﾠto	 ﾠwithdraw	 ﾠyour	 ﾠbaby	 ﾠfrom	 ﾠthe	 ﾠstudy	 ﾠat	 ﾠany	 ﾠstage	 ﾠwithout	 ﾠ
any	 ﾠexplanations	 ﾠ
	 ﾠ
If	 ﾠyou	 ﾠagree	 ﾠthen	 ﾠwe	 ﾠwould	 ﾠrequest	 ﾠyou	 ﾠto	 ﾠinitial	 ﾠand	 ﾠdate	 ﾠthe	 ﾠfront	 ﾠof	 ﾠthe	 ﾠconsent	 ﾠ
form,	 ﾠin	 ﾠthe	 ﾠboxes	 ﾠprovided,	 ﾠand	 ﾠsign	 ﾠthe	 ﾠconsent	 ﾠform	 ﾠon	 ﾠthe	 ﾠback.	 ﾠ
	 ﾠ
Are	 ﾠThere	 ﾠAny	 ﾠDisadvantages	 ﾠor	 ﾠRisks	 ﾠto	 ﾠTaking	 ﾠPart	 ﾠin	 ﾠthe	 ﾠStudy?	 ﾠ
This	 ﾠstudy	 ﾠhas	 ﾠbeen	 ﾠmade	 ﾠas	 ﾠsafe	 ﾠas	 ﾠpossible	 ﾠbut	 ﾠdoes	 ﾠinvolve	 ﾠgiving	 ﾠyour	 ﾠbaby	 ﾠa	 ﾠ
short	 ﾠ infusion	 ﾠ of	 ﾠ a	 ﾠ labelled	 ﾠ nutrient	 ﾠ beyond	 ﾠ their	 ﾠ routine	 ﾠ care.	 ﾠ The	 ﾠ marked	 ﾠ
nutrient	 ﾠhas	 ﾠnot	 ﾠbeen	 ﾠused	 ﾠin	 ﾠpremature	 ﾠbabies	 ﾠbefore,	 ﾠbut	 ﾠit	 ﾠhas	 ﾠbeen	 ﾠused	 ﾠin	 ﾠ
normal	 ﾠ babies	 ﾠ without	 ﾠ any	 ﾠ known	 ﾠ side	 ﾠ effects.	 ﾠ This	 ﾠ nutrient	 ﾠ has	 ﾠ been	 ﾠ used	 ﾠ in	 ﾠ
studies	 ﾠ involving	 ﾠ older	 ﾠ children	 ﾠ with	 ﾠ lung	 ﾠ problems	 ﾠ and	 ﾠ there	 ﾠ have	 ﾠ been	 ﾠ no	 ﾠ
reported	 ﾠproblems	 ﾠassociated	 ﾠwith	 ﾠits	 ﾠuse.	 ﾠ	 ﾠ
	 ﾠ
What	 ﾠIf	 ﾠThere	 ﾠIs	 ﾠA	 ﾠProblem?	 ﾠAny	 ﾠcomplaint	 ﾠabout	 ﾠthe	 ﾠway	 ﾠyou	 ﾠhave	 ﾠbeen	 ﾠdealt	 ﾠ
with	 ﾠduring	 ﾠthe	 ﾠstudy	 ﾠor	 ﾠany	 ﾠpossible	 ﾠharm	 ﾠyou	 ﾠmight	 ﾠsuffer	 ﾠwill	 ﾠbe	 ﾠaddressed.	 ﾠ
Please	 ﾠraise	 ﾠyour	 ﾠconcerns	 ﾠin	 ﾠthe	 ﾠfirst	 ﾠinstance	 ﾠwith	 ﾠthe	 ﾠPrincipal	 ﾠInvestigator,	 ﾠDr	 ﾠ
Kevin	 ﾠGoss;	 ﾠhis	 ﾠcontact	 ﾠdetails	 ﾠare	 ﾠat	 ﾠthe	 ﾠend	 ﾠof	 ﾠthis	 ﾠform.	 ﾠIf	 ﾠyou	 ﾠwish	 ﾠto	 ﾠmake	 ﾠa	 ﾠ
more	 ﾠ formal	 ﾠ complaint,	 ﾠ please	 ﾠ contact	 ﾠ the	 ﾠ Patient	 ﾠ Advice	 ﾠ and	 ﾠ Liaison	 ﾠ Service	 ﾠ




Email:	 ﾠPALS@suht.swest.nhs.uk	 ﾠ	 ﾠ  161	 ﾠ
Tel:	 ﾠ	 ﾠ 023	 ﾠ8079	 ﾠ8498	 ﾠ
Or	 ﾠwrite	 ﾠto	 ﾠthem	 ﾠat:	 ﾠ
PALS	 ﾠ	 ﾠ
C	 ﾠLevel	 ﾠCentre	 ﾠBlock	 ﾠ
Mailpoint	 ﾠ81	 ﾠ





Which	 ﾠInsurance	 ﾠProvisions	 ﾠAre	 ﾠIn	 ﾠPlace?	 ﾠIn	 ﾠthe	 ﾠevent	 ﾠthat	 ﾠsomething	 ﾠdoes	 ﾠgo	 ﾠ
wrong	 ﾠand	 ﾠyou	 ﾠor	 ﾠyour	 ﾠbaby	 ﾠare	 ﾠharmed	 ﾠduring	 ﾠthe	 ﾠresearch	 ﾠand	 ﾠthis	 ﾠis	 ﾠdue	 ﾠto	 ﾠ
someone’s	 ﾠ negligence	 ﾠ then	 ﾠ you	 ﾠ may	 ﾠ have	 ﾠ grounds	 ﾠ for	 ﾠ a	 ﾠ legal	 ﾠ action	 ﾠ for	 ﾠ
compensation	 ﾠagainst	 ﾠthe	 ﾠSponsor,	 ﾠSouthampton	 ﾠUniversity	 ﾠHospitals	 ﾠNHS	 ﾠTrust	 ﾠ
but	 ﾠyou	 ﾠmay	 ﾠhave	 ﾠto	 ﾠpay	 ﾠyour	 ﾠlegal	 ﾠcosts.	 ﾠThe	 ﾠnormal	 ﾠNational	 ﾠHealth	 ﾠService	 ﾠ
complaints	 ﾠmechanism	 ﾠwill	 ﾠstill	 ﾠbe	 ﾠavailable	 ﾠto	 ﾠyou.	 ﾠAs	 ﾠthe	 ﾠPrincipal	 ﾠInvestigator	 ﾠis	 ﾠ
an	 ﾠemployee	 ﾠof	 ﾠthe	 ﾠUniversity	 ﾠof	 ﾠSouthampton,	 ﾠadditional	 ﾠprofessional	 ﾠindemnity	 ﾠ
and	 ﾠclinical	 ﾠtrials	 ﾠinsurance	 ﾠis	 ﾠin	 ﾠplace.	 ﾠ
	 ﾠ
Are	 ﾠThere	 ﾠAny	 ﾠBenefits	 ﾠto	 ﾠTaking	 ﾠPart?	 ﾠ
This	 ﾠstudy	 ﾠwill	 ﾠnot	 ﾠbe	 ﾠof	 ﾠany	 ﾠdirect	 ﾠbenefit	 ﾠto	 ﾠyour	 ﾠbaby,	 ﾠthough	 ﾠthere	 ﾠwill	 ﾠbe	 ﾠ
benefit	 ﾠto	 ﾠbabies	 ﾠborn	 ﾠtoo	 ﾠearly	 ﾠin	 ﾠthe	 ﾠfuture.	 ﾠ
	 ﾠ
What	 ﾠWill	 ﾠHappen	 ﾠto	 ﾠthe	 ﾠResults	 ﾠof	 ﾠthe	 ﾠResearch?	 ﾠ
The	 ﾠresults	 ﾠof	 ﾠthe	 ﾠresearch	 ﾠwill	 ﾠbe	 ﾠthe	 ﾠwritten	 ﾠup	 ﾠas	 ﾠpart	 ﾠof	 ﾠmy	 ﾠdoctoral	 ﾠthesis.	 ﾠ
They	 ﾠ will	 ﾠ be	 ﾠ the	 ﾠ subject	 ﾠ of	 ﾠ presentations	 ﾠ at	 ﾠ scientific	 ﾠ meetings	 ﾠ and	 ﾠ will	 ﾠ be	 ﾠ
published	 ﾠin	 ﾠpeer-ﾭ‐reviewed	 ﾠjournals.	 ﾠNo	 ﾠpatients	 ﾠwill	 ﾠbe	 ﾠidentifiable	 ﾠin	 ﾠany	 ﾠof	 ﾠthis	 ﾠ
material.	 ﾠ
Who	 ﾠHas	 ﾠReviewed	 ﾠthe	 ﾠStudy?	 ﾠ
The	 ﾠstudy	 ﾠwas	 ﾠreviewed	 ﾠby	 ﾠa	 ﾠrange	 ﾠof	 ﾠprofessionals	 ﾠduring	 ﾠits	 ﾠdevelopment	 ﾠand	 ﾠ
has	 ﾠbeen	 ﾠapproved	 ﾠby	 ﾠthe	 ﾠSouthampton	 ﾠ&	 ﾠSouth	 ﾠWest	 ﾠHampshire	 ﾠResearch	 ﾠEthics	 ﾠ
Committee.	 ﾠ
	 ﾠ
Thank	 ﾠyou	 ﾠvery	 ﾠmuch	 ﾠfor	 ﾠtaking	 ﾠtime	 ﾠto	 ﾠread	 ﾠthis	 ﾠleaflet.	 ﾠPlease	 ﾠdon’t	 ﾠhesitate	 ﾠto	 ﾠ
ask	 ﾠmembers	 ﾠof	 ﾠstaff	 ﾠfor	 ﾠfurther	 ﾠinformation;	 ﾠone	 ﾠof	 ﾠthe	 ﾠsenior	 ﾠdoctors	 ﾠwill	 ﾠcontact	 ﾠ
you	 ﾠto	 ﾠconfirm	 ﾠwhether	 ﾠor	 ﾠnot	 ﾠyou	 ﾠare	 ﾠhappy	 ﾠto	 ﾠbe	 ﾠincluded	 ﾠin	 ﾠthe	 ﾠstudy.	 ﾠIf	 ﾠthere	 ﾠ
are	 ﾠ points	 ﾠ that	 ﾠ you	 ﾠ still	 ﾠ need	 ﾠ to	 ﾠ clarify	 ﾠ after	 ﾠ reading	 ﾠ the	 ﾠ leaflet,	 ﾠ the	 ﾠ doctors	 ﾠ
involved	 ﾠwith	 ﾠthe	 ﾠstudy	 ﾠwould	 ﾠbe	 ﾠhappy	 ﾠto	 ﾠdo	 ﾠso.	 ﾠ	 ﾠ
	 ﾠ
If	 ﾠyou	 ﾠagree	 ﾠfor	 ﾠyour	 ﾠbaby	 ﾠto	 ﾠbe	 ﾠincluded	 ﾠin	 ﾠthe	 ﾠstudy	 ﾠwe	 ﾠwill	 ﾠask	 ﾠyou	 ﾠto	 ﾠsign	 ﾠa	 ﾠ
consent	 ﾠform.	 ﾠA	 ﾠcopy	 ﾠof	 ﾠthe	 ﾠform	 ﾠwill	 ﾠbe	 ﾠgiven	 ﾠto	 ﾠyou,	 ﾠone	 ﾠcopy	 ﾠwill	 ﾠgo	 ﾠinto	 ﾠyour	 ﾠ
baby’s	 ﾠnotes	 ﾠand	 ﾠthe	 ﾠresearchers	 ﾠwill	 ﾠretain	 ﾠone.	 ﾠ
	 ﾠ
Your	 ﾠGP	 ﾠwill	 ﾠbe	 ﾠinformed	 ﾠby	 ﾠletter	 ﾠthat	 ﾠyou	 ﾠare	 ﾠparticipating	 ﾠin	 ﾠthis	 ﾠstudy.	 ﾠ
	 ﾠ
For	 ﾠ independent	 ﾠ advice	 ﾠ about	 ﾠ taking	 ﾠ part	 ﾠ in	 ﾠ clinical	 ﾠ studies	 ﾠ you	 ﾠ can	 ﾠ contact	 ﾠ
Involve:	 ﾠInvolve,	 ﾠWessex	 ﾠHouse,	 ﾠUpper	 ﾠMarket	 ﾠStreet,	 ﾠEastleigh,	 ﾠHampshire	 ﾠSO50	 ﾠ
9FD.	 ﾠTelephone:	 ﾠ023	 ﾠ8065	 ﾠ1088.	 ﾠEmail:	 ﾠadmin@invo.org.uk	 ﾠ
	 ﾠ
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If	 ﾠyou	 ﾠhave	 ﾠany	 ﾠquestions	 ﾠplease	 ﾠspeak	 ﾠto	 ﾠthe	 ﾠsenior	 ﾠmedical	 ﾠstaff	 ﾠlooking	 ﾠafter	 ﾠ
your	 ﾠbaby	 ﾠor	 ﾠif	 ﾠthey	 ﾠare	 ﾠnot	 ﾠavailable	 ﾠplease	 ﾠcontact	 ﾠme	 ﾠdirectly:	 ﾠ
	 ﾠ
Dr	 ﾠKevin	 ﾠGoss	 ﾠ
Research	 ﾠFellow	 ﾠ
Biomedical	 ﾠResearch	 ﾠUnit,	 ﾠ	 ﾠ
MP803	 ﾠ
Southampton	 ﾠGeneral	 ﾠHospital	 ﾠ




Phone	 ﾠnumber:	 ﾠ02380777222	 ﾠ
Extension:	 ﾠ4714	 ﾠ(during	 ﾠoffice	 ﾠhours)	 ﾠ	 ﾠ
	 ﾠ
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Appendix	 ﾠII:	 ﾠCase	 ﾠReport	 ﾠForm	 ﾠfor	 ﾠDaily	 ﾠData	 ﾠCollection	 ﾠ
	 ﾠ
Baseline information study form 1 of 3   
 
Date of Gastric aspirate:  _____/_____/_____ Time of Gastric 
aspirate:  ________ 
Date of ET aspirate:  _____/_____/_____ Time of ET aspirate:
  ________ 
Date of Blood sample:  _____/_____/_____ Time of Blood sample:
  ________ 
Date of Urine sample:  _____/_____/_____ Time of Urine sample:




   
 Choline  Date  Time start  Time finish 
1st          
2nd (if given on day 5)*          
*Remember to complete Form 6, if a SECOND choline infusion is given 
 
Baseline Ventilation Settings (at start of 1
st choline infusion) 
Mode   
FiO2   
PIP   
PEEP   
Ti   
Rate   
Delta P (HFOV)   
MAP (HFOV)   
 
 
Baseline Growth (most recent weight and head circumference) 
 
Weight (g): _______  Date of weight:   ____/____/____  Time of 
weight: ______ 
   164	 ﾠ




Baseline information study form 2 of 3    
Baseline Nutrition (at start of choline infusion) 
 
Total prescribed fluids (ml/kg/day): _______________ 
Any feeds?      Yes/No 
Trophic feeds?       Yes/No 
Parenteral fluid (ml/kg):  _______________ 
Type of parenteral:   
stock TPN/ prescribed or tailored TPN/ dextrose 
Enteral feeds (ml/kg):  _______________ 
Frequency of feeds:  _______________ 
Type of feeds:    _______________ 
 
Baseline Blood results (most recent sample prior to choline infusion) 
Date of Blood sample:  _____/_____/_____  
Time of sample:    ________ 
 
  Results    Results 
Hb    Ur 
 
WCC    Cr 
 
Neutrophils    Corrected Ca 
 
Platelet    Phosphate 
 
CRP    Alk phos 
 
Na    ALT 
 




Baseline information study form 3 of 3   
 
Baseline Infection Status (at time of choline infusion) 
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Current Antibiotics/Antifungals 
Antibiotics/ 
Antifungals  Type  Date started 
1st       
2nd       
3rd       




Cultures  Type  Date  Culture Result 
1st          
2nd          







Blood products received since birth: 
 
Blood 
Product  Type 
Volume 
(ml/kg)  Date  Time 
1st             
2nd             
3rd         
4th             
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Daily Nutrition Data: 
Date:            dd / mm / yyyy 
Working weight         ____________________ (grams) 
Total prescribed fluids      ____________________ (ml/kg/day) 
TPN:    Yes o No o   
       
PN     Stock Preterm Bag    o 
    Stock Preterm 5+ Bag  o 
    Bespoke Bag      o 
    Total received in 24 hours  ____________________ ml 
 
Lipid    Clenoleic      o     SMOF o 
    Stock lipid syringe    o 
    Bespoke lipid syringe  o 
    Total received in 24 hours  ____________________ ml 
 
Other Infusions received: 
 
Infusion – 1  ____________________   ____________________ ml/day 
 
Infusion – 2  ____________________   ____________________ ml/day 
 
Infusion – 3  ____________________   ____________________ ml/day 
 
Infusion – 4  ____________________   ____________________ ml/day 
 
 
Enteral feeds:  Yes o No o    Fortifier:  Yes o Noo 
Total feeds received in 24 hours    ____________________ ml 
 
Type of feed (all that apply) 
MBM o DBM o Preterm Formula o Term formula o other ______ 
 
Frequency of feeds: 
1hrly  o  2hrly  o  3hrly  o  4hrly  o  8hrly  o 
 
Frequency of increments:  6hrly  o  8hrly  o  12hrly o  24hrly o 
 
Feeds omitted in previous 24 hours:  No  o  Yes   o 
On Insulin:          No  o  Yes  o 
	 ﾠ
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Appendix	 ﾠIII:	 ﾠSample	 ﾠProcessing	 ﾠProtocol	 ﾠ
TSuNaMI	 ﾠSample	 ﾠProcessing	 ﾠProtocol	 ﾠ
Blood	 ﾠSamples	 ﾠ
1.  Balance	 ﾠcentrifuge	 ﾠcarefully	 ﾠ
2.  Spin	 ﾠat	 ﾠ3k	 ﾠrpm	 ﾠfor	 ﾠ15	 ﾠminutes	 ﾠ	 ﾠ
3.  Carefully	 ﾠaspirate	 ﾠthe	 ﾠupper	 ﾠplasma	 ﾠlayer-ﾭ‐	 ﾠif	 ﾠcontamination	 ﾠoccurs	 ﾠwith	 ﾠred	 ﾠ
blood	 ﾠcells	 ﾠthen	 ﾠsamples	 ﾠmust	 ﾠbe	 ﾠre-ﾭ‐spun	 ﾠto	 ﾠensure	 ﾠthese	 ﾠare	 ﾠremoved	 ﾠfrom	 ﾠ
the	 ﾠfinal	 ﾠstored	 ﾠaliquots	 ﾠ
4.  Store	 ﾠin	 ﾠ100	 ﾠµl	 ﾠaliquots	 ﾠin	 ﾠlabelled	 ﾠeppendorfs	 ﾠ(Tsunami,	 ﾠstudy	 ﾠnumber,	 ﾠ
type	 ﾠof	 ﾠsample,	 ﾠtime	 ﾠpoint	 ﾠi.e.	 ﾠT=X)	 ﾠ
5.  Store	 ﾠresidue	 ﾠin	 ﾠblood	 ﾠbottle,	 ﾠlabel	 ﾠwith	 ﾠStudy	 ﾠID	 ﾠnumber	 ﾠand	 ﾠtime	 ﾠpoint	 ﾠ
6.  Transfer	 ﾠall	 ﾠsamples	 ﾠto	 ﾠthe	 ﾠfreezer	 ﾠand	 ﾠplace	 ﾠin	 ﾠappropriate	 ﾠboxes	 ﾠ
Urine	 ﾠSamples	 ﾠ
1.  Store	 ﾠin	 ﾠ2	 ﾠx	 ﾠ0.5	 ﾠml	 ﾠaliquots	 ﾠand	 ﾠ1	 ﾠml	 ﾠaliquots	 ﾠthereafter	 ﾠin	 ﾠlabelled	 ﾠ
eppendorfs	 ﾠ(Tsunami,	 ﾠstudy	 ﾠnumber,	 ﾠtype	 ﾠof	 ﾠsample,	 ﾠtime	 ﾠpoint	 ﾠi.e.	 ﾠT=X)	 ﾠ
2.  Any	 ﾠremaining	 ﾠsample	 ﾠshould	 ﾠbe	 ﾠstored	 ﾠand	 ﾠa	 ﾠnote	 ﾠmade	 ﾠon	 ﾠthe	 ﾠsample	 ﾠvial	 ﾠ
of	 ﾠvolume	 ﾠ
3.  Transfer	 ﾠall	 ﾠsamples	 ﾠto	 ﾠthe	 ﾠfreezer	 ﾠand	 ﾠplace	 ﾠin	 ﾠappropriate	 ﾠboxes	 ﾠ
Gastric	 ﾠAspirate	 ﾠ	 ﾠ
1.  Ensure	 ﾠsamples	 ﾠhave	 ﾠbeen	 ﾠappropriately	 ﾠlabelled	 ﾠ(Tsunami,	 ﾠstudy	 ﾠnumber,	 ﾠ
type	 ﾠof	 ﾠsample)	 ﾠ
2.  Transfer	 ﾠsamples	 ﾠto	 ﾠthe	 ﾠfreezer	 ﾠand	 ﾠplace	 ﾠin	 ﾠappropriate	 ﾠboxes	 ﾠ
Endotracheal	 ﾠAspirates	 ﾠ
1.  Add	 ﾠ200	 ﾠµl	 ﾠof	 ﾠ0.9%	 ﾠNaCl	 ﾠsolution	 ﾠto	 ﾠthe	 ﾠsample	 ﾠusing	 ﾠthe	 ﾠHamilton	 ﾠsyringe	 ﾠ	 ﾠ
2.  Use	 ﾠthis	 ﾠplus	 ﾠother	 ﾠfluid	 ﾠto	 ﾠcarefully	 ﾠand	 ﾠthoroughly	 ﾠflush	 ﾠthe	 ﾠinside	 ﾠand	 ﾠ
outside	 ﾠof	 ﾠany	 ﾠET	 ﾠtubing	 ﾠprovided.	 ﾠEnsure	 ﾠthat	 ﾠas	 ﾠmuch	 ﾠresidue	 ﾠas	 ﾠpossible	 ﾠ
is	 ﾠremoved	 ﾠby	 ﾠusing	 ﾠa	 ﾠcombination	 ﾠof	 ﾠpushing	 ﾠmucus	 ﾠusing	 ﾠthe	 ﾠsyringe	 ﾠand	 ﾠ
air	 ﾠand	 ﾠliquid	 ﾠflushes	 ﾠto	 ﾠclean	 ﾠthe	 ﾠtubing	 ﾠ
3.  Store	 ﾠin	 ﾠ300µl	 ﾠaliquots	 ﾠin	 ﾠlabelled	 ﾠeppendorfs	 ﾠ((Tsunami,	 ﾠstudy	 ﾠnumber,	 ﾠ
type	 ﾠof	 ﾠsample,	 ﾠtime	 ﾠpoint	 ﾠi.e.	 ﾠT=X,	 ﾠnote	 ﾠalso	 ﾠmucus	 ﾠcontent)	 ﾠ
Transfer	 ﾠall	 ﾠsamples	 ﾠto	 ﾠthe	 ﾠfreezer	 ﾠand	 ﾠplace	 ﾠin	 ﾠappropriate	 ﾠboxes	 ﾠ
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